

Cancer drug resistance: an evolving paradigm

Nature Reviews Cancer

13, 714-726

DOI: [10.1038/nrc3599](https://doi.org/10.1038/nrc3599)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Autophagy and senescence in cancer therapy. <i>Journal of Cellular Physiology</i> , 2013, 229, n/a-n/a.	2.0	87
2	Metformin trims fats to restore insulin sensitivity. <i>Nature Medicine</i> , 2013, 19, 1570-1572.	15.2	27
3	Poker face no more: cancer recurrence reveals its hand. <i>Nature Medicine</i> , 2013, 19, 1569-1570.	15.2	4
4	Multidrug Resistance and Cancer Stem Cells in Neuroblastoma and Hepatoblastoma. <i>International Journal of Molecular Sciences</i> , 2013, 14, 24706-24725.	1.8	80
5	Identification of Drug Combinations Containing Imatinib for Treatment of BCR-ABL+ Leukemias. <i>PLoS ONE</i> , 2014, 9, e102221.	1.1	18
6	Integrative Genomic and Transcriptomic Analysis Identified Candidate Genes Implicated in the Pathogenesis of Hepatosplenic T-Cell Lymphoma. <i>PLoS ONE</i> , 2014, 9, e102977.	1.1	48
7	Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. <i>ELife</i> , 2014, 3, e02523.	2.8	1,296
8	Lentiviral-based approach for the validation of cancer therapeutic targets in vivo. <i>BioTechniques</i> , 2014, 57, 179, 181-7.	0.8	0
9	Editorial (Thematic Issue: Signalling Pathways in Anti-cancer Drug Resistance). <i>Current Medicinal Chemistry</i> , 2014, 21, 3007-3008.	1.2	11
10	Cell Cycle Control by Natural Phenols in Cisplatin-Resistant Cell Lines. <i>Natural Product Communications</i> , 2014, 9, 1934578X1400901.	0.2	10
11	E3 Ubiquitin Ligase HOIP Attenuates Apoptotic Cell Death Induced by Cisplatin. <i>Cancer Research</i> , 2014, 74, 2246-2257.	0.4	61
12	Establishment and characterization of a cisplatin-resistant human osteosarcoma cell line. <i>Oncology Reports</i> , 2014, 32, 1133-1139.	1.2	10
13	MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer. <i>BMC Cancer</i> , 2014, 14, 837.	1.1	52
14	When Will Resistance Be Futile?. <i>Cancer Research</i> , 2014, 74, 7175-7180.	0.4	5
15	From computational modelling of the intrinsic apoptosis pathway to a systems-based analysis of chemotherapy resistance: achievements, perspectives and challenges in systems medicine. <i>Cell Death and Disease</i> , 2014, 5, e1258-e1258.	2.7	30
16	IGFBP7 induces apoptosis of acute myeloid leukemia cells and synergizes with chemotherapy in suppression of leukemia cell survival. <i>Cell Death and Disease</i> , 2014, 5, e1300-e1300.	2.7	28
17	Acquisition of epithelial-mesenchymal transition is associated with Skp2 expression in paclitaxel-resistant breast cancer cells. <i>British Journal of Cancer</i> , 2014, 110, 1958-1967.	2.9	90
18	Acquired resistance to metformin in breast cancer cells triggers transcriptome reprogramming toward a degradome-related metastatic stem-like profile. <i>Cell Cycle</i> , 2014, 13, 1132-1144.	1.3	57

#	ARTICLE	IF	CITATIONS
19	Sphingolipids: Key Regulators of Apoptosis and Pivotal Players in Cancer Drug Resistance. <i>International Journal of Molecular Sciences</i> , 2014, 15, 4356-4392.	1.8	94
20	Resistance to dual blockade of the kinases PI3K and mTOR in <i>KRAS</i> -mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR. <i>Science Signaling</i> , 2014, 7, ra107.	1.6	30
21	Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies. <i>International Journal of Molecular Sciences</i> , 2014, 15, 13768-13801.	1.8	174
22	Cancer Microenvironments as Therapeutic Targets. , 2014, , 412-422.		0
23	Drug Resistance in Cancer: An Overview. <i>Cancers</i> , 2014, 6, 1769-1792.	1.7	1,810
24	ABC transporters in CSCs membranes as a novel target for treating tumor relapse. <i>Frontiers in Pharmacology</i> , 2014, 5, 163.	1.6	58
26	Cancer stem cells – important players in tumor therapy resistance. <i>FEBS Journal</i> , 2014, 281, 4779-4791.	2.2	225
27	DNA synthesis inhibitors for the treatment of gastrointestinal cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 2361-2372.	0.9	4
28	Nano-Oncologicals. <i>Advances in Delivery Science and Technology</i> , 2014, , .	0.4	7
29	Design and Synthesis of Pironetin Analogue/Colchicine Hybrids and Study of Their Cytotoxic Activity and Mechanisms of Interaction with Tubulin. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 10391-10403.	2.9	46
31	Mild thermotolerance induced at 40%°C protects cells against hyperthermia-induced pro-apoptotic changes in Bcl-2 family proteins. <i>International Journal of Hyperthermia</i> , 2014, 30, 502-512.	1.1	20
32	A short update on cancer chemoresistance. <i>Wiener Medizinische Wochenschrift</i> , 2014, 164, 456-460.	0.5	29
33	Aurora-A contributes to cisplatin resistance and lymphatic metastasis in non-small cell lung cancer and predicts poor prognosis. <i>Journal of Translational Medicine</i> , 2014, 12, 200.	1.8	55
34	Estrogen receptor mutations and their role in breast cancer progression. <i>Breast Cancer Research</i> , 2014, 16, 494.	2.2	83
35	Implementing precision medicine initiatives in the clinic. <i>Current Opinion in Oncology</i> , 2014, 26, 340-346.	1.1	17
36	Multidrug resistance in fungi: regulation of transporter-encoding gene expression. <i>Frontiers in Physiology</i> , 2014, 5, 143.	1.3	112
37	Multimodal Nano-Systems for Cancer Diagnosis, Imaging, and Therapy. <i>Advances in Delivery Science and Technology</i> , 2014, , 351-388.	0.4	0
38	A Metabonomic Study of the Effect of Methanol Extract of Ginger on Raji Cells Using ¹ HNMR Spectroscopy. <i>Biotechnology Research International</i> , 2014, 2014, 1-8.	1.4	9

#	ARTICLE	IF	CITATIONS
39	The role of ABC transporters in anticancer drug transport. Turkish Journal of Biology, 2014, 38, 800-805.	2.1	9
40	Design and Synthesis of Pironetin Analogue/Combretastatin A β Hybrids and Evaluation of Their Cytotoxic Activity. European Journal of Organic Chemistry, 2014, 2014, 2284-2296.	1.2	13
41	Stress-induced cellular adaptive strategies: Ancient evolutionarily conserved programs as new anticancer therapeutic targets. BioEssays, 2014, 36, 552-560.	1.2	9
42	Metastatic Stem Cells: Sources, Niches, and Vital Pathways. Cell Stem Cell, 2014, 14, 306-321.	5.2	591
43	The paradigm of mutant p53-expressing cancer stem cells and drug resistance. Carcinogenesis, 2014, 35, 1196-1208.	1.3	87
44	HCC cells with high levels of Bcl-2 are resistant to ABT-737 via activation of the ROS-JNK autophagy pathway. Free Radical Biology and Medicine, 2014, 70, 194-203.	1.3	76
45	The Cancer Stem Cell Marker Aldehyde Dehydrogenase Is Required to Maintain a Drug-Tolerant Tumor Cell Subpopulation. Cancer Research, 2014, 74, 3579-3590.	0.4	238
47	Cancer stem cells: A contentious hypothesis now moving forward. Cancer Letters, 2014, 344, 180-187.	3.2	217
48	Determining Drug Efficacy Using Plasmonically Enhanced Imaging of the Morphological Changes of Cells upon Death. Journal of Physical Chemistry Letters, 2014, 5, 3514-3518.	2.1	4
49	Dual drug loaded vitamin D3 nanoparticle to target drug resistance in cancer. RSC Advances, 2014, 4, 57271-57281.	1.7	11
50	Mitochondria-Targeted Cancer Therapy Using a Light-Up Probe with Aggregation-Induced Emission Characteristics. Angewandte Chemie - International Edition, 2014, 53, 14225-14229.	7.2	361
51	Glioblastoma cells inhibit astrocytic p53-expression favoring cancer malignancy. Oncogenesis, 2014, 3, e123-e123.	2.1	44
52	Eine niedermolekulare Verbindung inhibiert die Proteindisulfidomerase und sensibilisiert Krebszellen für die Chemotherapie. Angewandte Chemie, 2014, 126, 13174-13179.	1.6	5
53	Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine. Genome Biology, 2014, 15, 453.	3.8	180
54	Combinatorial delivery of Crizotinib-Palbociclib-Sildenafil using TPGS-PLA micelles for improved cancer treatment. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 88, 718-729.	2.0	53
55	SET-mediated NDRG1 inhibition is involved in acquisition of epithelial-to-mesenchymal transition phenotype and cisplatin resistance in human lung cancer cell. Cellular Signalling, 2014, 26, 2710-2720.	1.7	31
56	Ursolic acid triggers nonprogrammed death (necrosis) in human glioblastoma multiforme DBTRG-G05MG cells through MPT pore opening and ATP decline. Molecular Nutrition and Food Research, 2014, 58, 2146-2156.	1.5	30
57	A Small Molecule Inhibits Protein Disulfide Isomerase and Triggers the Chemosensitization of Cancer Cells. Angewandte Chemie - International Edition, 2014, 53, 12960-12965.	7.2	23

#	ARTICLE	IF	CITATIONS
58	Design and synthesis of pironetin analogue/combretastatin A-4 hybrids containing a 1,2,3-triazole ring and evaluation of their cytotoxic activity. <i>European Journal of Medicinal Chemistry</i> , 2014, 87, 125-130.	2.6	27
59	Targeting the microRNA-regulating DNA damage/repair pathways in cancer. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 1667-1683.	1.4	36
60	Identification of Mitochondria-Targeting Anticancer Compounds by an <i>in Vitro</i> Strategy. <i>Analytical Chemistry</i> , 2014, 86, 5232-5237.	3.2	28
61	Caveolin-1 mediates chemoresistance in breast cancer stem cells via β -catenin/ABCG2 signaling pathway. <i>Carcinogenesis</i> , 2014, 35, 2346-2356.	1.3	75
62	Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells. <i>Cancer Cell</i> , 2014, 26, 207-221.	7.7	452
63	Lentiviral Vector-based Insertional Mutagenesis Identifies Genes Involved in the Resistance to Targeted Anticancer Therapies. <i>Molecular Therapy</i> , 2014, 22, 2056-2068.	3.7	16
64	Targeting Cancer Stem-like Cells as an Approach to Defeating Cellular Heterogeneity in Ewing Sarcoma. <i>Cancer Research</i> , 2014, 74, 6610-6622.	0.4	28
65	Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: Current progress and advances. <i>Journal of Controlled Release</i> , 2014, 194, 238-256.	4.8	318
66	Is target validation all we need?. <i>Current Opinion in Pharmacology</i> , 2014, 17, 81-86.	1.7	5
67	Poised epigenetic states and acquired drug resistance in cancer. <i>Nature Reviews Cancer</i> , 2014, 14, 747-753.	12.8	252
68	Finding needles in a haystack: recognition of mismatched base pairs in DNA by small molecules. <i>Chemical Society Reviews</i> , 2014, 43, 3630.	18.7	97
69	<i>In vivo</i> RNAi screening identifies a mechanism of sorafenib resistance in liver cancer. <i>Nature Medicine</i> , 2014, 20, 1138-1146.	15.2	242
70	Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies. <i>Journal of Molecular Medicine</i> , 2014, 92, 709-722.	1.7	75
71	Targeted therapies in cancer and mechanisms of resistance. <i>Journal of Molecular Medicine</i> , 2014, 92, 677-679.	1.7	6
72	Immune regulation of therapy-resistant niches: emerging targets for improving anticancer drug responses. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 737-745.	2.7	10
73	Tumour heterogeneity and the evolution of polyclonal drug resistance. <i>Molecular Oncology</i> , 2014, 8, 1095-1111.	2.1	347
74	Multi-marker analysis of circulating cell-free DNA toward personalized medicine for colorectal cancer. <i>Molecular Oncology</i> , 2014, 8, 927-941.	2.1	192
75	Engineered microenvironments provide new insights into ovarian and prostate cancer progression and drug responses. <i>Advanced Drug Delivery Reviews</i> , 2014, 79-80, 193-213.	6.6	45

#	ARTICLE	IF	CITATIONS
76	Priming cancer cells for drug resistance: role of the fibroblast niche. <i>Frontiers in Biology</i> , 2014, 9, 114-126.	0.7	27
77	Analysis of the Lipidome of Xenografts Using MALDI-IMS and UHPLC-ESI-QTOF. <i>Journal of the American Society for Mass Spectrometry</i> , 2014, 25, 1237-1246.	1.2	20
78	Epigenetics of cancer stem cells: Pathways and therapeutics. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2014, 1840, 3494-3502.	1.1	113
79	Evaluation of one- and two-photon activated photodynamic therapy with pyropheophorbide-a methyl ester in human cervical, lung and ovarian cancer cells. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2014, 132, 102-110.	1.7	23
80	Molecular Mechanisms of Angiogenesis. , 2014, , .		5
81	Folding graft copolymer with pendant drug segments for co-delivery of anticancer drugs. <i>Biomaterials</i> , 2014, 35, 7194-7203.	5.7	71
82	The pharmacological point of view of resistance to therapy in tumors. <i>Cancer Treatment Reviews</i> , 2014, 40, 909-916.	3.4	39
83	Nano carriers that enable co-delivery of chemotherapy and RNAi agents for treatment of drug-resistant cancers. <i>Biotechnology Advances</i> , 2014, 32, 1037-1050.	6.0	110
84	The novel bis-benzylisoquinoline PY35 reverses P-glycoprotein-mediated multidrug resistance. <i>Oncology Reports</i> , 2014, 32, 1211-1217.	1.2	6
85	Challenge to Solid Cancer Treatment Using <i>Bifidobacterium</i> . <i>Japanese Journal of Lactic Acid Bacteria</i> , 2014, 25, 18-23.	0.1	0
86	New trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapies. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 159.	3.5	72
87	Protecting the normal in order to better kill the cancer. <i>Cancer Medicine</i> , 2015, 4, 1394-1403.	1.3	84
88	Signaling pathways in HPV-associated cancers and therapeutic implications. <i>Reviews in Medical Virology</i> , 2015, 25, 24-53.	3.9	77
89	Basal expression of insulin-like growth factor 1 receptor determines intrinsic resistance of cancer cells to a phosphatidylinositol 3-kinase inhibitor ZSTK474. <i>Cancer Science</i> , 2015, 106, 171-178.	1.7	12
90	The importance of molecular markers for diagnosis and selection of targeted treatments in patients with cancer. <i>Journal of Internal Medicine</i> , 2015, 278, 545-570.	2.7	46
92	High-Throughput Cancer Cell Sphere Formation for Characterizing the Efficacy of Photo Dynamic Therapy in 3D Cell Cultures. <i>Scientific Reports</i> , 2015, 5, 12175.	1.6	85
93	Poly-nitrosated human albumin enhances the antitumor and antimetastasis effect of bevacizumab, partly by inhibiting autophagy through the generation of nitric oxide. <i>Cancer Science</i> , 2015, 106, 194-200.	1.7	24
94	Silencing of RUNX2 enhances gemcitabine sensitivity of p53-deficient human pancreatic cancer AsPC-1 cells through the stimulation of TAp63-mediated cell death. <i>Cell Death Discovery</i> , 2015, 1, 15010.	2.0	14

#	ARTICLE	IF	CITATIONS
97	<sc>ZEB</sc> 1-associated drug resistance in cancer cells is reversed by the class I <sc>HDAC</sc> inhibitor mocetinostat. EMBO Molecular Medicine, 2015, 7, 831-847.	3.3	191
98	Breast cancer resistance protein (BCRP)-containing circulating microvesicles contribute to chemoresistance in breast cancer. Oncology Letters, 2015, 10, 3742-3748.	0.8	36
99	Photoacoustic 1nanobombs1fight against undesirable vesicular compartmentalization of anticancer drugs. Scientific Reports, 2015, 5, 15527.	1.6	13
101	Targeting Breast Cancer Metastasis. Breast Cancer: Basic and Clinical Research, 2015, 9s1, BCBCR.S25460.	0.6	145
102	Evaluation of drug-targetable genes by defining modes of abnormality in gene expression. Scientific Reports, 2015, 5, 13576.	1.6	12
103	Pan-Bcl-2 inhibitor Obatoclax is a potent late stage autophagy inhibitor in colorectal cancer cells independent of canonical autophagy signaling. BMC Cancer, 2015, 15, 919.	1.1	27
104	Reinvention of chemotherapy. Current Opinion in Oncology, 2015, 27, 232-242.	1.1	12
105	Modeling drug resistance in a conjoint normal-tumor setting. Theoretical Biology and Medical Modelling, 2015, 12, 3.	2.1	5
106	Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds. BMC Cancer, 2015, 15, 910.	1.1	21
108	IL-12 Augments Antitumor Responses to Cycled Chemotherapy. Journal of Immunotherapy, 2015, 38, 137-144.	1.2	11
109	Enzymatic Prenylation and Oxime Ligation for the Synthesis of Stable and Homogeneous Protein1Drug Conjugates for Targeted Therapy. Angewandte Chemie - International Edition, 2015, 54, 12020-12024.	7.2	67
110	Near1Infrared Light1Absorptive Stealth Liposomes for Localized Photothermal Ablation of Tumors Combined with Chemotherapy. Advanced Functional Materials, 2015, 25, 5602-5610.	7.8	65
111	Effect of Shape, Size, and Aspect Ratio on Nanoparticle Penetration and Distribution inside Solid Tissues Using 3D Spheroid Models. Advanced Healthcare Materials, 2015, 4, 2269-2280.	3.9	111
113	3.5 Current Trends and Developments for Nanotechnology in Cancer. , 2015, , 290-342.		0
114	Knockdown of the Inhibitor of Apoptosis BRUCE Sensitizes Resistant Breast Cancer Cells to Chemotherapeutic Agents. Journal of Cancer Science & Therapy, 2015, 07, 121-126.	1.7	9
115	Small-molecule BH3 mimetic and pan-Bcl-2 inhibitor AT-101 enhances the antitumor efficacy of cisplatin through inhibition of APE1 repair and redox activity in non-small-cell lung cancer. Drug Design, Development and Therapy, 2015, 9, 2887.	2.0	20
116	Engineering Nanomedicines to Overcome Multidrug Resistance in Cancer Therapy. Current Medicinal Chemistry, 2015, 23, 3-22.	1.2	29
117	p27Kip1 and Ser10-phosphorylated p27Kip1 in breast cancer: clinical significance and expression. OncoTargets and Therapy, 2015, 8, 1863.	1.0	1

#	ARTICLE	IF	CITATIONS
118	Crosstalk with cancer-associated fibroblasts induces resistance of non-small cell lung cancer cells to epidermal growth factor receptor tyrosine kinase inhibition. <i>OncoTargets and Therapy</i> , 2015, 8, 3665.	1.0	54
119	Akt inhibition improves irinotecan treatment and prevents cell emergence by switching the senescence response to apoptosis. <i>Oncotarget</i> , 2015, 6, 43342-43362.	0.8	27
120	Mitochondrial Transcription Factor A and Mitochondrial Genome as Molecular Targets for Cisplatin-Based Cancer Chemotherapy. <i>International Journal of Molecular Sciences</i> , 2015, 16, 19836-19850.	1.8	23
121	Combined Treatments with Photodynamic Therapy for Non-Melanoma Skin Cancer. <i>International Journal of Molecular Sciences</i> , 2015, 16, 25912-25933.	1.8	111
122	DNA Repair—A Double-Edged Sword in the Genomic Stability of Cancer Cells—The Case of Chronic Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2015, 16, 27535-27549.	1.8	25
123	EpCAM Aptamer-mediated Survivin Silencing Sensitized Cancer Stem Cells to Doxorubicin in a Breast Cancer Model. <i>Theranostics</i> , 2015, 5, 1456-1472.	4.6	84
124	Esculetin, a coumarin derivative, exerts in vitro and in vivo antiproliferative activity against hepatocellular carcinoma by initiating a mitochondrial-dependent apoptosis pathway. <i>Brazilian Journal of Medical and Biological Research</i> , 2015, 48, 245-253.	0.7	55
125	Collateral Chemoresistance to Anti-Microtubule Agents in a Lung Cancer Cell Line with Acquired Resistance to Erlotinib. <i>PLoS ONE</i> , 2015, 10, e0123901.	1.1	12
126	Selective Cytotoxicity of 1,3,4-Thiadiazolium Mesoionic Derivatives on Hepatocarcinoma Cells (HepG2). <i>PLoS ONE</i> , 2015, 10, e0130046.	1.1	13
127	Aptamer-Dendrimer Bioconjugates for Targeted Delivery of miR-34a Expressing Plasmid and Antitumor Effects in Non-Small Cell Lung Cancer Cells. <i>PLoS ONE</i> , 2015, 10, e0139136.	1.1	65
128	Downregulation of Choline Kinase-Alpha Enhances Autophagy in Tamoxifen-Resistant Breast Cancer Cells. <i>PLoS ONE</i> , 2015, 10, e0141110.	1.1	14
129	Developing multi-target therapeutics to fine-tune the evolutionary dynamics of the cancer ecosystem. <i>Frontiers in Pharmacology</i> , 2015, 6, 209.	1.6	47
130	Cytotoxicity of the Sesquiterpene Lactones Neoambrosin and Damsin from <i>Ambrosia maritima</i> Against Multidrug-Resistant Cancer Cells. <i>Frontiers in Pharmacology</i> , 2015, 6, 267.	1.6	41
131	Targeting Apoptosis and Multiple Signaling Pathways with Icariside II in Cancer Cells. <i>International Journal of Biological Sciences</i> , 2015, 11, 1100-1112.	2.6	116
132	Indirubin and Indirubin Derivatives for Counteracting Proliferative Diseases. <i>Evidence-based Complementary and Alternative Medicine</i> , 2015, 2015, 1-12.	0.5	52
133	The Affymetrix DMET Plus Platform Reveals Unique Distribution of ADME-Related Variants in Ethnic Arabs. <i>Disease Markers</i> , 2015, 2015, 1-8.	0.6	8
134	Cytotoxic Effect of <i>Coscinium fenestratum</i> on Human Head and Neck Cancer Cell Line (HN31). <i>Evidence-based Complementary and Alternative Medicine</i> , 2015, 2015, 1-8.	0.5	3
135	Lysosomal sequestration of hydrophobic weak base chemotherapeutics triggers lysosomal biogenesis and lysosome-dependent cancer multidrug resistance. <i>Oncotarget</i> , 2015, 6, 1143-1156.	0.8	171

#	ARTICLE	IF	CITATIONS
136	Caveolin-1, a stress-related oncotarget, in drug resistance. <i>Oncotarget</i> , 2015, 6, 37135-37150.	0.8	57
137	Identification of short-form RON as a novel intrinsic resistance mechanism for anti-MET therapy in MET-positive gastric cancer. <i>Oncotarget</i> , 2015, 6, 40519-40534.	0.8	16
138	Signal Transduction in Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2015, 5, a006098-a006098.	2.9	665
139	Enhancement of oxaliplatin-induced cell apoptosis and tumor suppression by 3-methyladenine in colon cancer. <i>Oncology Letters</i> , 2015, 9, 2056-2062.	0.8	30
140	GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1. <i>Scientific Reports</i> , 2015, 5, 9489.	1.6	77
141	The Roles of MicroRNAs in Breast Cancer. <i>Cancers</i> , 2015, 7, 598-616.	1.7	125
142	Thymidylate synthase expression in circulating tumor cells: A new tool to predict 5-Fluorouracil resistance in metastatic colorectal cancer patients. <i>International Journal of Cancer</i> , 2015, 137, 1397-1405.	2.3	52
143	Sub-chronic administration of LY294002 sensitizes cervical cancer cells to chemotherapy by enhancing mitochondrial JNK signaling. <i>Biochemical and Biophysical Research Communications</i> , 2015, 463, 538-544.	1.0	9
144	Src/STAT3-dependent heme oxygenase-1 induction mediates chemoresistance of breast cancer cells to doxorubicin by promoting autophagy. <i>Cancer Science</i> , 2015, 106, 1023-1032.	1.7	104
145	2-Deoxy-D-Glucose Sensitizes Human Ovarian Cancer Cells to Cisplatin by Increasing ER Stress and Decreasing ATP Stores in Acidic Vesicles. <i>Journal of Biochemical and Molecular Toxicology</i> , 2015, 29, 572-578.	1.4	9
146	Redox-Responsive Polyphosphoester-Based Micellar Nanomedicines for Overriding Chemoresistance in Breast Cancer Cells. <i>ACS Applied Materials & Interfaces</i> , 2015, 7, 26315-26325.	4.0	48
147	The inhibition of NF- κ B activation decreases the resistance of acute myeloid leukemia cells to TRAIL-induced apoptosis in multicellular aggregates. <i>Biophysics (Russian Federation)</i> , 2015, 60, 953-956.	0.2	3
148	Plant-Derived Polyphenols. <i>Advances in Molecular Toxicology</i> , 2015, 9, 161-214.	0.4	27
149	Nitroreductase gene-directed enzyme prodrug therapy: insights and advances toward clinical utility. <i>Biochemical Journal</i> , 2015, 471, 131-153.	1.7	111
150	Cell aggregation increases drug resistance of acute myeloid leukemia cells. <i>Biochemistry (Moscow) Supplement Series A: Membrane and Cell Biology</i> , 2015, 9, 135-143.	0.3	1
151	Molecular aspects of breast cancer resistance to drugs (Review). <i>International Journal of Oncology</i> , 2015, 47, 437-445.	1.4	20
152	Isorhamnetin inhibits cell proliferation and induces apoptosis in breast cancer via Akt and mitogen-activated protein kinase signaling pathways. <i>Molecular Medicine Reports</i> , 2015, 12, 6745-6751.	1.1	61
153	EGF inhibits constitutive internalization and palmitoylation-dependent degradation of membrane-spanning procancer CDCP1 promoting its availability on the cell surface. <i>Oncogene</i> , 2015, 34, 1375-1383.	2.6	33

#	ARTICLE	IF	CITATIONS
154	CancerPPD: a database of anticancer peptides and proteins. <i>Nucleic Acids Research</i> , 2015, 43, D837-D843.	6.5	253
155	A novel series of thiazolyl-pyrazoline derivatives: Synthesis and evaluation of antifungal activity, cytotoxicity and genotoxicity. <i>European Journal of Medicinal Chemistry</i> , 2015, 92, 342-352.	2.6	71
156	Integrative analysis of cancer imaging readouts by networks. <i>Molecular Oncology</i> , 2015, 9, 1-16.	2.1	16
157	The value of monitoring to control evolving populations. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 1007-1012.	3.3	50
158	Synthesis and Biological Evaluation of Indolyl-Pyridinyl-Propenones Having Either Methuosis or Microtubule Disruption Activity. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 2489-2512.	2.9	36
159	Cell of Origin for Malignant Gliomas and Its Implication in Therapeutic Development. <i>Cold Spring Harbor Perspectives in Biology</i> , 2015, 7, a020610.	2.3	163
160	ZEB1: At the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance. <i>Cell Cycle</i> , 2015, 14, 481-487.	1.3	482
161	Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts. <i>Journal of Controlled Release</i> , 2015, 205, 144-154.	4.8	250
162	Antitumor activity of an anti-CD98 antibody. <i>International Journal of Cancer</i> , 2015, 137, 710-720.	2.3	51
163	Nanocarrier-mediated drugs targeting cancer stem cells: an emerging delivery approach. <i>Expert Opinion on Drug Delivery</i> , 2015, 12, 1177-1201.	2.4	15
164	Translational Horizons in the Tumor Microenvironment: Harnessing Breakthroughs and Targeting Cures. <i>Medicinal Research Reviews</i> , 2015, 35, 408-36.	5.0	62
165	Understanding cancer and the anticancer activities of naphthoquinones – a review. <i>RSC Advances</i> , 2015, 5, 20309-20338.	1.7	240
166	Suppression of cancer relapse and metastasis by inhibiting cancer stemness. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 1839-1844.	3.3	380
167	The Upregulation of PI3K/Akt and MAP Kinase Pathways is Associated with Resistance of Microtubule-Targeting Drugs in Prostate Cancer. <i>Journal of Cellular Biochemistry</i> , 2015, 116, 1341-1349.	1.2	97
168	Emergence of Drug Tolerance in Cancer Cell Populations: An Evolutionary Outcome of Selection, Nongenetic Instability, and Stress-Induced Adaptation. <i>Cancer Research</i> , 2015, 75, 930-939.	0.4	120
169	Unexpected Off-Targets and Paradoxical Pathway Activation by Kinase Inhibitors. <i>ACS Chemical Biology</i> , 2015, 10, 234-245.	1.6	52
170	Combination delivery of Adjuvin and Doxorubicin via integrating drug conjugation and nanocarrier approaches for the treatment of drug-resistant cancer cells. <i>Journal of Materials Chemistry B</i> , 2015, 3, 1556-1564.	2.9	55
171	Self-Assembled Core-Shell Nanoparticles for Combined Chemotherapy and Photodynamic Therapy of Resistant Head and Neck Cancers. <i>ACS Nano</i> , 2015, 9, 991-1003.	7.3	247

#	ARTICLE	IF	CITATIONS
172	Enzymatically and Reductively Degradable α -Amino Acid-Based Poly(ester amide)s: Synthesis, Cell Compatibility, and Intracellular Anticancer Drug Delivery. <i>Biomacromolecules</i> , 2015, 16, 597-605.	2.6	51
173	Using tumour phylogenetics to identify the roots of metastasis in humans. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 258-272.	12.5	122
174	Systemic treatment of advanced hepatocellular carcinoma: From disillusion to new horizons. <i>European Journal of Cancer</i> , 2015, 51, 327-339.	1.3	63
175	Oxidatively induced DNA damage and its repair in cancer. <i>Mutation Research - Reviews in Mutation Research</i> , 2015, 763, 212-245.	2.4	191
176	Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapy. <i>Oncogene</i> , 2015, 34, 1083-1093.	2.6	29
177	The Apoptotic Mechanism of Action of the Sphingosine Kinase 1 Selective Inhibitor SKI-178 in Human Acute Myeloid Leukemia Cell Lines. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015, 352, 494-508.	1.3	40
178	Anticancer drug nanomicelles formed by self-assembling amphiphilic dendrimer to combat cancer drug resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 2978-2983.	3.3	318
179	Influence of P-Glycoprotein Inhibition or Deficiency at the Blood-Brain Barrier on 18F-2-Fluoro-2-Deoxy-d-glucose (18F-FDG) Brain Kinetics. <i>AAPS Journal</i> , 2015, 17, 652-659.	2.2	6
180	PGRMC1 contributes to doxorubicin-induced chemoresistance in MES-SA uterine sarcoma. <i>Cellular and Molecular Life Sciences</i> , 2015, 72, 2395-2409.	2.4	32
181	miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. <i>Cell Research</i> , 2015, 25, 477-495.	5.7	75
182	The Role of Matrix Compliance on Cell Responses to Drugs and Toxins: Towards Predictive Drug Screening Platforms. <i>Macromolecular Bioscience</i> , 2015, 15, 589-599.	2.1	14
183	Repression of Nrf2 enhances antitumor effect of 5-fluorouracil and gemcitabine on cholangiocarcinoma cells. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2015, 388, 601-612.	1.4	19
184	Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules. <i>Cancer Cell</i> , 2015, 28, 82-96.	7.7	125
185	Imperfect drug penetration leads to spatial monotherapy and rapid evolution of multidrug resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E2874-83.	3.3	142
186	N-of-1 trials in oncology. <i>Lancet Oncology</i> , The, 2015, 16, 885-886.	5.1	18
187	Notch Pathway Inhibition Using PF-03084014, a γ -Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 4619-4629.	3.2	73
188	Aloe-emodin exerts a potent anticancer and immunomodulatory activity on BRAF-mutated human melanoma cells. <i>European Journal of Pharmacology</i> , 2015, 762, 283-292.	1.7	43
189	Evolutionary Determinants of Cancer. <i>Cancer Discovery</i> , 2015, 5, 806-820.	7.7	350

#	ARTICLE	IF	CITATIONS
190	Anti-tumoral activity of human salivary peptides. <i>Peptides</i> , 2015, 71, 170-178.	1.2	10
191	Quantitative interactome analysis reveals a chemoresistant edgotype. <i>Nature Communications</i> , 2015, 6, 7928.	5.8	77
192	<i>miR-634</i> Activates the Mitochondrial Apoptosis Pathway and Enhances Chemotherapy-Induced Cytotoxicity. <i>Cancer Research</i> , 2015, 75, 3890-3901.	0.4	50
193	Phosphodiesterase Type 5 as a Candidate Therapeutic Target in Cancers. <i>Current Pathobiology Reports</i> , 2015, 3, 193-201.	1.6	8
194	Exploring the size adaptability of the B ring binding zone of the colchicine site of tubulin with para-nitrogen substituted isocombretastatins. <i>European Journal of Medicinal Chemistry</i> , 2015, 100, 210-222.	2.6	27
195	APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells. <i>Cell Death and Disease</i> , 2015, 6, e1794-e1794.	2.7	151
196	An overview of nanotoxicity and nanomedicine research: principles, progress and implications for cancer therapy. <i>Journal of Materials Chemistry B</i> , 2015, 3, 7153-7172.	2.9	108
197	Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms. <i>Nature Reviews Genetics</i> , 2015, 16, 459-471.	7.7	201
198	New approach to develop ultra-high inhibitory drug using the power function of the stoichiometry of the targeted nanomachine or biocomplex. <i>Nanomedicine</i> , 2015, 10, 1881-1897.	1.7	9
199	Chronic hepatitis B: A wave of new therapies on the horizon. <i>Antiviral Research</i> , 2015, 121, 69-81.	1.9	65
200	Recent advances in cyclodextrin delivery techniques. <i>Expert Opinion on Drug Delivery</i> , 2015, 12, 1425-1441.	2.4	44
201	Co-delivery of doxorubicin and PEGylated C16-ceramide by nanoliposomes for enhanced therapy against multidrug resistance. <i>Nanomedicine</i> , 2015, 10, 2033-2050.	1.7	38
202	H3K9 Trimethylation Silences Fas Expression To Confer Colon Carcinoma Immune Escape and 5-Fluorouracil Chemoresistance. <i>Journal of Immunology</i> , 2015, 195, 1868-1882.	0.4	86
203	Addiction to MTH1 protein results in intense expression in human breast cancer tissue as measured by liquid chromatography-isotope-dilution tandem mass spectrometry. <i>DNA Repair</i> , 2015, 33, 101-110.	1.3	29
204	Effects of microRNA-221/222 on cell proliferation and apoptosis in prostate cancer cells. <i>Gene</i> , 2015, 572, 252-258.	1.0	49
205	Tumor Cells Chronically Treated with a Trastuzumab-Maytansinoid Antibody-Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 952-963.	1.9	158
206	Synthesis and antileukemic activities of C1-C10-modified parthenolide analogues. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 4737-4745.	1.4	23
207	Exosomes derived from human mesenchymal stem cells confer drug resistance in gastric cancer. <i>Cell Cycle</i> , 2015, 14, 2473-2483.	1.3	181

#	ARTICLE	IF	CITATIONS
208	Tid1, the Mammalian Homologue of Drosophila Tumor Suppressor Tid56, Mediates Macroautophagy by Interacting with Beclin1-containing Autophagy Protein Complex. <i>Journal of Biological Chemistry</i> , 2015, 290, 18102-18110.	1.6	12
209	Spatial Heterogeneity in Drug Concentrations Can Facilitate the Emergence of Resistance to Cancer Therapy. <i>PLoS Computational Biology</i> , 2015, 11, e1004142.	1.5	100
210	Evaluation of the pharmacokinetics of ixabepilone for the treatment of breast cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1177-1185.	1.5	11
211	BRD4 Inhibitor Inhibits Colorectal Cancer Growth and Metastasis. <i>International Journal of Molecular Sciences</i> , 2015, 16, 1928-1948.	1.8	77
212	Targeting cancer with kinase inhibitors. <i>Journal of Clinical Investigation</i> , 2015, 125, 1780-1789.	3.9	364
213	Host effects contributing to cancer therapy resistance. <i>Drug Resistance Updates</i> , 2015, 19, 33-42.	6.5	38
214	Multiscale characterization of ageing and cancer progression by a novel network entropy measure. <i>Molecular BioSystems</i> , 2015, 11, 1824-1831.	2.9	22
215	Design and evaluation of a peptide-based immunotoxin for breast cancer therapeutics. <i>FEBS Open Bio</i> , 2015, 5, 202-208.	1.0	6
216	The design, synthesis and biological evaluation of conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multi-targeted receptor tyrosine kinase and microtubule inhibitors as potential antitumor agents. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 2408-2423.	1.4	32
217	Beyond 3D culture models of cancer. <i>Science Translational Medicine</i> , 2015, 7, 283ps9.	5.8	80
218	Drug testing in the patient: Toward personalized cancer treatment. <i>Science Translational Medicine</i> , 2015, 7, 284ps10.	5.8	13
219	Phenotypic screening of a library of compounds against metastatic and non-metastatic clones of a canine mammary gland tumour cell line. <i>Veterinary Journal</i> , 2015, 205, 288-296.	0.6	6
220	Clinical observations on chemotherapy curable malignancies: unique genetic events, frozen development and enduring apoptotic potential. <i>BMC Cancer</i> , 2015, 15, 11.	1.1	9
221	In vitro and in vivo antiproliferative activity of metformin on stem-like cells isolated from spontaneous canine mammary carcinomas: translational implications for human tumors. <i>BMC Cancer</i> , 2015, 15, 228.	1.1	47
222	New horizons in tumor microenvironment biology: challenges and opportunities. <i>BMC Medicine</i> , 2015, 13, 45.	2.3	535
223	CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma. <i>Molecular Cancer</i> , 2015, 14, 44.	7.9	38
224	Molecular Imaging of Membrane Transporters' Activity in Cancer: a Picture is Worth a Thousand Tubes. <i>AAPS Journal</i> , 2015, 17, 788-801.	2.2	21
225	Autophagy in Cancer Stem Cells: A Potential Link Between Chemoresistance, Recurrence, and Metastasis. <i>BioResearch Open Access</i> , 2015, 4, 97-108.	2.6	130

#	ARTICLE	IF	CITATIONS
226	Cinnamaldehyde Derivative (CB-PIC) Sensitizes Chemo-Resistant Cancer Cells to Drug-Induced Apoptosis via Suppression of MDR1 and its Upstream STAT3 and AKT Signalling. Cellular Physiology and Biochemistry, 2015, 35, 1821-1830.	1.1	56
227	Resistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategies. Frontiers of Medicine, 2015, 9, 134-138.	1.5	37
228	Isolation and characterization of PDT-resistant cancer cells. Photochemical and Photobiological Sciences, 2015, 14, 1378-1389.	1.6	23
229	Enzyme-Instructed Self-Assembly: A Multistep Process for Potential Cancer Therapy. Bioconjugate Chemistry, 2015, 26, 987-999.	1.8	127
230	The Role of C/EBP- β LIP in Multidrug Resistance. Journal of the National Cancer Institute, 2015, 107, .	3.0	39
231	pH-Responsive Chimaeric Pepsomes Based on Asymmetric Poly(ethylene) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 552 Td (glyco) Copolymer for Efficient Loading and Active Intracellular Delivery of Doxorubicin Hydrochloride. Biomacromolecules, 2015, 16, 1322-1330.	2.6	61
232	The role of photodynamic therapy in overcoming cancer drug resistance. Photochemical and Photobiological Sciences, 2015, 14, 1476-1491.	1.6	242
233	Metastasis prevention by targeting the dormant niche. Nature Reviews Cancer, 2015, 15, 238-247.	12.8	279
234	Therapy-induced tumour secretomes promote resistance and tumour progression. Nature, 2015, 520, 368-372.	13.7	389
235	In vitro and in vivo Anticancer Effects of a Novel 9-Phenyldibenzo[a,c]phenazin-9-ium Cation and Its Ligands. Chemotherapy, 2015, 60, 261-266.	0.8	0
236	The emerging molecular machinery and therapeutic targets of metastasis. Trends in Pharmacological Sciences, 2015, 36, 349-359.	4.0	52
237	A pH-responsive natural cyclopeptide RA-V drug formulation for improved breast cancer therapy. Journal of Materials Chemistry B, 2015, 3, 4514-4523.	2.9	17
238	Induction of Human UDP-Glucuronosyltransferase 2B7 Gene Expression by Cytotoxic Anticancer Drugs in Liver Cancer HepG2 Cells. Drug Metabolism and Disposition, 2015, 43, 660-668.	1.7	25
239	A bispecific fusion protein and a bifunctional enediyne-energized fusion protein consisting of TRAIL, EGFR peptide ligand, and apoprotein of lidamycin against EGFR and DR4/5 show potent antitumor activity. Anti-Cancer Drugs, 2015, 26, 64-73.	0.7	3
240	HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIPL. Clinical Cancer Research, 2015, 21, 3230-3240.	3.2	53
241	Photochemical activation of drugs for the treatment of therapy-resistant cancers. Photochemical and Photobiological Sciences, 2015, 14, 1465-1475.	1.6	29
242	Measurement of oxidatively induced DNA damage and its repair, by mass spectrometric techniques. Free Radical Research, 2015, 49, 525-548.	1.5	66
243	Hes1: a key role in stemness, metastasis and multidrug resistance. Cancer Biology and Therapy, 2015, 16, 353-359.	1.5	145

#	ARTICLE	IF	CITATIONS
244	Toward a Cancer Drug of Fungal Origin. <i>Medicinal Research Reviews</i> , 2015, 35, 937-967.	5.0	59
245	Dual Drug Conjugated Nanoparticle for Simultaneous Targeting of Mitochondria and Nucleus in Cancer Cells. <i>ACS Applied Materials & Interfaces</i> , 2015, 7, 7584-7598.	4.0	105
246	Mechanisms and therapeutic potential of inhibiting drug efflux transporters. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 907-920.	1.5	21
247	Large-scale determination of absolute phosphorylation stoichiometries in human cells by motif-targeting quantitative proteomics. <i>Nature Communications</i> , 2015, 6, 6622.	5.8	139
248	Studying clonal dynamics in response to cancer therapy using high-complexity barcoding. <i>Nature Medicine</i> , 2015, 21, 440-448.	15.2	408
249	Activation of insulin-like growth factor receptor signaling mediates resistance to histone deacetylase inhibitors. <i>Cancer Letters</i> , 2015, 361, 197-206.	3.2	11
250	Intrinsic and induced drug resistance mechanisms: in silico investigations at the cellular and tissue scales. <i>Integrative Biology (United Kingdom)</i> , 2015, 7, 1044-1060.	0.6	4
251	Self-assembled multifunctional DNA nanoflowers for the circumvention of multidrug resistance in targeted anticancer drug delivery. <i>Nano Research</i> , 2015, 8, 3447-3460.	5.8	95
252	Blocking the epithelial-to-mesenchymal transition pathway abrogates resistance to anti-folate chemotherapy in lung cancer. <i>Cell Death and Disease</i> , 2015, 6, e1824-e1824.	2.7	70
253	Multifunctional receptor-targeting antibodies for cancer therapy. <i>Lancet Oncology, The</i> , 2015, 16, e543-e554.	5.1	36
254	Identification of the specific epigenetic alterations associated with chemo-resistance via reprogramming of cancer cells. <i>Medical Hypotheses</i> , 2015, 85, 710-714.	0.8	1
255	Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease. <i>Trends in Pharmacological Sciences</i> , 2015, 36, 822-846.	4.0	242
256	Gambogic acid-loaded pH-sensitive mixed micelles for overcoming breast cancer resistance. <i>International Journal of Pharmaceutics</i> , 2015, 495, 840-848.	2.6	42
257	The impact of insulin on chemotherapeutic sensitivity to 5-fluorouracil in gastric cancer cell lines SGC7901, MKN45 and MKN28. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 64.	3.5	10
258	Precision medicine for cancer with next-generation functional diagnostics. <i>Nature Reviews Cancer</i> , 2015, 15, 747-756.	12.8	466
259	c-Myc Alterations Confer Therapeutic Response and Acquired Resistance to c-Met Inhibitors in MET-Addicted Cancers. <i>Cancer Research</i> , 2015, 75, 4548-4559.	0.4	47
260	Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset. <i>Cancer Discovery</i> , 2015, 5, 1210-1223.	7.7	575
261	Synthesis and bio-evaluation of novel quinolino-stilbene derivatives as potential anticancer agents. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 7629-7640.	1.4	25

#	ARTICLE	IF	CITATIONS
262	Cytotoxic potentiation of vinblastine and paclitaxel by L-canavanine in human cervical cancer and hepatocellular carcinoma cells. <i>Phytomedicine</i> , 2015, 22, 1232-1237.	2.3	14
263	Modulators of the human ABCC2: hope from natural sources?. <i>Future Medicinal Chemistry</i> , 2015, 7, 2041-2063.	1.1	17
264	Acquired resistance to EGFR tyrosine kinase inhibitors alters the metabolism of human head and neck squamous carcinoma cells and xenograft tumours. <i>British Journal of Cancer</i> , 2015, 112, 1206-1214.	2.9	21
265	Multifunctional T Lymphocytes Generated After Therapy With an Antitumor Gallotanin-Rich Normalized Fraction Are Related to Primary Tumor Size Reduction in a Breast Cancer Model. <i>Integrative Cancer Therapies</i> , 2015, 14, 468-483.	0.8	29
266	Chimeric Nanoparticle: A Platform for Simultaneous Targeting of Phosphatidylinositol-3-Kinase Signaling and Damaging DNA in Cancer Cells. <i>ACS Applied Materials & Interfaces</i> , 2015, 7, 18327-18335.	4.0	16
267	Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling. <i>Cancer Research</i> , 2015, 75, 3373-3383.	0.4	32
268	APC selectively mediates response to chemotherapeutic agents in breast cancer. <i>BMC Cancer</i> , 2015, 15, 457.	1.1	36
269	Epigenetic and Immune Regulation of Colorectal Cancer Stem Cells. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 414-421.	1.0	5
270	Co-targeting cancer drug escape pathways confers clinical advantage for multi-target anticancer drugs. <i>Pharmacological Research</i> , 2015, 102, 123-131.	3.1	51
271	Insider information: Testing cancer drug sensitivity for personalized therapy. <i>Genes and Diseases</i> , 2015, 2, 219-221.	1.5	1
272	Predicting Response to Histone Deacetylase Inhibitors Using High-Throughput Genomics. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv247.	3.0	18
273	Maspin Expression in Prostate Tumor Cells Averts Stemness and Stratifies Drug Sensitivity. <i>Cancer Research</i> , 2015, 75, 3970-3979.	0.4	25
274	MicroRNA-induced drug resistance in gastric cancer. <i>Biomedicine and Pharmacotherapy</i> , 2015, 74, 191-199.	2.5	49
275	Quick Serological Detection of a Cancer Biomarker with an Agglutinated Supramolecular Glycprobe. <i>Analytical Chemistry</i> , 2015, 87, 9078-9083.	3.2	22
276	Personalizing chemotherapy dosing using pharmacological methods. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 879-896.	1.1	21
277	A self-assembled nanoparticle platform based on poly(ethylene glycol)-diosgenin conjugates for co-delivery of anticancer drugs. <i>RSC Advances</i> , 2015, 5, 74828-74834.	1.7	14
278	BET inhibitor resistance emerges from leukaemia stem cells. <i>Nature</i> , 2015, 525, 538-542.	13.7	441
279	Multipronged Design of Light-Triggered Nanoparticles To Overcome Cisplatin Resistance for Efficient Ablation of Resistant Tumor. <i>ACS Nano</i> , 2015, 9, 9626-9637.	7.3	136

#	ARTICLE	IF	CITATIONS
280	Nanoparticle approaches to combating drug resistance. <i>Future Medicinal Chemistry</i> , 2015, 7, 1503-1510.	1.1	24
281	Hyaluronic acid-decorated dual responsive nanoparticles of Pluronic F127, PLGA, and chitosan for targeted co-delivery of doxorubicin and irinotecan to eliminate cancer stem-like cells. <i>Biomaterials</i> , 2015, 72, 74-89.	5.7	183
282	Reversal of multidrug resistance by co-delivery of paclitaxel and lonidamine using a TPGS and hyaluronic acid dual-functionalized liposome for cancer treatment. <i>Biomaterials</i> , 2015, 73, 284-295.	5.7	180
283	Current state of biomarkers in ovarian cancer prognosis. <i>Future Oncology</i> , 2015, 11, 3187-3195.	1.1	45
284	Bioinert Anodic Alumina Nanotubes for Targeting of Endoplasmic Reticulum Stress and Autophagic Signaling: A Combinatorial Nanotube-Based Drug Delivery System for Enhancing Cancer Therapy. <i>ACS Applied Materials & Interfaces</i> , 2015, 7, 27140-27151.	4.0	30
285	Personalized medicine in cancer: where are we today?. <i>Future Oncology</i> , 2015, 11, 2795-2798.	1.1	10
286	Improving Cancer Treatment via Mathematical Modeling: Surmounting the Challenges Is Worth the Effort. <i>Cell</i> , 2015, 163, 1059-1063.	13.5	115
287	Molecular determinants of chemotherapy resistance in ovarian cancer. <i>Pharmacogenomics</i> , 2015, 16, 1763-1767.	0.6	5
288	The role of interleukin-8 (CXCL8) and CXCR2 in acquired chemoresistance of human colorectal carcinoma cells HCT116. <i>Medical Oncology</i> , 2015, 32, 258.	1.2	44
289	GTSE1 expression represses apoptotic signaling and confers cisplatin resistance in gastric cancer cells. <i>BMC Cancer</i> , 2015, 15, 550.	1.1	40
290	Microenvironmental regulation of therapeutic response in cancer. <i>Trends in Cell Biology</i> , 2015, 25, 198-213.	3.6	604
291	Resistance to Photodynamic Therapy in Cancer. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2015, , .	0.1	8
292	The molecular mechanisms underlying the therapeutic resistance of cancer stem cells. <i>Archives of Pharmacal Research</i> , 2015, 38, 389-401.	2.7	54
293	Advances in an active and passive targeting to tumor and adipose tissues. <i>Expert Opinion on Drug Delivery</i> , 2015, 12, 41-52.	2.4	43
294	Regulation of DNA damage responses and cell cycle progression by hMOB2. <i>Cellular Signalling</i> , 2015, 27, 326-339.	1.7	30
295	Advances in Combination Therapies Based on Nanoparticles for Efficacious Cancer Treatment: An Analytical Report. <i>Biomacromolecules</i> , 2015, 16, 1-27.	2.6	117
296	Bridging scales in cancer progression: Mapping genotype to phenotype using neural networks. <i>Seminars in Cancer Biology</i> , 2015, 30, 30-41.	4.3	14
297	Control and utilization of ruthenium and rhodium metal complex excited states for photoactivated cancer therapy. <i>Coordination Chemistry Reviews</i> , 2015, 282-283, 110-126.	9.5	342

#	ARTICLE	IF	CITATIONS
298	Nanoscale drug delivery for taxanes based on the mechanism of multidrug resistance of cancer. <i>Biotechnology Advances</i> , 2015, 33, 224-241.	6.0	35
299	Self-assembled nanoscale coordination polymers carrying siRNAs and cisplatin for effective treatment of resistant ovarian cancer. <i>Biomaterials</i> , 2015, 36, 124-133.	5.7	112
300	Inhalable self-assembled albumin nanoparticles for treating drug-resistant lung cancer. <i>Journal of Controlled Release</i> , 2015, 197, 199-207.	4.8	128
301	Synthetic Biology for Therapeutic Applications. <i>Molecular Pharmaceutics</i> , 2015, 12, 322-331.	2.3	25
302	Combination of microRNA therapeutics with small-molecule anticancer drugs: Mechanism of action and co-delivery nanocarriers. <i>Advanced Drug Delivery Reviews</i> , 2015, 81, 184-197.	6.6	129
303	Identification of drug-resistant subpopulations in canine hemangiosarcoma. <i>Veterinary and Comparative Oncology</i> , 2016, 14, e113-25.	0.8	14
304	Autophagy in Multidrug-Resistant Cancers. , 0, , .		1
305	CpG Oligodeoxynucleotides Debate the Damaging Action of Cisplatin on Immune Cell DNA: A PCR Array Application on Repair Genes Expression. <i>American Journal of Biochemistry and Biotechnology</i> , 2016, 12, 159-170.	0.1	0
306	Molecular Mechanisms of Anti-cancer Activities of \hat{I}^2 -elemene: Targeting Hallmarks of Cancer. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2016, 16, 1426-1434.	0.9	26
307	Targeting the chromatin remodeling enzyme BRG1 increases the efficacy of chemotherapy drugs in breast cancer cells. <i>Oncotarget</i> , 2016, 7, 27158-27175.	0.8	49
308	Effect of SNX-2112 on proliferation of esophageal cancer cells via regulation of excision repair cross-complementing 1, epidermal growth factor receptor, and p53 expression. <i>Genetics and Molecular Research</i> , 2016, 15, .	0.3	2
309	Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds. <i>Oncotarget</i> , 2016, 7, 58743-58758.	0.8	37
310	The Isoquinoline Alkaloid Berberine Augments Radiation Effect by Enhancing the DNA Damage at Molecular Level in HeLa Cells Irradiated with Various Doses of \hat{I}^3 -Radiation: Correlation Between DNA Damage and Clonogenicity. <i>Journal of Molecular and Genetic Medicine: an International Journal of Biomedical Research</i> , 2016, 10, .	0.1	1
311	Darwinian Principles toward Multidrug-Resistant Cancer Cells. <i>Journal of Applied Pharmacy</i> , 2016, 8, .	0.1	1
312	Artemisinin and its derivatives can significantly inhibit lung tumorigenesis and tumor metastasis through Wnt/ \hat{I}^2 -catenin signaling. <i>Oncotarget</i> , 2016, 7, 31413-31428.	0.8	100
313	Promoter methylation patterns of <i>ABCB1</i> , <i>ABCC1</i> and <i>ABCG2</i> in human cancer cell lines, multidrug-resistant cell models and tumor, tumor-adjacent and tumor-distant tissues from breast cancer patients. <i>Oncotarget</i> , 2016, 7, 73347-73369.	0.8	31
314	Mechanisms of drug resistance in colon cancer and its therapeutic strategies. <i>World Journal of Gastroenterology</i> , 2016, 22, 6876.	1.4	289
315	Gastric Adenocarcinoma: An Update on Genomics, Immune System Modulations, and Targeted Therapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, 104-111.	1.8	12

#	ARTICLE	IF	CITATIONS
316	Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 4345-4353.	0.8	68
317	Suppression of STN1 enhances the cytotoxicity of chemotherapeutic agents in cancer cells by elevating DNA damage. <i>Oncology Letters</i> , 2016, 12, 800-808.	0.8	10
318	Biomolecular Network-Based Synergistic Drug Combination Discovery. <i>BioMed Research International</i> , 2016, 2016, 1-11.	0.9	22
319	Simultaneous delivery of anti-miR21 with doxorubicin prodrug by mimetic lipoprotein nanoparticles for synergistic effect against drug resistance in cancer cells. <i>International Journal of Nanomedicine</i> , 2017, Volume 12, 217-237.	3.3	46
320	Curcumin sensitizes human gastric cancer cells to 5-fluorouracil through inhibition of the NF κ B survival-signaling pathway. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 7373-7384.	1.0	34
321	The combination of NVP-BKM120 with trastuzumab or RAD001 synergistically inhibits the growth of breast cancer stem cells in vivo. <i>Oncology Reports</i> , 2016, 36, 356-364.	1.2	19
322	Systems Perturbation Analysis of a Large-Scale Signal Transduction Model Reveals Potentially Influential Candidates for Cancer Therapeutics. <i>Frontiers in Bioengineering and Biotechnology</i> , 2016, 4, 10.	2.0	29
323	Multifunctional nanocarriers for codelivery of nucleic acids and chemotherapeutics to cancer cells. , 2016, , 163-207.		5
324	Export of microRNAs: A Bridge between Breast Carcinoma and Their Neighboring Cells. <i>Frontiers in Oncology</i> , 2016, 6, 147.	1.3	20
325	Cancer Stem Cell Plasticity Drives Therapeutic Resistance. <i>Cancers</i> , 2016, 8, 8.	1.7	132
326	Bladder Cancer Stem-Like Cells: Their Origin and Therapeutic Perspectives. <i>International Journal of Molecular Sciences</i> , 2016, 17, 43.	1.8	42
327	ROS and Brain Gliomas: An Overview of Potential and Innovative Therapeutic Strategies. <i>International Journal of Molecular Sciences</i> , 2016, 17, 984.	1.8	104
328	Pharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical Use. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1502.	1.8	27
329	Hydroxylated Dimeric Naphthoquinones Increase the Generation of Reactive Oxygen Species, Induce Apoptosis of Acute Myeloid Leukemia Cells and Are Not Substrates of the Multidrug Resistance Proteins ABCB1 and ABCG2. <i>Pharmaceuticals</i> , 2016, 9, 4.	1.7	9
330	Activated Charge-Reversal Polymeric Nano-System: The Promising Strategy in Drug Delivery for Cancer Therapy. <i>Polymers</i> , 2016, 8, 99.	2.0	36
331	Feasibility of spatial frequency domain imaging (SFDI) for optically characterizing a preclinical oncology model. <i>Biomedical Optics Express</i> , 2016, 7, 4154.	1.5	47
332	Drug Delivery Using Nanoparticles for Cancer Stem-Like Cell Targeting. <i>Frontiers in Pharmacology</i> , 2016, 7, 84.	1.6	61
333	Using Pharmacogenomic Databases for Discovering Patient-Target Genes and Small Molecule Candidates to Cancer Therapy. <i>Frontiers in Pharmacology</i> , 2016, 7, 312.	1.6	22

#	ARTICLE	IF	CITATIONS
334	Evaluation of Near Infrared Dyes as Markers of P-Glycoprotein Activity in Tumors. <i>Frontiers in Pharmacology</i> , 2016, 7, 426.	1.6	4
335	miR-20a induces cisplatin resistance of a human gastric cancer cell line via targeting CYLD. <i>Molecular Medicine Reports</i> , 2016, 14, 1742-1750.	1.1	55
337	Cardamonin reduces chemotherapy-enriched breast cancer stem-like cells <i>in vitro</i> and <i>in vivo</i> . <i>Oncotarget</i> , 2016, 7, 771-785.	0.8	66
338	Spectrum of genomic alterations in <i>FGFR3</i> : current appraisal of the potential role of <i>FGFR3</i> in advanced urothelial carcinoma. <i>BJU International</i> , 2016, 118, 681-691.	1.3	15
339	Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view. <i>Chemical Society Reviews</i> , 2016, 45, 4929-4952.	18.7	150
340	Imaging transporters: Transforming diagnostic and therapeutic development. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 100, 479-488.	2.3	14
341	MALDI-MS Patterning of Caspase Activities and Its Application in the Assessment of Drug Resistance. <i>Angewandte Chemie</i> , 2016, 128, 6779-6782.	1.6	2
342	Tissue inhibitor of metalloproteinases-4 (TIMP-4) regulates stemness in cervical cancer cells. <i>Molecular Carcinogenesis</i> , 2016, 55, 1952-1961.	1.3	23
343	Stress management by autophagy: Implications for chemoresistance. <i>International Journal of Cancer</i> , 2016, 139, 23-32.	2.3	86
344	Activity of ABCG2 Is Regulated by Its Expression and Localization in DHT and Cyclopamine-Treated Breast Cancer Cells. <i>Journal of Cellular Biochemistry</i> , 2016, 117, 2249-2259.	1.2	6
345	Noncoding RNAs in Therapeutic Resistance of Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2016, 927, 265-295.	0.8	5
346	The Long and Short Non-coding RNAs in Cancer Biology. <i>Advances in Experimental Medicine and Biology</i> , 2016, , .	0.8	4
347	A novel EGR1 dependent mechanism for YB1 modulation of paclitaxel response in a triple negative breast cancer cell line. <i>International Journal of Cancer</i> , 2016, 139, 1157-1170.	2.3	32
348	Anti-gastric cancer activity in three-dimensional tumor spheroids of bufadienolides. <i>Scientific Reports</i> , 2016, 6, 24772.	1.6	16
349	Cancer biomarker discovery is improved by accounting for variability in general levels of drug sensitivity in pre-clinical models. <i>Genome Biology</i> , 2016, 17, 190.	3.8	35
350	Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK. <i>Nature Communications</i> , 2016, 7, 11363.	5.8	74
351	LncRNA HOTAIR promotes cisplatin resistance in gastric cancer by targeting miR-126 to activate the PI3K/AKT/MRP1 genes. <i>Tumor Biology</i> , 2016, 37, 16345-16355.	0.8	132
352	Stochastic modeling suggests that noise reduces differentiation efficiency by inducing a heterogeneous drug response in glioma differentiation therapy. <i>BMC Systems Biology</i> , 2016, 10, 73.	3.0	8

#	ARTICLE	IF	CITATIONS
353	Analysis of drug resistance in non-small-cell lung cancer based on singular value decomposition. , 2016, , .		0
354	A systematic study on drug-response associated genes using baseline gene expressions of the Cancer Cell Line Encyclopedia. Scientific Reports, 2016, 6, 22811.	1.6	54
355	Genomic and transcriptomic profiling of resistant CEM/ADR-5000 and sensitive CCRF-CEM leukaemia cells for unravelling the full complexity of multi-factorial multidrug resistance. Scientific Reports, 2016, 6, 36754.	1.6	41
356	Targeting the ataxia telangiectasia mutated pathway for effective therapy against hirsutine-resistant breast cancer cells. Oncology Letters, 2016, 12, 295-300.	0.8	2
357	Receptor Tyrosine Kinases and Their Ligands. , 2016, , 8-21.		0
358	Upregulation of microRNA-34a enhances the DDP sensitivity of gastric cancer cells by modulating proliferation and apoptosis via targeting MET. Oncology Reports, 2016, 36, 2391-2397.	1.2	45
359	Effect of AKT 3 expression on MYC and caspase-8 dependent apoptosis caused by polo-like kinase inhibitors in HCT 116 cells. Cancer Science, 2016, 107, 1877-1887.	1.7	10
361	Î±-Amanitin Restrains Cancer Relapse from Drug-Tolerant Cell Subpopulations via TAF15. Scientific Reports, 2016, 6, 25895.	1.6	27
362	A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS. Chinese Journal of Cancer, 2016, 35, 92.	4.9	5
363	Arid awakening: new opportunities for Australian plant natural product research. Rangeland Journal, 2016, 38, 467.	0.4	5
364	PEPlife: A Repository of the Half-life of Peptides. Scientific Reports, 2016, 6, 36617.	1.6	108
365	Sympathectomized tumor-bearing mice survive longer but develop bigger melanomas. Endocrine Regulations, 2016, 50, 207-214.	0.5	7
366	Cucurbitacin B reverses multidrug resistance by targeting CIP2A to reactivate protein phosphatase 2A in MCF-7/Adriamycin cells. Oncology Reports, 2016, 36, 1180-1186.	1.2	20
367	Data integration to prioritize drugs using genomics and curated data. BioData Mining, 2016, 9, 21.	2.2	14
368	Role of <i>p</i> -H-responsiveness in the design of chitosan-based cancer nanotherapeutics: A review. Biointerphases, 2016, 11, 04B201.	0.6	35
369	Dysregulated FGF signalling in neoplastic disorders. Seminars in Cell and Developmental Biology, 2016, 53, 126-135.	2.3	69
370	Cladribine and Fludarabine Nucleotides Induce Distinct Hexamers Defining a Common Mode of Reversible RNR Inhibition. ACS Chemical Biology, 2016, 11, 2021-2032.	1.6	33
371	Association analysis of the perturbation of interactions in biological pathways and anticancer drug activity. Biochemical and Biophysical Research Communications, 2016, 470, 137-143.	1.0	0

#	ARTICLE	IF	CITATIONS
372	Role of the tumor microenvironment in regulating apoptosis and cancer progression. <i>Cancer Letters</i> , 2016, 378, 150-159.	3.2	96
373	New halogenated constituents from <i>Mangifera zeylanica</i> Hook.f. and their potential anti-cancer effects in breast and ovarian cancer cells. <i>Journal of Ethnopharmacology</i> , 2016, 189, 165-174.	2.0	17
374	Microfluidic Methods for Molecular Biology. , 2016, , .		4
375	Microfluidic Single-Cell Functional Proteomics. , 2016, , 141-159.		0
376	Cancer-targeted tri-block copolymer nanoparticles as payloads of metal complexes to achieve enhanced cancer theranosis. <i>Journal of Materials Chemistry B</i> , 2016, 4, 4517-4525.	2.9	22
377	Quantitative evaluation of ABC transporter-mediated drug resistance based on the determination of the anticancer activity of camptothecin against breast cancer stem cells using TIRF. <i>Integrative Biology (United Kingdom)</i> , 2016, 8, 704-711.	0.6	7
378	The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas. <i>Science</i> , 2016, 352, aad3018.	6.0	477
379	Combining ABCG2 Inhibitors with IMMU-132, an Anti-Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1910-1919.	1.9	30
380	Discovery of monocarbonyl curcumin hybrids as a novel class of human DNA ligase I inhibitors: in silico design, synthesis and biology. <i>RSC Advances</i> , 2016, 6, 26003-26018.	1.7	13
381	Resisting resistance: is there a solution for malaria?. <i>Expert Opinion on Drug Discovery</i> , 2016, 11, 395-406.	2.5	28
382	Autophagy inhibition sensitizes WYE-354-induced anti-colon cancer activity in vitro and in vivo. <i>Tumor Biology</i> , 2016, 37, 11743-11752.	0.8	16
383	Defining a Population of Stem-like Human Prostate Cancer Cells That Can Generate and Propagate Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 4505-4516.	3.2	78
384	Attacking the supply wagons to starve cancer cells to death. <i>FEBS Letters</i> , 2016, 590, 885-907.	1.3	66
385	Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs. <i>Cancer Cell</i> , 2016, 29, 464-476.	7.7	122
386	Immune checkpoint inhibitors in gynecologic cancers with lessons learned from non-gynecologic cancers. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 989-1004.	1.4	10
387	Gene therapy as a potential tool for treating neuroblastoma—a focused review. <i>Cancer Gene Therapy</i> , 2016, 23, 115-124.	2.2	14
388	Pharmacokinetic variations in cancer patients with liver dysfunction: applications and challenges of pharmacometabolomics. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 465-489.	1.1	6
389	Distinctive properties of metastasis-initiating cells. <i>Genes and Development</i> , 2016, 30, 892-908.	2.7	277

#	ARTICLE	IF	CITATIONS
390	Cancer chemoresistance; biochemical and molecular aspects: a brief overview. <i>European Journal of Pharmaceutical Sciences</i> , 2016, 89, 20-30.	1.9	123
391	Chemical Reactivity Window Determines Prodrug Efficiency toward Glutathione Transferase Overexpressing Cancer Cells. <i>Molecular Pharmaceutics</i> , 2016, 13, 2010-2025.	2.3	37
392	Formulation and dosage of therapeutic nanosuspension for active targeting of docetaxel (WO) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 66	2.4	8
393	Allosteric Inhibition of Bcr-Abl Kinase by High Affinity Monobody Inhibitors Directed to the Src Homology 2 (SH2)-Kinase Interface. <i>Journal of Biological Chemistry</i> , 2016, 291, 8836-8847.	1.6	33
394	miR-106b~25 cluster regulates multidrug resistance in an ABC transporter-independent manner via downregulation of EP300. <i>Oncology Reports</i> , 2016, 35, 1170-1178.	1.2	22
395	Cell-to-Cell Variation in p53 Dynamics Leads to Fractional Killing. <i>Cell</i> , 2016, 165, 631-642.	13.5	253
396	Simple avarone mimetics as selective agents against multidrug resistant cancer cells. <i>European Journal of Medicinal Chemistry</i> , 2016, 118, 107-120.	2.6	4
397	Mechanisms of tumor cell resistance to the current targeted-therapy agents. <i>Tumor Biology</i> , 2016, 37, 10021-10039.	0.8	60
398	Non-CSCs nourish CSCs through interleukin-17E-mediated activation of NF- κ B and JAK/STAT3 signaling in human hepatocellular carcinoma. <i>Cancer Letters</i> , 2016, 375, 390-399.	3.2	36
399	Epigenetic changes mediated by polycomb repressive complex 2 and E2a are associated with drug resistance in a mouse model of lymphoma. <i>Genome Medicine</i> , 2016, 8, 54.	3.6	12
400	Prediction of key genes in ovarian cancer treated with decitabine based on network strategy. <i>Oncology Reports</i> , 2016, 35, 3548-3558.	1.2	5
401	A Synthetic Cell-Penetrating Dominant-Negative ATF5 Peptide Exerts Anticancer Activity against a Broad Spectrum of Treatment-Resistant Cancers. <i>Clinical Cancer Research</i> , 2016, 22, 4698-4711.	3.2	63
402	Dual responsive mesoporous silica nanoparticles for targeted co-delivery of hydrophobic and hydrophilic anticancer drugs to tumor cells. <i>Journal of Materials Chemistry B</i> , 2016, 4, 4382-4388.	2.9	55
403	Glucose Modulation Induces Lysosome Formation and Increases Lysosomotropic Drug Sequestration via the P-Glycoprotein Drug Transporter. <i>Journal of Biological Chemistry</i> , 2016, 291, 3796-3820.	1.6	51
404	MMP2-Sensitive PEG-Lipid Copolymers: A New Type of Tumor-Targeted P-Glycoprotein Inhibitor. <i>ACS Applied Materials & Interfaces</i> , 2016, 8, 12661-12673.	4.0	60
405	Nanoparticle-Mediated Mitochondrial Damage Induces Apoptosis in Cancer. <i>ACS Applied Materials & Interfaces</i> , 2016, 8, 13218-13231.	4.0	64
406	Carrier-Free, Chemophotodynamic Dual Nanodrugs via Self-Assembly for Synergistic Antitumor Therapy. <i>ACS Applied Materials & Interfaces</i> , 2016, 8, 13262-13269.	4.0	281
407	Autophagy as a Therapeutic Target in Cancer. <i>Current Cancer Research</i> , 2016, , 1-16.	0.2	0

#	ARTICLE	IF	CITATIONS
408	An in vitro model for the development of acquired tamoxifen resistance. <i>Cell Biology and Toxicology</i> , 2016, 32, 563-581.	2.4	13
409	Engineered Breast Cancer Cell Spheroids Reproduce Biologic Properties of Solid Tumors. <i>Advanced Healthcare Materials</i> , 2016, 5, 2788-2798.	3.9	51
410	Mitochondria-Targeted Chimeric Peptide for Trinitarian Overcoming of Drug Resistance. <i>ACS Applied Materials & Interfaces</i> , 2016, 8, 25060-25068.	4.0	61
411	Resistencia al tratamiento no quirúrgico en cáncer cutáneo no melanoma. Parte II: terapia fotodinámica, vismodegib, cetuximab, metotrexato intralesional y radioterapia. <i>Actas Dermo-sifilográficas</i> , 2016, 107, 740-750.	0.2	14
412	Role of androgen receptor splice variants in prostate cancer metastasis. <i>Asian Journal of Urology</i> , 2016, 3, 177-184.	0.5	30
413	Chalcone-benzoxaborole hybrids as novel anticancer agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 5797-5801.	1.0	24
414	The Involvement of Mitochondrial Membrane Potential in Cross-Resistance Between Radiation and Docetaxel. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 556-565.	0.4	28
415	Exploring the physicochemical profile and the binding patterns of selected novel anticancer Himalayan plant derived active compounds with macromolecular targets. <i>Informatics in Medicine Unlocked</i> , 2016, 5, 1-14.	1.9	40
416	Development of a novel berberine-mediated mitochondria-targeting nano-platform for drug-resistant cancer therapy. <i>Journal of Materials Chemistry B</i> , 2016, 4, 6856-6864.	2.9	38
417	Glycogen synthase kinase-3 is a pivotal mediator of cancer invasion and resistance to therapy. <i>Cancer Science</i> , 2016, 107, 1363-1372.	1.7	130
418	Cancer network activity associated with therapeutic response and synergism. <i>Genome Medicine</i> , 2016, 8, 88.	3.6	7
419	Plasticity of Cancer Cell Invasion Mechanisms and Implications for Therapy. <i>Advances in Cancer Research</i> , 2016, 132, 209-264.	1.9	71
420	Resistance of Nonmelanoma Skin Cancer to Nonsurgical Treatments. Part II: Photodynamic Therapy, Vismodegib, Cetuximab, Intralesional Methotrexate, and Radiotherapy. <i>Actas Dermo-sifilográficas</i> , 2016, 107, 740-750.	0.2	9
421	Morphological single cell profiling of the epithelial-mesenchymal transition. <i>Integrative Biology (United Kingdom)</i> , 2016, 8, 1133-1144.	0.6	56
422	Sageone, a diterpene from <i>Rosmarinus officinalis</i> , synergizes with cisplatin cytotoxicity in SNU-1 human gastric cancer cells. <i>Phytomedicine</i> , 2016, 23, 1671-1679.	2.3	22
423	Cell-Cycle Control and DNA-Damage Signaling in Mammals. , 2016, , 227-242.		3
424	Inorganic Nanocarriers Overcoming Multidrug Resistance for Cancer Theranostics. <i>Advanced Science</i> , 2016, 3, 1600134.	5.6	107
425	Engineering and In Vitro Evaluation of Acid Labile Cholesterol Tethered MG132 Nanoparticle for Targeting Ubiquitin-Proteasome System in Cancer. <i>ChemistrySelect</i> , 2016, 1, 5099-5106.	0.7	0

#	ARTICLE	IF	CITATIONS
426	Nanoceria-Mediated Drug Delivery for Targeted Photodynamic Therapy on Drug-Resistant Breast Cancer. <i>ACS Applied Materials & Interfaces</i> , 2016, 8, 31510-31523.	4.0	92
427	High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells. <i>Cancer Research</i> , 2016, 76, 6950-6963.	0.4	30
428	Heterodinuclear Pt(<i>iv</i>)-Ru(<i>ii</i>) anticancer prodrugs to combat both drug resistance and tumor metastasis. <i>Chemical Communications</i> , 2016, 52, 10735-10738.	2.2	70
429	Reactive oxygen species-mediated synergistic and preferential induction of cell death and reduction of clonogenic resistance in breast cancer cells by combined cisplatin and FK228. <i>Cancer Letters</i> , 2016, 381, 124-132.	3.2	17
430	Chalcogen containing heterocyclic scaffolds: New hybrids with antitumoral activity. <i>European Journal of Medicinal Chemistry</i> , 2016, 123, 407-418.	2.6	40
431	Ultrashort cationic lipopeptides and lipopeptoids: Evaluation and mechanistic insights against epithelial cancer cells. <i>Peptides</i> , 2016, 84, 58-67.	1.2	30
432	Suppression of TWIST1 enhances the sensitivity of colon cancer cells to 5-fluorouracil. <i>International Journal of Biochemistry and Cell Biology</i> , 2016, 78, 268-278.	1.2	21
433	Vitamin D Enhances the Efficacy of Irinotecan through miR-627-Mediated Inhibition of Intratumoral Drug Metabolism. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2086-2095.	1.9	29
434	Î- <i>l</i> -ionone and its analogs as promising anticancer agents. <i>European Journal of Medicinal Chemistry</i> , 2016, 123, 141-154.	2.6	63
435	Delivering a research-enabled multistakeholder partnership for enhanced patient care at a population level: The Northern Ireland Comprehensive Cancer Program. <i>Cancer</i> , 2016, 122, 664-673.	2.0	5
436	Killing cancer with platycodin D through multiple mechanisms. <i>Journal of Cellular and Molecular Medicine</i> , 2016, 20, 389-402.	1.6	115
437	Metabolism in Cancer. <i>Recent Results in Cancer Research</i> , 2016, , .	1.8	5
438	Metabolic Features of Cancer Treatment Resistance. <i>Recent Results in Cancer Research</i> , 2016, 207, 135-156.	1.8	34
439	Prediction of multidimensional drug dose responses based on measurements of drug pairs. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 10442-10447.	3.3	139
440	Old drugs, novel ways out: Drug resistance toward cytotoxic chemotherapeutics. <i>Drug Resistance Updates</i> , 2016, 28, 65-81.	6.5	147
441	Tumor-Triggered Drug Release with Tumor-Targeted Accumulation and Elevated Drug Retention To Overcome Multidrug Resistance. <i>Chemistry of Materials</i> , 2016, 28, 6742-6752.	3.2	61
442	Discovery and Optimization of <i>N</i> -(4-(3-Aminophenyl)thiazol-2-yl)acetamide as a Novel Scaffold Active against Sensitive and Resistant Cancer Cells. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 8276-8292.	2.9	20
443	Î±-Hederin Induces Apoptosis, Membrane Permeabilization and Morphologic Changes in Two Cancer Cell Lines Through a Cholesterol-Dependent Mechanism. <i>Planta Medica</i> , 2016, 82, 1532-1539.	0.7	30

#	ARTICLE	IF	CITATIONS
444	Design, synthesis, and cytostatic activity of novel pyrazine sorafenib analogs. <i>Medicinal Chemistry Research</i> , 2016, 25, 2729-2741.	1.1	7
445	Chemotherapy-Induced IL34 Enhances Immunosuppression by Tumor-Associated Macrophages and Mediates Survival of Chemoresistant Lung Cancer Cells. <i>Cancer Research</i> , 2016, 76, 6030-6042.	0.4	142
446	11a-N-Tosyl-5-deoxy-pterocarpan, LQB-223, a novel compound with potent antineoplastic activity toward breast cancer cells with different phenotypes. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 2119-2130.	1.2	4
447	SIAH and EGFR, Two RAS Pathway Biomarkers, are Highly Prognostic in Locally Advanced and Metastatic Breast Cancer. <i>EBioMedicine</i> , 2016, 11, 183-198.	2.7	23
449	NOTCH1 inhibition enhances the efficacy of conventional chemotherapeutic agents by targeting head neck cancer stem cell. <i>Scientific Reports</i> , 2016, 6, 24704.	1.6	76
450	Rapid emergence and mechanisms of resistance by U87 glioblastoma cells to doxorubicin in an in vitro tumor microfluidic ecology. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 14283-14288.	3.3	62
451	Magnetic Tandem Apoptosis for Overcoming Multidrug-Resistant Cancer. <i>Nano Letters</i> , 2016, 16, 7455-7460.	4.5	41
452	Looking beyond the cancer cell for effective drug combinations. <i>Genome Medicine</i> , 2016, 8, 125.	3.6	31
453	Metabolism, Biochemical Actions, and Chemical Synthesis of Anticancer Nucleosides, Nucleotides, and Base Analogs. <i>Chemical Reviews</i> , 2016, 116, 14379-14455.	23.0	265
454	Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth Factors. <i>Cancer Research</i> , 2016, 76, 6851-6863.	0.4	209
455	Mutual regulation and targeting of multidrug resistance and cancer stem phenotype. <i>MedChemComm</i> , 2016, 7, 2265-2281.	3.5	1
456	The DNA Damage Transducer RNF8 Facilitates Cancer Chemoresistance and Progression through Twist Activation. <i>Molecular Cell</i> , 2016, 63, 1021-1033.	4.5	82
457	Influence of molecular design on biodistribution and targeting properties of an Affibody-fused HER2-recognising anticancer toxin. <i>International Journal of Oncology</i> , 2016, 49, 1185-1194.	1.4	24
458	Impact of Membrane Drug Transporters on Resistance to Small-Molecule Tyrosine Kinase Inhibitors. <i>Trends in Pharmacological Sciences</i> , 2016, 37, 904-932.	4.0	72
459	CT-707, a Novel FAK Inhibitor, Synergizes with Cabozantinib to Suppress Hepatocellular Carcinoma by Blocking Cabozantinib-Induced FAK Activation. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2916-2925.	1.9	27
460	Phenyltetrazolyl-phenylamides: Substituent impact on modulation capability and selectivity toward the efflux protein ABCG2 and investigation of interaction with the transporter. <i>European Journal of Medicinal Chemistry</i> , 2016, 124, 881-895.	2.6	16
461	Comparing Drug Images and Repurposing Drugs with BioGPS and FLAPdock: The Thymidylate Synthase Case. <i>ChemMedChem</i> , 2016, 11, 1653-1666.	1.6	21
462	Reversing Cancer Multidrug Resistance in Xenograft Models via Orchestrating Multiple Actions of Functional Mesoporous Silica Nanoparticles. <i>ACS Applied Materials & Interfaces</i> , 2016, 8, 22431-22441.	4.0	28

#	ARTICLE	IF	CITATIONS
463	Tumor deconstruction as a tool for advanced drug screening and repositioning. <i>Pharmacological Research</i> , 2016, 111, 815-819.	3.1	2
464	Necroptosis: A new way of dying?. <i>Cancer Biology and Therapy</i> , 2016, 17, 899-910.	1.5	70
465	Nanoparticle-mediated delivery of suicide genes in cancer therapy. <i>Pharmacological Research</i> , 2016, 111, 619-641.	3.1	38
466	A place for precision medicine in bladder cancer: targeting the FGFRs. <i>Future Oncology</i> , 2016, 12, 2243-2263.	1.1	39
467	Systems Biology of Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2016, , .	0.8	7
468	Microenvironmental Niches and Sanctuaries: A Route to Acquired Resistance. <i>Advances in Experimental Medicine and Biology</i> , 2016, 936, 149-164.	0.8	24
469	Arsenite-loaded nanoparticles inhibit PARP-1 to overcome multidrug resistance in hepatocellular carcinoma cells. <i>Scientific Reports</i> , 2016, 6, 31009.	1.6	33
470	Porous Pt Nanoparticles with High Near-Infrared Photothermal Conversion Efficiencies for Photothermal Therapy. <i>Advanced Healthcare Materials</i> , 2016, 5, 3165-3172.	3.9	71
472	Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXCR4-Chemokine/NF- κ B signalling pathway. <i>Scientific Reports</i> , 2016, 6, 24675.	1.6	103
473	Activation of concurrent apoptosis and necroptosis by SMAC mimetics for the treatment of refractory and relapsed ALL. <i>Science Translational Medicine</i> , 2016, 8, 339ra70.	5.8	92
474	MicroRNA profiling of cisplatin-resistant oral squamous cell carcinoma cell lines enriched with cancer-stem-cell-like and epithelial-mesenchymal transition-type features. <i>Scientific Reports</i> , 2016, 6, 23932.	1.6	51
475	Mechanisms of Resistance to Antibody-Drug Conjugates. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2825-2834.	1.9	119
476	Multifunctional Magnetic Liposomes for Cancer Imaging and Therapeutic Applications. , 2016, , 743-782.		15
477	Injectable Self-Assembled Dipeptide-Based Nanocarriers for Tumor Delivery and Effective In Vivo Photodynamic Therapy. <i>ACS Applied Materials & Interfaces</i> , 2016, 8, 30759-30767.	4.0	59
478	Mathematical Modeling of Therapy-induced Cancer Drug Resistance: Connecting Cancer Mechanisms to Population Survival Rates. <i>Scientific Reports</i> , 2016, 6, 22498.	1.6	96
479	Redox-sensitive mPEG-SS-PTX/TPGS mixed micelles: An efficient drug delivery system for overcoming multidrug resistance. <i>International Journal of Pharmaceutics</i> , 2016, 515, 281-292.	2.6	72
480	Cross-talk between AMPK and EGFR dependent Signaling in Non-Small Cell Lung Cancer. <i>Scientific Reports</i> , 2016, 6, 27514.	1.6	8
481	Putative RNA-directed adaptive mutations in cancer evolution. <i>Transcription</i> , 2016, 7, 164-187.	1.7	5

#	ARTICLE	IF	CITATIONS
482	A nanoparticulate pre-chemosensitizer for efficacious chemotherapy of multidrug resistant breast cancer. <i>Scientific Reports</i> , 2016, 6, 21459.	1.6	50
483	COPS5 amplification and overexpression confers tamoxifen-resistance in ER \pm -positive breast cancer by degradation of NCoR. <i>Nature Communications</i> , 2016, 7, 12044.	5.8	56
484	Directed evolution using dCas9-targeted somatic hypermutation in mammalian cells. <i>Nature Methods</i> , 2016, 13, 1036-1042.	9.0	378
485	Autocrine Semaphorin3A signaling is essential for the maintenance of stem-like cells in lung cancer. <i>Biochemical and Biophysical Research Communications</i> , 2016, 480, 375-379.	1.0	11
486	Single and Combinational siRNA Therapy of Cancer Cells: Probing Changes in Targeted and Nontargeted Mediators after siRNA Treatment. <i>Molecular Pharmaceutics</i> , 2016, 13, 4116-4128.	2.3	17
487	Functional screening implicates miR-371-3p and peroxiredoxin 6 in reversible tolerance to cancer drugs. <i>Nature Communications</i> , 2016, 7, 12351.	5.8	28
488	Supramolecular cyclodextrin nanocarriers for chemo- and gene therapy towards the effective treatment of drug resistant cancers. <i>Nanoscale</i> , 2016, 8, 18876-18881.	2.8	70
489	Mapping lung tumor cell drug responses as a function of matrix context and genotype using cell microarrays. <i>Integrative Biology (United Kingdom)</i> , 2016, 8, 1221-1231.	0.6	10
490	ABCB1 Is Upregulated in Acquisition of Taxane Resistance: Lessons from Esophageal Squamous Cell Carcinoma Cell Lines. <i>Tohoku Journal of Experimental Medicine</i> , 2016, 240, 295-301.	0.5	11
491	Characterization of multidrug-resistant osteosarcoma sublines and the molecular mechanisms of resistance. <i>Molecular Medicine Reports</i> , 2016, 14, 3269-3276.	1.1	13
492	Bioluminescence Microscopy as a Method to Measure Single Cell Androgen Receptor Activity Heterogeneous Responses to Antiandrogens. <i>Scientific Reports</i> , 2016, 6, 33968.	1.6	11
493	Correlation between Gene Variants, Signaling Pathways, and Efficacy of Chemotherapy Drugs against Colon Cancers. <i>Cancer Informatics</i> , 2016, 15, CIN.S34506.	0.9	13
494	The pharmacological audit trail (PhAT): Use of tumor models to address critical issues in the preclinical development of targeted anticancer drugs. <i>Drug Discovery Today: Disease Models</i> , 2016, 21, 23-32.	1.2	8
495	Baicalein Induces Caspase-Dependent Apoptosis Associated with the Generation of ROS and the Activation of AMPK in Human Lung Carcinoma A549 Cells. <i>Drug Development Research</i> , 2016, 77, 73-86.	1.4	31
496	Rationally Designed 2-in-1 Nanoparticles Can Overcome Adaptive Resistance in Cancer. <i>ACS Nano</i> , 2016, 10, 5823-5834.	7.3	64
497	Vascular endothelial growth factor A as predictive marker for mTOR inhibition in relapsing high-grade serous ovarian cancer. <i>BMC Systems Biology</i> , 2016, 10, 33.	3.0	13
498	Current situation and future usage of anticancer drug databases. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2016, 21, 778-794.	2.2	12
499	Paclitaxel and curcumin co-bound albumin nanoparticles having antitumor potential to pancreatic cancer. <i>Asian Journal of Pharmaceutical Sciences</i> , 2016, 11, 708-714.	4.3	64

#	ARTICLE	IF	CITATIONS
500	Mitochondria-targeted aggregation induced emission theranostics: crucial importance of in situ activation. <i>Chemical Science</i> , 2016, 7, 6050-6059.	3.7	83
501	Molecular Radio-Oncology. <i>Recent Results in Cancer Research</i> , 2016, , .	1.8	1
502	Transfer of Drug Resistance Characteristics Between Cancer Cell Subpopulations: A Study Using Simple Mathematical Models. <i>Bulletin of Mathematical Biology</i> , 2016, 78, 1218-1237.	0.9	9
503	Cancer Stem Cells. <i>Recent Results in Cancer Research</i> , 2016, 198, 25-44.	1.8	7
504	PKIB promotes cell proliferation and the invasion-metastasis cascade through the PI3K/Akt pathway in NSCLC cells. <i>Experimental Biology and Medicine</i> , 2016, 241, 1911-1918.	1.1	24
505	MDR1 mediated chemoresistance: BMI1 and TIP60 in action. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2016, 1859, 983-993.	0.9	25
506	Challenges influencing next generation technologies for precision medicine. <i>Expert Review of Precision Medicine and Drug Development</i> , 2016, 1, 121-123.	0.4	2
507	Deoxyrhapontigenin, a Natural Stilbene Derivative Isolated From <i>Rheum undulatum</i> L. Induces Endoplasmic Reticulum Stress-Mediated Apoptosis in Human Breast Cancer Cells. <i>Integrative Cancer Therapies</i> , 2016, 15, NP44-NP52.	0.8	13
508	Jatrophane diterpenes and cancer multidrug resistance – ABCB1 efflux modulation and selective cell death induction. <i>Phytomedicine</i> , 2016, 23, 968-978.	2.3	41
509	Enhancement of chlorpromazine antitumor activity by Pluronic F127/L81 nanostructured system against human multidrug resistant leukemia. <i>Pharmacological Research</i> , 2016, 111, 102-112.	3.1	27
510	Extracellular vesicles released from cells exposed to reactive oxygen species increase annexin A2 expression and survival of target cells exposed to the same conditions. <i>Communicative and Integrative Biology</i> , 2016, 9, e1191715.	0.6	8
511	Improving gastric cancer preclinical studies using diverse in vitro and in vivo model systems. <i>BMC Cancer</i> , 2016, 16, 200.	1.1	14
512	The voltage gated Ca ²⁺ -channel Cav3.2 and therapeutic responses in breast cancer. <i>Cancer Cell International</i> , 2016, 16, 24.	1.8	34
513	NANOMEDICINE: will it offer possibilities to overcome multiple drug resistance in cancer?. <i>Journal of Nanobiotechnology</i> , 2016, 14, 17.	4.2	35
514	Synthesis and biological evaluation of isomeric methoxy substitutions on anti-cancer indolyl-pyridinyl-propenones: Effects on potency and mode of activity. <i>European Journal of Medicinal Chemistry</i> , 2016, 122, 79-91.	2.6	27
515	Evaluating the molecule-based prediction of clinical drug responses in cancer. <i>Bioinformatics</i> , 2016, 32, 2891-2895.	1.8	113
516	Oncogenic Mutant p53 Gain of Function Nourishes the Vicious Cycle of Tumor Development and Cancer Stem-Cell Formation. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2016, 6, a026203.	2.9	42
517	pH- and NIR Light-Responsive Polymeric Prodrug Micelles for Hyperthermia-Assisted Site-Specific Chemotherapy to Reverse Drug Resistance in Cancer Treatment. <i>Small</i> , 2016, 12, 2731-2740.	5.2	102

#	ARTICLE	IF	CITATIONS
518	Silver Nanocluster Embedded Composite Nanoparticles for Targeted Prodrug Delivery in Cancer Theranostics. <i>ACS Biomaterials Science and Engineering</i> , 2016, 2, 1395-1402.	2.6	33
519	The role of enhancers in cancer. <i>Nature Reviews Cancer</i> , 2016, 16, 483-493.	12.8	320
520	MALDI-MS Patterning of Caspase Activities and Its Application in the Assessment of Drug Resistance. <i>Angewandte Chemie - International Edition</i> , 2016, 55, 6667-6670.	7.2	38
521	Emerging Adjuvant Therapy for Cancer: Propolis and its Constituents. <i>Journal of Dietary Supplements</i> , 2016, 13, 245-268.	1.4	114
522	Rheb promotes cancer cell survival through p27Kip1-dependent activation of autophagy. <i>Molecular Carcinogenesis</i> , 2016, 55, 220-229.	1.3	22
523	Discovery of a new method for potent drug development using power function of stoichiometry of homomeric biocomplexes or biological nanomotors. <i>Expert Opinion on Drug Delivery</i> , 2016, 13, 23-36.	2.4	12
524	Five-Membered Ring Peroxide Selectively Initiates Ferroptosis in Cancer Cells. <i>ACS Chemical Biology</i> , 2016, 11, 1305-1312.	1.6	128
525	A photoactivable multi-inhibitor nanoliposome for tumour control and simultaneous inhibition of treatment escape pathways. <i>Nature Nanotechnology</i> , 2016, 11, 378-387.	15.6	201
526	NF- κ B signaling plays irreplaceable roles in cisplatin-induced bladder cancer chemoresistance and tumor progression. <i>International Journal of Oncology</i> , 2016, 48, 225-234.	1.4	37
527	Metastatic colonization by circulating tumour cells. <i>Nature</i> , 2016, 529, 298-306.	13.7	1,498
528	Identification of Dormancy-Associated MicroRNAs for the Design of Osteosarcoma-Targeted Dendritic Polyglycerol Nanopolyplexes. <i>ACS Nano</i> , 2016, 10, 2028-2045.	7.3	64
529	Nanotechnology-based strategies for combating toxicity and resistance in melanoma therapy. <i>Biotechnology Advances</i> , 2016, 34, 565-577.	6.0	39
530	Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer. <i>British Journal of Cancer</i> , 2016, 114, 269-280.	2.9	81
531	Lysosomes as mediators of drug resistance in cancer. <i>Drug Resistance Updates</i> , 2016, 24, 23-33.	6.5	330
532	Targeting tumor microenvironment with PEG-based amphiphilic nanoparticles to overcome chemoresistance. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2016, 12, 269-286.	1.7	95
533	The New Antitumor Drug ABTL0812 Inhibits the Akt/mTORC1 Axis by Upregulating Tribbles-3 Pseudokinase. <i>Clinical Cancer Research</i> , 2016, 22, 2508-2519.	3.2	58
534	AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 3593-3608.	2.9	167
535	MiRNA-21 induces epithelial to mesenchymal transition and gemcitabine resistance via the PTEN/AKT pathway in breast cancer. <i>Tumor Biology</i> , 2016, 37, 7245-7254.	0.8	81

#	ARTICLE	IF	CITATIONS
536	Mitotic catastrophe and cancer drug resistance: A link that must to be broken. <i>Drug Resistance Updates</i> , 2016, 24, 1-12.	6.5	79
537	Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs. <i>European Journal of Medicinal Chemistry</i> , 2016, 108, 495-504.	2.6	68
538	SATPdb: a database of structurally annotated therapeutic peptides. <i>Nucleic Acids Research</i> , 2016, 44, D1119-D1126.	6.5	131
539	High-throughput single cell multidrug resistance analysis with multifunctional gradients-customizing microfluidic device. <i>Sensors and Actuators B: Chemical</i> , 2016, 225, 563-571.	4.0	41
540	BET inhibition represses miR17-92 to drive BIM-initiated apoptosis of normal and transformed hematopoietic cells. <i>Leukemia</i> , 2016, 30, 1531-1541.	3.3	29
541	Cytokines in cancer drug resistance: Cues to new therapeutic strategies. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2016, 1865, 255-265.	3.3	122
542	Synthesis of α,β -Unsaturated Carbonyl-Based Compounds, Oxime and Oxime Ether Analogs as Potential Anticancer Agents for Overcoming Cancer Multidrug Resistance by Modulation of Efflux Pumps in Tumor Cells. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 3549-3561.	2.9	74
543	FGFR antagonist induces protective autophagy in FGFR1-amplified breast cancer cell. <i>Biochemical and Biophysical Research Communications</i> , 2016, 474, 1-7.	1.0	19
544	Emerging therapeutic targets in metastatic progression: A focus on breast cancer. , 2016, 161, 79-96.		53
545	The role of tumor microenvironment in melanoma therapy resistance. <i>Melanoma Management</i> , 2016, 3, 23-32.	0.1	18
546	Wingless/ β -catenin signaling as a modulator of chemoresistance in cancer. <i>Molecular and Cellular Oncology</i> , 2016, 3, e1131356.	0.3	7
547	Discovery of New Monocarbonyl Ligustrazine α -Curcumin Hybrids for Intervention of Drug-Sensitive and Drug-Resistant Lung Cancer. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 1747-1760.	2.9	61
548	Cancer stem cells, metabolism, and therapeutic significance. <i>Tumor Biology</i> , 2016, 37, 5735-5742.	0.8	69
549	Natural product modulators of transient receptor potential (TRP) channels as potential anti-cancer agents. <i>Chemical Society Reviews</i> , 2016, 45, 6130-6137.	18.7	57
550	Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach. <i>Lancet Psychiatry</i> , 2016, 3, 350-357.	3.7	107
551	Anti-CD73 in Cancer Immunotherapy: Awakening New Opportunities. <i>Trends in Cancer</i> , 2016, 2, 95-109.	3.8	177
552	Development of Heat Shock Protein (Hsp90) Inhibitors To Combat Resistance to Tyrosine Kinase Inhibitors through Hsp90 α -Kinase Interactions. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 5563-5586.	2.9	53
553	In vitro anticancer potential of BaCO ₃ nanoparticles synthesized via green route. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2016, 156, 29-34.	1.7	34

#	ARTICLE	IF	CITATIONS
554	Nanostructured SERS-electrochemical biosensors for testing of anticancer drug interactions with DNA. <i>Biosensors and Bioelectronics</i> , 2016, 80, 257-264.	5.3	151
555	HIF-1 α /MDR1 pathway confers chemoresistance to cisplatin in bladder cancer. <i>Oncology Reports</i> , 2016, 35, 1549-1556.	1.2	34
557	Cancer Drug Resistance: A Brief Overview from a Genetic Viewpoint. <i>Methods in Molecular Biology</i> , 2016, 1395, 1-18.	0.4	84
558	MicroRNAs and Cancer Drug Resistance. <i>Methods in Molecular Biology</i> , 2016, 1395, 137-162.	0.4	34
559	The Regulatory Role of Long Noncoding RNAs in Cancer Drug Resistance. <i>Methods in Molecular Biology</i> , 2016, 1395, 207-227.	0.4	20
560	Cancer therapy in the necroptosis era. <i>Cell Death and Differentiation</i> , 2016, 23, 748-756.	5.0	256
561	The application of mathematical modelling to the design of bispecific monoclonal antibodies. <i>MAbs</i> , 2016, 8, 585-592.	2.6	11
562	Phosphorylation of thymidylate synthase affects slow-binding inhibition by 5-fluoro-dUMP and N ⁴ -hydroxy-dCMP. <i>Molecular BioSystems</i> , 2016, 12, 1333-1341.	2.9	12
563	Nanoscale characterization illustrates the cisplatin-mediated biomechanical changes of B16-F10 melanoma cells. <i>Physical Chemistry Chemical Physics</i> , 2016, 18, 7124-7131.	1.3	17
564	Modeling Tumor Clonal Evolution for Drug Combinations Design. <i>Trends in Cancer</i> , 2016, 2, 144-158.	3.8	43
565	Loss of Scribble Promotes Snail Translation through Translocation of HuR and Enhances Cancer Drug Resistance. <i>Journal of Biological Chemistry</i> , 2016, 291, 291-302.	1.6	29
566	Trial Watch"Small molecules targeting the immunological tumor microenvironment for cancer therapy. <i>Oncotarget</i> , 2016, 5, e1149674.	2.1	46
567	Locoregional cancer therapy using polymer-based drug depots. <i>Drug Discovery Today</i> , 2016, 21, 640-647.	3.2	25
569	Near-Infrared Light-Mediated Gold Nanoplatfoms for Cancer Theranostics. <i>Springer Series in Biomaterials Science and Engineering</i> , 2016, , 3-52.	0.7	3
570	Biomaterials and emerging anticancer therapeutics: engineering the microenvironment. <i>Nature Reviews Cancer</i> , 2016, 16, 56-66.	12.8	341
571	Upregulation of CD44v6 contributes to acquired chemoresistance via the modulation of autophagy in colon cancer SW480 cells. <i>Tumor Biology</i> , 2016, 37, 8811-8824.	0.8	64
572	SFRP2 augments WNT16B signaling to promote therapeutic resistance in the damaged tumor microenvironment. <i>Oncogene</i> , 2016, 35, 4321-4334.	2.6	91
573	Recent advances in multifunctional silica-based hybrid nanocarriers for bioimaging and cancer therapy. <i>Nanoscale</i> , 2016, 8, 12510-12519.	2.8	75

#	ARTICLE	IF	CITATIONS
574	The pleiotropic role of exchange protein directly activated by cAMP 1 (EPAC1) in cancer: implications for therapeutic intervention. <i>Acta Biochimica Et Biophysica Sinica</i> , 2016, 48, 75-81.	0.9	30
575	miR-20a enhances cisplatin resistance of human gastric cancer cell line by targeting NFKBIB. <i>Tumor Biology</i> , 2016, 37, 1261-1269.	0.8	41
576	Integrative computational in-depth analysis of dysregulated miRNA-mRNA interactions in drug-resistant pediatric acute lymphoblastic leukemia cells: an attempt to obtain new potential gene-miRNA pathways involved in response to treatment. <i>Tumor Biology</i> , 2016, 37, 7861-7872.	0.8	28
577	Modeling K-Ras-driven lung adenocarcinoma in mice: preclinical validation of therapeutic targets. <i>Journal of Molecular Medicine</i> , 2016, 94, 121-135.	1.7	12
578	“Combo” nanomedicine: Co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy. <i>Advanced Drug Delivery Reviews</i> , 2016, 98, 3-18.	6.6	399
579	Light-Responsive Nanostructured Systems for Applications in Nanomedicine. <i>Topics in Current Chemistry</i> , 2016, , .	4.0	9
580	Polymeric Nanoparticles for Cancer Photodynamic Therapy. <i>Topics in Current Chemistry</i> , 2016, 370, 61-112.	4.0	38
581	Quantitative proteomic analysis of anticancer drug RH1 resistance in liver carcinoma. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2016, 1864, 219-232.	1.1	13
582	Cancer cell-selective killing polymer/copper combination. <i>Biomaterials Science</i> , 2016, 4, 115-120.	2.6	19
583	Tumor microenvironment and cancer therapy resistance. <i>Cancer Letters</i> , 2016, 380, 205-215.	3.2	246
584	Dominant mechanisms of primary resistance differ from dominant mechanisms of secondary resistance to targeted therapies. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 97, 178-196.	2.0	25
585	Dietary Factors May Influence the Clinical Outcome of Chemotherapy in Cancer Multidrug Resistance. , 2016, , 307-319.		1
586	Sonodynamic Therapy: Concept, Mechanism and Application to Cancer Treatment. <i>Advances in Experimental Medicine and Biology</i> , 2016, 880, 429-450.	0.8	237
587	Synthesis and evaluation of bis-thiazole derivatives as new anticancer agents. <i>European Journal of Medicinal Chemistry</i> , 2016, 107, 288-294.	2.6	74
588	Immunotherapy and tumor microenvironment. <i>Cancer Letters</i> , 2016, 370, 85-90.	3.2	242
589	Effect of lipid peroxidation on membrane permeability of cancer and normal cells subjected to oxidative stress. <i>Chemical Science</i> , 2016, 7, 489-498.	3.7	307
591	Mechanisms of tumour resistance against chemotherapeutic agents in veterinary oncology. <i>Veterinary Journal</i> , 2016, 207, 63-72.	0.6	20
592	Methotrexate-conjugated quantum dots: synthesis, characterisation and cytotoxicity in drug resistant cancer cells. <i>Journal of Drug Targeting</i> , 2016, 24, 120-133.	2.1	45

#	ARTICLE	IF	CITATIONS
593	RNA interference for multiple myeloma therapy: targeting signal transduction pathways. <i>Expert Opinion on Therapeutic Targets</i> , 2016, 20, 107-121.	1.5	16
594	Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors. <i>Oncogene</i> , 2016, 35, 558-566.	2.6	121
595	Imatinib Inhibits the Renewal and Tumorigenicity of CT-26 Colon Cancer Cells after Cytoreductive Treatment with Doxorubicin. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2017, 65, 51-67.	1.0	6
596	Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant. <i>Leukemia</i> , 2017, 31, 177-185.	3.3	40
597	Overcoming treatment resistance in cancer: Current understanding and tactics. <i>Cancer Letters</i> , 2017, 387, 69-76.	3.2	35
598	Combine and conquer: challenges for targeted therapy combinations in early phase trials. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 57-66.	12.5	239
599	MicroRNAs are important regulators of drug resistance in colorectal cancer. <i>Biological Chemistry</i> , 2017, 398, 929-938.	1.2	52
600	PTK2-mediated degradation of ATG3 impedes cancer cells susceptible to DNA damage treatment. <i>Autophagy</i> , 2017, 13, 579-591.	4.3	15
601	Betulinic acid promotes TRAIL function on liver cancer progression inhibition through p53/Caspase-3 signaling activation. <i>Biomedicine and Pharmacotherapy</i> , 2017, 88, 349-358.	2.5	34
602	Bacterial Carriers for Glioblastoma Therapy. <i>Molecular Therapy - Oncolytics</i> , 2017, 4, 1-17.	2.0	26
603	Role of Reactive Oxygen Species (ROS) in Therapeutics and Drug Resistance in Cancer and Bacteria. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 3221-3240.	2.9	394
604	<scp>PAX3</scp> is essential for tumour initiation and maintenance but not recurrence in a human myoblast model of rhabdomyosarcoma. <i>Journal of Pathology</i> , 2017, 241, 626-637.	2.1	52
605	New oral targeted therapies for metastatic breast cancer disrupt the traditional patients' management-A healthcare providers' view. <i>European Journal of Cancer Care</i> , 2017, 26, e12624.	0.7	4
606	Tumor-induced Stromal STAT1 Accelerates Breast Cancer via Deregulating Tissue Homeostasis. <i>Molecular Cancer Research</i> , 2017, 15, 585-597.	1.5	17
607	Activation of EIF4E by Aurora Kinase A Depicts a Novel Druggable Axis in Everolimus-Resistant Cancer Cells. <i>Clinical Cancer Research</i> , 2017, 23, 3756-3768.	3.2	27
608	1,2:5,6-dianhydrogalactitol inhibits human glioma cell growth in vivo and in vitro by arresting the cell cycle at G2/M phase. <i>Acta Pharmacologica Sinica</i> , 2017, 38, 561-570.	2.8	12
609	Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas. , 2017, 174, 145-172.		22
610	Proteogenomic studies on cancer drug resistance: towards biomarker discovery and target identification. <i>Expert Review of Proteomics</i> , 2017, 14, 351-362.	1.3	10

#	ARTICLE	IF	CITATIONS
611	Argininosuccinate lyase interacts with cyclin A2 in cytoplasm and modulates growth of liver tumor cells. <i>Oncology Reports</i> , 2017, 37, 969-978.	1.2	23
612	A mitochondria-targeting supramolecular photosensitizer based on pillar[5]arene for photodynamic therapy. <i>Chemical Communications</i> , 2017, 53, 3126-3129.	2.2	66
613	Tumor cell resistance against targeted therapeutics: the density of cultured glioma tumor cells enhances Stat3 activity and offers protection against the tyrosine kinase inhibitor canertinib. <i>MedChemComm</i> , 2017, 8, 96-102.	3.5	9
614	Microfluidic Encapsulation of Prickly Zinc-Doped Copper Oxide Nanoparticles with VD1142 Modified Spermine Acetalated Dextran for Efficient Cancer Therapy. <i>Advanced Healthcare Materials</i> , 2017, 6, 1601406.	3.9	38
615	Multifunctional Nanographene Oxide for Targeted Gene-Mediated Thermochemotherapy of Drug-resistant Tumour. <i>Scientific Reports</i> , 2017, 7, 43506.	1.6	45
616	Cancer reversion, a renewed challenge in systems biology. <i>Current Opinion in Systems Biology</i> , 2017, 2, 49-58.	1.3	12
617	Major Physiological Signaling Pathways in the Regulation of Cell Proliferation and Survival. <i>Handbook of Experimental Pharmacology</i> , 2017, 249, 13-30.	0.9	8
618	Hepatitis B X-interacting protein promotes cisplatin resistance and regulates CD147 via Sp1 in ovarian cancer. <i>Experimental Biology and Medicine</i> , 2017, 242, 497-504.	1.1	9
619	A New View of Pathway-Driven Drug Resistance in Tumor Proliferation. <i>Trends in Pharmacological Sciences</i> , 2017, 38, 427-437.	4.0	68
620	Cellular Hierarchy as a Determinant of Tumor Sensitivity to Chemotherapy. <i>Cancer Research</i> , 2017, 77, 2231-2241.	0.4	20
621	Cyclometalated Gold(III) Complexes Containing N-Heterocyclic Carbene Ligands Engage Multiple Anti-Cancer Molecular Targets. <i>Angewandte Chemie - International Edition</i> , 2017, 56, 3892-3896.	7.2	119
622	Discovery of tetrahydrocarbazoles as dual pERK and pRb inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2017, 134, 366-378.	2.6	10
623	Polymers in the Co-delivery of siRNA and Anticancer Drugs for the Treatment of Drug-resistant Cancers. <i>Topics in Current Chemistry</i> , 2017, 375, 24.	3.0	22
624	Head and Neck Squamous Cell Carcinoma Metabolism Draws on Glutaminolysis, and Stemness Is Specifically Regulated by Glutaminolysis via Aldehyde Dehydrogenase. <i>Journal of Proteome Research</i> , 2017, 16, 1315-1326.	1.8	43
625	Cytotoxic effects of the cardenolide convallatoxin and its Na,K-ATPase regulation. <i>Molecular and Cellular Biochemistry</i> , 2017, 428, 23-39.	1.4	11
626	Inverse correlation between the metastasis suppressor RKIP and the metastasis inducer YY1: Contrasting roles in the regulation of chemo/immuno-resistance in cancer. <i>Drug Resistance Updates</i> , 2017, 30, 28-38.	6.5	39
627	The epithelial to mesenchymal transition (EMT) and cancer stem cells: implication for treatment resistance in pancreatic cancer. <i>Molecular Cancer</i> , 2017, 16, 52.	7.9	241
628	Anti-tumor activity of wogonin, an extract from <i>Scutellaria baicalensis</i> , through regulating different signaling pathways. <i>Chinese Journal of Natural Medicines</i> , 2017, 15, 15-40.	0.7	71

#	ARTICLE	IF	CITATIONS
629	Combination antitumor therapy with targeted dual-nanomedicines. <i>Advanced Drug Delivery Reviews</i> , 2017, 115, 23-45.	6.6	111
630	A population genetics perspective on the determinants of intra-tumor heterogeneity. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1867, 109-126.	3.3	37
631	Facial Layer-by-Layer Engineering of Upconversion Nanoparticles for Gene Delivery: Near-Infrared-Initiated Fluorescence Resonance Energy Transfer Tracking and Overcoming Drug Resistance in Ovarian Cancer. <i>ACS Applied Materials & Interfaces</i> , 2017, 9, 7941-7949.	4.0	64
632	Supramolecular "Trojan Horse" for Nuclear Delivery of Dual Anticancer Drugs. <i>Journal of the American Chemical Society</i> , 2017, 139, 2876-2879.	6.6	253
633	CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner. <i>Oncology Reports</i> , 2017, 37, 921-928.	1.2	25
634	Synthesis and evaluation of 5-(arylthio)-9 H -pyrimido[4,5- b]indole-2,4-diamines as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 1602-1607.	1.0	13
635	The importance of breast cancer resistance protein to the kidneys excretory function and chemotherapeutic resistance. <i>Drug Resistance Updates</i> , 2017, 30, 15-27.	6.5	29
636	Prodrug-Like, PEGylated Protein Toxin Trichosanthin for Reversal of Chemoresistance. <i>Molecular Pharmaceutics</i> , 2017, 14, 1429-1438.	2.3	39
637	Amino acid-modified chitosan nanoparticles for Cu ²⁺ chelation to suppress CuO nanoparticle cytotoxicity. <i>Journal of Materials Chemistry B</i> , 2017, 5, 3521-3530.	2.9	14
638	EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 611-629.	12.5	1,865
639	Therapeutic Nanocarriers via Cholesterol Directed Self-Assembly of Well-Defined Linear-Dendritic Polymeric Amphiphiles. <i>Chemistry of Materials</i> , 2017, 29, 3891-3898.	3.2	26
640	Establishment of a novel cellular model for myxofibrosarcoma heterogeneity. <i>Scientific Reports</i> , 2017, 7, 44700.	1.6	18
641	Piperine Triggers Apoptosis of Human Oral Squamous Carcinoma Through Cell Cycle Arrest and Mitochondrial Oxidative Stress. <i>Nutrition and Cancer</i> , 2017, 69, 791-799.	0.9	47
642	Cathepsin L silencing increases As ₂ O ₃ toxicity in malignantly transformed pilocytic astrocytoma MPA58 cells by activating caspases 3/7. <i>Experimental Cell Research</i> , 2017, 356, 64-73.	1.2	4
643	Mechanisms of Pinometostat (EPZ-5676) Treatment-Induced Emergent Resistance in MLL-Rearranged Leukemia. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1669-1679.	1.9	50
644	Biosynthesized Protein-Capped Silver Nanoparticles Induce ROS-Dependent Proapoptotic Signals and Prosurvival Autophagy in Cancer Cells. <i>ACS Omega</i> , 2017, 2, 1489-1504.	1.6	62
645	Knockdown of PRDX2 sensitizes colon cancer cells to 5-FU by suppressing the PI3K/AKT signaling pathway. <i>Bioscience Reports</i> , 2017, 37, .	1.1	30
646	Synthesis and SAR Study of Anticancer Protoflavone Derivatives: Investigation of Cytotoxicity and Interaction with ABCB1 and ABCG2 Multidrug Efflux Transporters. <i>ChemMedChem</i> , 2017, 12, 850-859.	1.6	11

#	ARTICLE	IF	CITATIONS
647	Ferrocenyl and organic novobiocin derivatives: Synthesis and their in vitro biological activity. <i>Journal of Inorganic Biochemistry</i> , 2017, 172, 88-93.	1.5	27
648	Hippo pathway mediates resistance to cytotoxic drugs. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E3729-E3738.	3.3	57
649	Harnessing Preclinical Molecular Imaging to Inform Advances in Personalized Cancer Medicine. <i>Journal of Nuclear Medicine</i> , 2017, 58, 689-696.	2.8	15
650	Single Cell Analysis. <i>Series in Bioengineering</i> , 2017, , .	0.3	1
651	Exploring Jolkinol D Derivatives To Overcome Multidrug Resistance in Cancer. <i>Journal of Natural Products</i> , 2017, 80, 1411-1420.	1.5	24
652	Coordinating Biointeraction and Bioreaction of a Nanocarrier Material and an Anticancer Drug to Overcome Membrane Rigidity and Target Mitochondria in Multidrug-Resistant Cancer Cells. <i>Advanced Functional Materials</i> , 2017, 27, 1700804.	7.8	29
653	Utility of urinary circulating tumor DNA for EGFR mutation detection in different stages of non-small cell lung cancer patients. <i>Clinical and Translational Oncology</i> , 2017, 19, 1283-1291.	1.2	30
654	Self-Assembled Nanoparticles from Phenolic Derivatives for Cancer Therapy. <i>Advanced Healthcare Materials</i> , 2017, 6, 1700467.	3.9	71
655	DNA origami/gold nanorod hybrid nanostructures for the circumvention of drug resistance. <i>Nanoscale</i> , 2017, 9, 7750-7754.	2.8	104
656	Identification of novel 1-indolyl acetate-5-nitroimidazole derivatives of combretastatin A-4 as potential tubulin polymerization inhibitors. <i>Biochemical Pharmacology</i> , 2017, 137, 10-28.	2.0	15
657	A new chemotherapy agent-free theranostic system composed of graphene oxide nano-complex and aptamers for treatment of cancer cells. <i>International Journal of Pharmaceutics</i> , 2017, 526, 391-399.	2.6	39
658	Ell3 stimulates 5-FU resistance in a breast cancer cell line. <i>Oncology Letters</i> , 2017, 13, 4173-4179.	0.8	7
659	Enhancing Tumor Cell Response to Multidrug Resistance with pH-Sensitive Quercetin and Doxorubicin Conjugated Multifunctional Nanoparticles. <i>Colloids and Surfaces B: Biointerfaces</i> , 2017, 156, 175-185.	2.5	35
660	Magnetically Guided Viral Transduction of Gene-Based Sensitization for Localized Photodynamic Therapy To Overcome Multidrug Resistance in Breast Cancer Cells. <i>Bioconjugate Chemistry</i> , 2017, 28, 1702-1708.	1.8	11
661	4-Connected azabicyclo[5.3.0]decane Smac mimetics-Zn ²⁺ chelators as dual action antitumoral agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 2336-2344.	1.0	4
662	Rational design of non-resistant targeted cancer therapies. <i>Scientific Reports</i> , 2017, 7, 46632.	1.6	11
663	Effect of mTHPC-mediated photodynamic therapy on 5-fluorouracil resistant human colorectal cancer cells. <i>Photochemical and Photobiological Sciences</i> , 2017, 16, 1063-1070.	1.6	6
664	Prediction of therapy response in ovarian cancer: Where are we now?. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2017, 54, 233-266.	2.7	28

#	ARTICLE	IF	CITATIONS
665	Exosomes derived from mesenchymal non-small cell lung cancer cells promote chemoresistance. <i>International Journal of Cancer</i> , 2017, 141, 614-620.	2.3	117
666	Spatiotemporally and Sequentially-Controlled Drug Release from Polymer Gatekeeper-“Hollow Silica Nanoparticles. <i>Scientific Reports</i> , 2017, 7, 46540.	1.6	45
667	Effective chemotherapy of heterogeneous and drug-resistant early colon cancers by intermittent dose schedules: a computer simulation study. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 889-898.	1.1	13
668	Doxorubicin-induced mitophagy contributes to drug resistance in cancer stem cells from HCT8 human colorectal cancer cells. <i>Cancer Letters</i> , 2017, 388, 34-42.	3.2	115
669	Design of nanocarriers for nanoscale drug delivery to enhance cancer treatment using hybrid polymer and lipid building blocks. <i>Nanoscale</i> , 2017, 9, 1334-1355.	2.8	132
670	Microfluidics Enabled Bottom-Up Engineering of 3D Vascularized Tumor for Drug Discovery. <i>ACS Nano</i> , 2017, 11, 6691-6702.	7.3	121
671	Cross-validation of genes potentially associated with overall survival and drug resistance in ovarian cancer. <i>Oncology Reports</i> , 2017, 37, 3084-3092.	1.2	35
672	Hybrid Prodrug Nanoparticles with Tumor Penetration and Programmed Drug Activation for Enhanced Chemoresistant Cancer Therapy. <i>ACS Applied Materials & Interfaces</i> , 2017, 9, 18450-18461.	4.0	24
673	Bioinorganic antimicrobial strategies in the resistance era. <i>Coordination Chemistry Reviews</i> , 2017, 351, 76-117.	9.5	124
674	Selective targeting and therapy of metastatic and multidrug resistant tumors using a long circulating podophyllotoxin nanoparticle. <i>Biomaterials</i> , 2017, 137, 11-22.	5.7	35
675	p53 and its mutants on the slippery road from stemness to carcinogenesis. <i>Carcinogenesis</i> , 2017, 38, 347-358.	1.3	28
676	Effectiveness of imatinib mesylate over etoposide in the treatment of sensitive and resistant chronic myeloid leukaemia cells in vitro. <i>Experimental and Therapeutic Medicine</i> , 2017, 13, 3209-3216.	0.8	4
677	BCL2: A promising cancer therapeutic target. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1868, 309-314.	3.3	103
678	Effect of trastuzumab on the micellization properties, endocytic pathways and antitumor activities of polyurethane-based drug delivery system. <i>Chinese Journal of Polymer Science (English Edition)</i> , 2017, 35, 909-923.	2.0	11
679	Targeting epithelial-mesenchymal transition: Metal organic network nano-complexes for preventing tumor metastasis. <i>Biomaterials</i> , 2017, 139, 116-126.	5.7	54
680	Pharmacokinetics-on-a-Chip Using Label-Free SERS Technique for Programmable Dual-Drug Analysis. <i>ACS Sensors</i> , 2017, 2, 773-780.	4.0	35
681	Mitochondrial dysfunction induced by a SH2 domain-targeting STAT3 inhibitor leads to metabolic synthetic lethality in cancer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E4924-E4933.	3.3	80
682	Functional Optical Imaging of Primary Human Tumor Organoids: Development of a Personalized Drug Screen. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1367-1372.	2.8	33

#	ARTICLE	IF	CITATIONS
683	Intrinsic protein disorder in oncogenic KRAS signaling. <i>Cellular and Molecular Life Sciences</i> , 2017, 74, 3245-3261.	2.4	45
684	A combinatorial screen of the CLOUD uncovers a synergy targeting the androgen receptor. <i>Nature Chemical Biology</i> , 2017, 13, 771-778.	3.9	39
685	A Microfluidic Immunostaining System Enables Quality Assured and Standardized Immunohistochemical Biomarker Analysis. <i>Scientific Reports</i> , 2017, 7, 45968.	1.6	20
686	Fibroblast growth factor-mediated crosstalk in cancer etiology and treatment. <i>Developmental Dynamics</i> , 2017, 246, 493-501.	0.8	17
687	Discovery of 1,4-Benzodiazepine-2,5-dione (BZD) Derivatives as Dual Nucleotide Binding Oligomerization Domain Containing 1/2 (NOD1/NOD2) Antagonists Sensitizing Paclitaxel (PTX) To Suppress Lewis Lung Carcinoma (LLC) Growth in Vivo. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 5162-5192.	2.9	18
688	Thermo-sensitive polypeptide hydrogel for locally sequential delivery of two-pronged antitumor drugs. <i>Acta Biomaterialia</i> , 2017, 58, 44-53.	4.1	97
689	Light-driven liquid metal nanotransformers for biomedical theranostics. <i>Nature Communications</i> , 2017, 8, 15432.	5.8	327
690	The advancement of multidimensional QSAR for novel drug discovery - where are we headed?. <i>Expert Opinion on Drug Discovery</i> , 2017, 12, 1-16.	2.5	32
691	Pharmacokinetics and Drug Interactions Determine Optimum Combination Strategies in Computational Models of Cancer Evolution. <i>Cancer Research</i> , 2017, 77, 3908-3921.	0.4	56
692	Oncogenic Roles of the PI3K/AKT/mTOR Axis. <i>Current Topics in Microbiology and Immunology</i> , 2017, 407, 153-189.	0.7	242
693	Circulating Tumor Cells as Cancer Biomarkers in the Clinic. <i>Advances in Experimental Medicine and Biology</i> , 2017, 994, 1-41.	0.8	20
694	Monoclonal antibodies against autocrine motility factor suppress gastric cancer. <i>Oncology Letters</i> , 2017, 13, 4925-4932.	0.8	8
695	Proteomic changes in a childhood acute lymphoblastic leukemia cell line during the adaptation to vincristine. <i>Boletín Médico Del Hospital Infantil De México</i> , 2017, 74, 181-192.	0.2	5
696	Transcription factor EB is involved in autophagy-mediated chemoresistance to doxorubicin in human cancer cells. <i>Acta Pharmacologica Sinica</i> , 2017, 38, 1305-1316.	2.8	40
697	The within-host population dynamics of <i>Mycobacterium tuberculosis</i> vary with treatment efficacy. <i>Genome Biology</i> , 2017, 18, 71.	3.8	95
698	Tumor-specific delivery of doxorubicin through conjugation of pH-responsive peptide for overcoming drug resistance in cancer. <i>International Journal of Pharmaceutics</i> , 2017, 528, 322-333.	2.6	29
699	Selective intracellular vaporisation of antibody-conjugated phase-change nano-droplets in vitro. <i>Scientific Reports</i> , 2017, 7, 44077.	1.6	25
700	Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer. <i>Drugs</i> , 2017, 77, 813-827.	4.9	42

#	ARTICLE	IF	CITATIONS
701	Molecular Mechanism of Drug Resistance. , 2017, , 47-110.		14
702	Structure activity relationship and optimization of N-(3-(2-aminothiazol-4-yl)aryl)benzenesulfonamides as anti-cancer compounds against sensitive and resistant cells. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 2192-2196.	1.0	11
703	Molecular and Pharmacological Mechanisms of Drug Resistance:An Evolving Paradigm. <i>Handbook of Experimental Pharmacology</i> , 2017, 249, 1-12.	0.9	18
704	Lectin, Galactoside-Binding Soluble 3 Binding Protein Promotes 17-N-Allylamino-17-demethoxygeldanamycin Resistance through PI3K/Akt Pathway in Lung Cancer Cell Line. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1355-1365.	1.9	14
705	Can a nanoparticle that mimics <i>Salmonella</i> effectively combat tumor chemotherapy resistance?. <i>Nanomedicine</i> , 2017, 12, 705-710.	1.7	2
706	Perturbed Signaling and Role of Posttranslational Modifications in Cancer Drug Resistance. , 2017, , 483-510.		7
707	Nitroxide radical-containing nanoparticles as potential candidates for overcoming drug resistance in epidermoid cancers. <i>Polymer</i> , 2017, 116, 429-438.	1.8	22
708	Contribution of tumor endothelial cells to drug resistance: anti-angiogenic tyrosine kinase inhibitors act as p-glycoprotein antagonists. <i>Angiogenesis</i> , 2017, 20, 233-241.	3.7	22
709	Genome-Wide Screen Reveals sec21 Mutants of <i>Saccharomyces cerevisiae</i> Are Methotrexate-Resistant. <i>G3: Genes, Genomes, Genetics</i> , 2017, 7, 1251-1257.	0.8	3
710	3-Hydroxyterphenyllin, a natural fungal metabolite, induces apoptosis and S phase arrest in human ovarian carcinoma cells. <i>International Journal of Oncology</i> , 2017, 50, 1392-1402.	1.4	18
711	Drug Resistance in Cancer. , 2017, , 449-473.		2
712	Antiproliferative effects of ruthenium-based nucleolipidic nanoaggregates in human models of breast cancer in vitro: insights into their mode of action. <i>Scientific Reports</i> , 2017, 7, 45236.	1.6	46
713	Geniposide reverses multidrug resistance in vitro and in vivo by inhibiting the efflux function and expression of P-glycoprotein. <i>Experimental and Therapeutic Medicine</i> , 2017, 13, 437-442.	0.8	12
714	Cyclometalated Gold(III) Complexes Containing N-Heterocyclic Carbene Ligands Engage Multiple Anti-Cancer Molecular Targets. <i>Angewandte Chemie</i> , 2017, 129, 3950-3954.	1.6	31
715	Chemosensitizing Effect of Saikosaponin B on B16F10 Melanoma Cells. <i>Nutrition and Cancer</i> , 2017, 69, 505-511.	0.9	12
716	A peptide-decorated and curcumin-loaded mesoporous silica nanomedicine for effectively overcoming multidrug resistance in cancer cells. <i>RSC Advances</i> , 2017, 7, 16401-16409.	1.7	24
717	Phosphoproteomics Reveals HMGA1, a CK2 Substrate, as a Drug-Resistant Target in Non-Small Cell Lung Cancer. <i>Scientific Reports</i> , 2017, 7, 44021.	1.6	31
718	Microbiota: a key orchestrator of cancer therapy. <i>Nature Reviews Cancer</i> , 2017, 17, 271-285.	12.8	699

#	ARTICLE	IF	CITATIONS
719	3-O-(Z)-coumaroyloleanolic acid overcomes Cks1b-induced chemoresistance in lung cancer by inhibiting Hsp90 and MEK pathways. <i>Biochemical Pharmacology</i> , 2017, 135, 35-49.	2.0	19
720	Drug Resistance in Bacteria, Fungi, Malaria, and Cancer. , 2017, , .		13
721	Folate-decorated PEGylated triblock copolymer as a pH/reduction dual-responsive nanovehicle for targeted intracellular co-delivery of doxorubicin and Bcl-2 siRNA. <i>Materials Science and Engineering C</i> , 2017, 76, 659-672.	3.8	38
722	Novel indolizino[8,7-b]indole hybrids as anti-small cell lung cancer agents: Regioselective modulation of topoisomerase II inhibitory and DNA crosslinking activities. <i>European Journal of Medicinal Chemistry</i> , 2017, 127, 235-249.	2.6	23
723	Apigenin potentiates the antitumor activity of 5-FU on solid Ehrlich carcinoma: Crosstalk between apoptotic and JNK-mediated autophagic cell death platforms. <i>Toxicology and Applied Pharmacology</i> , 2017, 316, 27-35.	1.3	30
724	Tumor-Specific Multiple Stimuli-Activated Dendrimeric Nanoassemblies with Metabolic Blockade Surmount Chemotherapy Resistance. <i>ACS Nano</i> , 2017, 11, 416-429.	7.3	118
725	Acridine Inhibits Acquired Drug Resistance by Blocking the Epithelial-to-Mesenchymal Transition and the Unfolded Protein Response. <i>Translational Oncology</i> , 2017, 10, 59-69.	1.7	37
726	Switching Apoptosis to Ferroptosis: Metal-Organic Network for High-Efficiency Anticancer Therapy. <i>Nano Letters</i> , 2017, 17, 284-291.	4.5	359
727	Soluble guanylate cyclase stimulators increase sensitivity to cisplatin in head and neck squamous cell carcinoma cells. <i>Cancer Letters</i> , 2017, 389, 33-40.	3.2	8
728	Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma. <i>Cancer Discovery</i> , 2017, 7, 252-263.	7.7	384
729	Ex Vivo Engineering of the Tumor Microenvironment. <i>Cancer Drug Discovery and Development</i> , 2017, , .	0.2	4
730	Introduction to Ex Vivo Cancer Models. <i>Cancer Drug Discovery and Development</i> , 2017, , 1-12.	0.2	1
731	Targeted Biomimetic Nanoparticles for Synergistic Combination Chemotherapy of Paclitaxel and Doxorubicin. <i>Molecular Pharmaceutics</i> , 2017, 14, 107-123.	2.3	74
732	Human influences on evolution, and the ecological and societal consequences. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2017, 372, 20160028.	1.8	202
734	Extracellular Matrix Remodeling and Stiffening Modulate Tumor Phenotype and Treatment Response. <i>Annual Review of Cancer Biology</i> , 2017, 1, 313-334.	2.3	101
735	Diagnostic and Therapeutic Potential of Exosomes in Cancer: The Beginning of a New Tale?. <i>Journal of Cellular Physiology</i> , 2017, 232, 3251-3260.	2.0	107
736	Targeted Degradation of Proteins Localized in Subcellular Compartments by Hybrid Small Molecules. <i>Molecular Pharmacology</i> , 2017, 91, 159-166.	1.0	45
737	Identification of acetylshikonin as the novel CYP2J2 inhibitor with anti-cancer activity in HepG2 cells. <i>Phytomedicine</i> , 2017, 24, 134-140.	2.3	35

#	ARTICLE	IF	CITATIONS
738	Role of cytochrome P450 2J2 on cell proliferation and resistance to an anticancer agent in hepatocellular carcinoma HepG2 cells. <i>Oncology Letters</i> , 2017, 14, 5484-5490.	0.8	9
739	Dual-target cancer theranostic for glutathione S-transferase and hypoxia-inducible factor-1 α inhibition. <i>Chemical Communications</i> , 2017, 53, 12406-12409.	2.2	11
740	Elacridar, a third-generation ABCB1 inhibitor, overcomes resistance to docetaxel in non-small cell lung cancer. <i>Oncology Letters</i> , 2017, 14, 4349-4354.	0.8	15
741	A Targetable EGFR-Dependent Tumor-Initiating Program in Breast Cancer. <i>Cell Reports</i> , 2017, 21, 1140-1149.	2.9	70
742	Not only P-glycoprotein: Amplification of the ABCB1- containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins. <i>Drug Resistance Updates</i> , 2017, 32, 23-46.	6.5	109
743	Balaglitazone reverses P-glycoprotein-mediated multidrug resistance via upregulation of PTEN in a PPAR γ -dependent manner in leukemia cells. <i>Tumor Biology</i> , 2017, 39, 101042831771650.	0.8	41
744	Cancer stem cells revisited. <i>Nature Medicine</i> , 2017, 23, 1124-1134.	15.2	1,895
745	pH-, redox dual-sensitive poly(β -amino ester)-g-TPGS copolymer nanoparticles for drug delivery and inhibition of multidrug resistance in cancer. <i>Reactive and Functional Polymers</i> , 2017, 120, 131-138.	2.0	16
746	Spatially graded hydrogels for preclinical testing of glioblastoma anticancer therapeutics. <i>MRS Communications</i> , 2017, 7, 442-449.	0.8	22
747	Predicting ligand-dependent tumors from multi-dimensional signaling features. <i>Npj Systems Biology and Applications</i> , 2017, 3, 27.	1.4	39
748	Computational Approaches to Identify Genetic Interactions for Cancer Therapeutics. <i>Journal of Integrative Bioinformatics</i> , 2017, 14, .	1.0	5
749	The design of peptide-grafted graphene oxide targeting the actin cytoskeleton for efficient cancer therapy. <i>Chemical Communications</i> , 2017, 53, 11433-11436.	2.2	16
750	Brachyury-YAP Regulatory Axis Drives Stemness and Growth in Cancer. <i>Cell Reports</i> , 2017, 21, 495-507.	2.9	59
751	CRISPR-Cas9-mediated saturated mutagenesis screen predicts clinical drug resistance with improved accuracy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 11751-11756.	3.3	50
752	Doxorubicin-loaded micelles of amphiphilic diblock copolymer with pendant dendron improve antitumor efficacy: In vitro and in vivo studies. <i>International Journal of Pharmaceutics</i> , 2017, 534, 136-143.	2.6	11
753	Leveraging Chemotype-Specific Resistance for Drug Target Identification and Chemical Biology. <i>Trends in Pharmacological Sciences</i> , 2017, 38, 1100-1109.	4.0	30
754	Nano-therapeutic Approaches for Targeting Cancer Stem Cells. , 2017, , 117-137.		0
755	New Generation Nanomedicines Constructed from Self-Assembling Small-Molecule Prodrugs Alleviate Cancer Drug Toxicity. <i>Cancer Research</i> , 2017, 77, 6963-6974.	0.4	128

#	ARTICLE	IF	CITATIONS
756	Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice. <i>Journal of Visualized Experiments</i> , 2017, , .	0.2	4
757	P2Y2 Receptor Functions in Cancer: A Perspective in the Context of Colorectal Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1051, 91-106.	0.8	5
758	Molecular mechanisms and clinical implications of miRNAs in drug resistance of esophageal cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 1151-1163.	1.4	28
759	Genome-Scale Genetic Interactions and Cell Imaging Confirm Cytokinesis as Deleterious to Transient Topoisomerase II Deficiency in <i>Saccharomyces cerevisiae</i> . <i>G3: Genes, Genomes, Genetics</i> , 2017, 7, 3379-3391.	0.8	8
760	Endoplasmic reticulum stress signaling and chemotherapy resistance in solid cancers. <i>Oncogenesis</i> , 2017, 6, e373-e373.	2.1	186
761	Tumor-homing, pH- and ultrasound-responsive polypeptide-doxorubicin nanoconjugates overcome doxorubicin resistance in cancer therapy. <i>Journal of Controlled Release</i> , 2017, 264, 66-75.	4.8	58
762	Anticancer Hybrids. , 2017, , 193-218.		8
763	PEGylated anticancer-carbon nanotubes complex targeting mitochondria of lung cancer cells. <i>Nanotechnology</i> , 2017, 28, 465102.	1.3	53
764	A Novel Arylurea Fatty Acid That Targets the Mitochondrion and Depletes Cardiolipin To Promote Killing of Breast Cancer Cells. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 8661-8666.	2.9	17
765	Visualizing Breast Cancer Cell Proliferation and Invasion for Assessing Drug Efficacy with a Fluorescent Nanoprobe. <i>Analytical Chemistry</i> , 2017, 89, 10601-10607.	3.2	27
766	Overcoming key biological barriers to cancer drug delivery and efficacy. <i>Journal of Controlled Release</i> , 2017, 267, 15-30.	4.8	92
767	IHC-based subcellular quantification provides new insights into prognostic relevance of FLIP and procaspase-8 in non-small-cell lung cancer. <i>Cell Death Discovery</i> , 2017, 3, 17050.	2.0	5
768	Use of Biocompatible Sorafenib-gold Nanoconjugates for Reversal of Drug Resistance in Human Hepatoblastoma Cells. <i>Scientific Reports</i> , 2017, 7, 8539.	1.6	18
769	SH003 reverses drug resistance by blocking signal transducer and activator of transcription 3 (STAT3) signaling in breast cancer cells. <i>Bioscience Reports</i> , 2017, 37, .	1.1	17
770	A dynamical framework for complex fractional killing. <i>Scientific Reports</i> , 2017, 7, 8002.	1.6	20
771	The medicinal chemistry of ferrocene and its derivatives. <i>Nature Reviews Chemistry</i> , 2017, 1, .	13.8	372
772	Codelivery for Paclitaxel and Bcl-2 Conversion Gene by PHB- ϵ -PDMAEMA Amphiphilic Cationic Copolymer for Effective Drug Resistant Cancer Therapy. <i>Macromolecular Bioscience</i> , 2017, 17, 1700186.	2.1	55
773	Pharmacological evaluation of phytochemicals from South Indian Black Turmeric (<i>Curcuma caesia</i>) Tj ETQq1 1 0.784314 rgBTJ /Overlock	2.0	28

#	ARTICLE	IF	CITATIONS
774	Cancer recurrence monitoring using hyperpolarized [1-13C]pyruvate metabolic imaging in murine breast cancer model. <i>Magnetic Resonance Imaging</i> , 2017, 43, 105-109.	1.0	13
775	18F-Labeled Carboplatin Derivative for PET Imaging of Platinum Drug Distribution. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1997-2003.	2.8	7
776	Regulatory players of DNA damage repair mechanisms: Role in Cancer Chemoresistance. <i>Biomedicine and Pharmacotherapy</i> , 2017, 93, 1238-1245.	2.5	59
777	Discovery of 9H-purins as potential tubulin polymerization inhibitors: Synthesis, biological evaluation and structure-activity relationships. <i>European Journal of Medicinal Chemistry</i> , 2017, 138, 1126-1134.	2.6	10
778	An efficient one-pot approach for the regio- and diastereoselective synthesis of trans-dihydrofuran derivatives: cytotoxicity and DNA-binding studies. <i>Organic and Biomolecular Chemistry</i> , 2017, 15, 6837-6853.	1.5	25
779	Chemical genetics in drug discovery. <i>Current Opinion in Systems Biology</i> , 2017, 4, 35-42.	1.3	26
780	Postsynthetic Modification of ZIF-90 for Potential Targeted Codelivery of Two Anticancer Drugs. <i>ACS Applied Materials & Interfaces</i> , 2017, 9, 27332-27337.	4.0	146
781	Role of Surface Hydrophobicity of Dicationic Amphiphile-Stabilized Gold Nanoparticles on A549 Lung Cancer Cells. <i>ACS Omega</i> , 2017, 2, 3527-3538.	1.6	28
782	pH-Responsive prodrug nanoparticles based on a sodium alginate derivative for selective co-release of doxorubicin and curcumin into tumor cells. <i>Nanoscale</i> , 2017, 9, 12533-12542.	2.8	102
783	Colony Lysate Arrays for Proteomic Profiling of Drug-Tolerant Persisters of Cancer Cell. <i>Analytical Chemistry</i> , 2017, 89, 8626-8631.	3.2	3
784	Covalent, Non-Covalent, Encapsulated Nanodrug Regulate the Fate of Intra- and Extracellular Trafficking: Impact on Cancer and Normal Cells. <i>Scientific Reports</i> , 2017, 7, 6454.	1.6	21
785	Combining TRAIL and liquiritin exerts synergistic effects against human gastric cancer cells and xenograft in nude mice through potentiating apoptosis and ROS generation. <i>Biomedicine and Pharmacotherapy</i> , 2017, 93, 948-960.	2.5	24
786	Tumor microenvironment confers mTOR inhibitor resistance in invasive intestinal adenocarcinoma. <i>Oncogene</i> , 2017, 36, 6480-6489.	2.6	27
787	Visfatin mediates doxorubicin resistance in human non-small cell lung cancer via Akt-mediated upregulation of ABCG1. <i>Cell Proliferation</i> , 2017, 50, .	2.4	21
788	Overexpression of NAC1 confers drug resistance via HOXA9 in colorectal carcinoma cells. <i>Molecular Medicine Reports</i> , 2017, 16, 3194-3200.	1.1	18
789	Isolation of Human Mesenchymal Stem Cells for Studying ErbB Receptor Signaling. <i>Methods in Molecular Biology</i> , 2017, 1652, 295-300.	0.4	0
790	Molecular Imaging of P-glycoprotein in Chemoresistant Tumors Using a Dual-Modality PET/Fluorescence Probe. <i>Molecular Pharmaceutics</i> , 2017, 14, 3391-3398.	2.3	18
791	ncDR: a comprehensive resource of non-coding RNAs involved in drug resistance. <i>Bioinformatics</i> , 2017, 33, 4010-4011.	1.8	48

#	ARTICLE	IF	CITATIONS
792	Synergistic antitumor effects of combination treatment with metronomic doxorubicin and VEGF-targeting RNAi nanoparticles. <i>Journal of Controlled Release</i> , 2017, 267, 203-213.	4.8	35
793	Hyperosmotic stress enhances cytotoxicity of SMAC mimetics. <i>Cell Death and Disease</i> , 2017, 8, e2967-e2967.	2.7	9
794	Auric Chloride Induced Micellization on Fractal Patterned Dicationic Amphiphiles and Stabilization of Gold Nanoparticles. <i>ACS Omega</i> , 2017, 2, 3539-3550.	1.6	4
795	Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. <i>Nature Medicine</i> , 2017, 23, 1063-1071.	15.2	240
796	ErbB Receptor Signaling. <i>Methods in Molecular Biology</i> , 2017, , .	0.4	10
797	Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents. <i>European Journal of Medicinal Chemistry</i> , 2017, 142, 271-289.	2.6	167
798	Dual Effects of N,N-dimethylformamide on Cell Proliferation and Apoptosis in Breast Cancer. <i>Dose-Response</i> , 2017, 15, 155932581774445.	0.7	14
800	Augmentation of Anticancer Drug Efficacy in Murine Hepatocellular Carcinoma Cells by a Peripherally Acting Competitive <i>N</i> -Methyl-D-aspartate (NMDA) Receptor Antagonist. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 9885-9904.	2.9	27
801	In vitro modulation of the cytochrome P450 and ABCB1/P-glycoprotein activities of the aqueous extract of <i>Allophylus cominia</i> (L) Sw. leaves. <i>Drug Metabolism and Personalized Therapy</i> , 2017, 32, 201-208.	0.3	1
802	Oral Cancer Stem Cells Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1041, 207-233.	0.8	11
803	DNA binding and Topoisomerase inhibition: How can these mechanisms be explored to design more specific anticancer agents?. <i>Biomedicine and Pharmacotherapy</i> , 2017, 96, 1538-1556.	2.5	38
804	Reversal of drug-resistance by noscapine chemo-sensitization in docetaxel resistant triple negative breast cancer. <i>Scientific Reports</i> , 2017, 7, 15824.	1.6	31
805	Ferroquine, the next generation antimalarial drug, has antitumor activity. <i>Scientific Reports</i> , 2017, 7, 15896.	1.6	72
806	From bench to clinical trials the EORTC experience in biology-based clinical cancer research. <i>Journal of the Egyptian National Cancer Institute</i> , 2017, 29, 171-176.	0.6	0
807	LAMPs: Shedding light on cancer biology. <i>Seminars in Oncology</i> , 2017, 44, 239-253.	0.8	103
808	Red Blood Cells for Drug Delivery. <i>Small Methods</i> , 2017, 1, 1700270.	4.6	62
809	Hyaluronic Acid Layered Chimeric Nanoparticles: Targeting MAPK-PI3K Signaling Hub in Colon Cancer Cells. <i>ACS Omega</i> , 2017, 2, 7868-7880.	1.6	14
810	Beta-mangostin from <i>Cratoxylum arborescens</i> activates the intrinsic apoptosis pathway through reactive oxygen species with downregulation of the HSP70 gene in the HL60 cells associated with a G ₀ /G ₁ cell-cycle arrest. <i>Tumor Biology</i> , 2017, 39, 101042831773145.	0.8	16

#	ARTICLE	IF	CITATIONS
811	Hit discovery of 4-amino- N -(4-(3-(trifluoromethyl)phenoxy)pyrimidin-5-yl)benzamide: A novel EGFR inhibitor from a designed small library. <i>Bioorganic Chemistry</i> , 2017, 75, 393-405.	2.0	25
812	YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC. <i>Neoplasia</i> , 2017, 19, 1012-1021.	2.3	77
813	Co-delivery of doxorubicin and methotrexate by dendritic chitosan-g-mPEG as a magnetic nanocarrier for multi-drug delivery in combination chemotherapy. <i>Polymer Chemistry</i> , 2017, 8, 7333-7350.	1.9	98
814	Hypoxia-induced mobilization of NHE6 to the plasma membrane triggers endosome hyperacidification and chemoresistance. <i>Nature Communications</i> , 2017, 8, 15884.	5.8	54
815	Co-delivery of paclitaxel and anti-survivin siRNA via redox-sensitive oligopeptide liposomes for the synergistic treatment of breast cancer and metastasis. <i>International Journal of Pharmaceutics</i> , 2017, 529, 102-115.	2.6	68
816	Exploring Selection Bias by Causal Frailty Models. <i>Epidemiology</i> , 2017, 28, 379-386.	1.2	27
817	Targeting cancer cell integrins using gold nanorods in photothermal therapy inhibits migration through affecting cytoskeletal proteins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E5655-E5663.	3.3	151
818	Efficient Dual siRNA and Drug Delivery Using Engineered Lipoproteoplexes. <i>Biomacromolecules</i> , 2017, 18, 2688-2698.	2.6	14
819	Revisiting the IGF-1R as a breast cancer target. <i>Npj Precision Oncology</i> , 2017, 1, .	2.3	75
820	Lessons Learned from Two Decades of Anticancer Drugs. <i>Trends in Pharmacological Sciences</i> , 2017, 38, 852-872.	4.0	74
821	Trackable Mitochondria-Targeting Nanomicellar Loaded with Doxorubicin for Overcoming Drug Resistance. <i>ACS Applied Materials & Interfaces</i> , 2017, 9, 25152-25163.	4.0	87
822	Overcoming multidrug resistance using folate receptor-targeted and pH-responsive polymeric nanogels containing covalently entrapped doxorubicin. <i>Nanoscale</i> , 2017, 9, 10404-10419.	2.8	58
823	Apigenin overcomes drug resistance by blocking the signal transducer and activator of transcription 3 signaling in breast cancer cells. <i>Oncology Reports</i> , 2017, 38, 715-724.	1.2	53
824	Proanthocyanidins from <i>Uncaria rhynchophylla</i> induced apoptosis in MDA-MB-231 breast cancer cells while enhancing cytotoxic effects of 5-fluorouracil. <i>Food and Chemical Toxicology</i> , 2017, 107, 248-260.	1.8	31
825	Inhibition of PI3K suppresses propagation of drug-tolerant cancer cell subpopulations enriched by 5-fluorouracil. <i>Scientific Reports</i> , 2017, 7, 2262.	1.6	8
826	Necroptosis in cancer: An angel or a demon?. <i>Tumor Biology</i> , 2017, 39, 101042831771153.	0.8	61
827	XLF-mediated NHEJ activity in hepatocellular carcinoma therapy resistance. <i>BMC Cancer</i> , 2017, 17, 344.	1.1	34
828	Modeling multi-mutation and drug resistance: analysis of some case studies. <i>Theoretical Biology and Medical Modelling</i> , 2017, 14, 6.	2.1	25

#	ARTICLE	IF	CITATIONS
829	Autophagy and multidrug resistance in cancer. <i>Chinese Journal of Cancer</i> , 2017, 36, 52.	4.9	497
830	Pro-apoptotic cationic host defense peptides rich in lysine or arginine to reverse drug resistance by disrupting tumor cell membrane. <i>Amino Acids</i> , 2017, 49, 1601-1610.	1.2	28
831	Dual Inhibition of PDK1 and Aurora Kinase A: An Effective Strategy to Induce Differentiation and Apoptosis of Human Glioblastoma Multiforme Stem Cells. <i>ACS Chemical Neuroscience</i> , 2017, 8, 100-114.	1.7	45
832	Pre-instillation of tumor microparticles enhances intravesical chemotherapy of nonmuscle-invasive bladder cancer through a lysosomal pathway. <i>Biomaterials</i> , 2017, 113, 93-104.	5.7	31
833	Transferrin-inspired vehicles based on pH-responsive coordination bond to combat multidrug-resistant breast cancer. <i>Biomaterials</i> , 2017, 113, 266-278.	5.7	61
834	Role of YAP/TAZ transcriptional regulators in resistance to anti-cancer therapies. <i>Cellular and Molecular Life Sciences</i> , 2017, 74, 1457-1474.	2.4	77
835	PIN1 in breast development and cancer: a clinical perspective. <i>Cell Death and Differentiation</i> , 2017, 24, 200-211.	5.0	51
836	Non-cell-autonomous Effects of Autophagy Inhibition in Tumor Cells Promote Growth of Drug-resistant Cells. <i>Molecular Pharmacology</i> , 2017, 91, 58-64.	1.0	11
837	Increasing the synthesis of bioactive abietane diterpenes in <i>Salvia sclarea</i> hairy roots by elicited transcriptional reprogramming. <i>Plant Cell Reports</i> , 2017, 36, 375-386.	2.8	39
838	Discovery and preclinical evaluation of 7-benzyl-N-(substituted)-pyrrolo[3,2-d]pyrimidin-4-amines as single agents with microtubule targeting effects along with triple-acting angiokinase inhibition as antitumor agents. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 545-556.	1.4	13
839	Curcumin promotes the oncolytic capacity of vesicular stomatitis virus for the treatment of prostate cancers. <i>Virus Research</i> , 2017, 228, 14-23.	1.1	15
840	Overcoming multidrug resistance via simultaneous delivery of cytostatic drug and P-glycoprotein inhibitor to cancer cells by HPMA copolymer conjugate. <i>Biomaterials</i> , 2017, 115, 65-80.	5.7	43
841	A drug-delivery strategy for overcoming drug resistance in breast cancer through targeting of oncofetal fibronectin. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2017, 13, 713-722.	1.7	38
842	The achievement of ligand-functionalized organic/polymeric nanoparticles for treating multidrug resistant cancer. <i>Expert Opinion on Drug Delivery</i> , 2017, 14, 937-957.	2.4	21
843	Semiconductor technology in protein kinase research and drug discovery: sensing a revolution. <i>Drug Discovery Today</i> , 2017, 22, 204-209.	3.2	4
844	Adaptive mechanisms of resistance to anti-neoplastic agents. <i>MedChemComm</i> , 2017, 8, 53-66.	3.5	12
845	Design new P-glycoprotein modulators based on molecular docking and CoMFA study of $\hat{1}\pm$, $\hat{2}$ -unsaturated carbonyl-based compounds and oxime analogs as anticancer agents. <i>Journal of Molecular Structure</i> , 2017, 1130, 922-928.	1.8	4
846	Drug resistance and cancer stem cells: the shared but distinct roles of hypoxia-inducible factors $\langle scp \rangle HIF \langle /scp \rangle 1\pm$ and $\langle scp \rangle HIF \langle /scp \rangle 2\pm$. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2017, 44, 153-161.	0.9	91

#	ARTICLE	IF	CITATIONS
847	PRPS1 silencing reverses cisplatin resistance in human breast cancer cells. <i>Biochemistry and Cell Biology</i> , 2017, 95, 385-393.	0.9	18
848	Targeting CXCR4 and FAK reverses doxorubicin resistance and suppresses invasion in non-small cell lung carcinoma. <i>Cellular Oncology (Dordrecht)</i> , 2017, 40, 47-62.	2.1	33
849	Defeat mutant <i>KRAS</i> with synthetic lethality. <i>Small GTPases</i> , 2017, 8, 212-219.	0.7	12
850	Potential role of bioactive peptides in prevention and treatment of chronic diseases: a narrative review. <i>British Journal of Pharmacology</i> , 2017, 174, 1378-1394.	2.7	219
851	Pogostone induces autophagy and apoptosis involving PI3K/Akt/mTOR axis in human colorectal carcinoma HCT116 cells. <i>Journal of Ethnopharmacology</i> , 2017, 202, 20-27.	2.0	39
852	Nanomedicine-based intraperitoneal therapy for the treatment of peritoneal carcinomatosis "Mission possible?". <i>Advanced Drug Delivery Reviews</i> , 2017, 108, 13-24.	6.6	76
853	Roles of tumor heterogeneity in the development of drug resistance: A call for precision therapy. <i>Seminars in Cancer Biology</i> , 2017, 42, 13-19.	4.3	54
854	Discovery of a Chemical Probe Bisamide (CCT251236): An Orally Bioavailable Efficacious Pirin Ligand from a Heat Shock Transcription Factor 1 (HSF1) Phenotypic Screen. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 180-201.	2.9	47
855	Synthesis of 4(3H)quinazolinimines with selective cytotoxic effect on human acute promyelocytic leukemia cells. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 2681-2688.	1.4	7
856	Acridone suppresses the proliferation of human breast cancer cells <i>in vitro</i> via ATP-binding cassette subfamily G member 2. <i>Oncology Letters</i> , 2018, 15, 2651-2654.	0.8	5
857	LIM kinase 1 serves an important role in the multidrug resistance of osteosarcoma cells. <i>Oncology Letters</i> , 2017, 15, 250-256.	0.8	7
858	Predicting and Overcoming Chemotherapeutic Resistance in Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1026, 59-104.	0.8	46
859	Drug-Triggered Self-Assembly of Linear Polymer into Nanoparticles for Simultaneous Delivery of Hydrophobic and Hydrophilic Drugs in Breast Cancer Cells. <i>ACS Omega</i> , 2017, 2, 8730-8740.	1.6	13
860	Inhibition of hedgehog pathway reveals the regulatory role of SMO in gastric cancer cells. <i>Tumor Biology</i> , 2017, 39, 101042831771554.	0.8	6
861	Proteomic changes in a childhood acute lymphoblastic leukemia cell line during the adaptation to vincristine. <i>Boletín Médico Del Hospital Infantil De México (English Edition)</i> , 2017, 74, 181-192.	0.0	1
862	PRMT5 Is a Critical Regulator of Breast Cancer Stem Cell Function via Histone Methylation and FOXP1 Expression. <i>Cell Reports</i> , 2017, 21, 3498-3513.	2.9	138
864	Src homology phosphotyrosyl phosphatase 2 mediates cisplatin-related drug resistance by inhibiting apoptosis and activating the Ras/PI3K/Akt1/survivin pathway in lung cancer cells. <i>Oncology Reports</i> , 2017, 39, 611-618.	1.2	15
865	Bafilomycin A1 triggers proliferative potential of senescent cancer cells <i>in vitro</i> and in NOD/SCID mice. <i>Oncotarget</i> , 2017, 8, 9303-9322.	0.8	40

#	ARTICLE	IF	CITATIONS
866	Managing CNS Tumors: The Nanomedicine Approach. , 2017, , .		2
867	Oxidative Stress, Nrf2, and Epigenetic Modification Contribute to Anticancer Drug Resistance. Toxicological Research, 2017, 33, 1-5.	1.1	80
868	The Role of Eukaryotic and Prokaryotic ABC Transporter Family in Failure of Chemotherapy. Frontiers in Pharmacology, 2016, 7, 535.	1.6	108
869	Tetrandrine, an Activator of Autophagy, Induces Autophagic Cell Death via PKC- ζ Inhibition and mTOR-Dependent Mechanisms. Frontiers in Pharmacology, 2017, 8, 351.	1.6	56
870	Epigenetic Modifications and Head and Neck Cancer: Implications for Tumor Progression and Resistance to Therapy. International Journal of Molecular Sciences, 2017, 18, 1506.	1.8	129
871	Marine Sponge Natural Products with Anticancer Potential: An Updated Review. Marine Drugs, 2017, 15, 310.	2.2	103
872	Design of polyaspartic acid peptide-poly (ethylene glycol)-poly (ε-caprolactone) nanoparticles as a carrier of hydrophobic drugs targeting cancer metastasized to bone. International Journal of Nanomedicine, 2017, Volume 12, 3561-3575.	3.3	25
873	Lung Cancer Stem Cells: An Epigenetic Perspective. Current Cancer Drug Targets, 2017, 18, 16-31.	0.8	10
874	Low-density lipoprotein-coupled micelles with reduction and pH dual sensitivity for intelligent co-delivery of paclitaxel and siRNA to breast tumor. International Journal of Nanomedicine, 2017, Volume 12, 3375-3393.	3.3	52
875	Antitumoural Sulphur and Selenium Heteroaryl Compounds: Thermal Characterization and Stability Evaluation. Molecules, 2017, 22, 1314.	1.7	3
876	Cancer's Achilles' Heel: Apoptosis and Necroptosis to the Rescue. International Journal of Molecular Sciences, 2017, 18, 23.	1.8	64
877	Epithelial-to-Pericyte Transition in Cancer. Cancers, 2017, 9, 77.	1.7	12
878	F-Box Protein FBXO22 Mediates Polyubiquitination and Degradation of CD147 to Reverse Cisplatin Resistance of Tumor Cells. International Journal of Molecular Sciences, 2017, 18, 212.	1.8	25
879	Evaluation of Apoptosis and Autophagy Inducing Potential of Berberis aristata, Azadirachta indica, and Their Synergistic Combinations in Parental and Resistant Human Osteosarcoma Cells. Frontiers in Oncology, 2017, 7, 296.	1.3	15
880	Kinase-Centric Computational Drug Development. Annual Reports in Medicinal Chemistry, 2017, , 197-236.	0.5	9
881	ZEB1 Promotes Oxaliplatin Resistance through the Induction of Epithelial - Mesenchymal Transition in Colon Cancer Cells. Journal of Cancer, 2017, 8, 3555-3566.	1.2	40
882	Super Aqueous Solubility of Albendazole in β -Cyclodextrin for Parenteral Application in Cancer therapy. Journal of Cancer, 2017, 8, 913-923.	1.2	17
883	Long noncoding RNA &emph;CRNDE&emph; functions as a competing endogenous RNA to promote metastasis and oxaliplatin resistance by sponging miR-136 in colorectal cancer. OncoTargets and Therapy, 2017, Volume 10, 205-216.	1.0	74

#	ARTICLE	IF	CITATIONS
884	The Different Mechanisms of Cancer Drug Resistance: A Brief Review. <i>Advanced Pharmaceutical Bulletin</i> , 2017, 7, 339-348.	0.6	1,143
885	Molecular Mimics of Classic P-Glycoprotein Inhibitors as Multidrug Resistance Suppressors and Their Synergistic Effect on Paclitaxel. <i>PLoS ONE</i> , 2017, 12, e0168938.	1.1	22
886	Co-Targeting IGF-1R and Autophagy Enhances the Effects of Cell Growth Suppression and Apoptosis Induced by the IGF-1R Inhibitor NVP-AEW541 in Triple-Negative Breast Cancer Cells. <i>PLoS ONE</i> , 2017, 12, e0169229.	1.1	23
887	Multi-scale model of drug induced adaptive resistance of Gram-negative bacteria to polymyxin B. <i>PLoS ONE</i> , 2017, 12, e0171834.	1.1	5
888	Acquired resistance to oxaliplatin is not directly associated with increased resistance to DNA damage in SK-N-ASrOXALI4000, a newly established oxaliplatin-resistant sub-line of the neuroblastoma cell line SK-N-AS. <i>PLoS ONE</i> , 2017, 12, e0172140.	1.1	6
889	Studies of the antitumor mechanism of action of dermaseptin B2, a multifunctional cationic antimicrobial peptide, reveal a partial implication of cell surface glycosaminoglycans. <i>PLoS ONE</i> , 2017, 12, e0182926.	1.1	29
890	Nitric Oxide Donors Sensitize Resistant Cancer Cells to Apoptosis Induced by Chemotherapy: Molecular Mechanisms of Sensitization. , 2017, , 15-34.		2
891	Bortezomib Alone and in Combination With Salinosporamid A Induces Apoptosis and Promotes Pheochromocytoma Cell Death In Vitro and in Female Nude Mice. <i>Endocrinology</i> , 2017, 158, 3097-3108.	1.4	10
892	Transcriptional and Post-Transcriptional Regulation of Thrombospondin-1 Expression: A Computational Model. <i>PLoS Computational Biology</i> , 2017, 13, e1005272.	1.5	18
893	Prediction of drug cocktail effects when the number of measurements is limited. <i>PLoS Biology</i> , 2017, 15, e2002518.	2.6	32
894	Annexin A2 contributes to cisplatin resistance by activation of JNK-p53 pathway in non-small cell lung cancer cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 123.	3.5	74
895	Cisplatin triggers cancer stem cell enrichment in platinum-resistant cells through NF- κ B-TNF α -PIK3CA loop. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 164.	3.5	75
896	The small vesicular culprits: the investigation of extracellular vesicles as new targets for cancer treatment. <i>Clinical and Translational Medicine</i> , 2017, 6, 45.	1.7	29
897	Array comparative genomic hybridization of 18 pancreatic ductal adenocarcinomas and their autologous metastases. <i>BMC Research Notes</i> , 2017, 10, 560.	0.6	8
898	Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study. <i>Breast Cancer Research</i> , 2017, 19, 130.	2.2	53
899	A network modeling approach to elucidate drug resistance mechanisms and predict combinatorial drug treatments in breast cancer. <i>Cancer Convergence</i> , 2017, 1, 5.	8.0	50
900	New perspectives of cobalt tris(bipyridine) system: anti-cancer effect and its collateral sensitivity towards multidrug-resistant (MDR) cancers. <i>Oncotarget</i> , 2017, 8, 55003-55021.	0.8	27
901	Base Excision Repair Manipulation in Breast Carcinoma: A Prospective Avenue to Potentiate Genome Insulting Approach. <i>Oncomedicine</i> , 2017, 2, 42-51.	1.1	3

#	ARTICLE	IF	CITATIONS
902	Chemotherapeutics-induced Oct4 expression contributes to drug resistance and tumor recurrence in bladder cancer. <i>Oncotarget</i> , 2017, 8, 30844-30858.	0.8	48
903	miR-93 and PTEN: Key regulators of doxorubicin-resistance and EMT in breast cancer. <i>Oncology Reports</i> , 2017, 38, 2401-2407.	1.2	33
904	Doxorubicin/Ce6-Loaded Nanoparticle Coated with Polymer via Singlet Oxygen-Sensitive Linker for Photodynamically Assisted Chemotherapy. <i>Nanotheranostics</i> , 2017, 1, 196-207.	2.7	28
905	Differential pharmacology and clinical utility of sonidegib in advanced basal cell carcinoma. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 515-520.	1.0	6
906	Integrated analysis profiles of long non-coding RNAs reveal potential biomarkers of drug resistance in lung cancer. <i>Oncotarget</i> , 2017, 8, 62868-62879.	0.8	12
907	Microtubule-associated protein tau is associated with the resistance to docetaxel in prostate cancer cell lines. <i>Research and Reports in Urology</i> , 2017, Volume 9, 71-77.	0.6	23
908	Lipid-based nanocarriers for cancer gene therapy. , 2017, , 239-280.		3
909	Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer. <i>Cancer Biology and Medicine</i> , 2017, 14, 212.	1.4	98
910	Three-dimensional bio-printing: A new frontier in oncology research. <i>World Journal of Clinical Oncology</i> , 2017, 8, 21.	0.9	55
911	In vitro single-strand DNA damage and cancer cell cytotoxicity effects of Temozolomide. <i>Oncomedicine</i> , 2017, 2, 102-110.	1.1	1
912	Clinical and biological significance of circulating tumor cells, circulating tumor DNA, and exosomes as biomarkers in colorectal cancer. <i>Oncotarget</i> , 2017, 8, 55632-55645.	0.8	116
913	Gambogic acid inhibits fibroblast growth factor receptor signaling pathway in erlotinib-resistant non-small-cell lung cancer and suppresses patient-derived xenograft growth. <i>Cell Death and Disease</i> , 2018, 9, 262.	2.7	43
914	Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy. <i>Cancer Letters</i> , 2018, 419, 210-221.	3.2	251
915	Translational models of tumor angiogenesis: A nexus of in silico and in vitro models. <i>Biotechnology Advances</i> , 2018, 36, 880-893.	6.0	39
916	Enzyme Degradable Hyperbranched Polyphosphoester Micellar Nanomedicines for NIR Imaging-Guided Chemo-Photothermal Therapy of Drug-Resistant Cancers. <i>Biomacromolecules</i> , 2018, 19, 1130-1141.	2.6	28
917	A putative role for Discoidin Domain Receptor 1 in cancer chemoresistance. <i>Cell Adhesion and Migration</i> , 2018, 12, 1-4.	1.1	9
918	Synthesis and in vitro study of modified chitosan-polycaprolactam nanocomplex as delivery system. <i>International Journal of Biological Macromolecules</i> , 2018, 113, 1287-1293.	3.6	41
919	Inferences of individual drug responses across diverse cancer types using a novel competing endogenous RNA network. <i>Molecular Oncology</i> , 2018, 12, 1429-1446.	2.1	29

#	ARTICLE	IF	CITATIONS
920	BAG3 Overexpression and Cytoprotective Autophagy Mediate Apoptosis Resistance in Chemoresistant Breast Cancer Cells. <i>Neoplasia</i> , 2018, 20, 263-279.	2.3	71
921	In Vivo Phosphoproteome Analysis Reveals Kinome Reprogramming in Hepatocellular Carcinoma. <i>Molecular and Cellular Proteomics</i> , 2018, 17, 1067-1083.	2.5	27
922	Single cell polarity in liquid phase facilitates tumour metastasis. <i>Nature Communications</i> , 2018, 9, 887.	5.8	45
923	Comparative Photothermal Performance among Various Substoichiometric 2D Oxygen-Deficient Molybdenum Oxide Nanoflakes and In Vivo Toxicity. <i>Chemistry - A European Journal</i> , 2018, 24, 7417-7427.	1.7	23
924	New tools for old drugs: Functional genetic screens to optimize current chemotherapy. <i>Drug Resistance Updates</i> , 2018, 36, 30-46.	6.5	33
925	Dual function of programmed cell death 10 (PDCD10) in drug resistance. <i>Biomedicine and Pharmacotherapy</i> , 2018, 101, 129-136.	2.5	15
926	PHLDA1 Mediates Drug Resistance in Receptor Tyrosine Kinase-Driven Cancer. <i>Cell Reports</i> , 2018, 22, 2469-2481.	2.9	34
927	Design, synthesis and anticancer evaluation of novel spirobenzo[h]chromene and spirochromane derivatives with dual EGFR and B-RAF inhibitory activities. <i>European Journal of Medicinal Chemistry</i> , 2018, 150, 567-578.	2.6	40
928	Sensitization of tumor cells to chemotherapy by natural products: A systematic review of preclinical data and molecular mechanisms. <i>FAA-toterapA-Åc</i> , 2018, 129, 383-400.	1.1	72
929	Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: Challenges and opportunities. <i>Journal of Controlled Release</i> , 2018, 277, 1-13.	4.8	214
930	The Evolving Landscape of Brain Metastasis. <i>Trends in Cancer</i> , 2018, 4, 176-196.	3.8	194
931	Prognostic biomarkers for cholangiocarcinoma and their clinical implications. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 579-592.	1.1	10
932	Enantiomeric pairs of copper(II) polypyridyl-alanine complex salts: anticancer studies. <i>Transition Metal Chemistry</i> , 2018, 43, 479-496.	0.7	8
933	Imaging techniques to study drug transporter function in vivo. , 2018, 189, 104-122.		57
934	Down-regulation of FOXR2 inhibits non-small cell lung cancer cell proliferation and invasion through the Wnt/ β -catenin signaling pathway. <i>Biochemical and Biophysical Research Communications</i> , 2018, 500, 229-235.	1.0	22
935	Identification of COL4A1 as a potential gene conferring trastuzumab resistance in gastric cancer based on bioinformatics analysis. <i>Molecular Medicine Reports</i> , 2018, 17, 6387-6396.	1.1	42
936	Resistance of Colorectal Tumors to Anti-EGFR Antibodies. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2018, , 1-27.	0.1	1
937	Methotrexate-conjugated to polymer quantum dot for cytotoxicity effect improved against MCF-7 and Hela cells. <i>Medicinal Chemistry Research</i> , 2018, 27, 1578-1588.	1.1	6

#	ARTICLE	IF	CITATIONS
938	One-Step Preparation of pH-Responsive Polymeric Nanogels as Intelligent Drug Delivery Systems for Tumor Therapy. <i>Biomacromolecules</i> , 2018, 19, 2062-2070.	2.6	67
939	Pharmacokinetics and disposition of anlotinib, an oral tyrosine kinase inhibitor, in experimental animal species. <i>Acta Pharmacologica Sinica</i> , 2018, 39, 1048-1063.	2.8	48
940	Bile Acids Increase Doxorubicin Sensitivity in ABCC1-expressing Tumour Cells. <i>Scientific Reports</i> , 2018, 8, 5413.	1.6	11
941	LncRNA PlncRNA-1 overexpression inhibits the growth of breast cancer by upregulating TGF- β 1 and downregulating PHGDH. <i>Breast Cancer</i> , 2018, 25, 619-625.	1.3	16
942	Reverse of non-small cell lung cancer drug resistance induced by cancer-associated fibroblasts via a paracrine pathway. <i>Cancer Science</i> , 2018, 109, 944-955.	1.7	38
943	Cancer development and therapy resistance: spotlights on the dark side of the genome. , 2018, 189, 22-30.		21
944	Chemical probes and drug leads from advances in synthetic planning and methodology. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 333-352.	21.5	182
945	Inhibition of cancer stem cell like cells by a synthetic retinoid. <i>Nature Communications</i> , 2018, 9, 1406.	5.8	40
946	MicroRNA-130b targets PTEN to induce resistance to cisplatin in lung cancer cells by activating Wnt/ β -catenin pathway. <i>Cell Biochemistry and Function</i> , 2018, 36, 194-202.	1.4	47
947	6-Shogaol induces caspase-independent paraptosis in cancer cells via proteasomal inhibition. <i>Experimental Cell Research</i> , 2018, 364, 243-251.	1.2	29
948	A glutathione-responsive sulfur dioxide polymer prodrug as a nanocarrier for combating drug-resistance in cancer chemotherapy. <i>Biomaterials</i> , 2018, 178, 706-719.	5.7	130
949	Vincristine resistance in relapsed neuroblastoma can be efficiently overcome by Smac mimetic LCL161 treatment. <i>Journal of Pediatric Surgery</i> , 2018, 53, 2059-2064.	0.8	5
950	Does the use of melatonin overcome drug resistance in cancer chemotherapy?. <i>Life Sciences</i> , 2018, 196, 143-155.	2.0	44
951	Impairing Powerhouse in Colon Cancer Cells by Hydrazide-Hydrazone-Based Small Molecule. <i>ACS Omega</i> , 2018, 3, 1470-1481.	1.6	27
952	Integration of Antibody Array Technology into Drug Discovery and Development. <i>Assay and Drug Development Technologies</i> , 2018, 16, 74-95.	0.6	8
953	Genome-Scale Signatures of Gene Interaction from Compound Screens Predict Clinical Efficacy of Targeted Cancer Therapies. <i>Cell Systems</i> , 2018, 6, 343-354.e5.	2.9	40
954	Co-loading of photothermal agents and anticancer drugs into porous silicon nanoparticles with enhanced chemo-photothermal therapeutic efficacy to kill multidrug-resistant cancer cells. <i>Colloids and Surfaces B: Biointerfaces</i> , 2018, 164, 291-298.	2.5	28
955	Flavonoids from Chinese bayberry leaves induced apoptosis and G1 cell cycle arrest via Erk pathway in ovarian cancer cells. <i>European Journal of Medicinal Chemistry</i> , 2018, 147, 218-226.	2.6	60

#	ARTICLE	IF	CITATIONS
956	The dichotomous role of H ₂ S in cancer cell biology? <i>D</i> Å©jÅ vu all over again. <i>Biochemical Pharmacology</i> , 2018, 149, 205-223.	2.0	44
957	MiR-192 and miR-662 enhance chemoresistance and invasiveness of squamous cell lung carcinoma. <i>Lung Cancer</i> , 2018, 118, 111-118.	0.9	38
958	<i>PIK3R3</i> promotes chemotherapeutic sensitivity of colorectal cancer through <i>PIK3R3</i> /NF- κ B/TP pathway. <i>Cancer Biology and Therapy</i> , 2018, 19, 222-229.	1.5	19
959	Ultrasound-mediated synthesis, biological evaluation, docking and in vivo acute oral toxicity study of novel indolin-2-one coupled pyrimidine derivatives. <i>Research on Chemical Intermediates</i> , 2018, 44, 3031-3059.	1.3	8
960	BIM and NOXA are mitochondrial effectors of TAF6 \uparrow -driven apoptosis. <i>Cell Death and Disease</i> , 2018, 9, 70.	2.7	9
961	Bis-(5-substituted-2-thiono-1,3,5-thiadiazinan-3-yl) butane as a scaffold of anti-proliferative activity, blended by a multicomponent process. <i>Medicinal Chemistry Research</i> , 2018, 27, 1103-1110.	1.1	10
962	Identification of Collateral Sensitivity to Dihydroorotate Dehydrogenase Inhibitors in <i>Plasmodium falciparum</i> . <i>ACS Infectious Diseases</i> , 2018, 4, 508-515.	1.8	15
963	Controlled synthesis and size effects of multifunctional mesoporous silica nanosystem for precise cancer therapy. <i>Drug Delivery</i> , 2018, 25, 293-306.	2.5	42
964	The Current Landscape of 3D In Vitro Tumor Models: What Cancer Hallmarks Are Accessible for Drug Discovery?. <i>Advanced Healthcare Materials</i> , 2018, 7, 1701174.	3.9	66
965	Dynamically PEGylated and Borate-Coordination-Polymer-Coated Polydopamine Nanoparticles for Synergetic Tumor-Targeted, Chemo-Photothermal Combination Therapy. <i>Small</i> , 2018, 14, e1703968.	5.2	162
966	HOXA13 contributes to gastric carcinogenesis through DHRS2 interacting with MDM2 and confers 5-FU resistance by a p53-dependent pathway. <i>Molecular Carcinogenesis</i> , 2018, 57, 722-734.	1.3	39
967	Hierarchically Self-Assembled Supramolecular Host-Guest Delivery System for Drug Resistant Cancer Therapy. <i>Biomacromolecules</i> , 2018, 19, 1926-1938.	2.6	55
968	The Static Magnetic Field Remotely Boosts the Efficiency of Doxorubicin through Modulating ROS Behaviors. <i>Scientific Reports</i> , 2018, 8, 990.	1.6	32
969	ZEB1 confers chemotherapeutic resistance to breast cancer by activating ATM. <i>Cell Death and Disease</i> , 2018, 9, 57.	2.7	80
970	The effect of subcellular localization on the efficiency of EGFR-targeted VHH photosensitizer conjugates. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2018, 124, 63-72.	2.0	32
971	Doxorubicin and rhein loaded nanomicelles attenuates multidrug resistance in human ovarian cancer. <i>Biochemical and Biophysical Research Communications</i> , 2018, 498, 178-185.	1.0	25
972	Chemosensitizing effects of metformin on cisplatin- and paclitaxel-resistant ovarian cancer cell lines. <i>Pharmacological Reports</i> , 2018, 70, 409-417.	1.5	40
973	Thermoresponsive Supramolecular Chemotherapy by α -V α -Shaped Armed β -Cyclodextrin Star Polymer to Overcome Drug Resistance. <i>Advanced Healthcare Materials</i> , 2018, 7, e1701143.	3.9	38

#	ARTICLE	IF	CITATIONS
974	Tumor-associated macrophages and the tumor immune microenvironment of primary and recurrent epithelial ovarian cancer. <i>Human Pathology</i> , 2018, 74, 135-147.	1.1	39
975	Transporter Expression in Noncancerous and Cancerous Liver Tissue from Donors with Hepatocellular Carcinoma and Chronic Hepatitis C Infection Quantified by LC-MS/MS Proteomics. <i>Drug Metabolism and Disposition</i> , 2018, 46, 189-196.	1.7	43
976	Molecular Oncology of Breast Cancer. , 2018, , 282-307.e5.		16
977	Translation of combination nanodrugs into nanomedicines: lessons learned and future outlook. <i>Journal of Drug Targeting</i> , 2018, 26, 435-447.	2.1	26
978	Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 5108-5121.	2.9	260
979	ER Stress Signaling Promotes the Survival of Cancer "Persister Cells" Tolerant to EGFR Tyrosine Kinase Inhibitors. <i>Cancer Research</i> , 2018, 78, 1044-1057.	0.4	87
980	HDACis (class I), cancer stem cell, and phytochemicals: Cancer therapy and prevention implications. <i>Biomedicine and Pharmacotherapy</i> , 2018, 97, 1445-1453.	2.5	35
981	Resistance-breaking profiling and gene expression analysis on an organometallic Re ^I -phenanthridine complex reveal parallel activation of two apoptotic pathways. <i>MedChemComm</i> , 2018, 9, 173-180.	3.5	23
982	Redox Paradox: A Novel Approach to Therapeutics-Resistant Cancer. <i>Antioxidants and Redox Signaling</i> , 2018, 29, 1237-1272.	2.5	93
983	Correlation of Gli1 and HER2 expression in gastric cancer: Identification of novel target. <i>Scientific Reports</i> , 2018, 8, 397.	1.6	16
984	Structure activity relationships, multidrug resistance reversal and selectivity of heteroarylphenyl ABCG2 inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2018, 146, 483-500.	2.6	23
985	In Situ shRNA Synthesis on DNA-Poly(lactide) Nanoparticles to Treat Multidrug Resistant Breast Cancer. <i>Advanced Materials</i> , 2018, 30, 1705737.	11.1	62
986	Cracking the regulatory code of biosynthetic gene clusters as a strategy for natural product discovery. <i>Biochemical Pharmacology</i> , 2018, 153, 24-34.	2.0	64
987	Collapsing the Tumor Ecosystem: Preventing Adaptive Response to Treatment by Inhibiting Transcription. <i>Cancer Discovery</i> , 2018, 8, 17-19.	7.7	5
988	Intelligent MoS ₂ Nanotheranostic for Targeted and Enzyme-/pH-/NIR-Responsive Drug Delivery To Overcome Cancer Chemotherapy Resistance Guided by PET Imaging. <i>ACS Applied Materials & Interfaces</i> , 2018, 10, 4271-4284.	4.0	137
989	A Transformable Chimeric Peptide for Cell Encapsulation to Overcome Multidrug Resistance. <i>Small</i> , 2018, 14, e1703321.	5.2	70
990	Self-Assembled Coumarin Nanoparticle in Aqueous Solution as Selective Mitochondrial-Targeting Drug Delivery System. <i>ACS Applied Materials & Interfaces</i> , 2018, 10, 3380-3391.	4.0	39
991	Therapy-Educated Mesenchymal Stem Cells Enrich for Tumor-Initiating Cells. <i>Cancer Research</i> , 2018, 78, 1253-1265.	0.4	81

#	ARTICLE	IF	CITATIONS
992	KRDS: a web server for evaluating drug resistance mutations in kinases by molecular docking. <i>Journal of Cheminformatics</i> , 2018, 10, 20.	2.8	6
993	Cancer cell metabolic plasticity allows resistance to NAMPT inhibition but invariably induces dependence on LDHA. <i>Cancer & Metabolism</i> , 2018, 6, 1.	2.4	29
994	A temporal examination of calcium signaling in cancer- from tumorigenesis, to immune evasion, and metastasis. <i>Cell and Bioscience</i> , 2018, 8, 25.	2.1	49
995	Mesenchymal stem cells drive paclitaxel resistance in ErbB2/ErbB3-coexpressing breast cancer cells via paracrine of neuregulin 1. <i>Biochemical and Biophysical Research Communications</i> , 2018, 501, 212-219.	1.0	16
996	Nobiletin (NOB) suppresses autophagic degradation via over-expressing AKT pathway and enhances apoptosis in multidrug-resistant SKOV3/TAX ovarian cancer cells. <i>Biomedicine and Pharmacotherapy</i> , 2018, 103, 29-37.	2.5	29
997	O-GlcNAc elevation through activation of the hexosamine biosynthetic pathway enhances cancer cell chemoresistance. <i>Cell Death and Disease</i> , 2018, 9, 485.	2.7	62
998	Treatment resistance in urothelial carcinoma: an evolutionary perspective. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 495-509.	12.5	37
999	Importance of integrating nanotechnology with pharmacology and physiology for innovative drug delivery and therapy – an illustration with firsthand examples. <i>Acta Pharmacologica Sinica</i> , 2018, 39, 825-844.	2.8	85
1000	Dysregulation of mitochondrial dynamics proteins are a targetable feature of human tumors. <i>Nature Communications</i> , 2018, 9, 1677.	5.8	96
1001	Preparation of psoralen polymer-lipid hybrid nanoparticles and their reversal of multidrug resistance in MCF-7/ADR cells. <i>Drug Delivery</i> , 2018, 25, 1044-1054.	2.5	21
1002	Isoharringtonine inhibits breast cancer stem-like properties and STAT3 signaling. <i>Biomedicine and Pharmacotherapy</i> , 2018, 103, 435-442.	2.5	12
1003	Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e219-e240.	0.2	16
1004	Targeting Nicotinamide N-Methyltransferase and miR-449a in EGFR-TKI-Resistant Non-Small-Cell Lung Cancer Cells. <i>Molecular Therapy - Nucleic Acids</i> , 2018, 11, 455-467.	2.3	52
1005	The senescence-associated secretory phenotype is potentiated by feedforward regulatory mechanisms involving Zscan4 and TAK1. <i>Nature Communications</i> , 2018, 9, 1723.	5.8	95
1006	EPHB6 augments both development and drug sensitivity of triple-negative breast cancer tumours. <i>Oncogene</i> , 2018, 37, 4073-4093.	2.6	30
1007	A transfer learning approach via procrustes analysis and mean shift for cancer drug sensitivity prediction. <i>Journal of Bioinformatics and Computational Biology</i> , 2018, 16, 1840014.	0.3	34
1008	Nano-Engineered Mesenchymal Stem Cells Increase Therapeutic Efficacy of Anticancer Drug Through True Active Tumor Targeting. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1196-1206.	1.9	87
1009	Enzyme-MOF Nanoreactor Activates Nontoxic Paracetamol for Cancer Therapy. <i>Angewandte Chemie - International Edition</i> , 2018, 57, 5725-5730.	7.2	217

#	ARTICLE	IF	CITATIONS
1010	Beyond Tissue Stiffness and Bioadhesivity: Advanced Biomaterials to Model Tumor Microenvironments and Drug Resistance. <i>Trends in Cancer</i> , 2018, 4, 281-291.	3.8	36
1011	Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas. <i>Blood</i> , 2018, 131, 2125-2137.	0.6	96
1012	A Nonquiescent "elding" Population State in Drug-Treated, BRAF-Mutated Melanoma. <i>Biophysical Journal</i> , 2018, 114, 1499-1511.	0.2	34
1013	How the Warburg effect supports aggressiveness and drug resistance of cancer cells?. <i>Drug Resistance Updates</i> , 2018, 38, 1-11.	6.5	340
1014	Arylureas derived from colchicine: Enhancement of colchicine oncogene downregulation activity. <i>European Journal of Medicinal Chemistry</i> , 2018, 150, 817-828.	2.6	8
1015	Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies. <i>Immunity</i> , 2018, 48, 417-433.	6.6	416
1016	Aqueous extract of <i>Sapindus mukorossi</i> induced cell death of A549 cells and exhibited antitumor property in vivo. <i>Scientific Reports</i> , 2018, 8, 4831.	1.6	14
1017	Chemotherapeutic agents for the treatment of metastatic breast cancer: An update. <i>Biomedicine and Pharmacotherapy</i> , 2018, 101, 458-477.	2.5	124
1018	Enzyme-MOF Nanoreactor Activates Nontoxic Paracetamol for Cancer Therapy. <i>Angewandte Chemie</i> , 2018, 130, 5827-5832.	1.6	42
1019	An Enzyme-Directed Imidazoquinoline Activated by Drug Resistance. <i>Biochemistry</i> , 2018, 57, 2184-2188.	1.2	14
1020	Caveolin-1, cancer and therapy resistance. <i>International Journal of Cancer</i> , 2018, 143, 2092-2104.	2.3	94
1021	Targeting epigenetic pathway with gold nanoparticles for acute myeloid leukemia therapy. <i>Biomaterials</i> , 2018, 167, 80-90.	5.7	83
1022	Relevance of small GTPase Rac1 pathway in drug and radio-resistance mechanisms: Opportunities in cancer therapeutics. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 124, 29-36.	2.0	35
1023	Predictive approaches for drug combination discovery in cancer. <i>Briefings in Bioinformatics</i> , 2018, 19, 263-276.	3.2	75
1024	Epigenomics alternations and dynamic transcriptional changes in responses to 5-fluorouracil stimulation reveal mechanisms of acquired drug resistance of colorectal cancer cells. <i>Pharmacogenomics Journal</i> , 2018, 18, 23-28.	0.9	27
1025	Application of Combination High-Throughput Phenotypic Screening and Target Identification Methods for the Discovery of Natural Product-Based Combination Drugs. <i>Medicinal Research Reviews</i> , 2018, 38, 504-524.	5.0	55
1026	Actein enhances TRAIL effects on suppressing gastric cancer progression by activating p53/Caspase-3 signaling. <i>Biochemical and Biophysical Research Communications</i> , 2018, 497, 1177-1183.	1.0	12
1027	Breast cancer stem cells as last soldiers eluding therapeutic burn: A hard nut to crack. <i>International Journal of Cancer</i> , 2018, 142, 7-17.	2.3	32

#	ARTICLE	IF	CITATIONS
1028	Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers part 2: Neuroendocrine tumours, hepatocellular carcinoma, and gastro-intestinal stromal tumours. , 2018, 181, 49-75.		9
1029	Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression. <i>Cancer Discovery</i> , 2018, 8, 59-73.	7.7	96
1030	Panaxynol, a natural Hsp90 inhibitor, effectively targets both lung cancer stem and non-stem cells. <i>Cancer Letters</i> , 2018, 412, 297-307.	3.2	39
1031	Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1). <i>Molecular Cancer Therapeutics</i> , 2018, 17, 243-253.	1.9	117
1032	IL6 derived from cancer-associated fibroblasts promotes chemoresistance via CXCR7 in esophageal squamous cell carcinoma. <i>Oncogene</i> , 2018, 37, 873-883.	2.6	128
1033	Lab-on-a-chip systems for photodynamic therapy investigations. <i>Biosensors and Bioelectronics</i> , 2018, 101, 37-51.	5.3	35
1034	Physical and Chemical Enhancement of and Adaptive Resistance to Irreversible Electroporation of Pancreatic Cancer. <i>Annals of Biomedical Engineering</i> , 2018, 46, 25-36.	1.3	16
1035	Acid-activatable doxorubicin prodrug micelles with folate-targeted and ultra-high drug loading features for efficient antitumor drug delivery. <i>Journal of Materials Science</i> , 2018, 53, 892-907.	1.7	11
1036	Co-delivery of Vorinostat and Etoposide Via Disulfide Cross-Linked Biodegradable Polymeric Nanogels: Synthesis, Characterization, Biodegradation, and Anticancer Activity. <i>AAPS PharmSciTech</i> , 2018, 19, 634-647.	1.5	33
1037	Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical researchâ€practice gaps, challenges, and insights. <i>Medicinal Research Reviews</i> , 2018, 38, 325-376.	5.0	50
1038	Mitochondria-targeting self-assembled nanoparticles derived from triphenylphosphonium-conjugated cyanostilbene enable site-specific imaging and anticancer drug delivery. <i>Nano Research</i> , 2018, 11, 1082-1098.	5.8	39
1039	Biological evaluation of p-toluene sulphonylhydrazone as carbonic anhydrase IX inhibitors: An approach to fight hypoxia-induced tumors. <i>International Journal of Biological Macromolecules</i> , 2018, 106, 840-850.	3.6	52
1040	Overcoming STC2 mediated drug resistance through drug and gene co -delivery by PHB-PDMAEMA cationic polyester in liver cancer cells. <i>Materials Science and Engineering C</i> , 2018, 83, 210-217.	3.8	81
1041	A review of Tunisian medicinal plants with anticancer activity. <i>Journal of Complementary and Integrative Medicine</i> , 2018, 15, .	0.4	11
1043	Curcumin mediated downâ€regulation of β 3 integrin and upâ€regulation of pyruvate dehydrogenase kinase 4 (PDK4) in Erlotinib resistant SW480 colon cancer cells. <i>Phytotherapy Research</i> , 2018, 32, 355-364.	2.8	33
1044	Homo- and heteroleptic Pt(II) complexes of ONN donor hydrazone and 4-picoline: A synthetic, structural and detailed mechanistic anticancer investigation. <i>European Journal of Medicinal Chemistry</i> , 2018, 143, 1039-1052.	2.6	22
1045	Diffusion mapping of drug targets on disease signaling network elements reveals drug combination strategies. , 2018, , .		9
1046	Exosomal microRNA: a novel biomarker for breast cancer. <i>Biomarkers in Medicine</i> , 2018, 12, 177-188.	0.6	49

#	ARTICLE	IF	CITATIONS
1047	Improved photodynamic efficiency for methylene blue from silica-methylene blue@tannic acid-Fe(III) ions complexes in aqueous solutions. <i>Advanced Powder Technology</i> , 2018, 29, 341-348.	2.0	14
1048	High-Content Screening Comparison of Cancer Drug Accumulation and Distribution in Two-Dimensional and Three-Dimensional Culture Models of Head and Neck Cancer. <i>Assay and Drug Development Technologies</i> , 2018, 16, 27-50.	0.6	26
1049	Aptamers as potential therapeutic agents for ovarian cancer. <i>Biochimie</i> , 2018, 145, 34-44.	1.3	17
1050	The Impact of Di(2-ethylhexyl)phthalate on Cancer Progression. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2018, 66, 183-197.	1.0	20
1051	Acidity-triggered TAT-presenting nanocarriers augment tumor retention and nuclear translocation of drugs. <i>Nano Research</i> , 2018, 11, 5716-5734.	5.8	27
1052	Tumor cell-intrinsic phenotypic plasticity facilitates adaptive cellular reprogramming driving acquired drug resistance. <i>Journal of Cell Communication and Signaling</i> , 2018, 12, 133-141.	1.8	47
1053	Photodynamic Priming Mitigates Chemotherapeutic Selection Pressures and Improves Drug Delivery. <i>Cancer Research</i> , 2018, 78, 558-571.	0.4	70
1054	Heat shock proteins and cancer: intracellular chaperones or extracellular signalling ligands?. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2018, 373, 20160524.	1.8	84
1055	Modulating secreted components of tumor microenvironment: A masterstroke in tumor therapeutics. <i>Cancer Biology and Therapy</i> , 2018, 19, 3-12.	1.5	51
1056	Autophagy and doxorubicin resistance in cancer. <i>Anti-Cancer Drugs</i> , 2018, 29, 1-9.	0.7	136
1058	Near-infrared light for on-demand drug delivery. <i>Journal of Biomaterials Science, Polymer Edition</i> , 2018, 29, 750-761.	1.9	8
1059	Tetrandrine and cancer – An overview on the molecular approach. <i>Biomedicine and Pharmacotherapy</i> , 2018, 97, 624-632.	2.5	84
1060	pH-Sensitive mesoporous silica nanoparticles for chemo-photodynamic combination therapy. <i>Colloids and Surfaces B: Biointerfaces</i> , 2018, 161, 442-448.	2.5	42
1061	Glutathione reductase mediates drug resistance in glioblastoma cells by regulating redox homeostasis. <i>Journal of Neurochemistry</i> , 2018, 144, 93-104.	2.1	111
1062	Modulators of Redox Metabolism in Head and Neck Cancer. <i>Antioxidants and Redox Signaling</i> , 2018, 29, 1660-1690.	2.5	14
1063	Molecular mechanisms of drug resistance in ovarian cancer. <i>Journal of Cellular Physiology</i> , 2018, 233, 4546-4562.	2.0	146
1064	A miR-20a/MAPK1/c-Myc regulatory feedback loop regulates breast carcinogenesis and chemoresistance. <i>Cell Death and Differentiation</i> , 2018, 25, 406-420.	5.0	83
1065	Doxorubicin synergism and resistance reversal in human neuroblastoma BE(2)C cell lines: An in vitro study with dextran-catechin nanohybrids. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2018, 122, 176-185.	2.0	24

#	ARTICLE	IF	CITATIONS
1066	Nanoscaled red blood cells facilitate breast cancer treatment by combining photothermal/photodynamic therapy and chemotherapy. <i>Biomaterials</i> , 2018, 155, 25-40.	5.7	161
1067	PAX3-FOXO1: Zooming in on an "undruggable" target. <i>Seminars in Cancer Biology</i> , 2018, 50, 115-123.	4.3	39
1068	Cytotoxic Effect of (Z)-Ethylidene-4,6-Dimethoxycoumaran-3-One Isolated from <i>Pogostemon quadrifolius</i> (Benth.) on PC-3 and DU-145 Prostate Cancer Cells. <i>Proceedings of the National Academy of Sciences India Section B - Biological Sciences</i> , 2018, 88, 1581-1588.	0.4	4
1069	The anticancer effects of pharmacological inhibition of autophagy in acute erythroid leukemia cells. <i>Anti-Cancer Drugs</i> , 2018, 29, 944-955.	0.7	15
1070	Autophagy as a Potential Therapeutic Target in Breast Cancer Treatment. <i>Current Cancer Drug Targets</i> , 2018, 18, 629-639.	0.8	10
1071	Reversal of docetaxel resistance in prostate cancer by Notch signaling inhibition. <i>Anti-Cancer Drugs</i> , 2018, 29, 871-879.	0.7	22
1072	Identification of cisplatin sensitizers through high-throughput combinatorial screening. <i>International Journal of Oncology</i> , 2018, 53, 1237-1246.	1.4	5
1073	Synthesis, Characterization, and Cytotoxic Evaluation of Some Newly Substituted Diazene Candidates. <i>Journal of Chemistry</i> , 2018, 2018, 1-9.	0.9	1
1074	2-Amino-3-methylcarboxy-5-heptyl-thiophene (TJ191) is a selective anti-cancer small molecule that targets low T ¹ R ¹ III-expressing malignant T-cell leukemia/lymphoma cells. <i>Oncotarget</i> , 2018, 9, 6259-6269.	0.8	1
1075	Control Structures of Drug Resistance in Cancer Chemotherapy. , 2018, , .		3
1076	XRCC1 polymorphism and overall survival in ovarian cancer patients treated with platinum-based chemotherapy. <i>Medicine (United States)</i> , 2018, 97, e12996.	0.4	6
1077	ALMMS suite: a web server dedicated for prediction of drug resistance on protein mutation. <i>Briefings in Bioinformatics</i> , 2018, , .	3.2	18
1078	P-glycoprotein targeted photodynamic therapy of chemoresistant tumors using recombinant Fab fragment conjugates. <i>Biomaterials Science</i> , 2018, 6, 3063-3074.	2.6	11
1079	A Pt(IV)-mediated polymer architecture for facile and stimuli-responsive intracellular gene silencing with chemotherapy. <i>Biomaterials Science</i> , 2018, 6, 3345-3355.	2.6	6
1080	Iso-pencillixanthone A from a marine-derived fungus reverses multidrug resistance in cervical cancer cells through down-regulating P-gp and re-activating apoptosis. <i>RSC Advances</i> , 2018, 8, 41192-41206.	1.7	11
1081	Targeted delivery of paclitaxel by functionalized selenium nanoparticles for anticancer therapy through ROS-mediated signaling pathways. <i>RSC Advances</i> , 2018, 8, 39957-39966.	1.7	8
1082	Polysaccharide Nanoparticles for Targeted Cancer Therapies. <i>Current Drug Metabolism</i> , 2018, 19, 781-792.	0.7	14
1083	Systematic identification of mutations and copy number alterations associated with cancer patient prognosis. <i>ELife</i> , 2018, 7, .	2.8	126

#	ARTICLE	IF	CITATIONS
1084	Acquired and Intrinsic Resistance to Colorectal Cancer Treatment. , 2018, , .		6
1086	Systems-Mapping of Herbal Effects on Complex Diseases Using the Network-Perturbation Signatures. <i>Frontiers in Pharmacology</i> , 2018, 9, 1174.	1.6	18
1087	Signaling Pathways Induced by Leptin during Epithelialâ€Mesenchymal Transition in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3493.	1.8	39
1088	Long-Circulating Amphiphilic Doxorubicin for Tumor Mitochondria-Specific Targeting. <i>ACS Applied Materials & Interfaces</i> , 2018, 10, 43482-43492.	4.0	33
1089	Genomic Deoxyxylulose Phosphate Reductoisomerase (DXR) Mutations Conferring Resistance to the Antimalarial Drug Fosmidomycin in <i>E.Âcoli</i> . <i>ACS Synthetic Biology</i> , 2018, 7, 2824-2832.	1.9	11
1090	The Influence of Metabolism on Drug Response in Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 500.	1.3	182
1091	Exosomal transfer of miR-214 mediates gefitinib resistance in non-small cell lung cancer. <i>Biochemical and Biophysical Research Communications</i> , 2018, 507, 457-464.	1.0	61
1092	Longitudinal single-cell RNA sequencing of patient-derived primary cells reveals drug-induced infidelity in stem cell hierarchy. <i>Nature Communications</i> , 2018, 9, 4931.	5.8	134
1093	MALAYSIAN MEDICINAL PLANTSâ€™ POTENTIAL FOR BREAST CANCER THERAPY. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 2018, 11, 101.	0.3	4
1094	Effect of five novel 5â€substituted tetrandrine derivatives on Pâ€glycoproteinâ€mediated inhibition and transport in Cacoâ€2 cells. <i>Oncology Letters</i> , 2018, 16, 6808-6814.	0.8	5
1095	Synthesis and Discovery Novel Anti-Cancer Stem Cells Compounds Derived from the Natural Triterpenic Acids. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 10814-10833.	2.9	17
1096	3D Bioprinting of Breast Cancer Models for Drug Resistance Study. <i>ACS Biomaterials Science and Engineering</i> , 2018, 4, 4401-4411.	2.6	104
1097	Mechanisms of Drug Resistance in High-Grade Serous Ovarian Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 983-996.	0.9	94
1098	Targeting Thioredoxin System with an Organosulfur Compound, Diallyl Trisulfide (DATS), Attenuates Progression and Metastasis of Triple-Negative Breast Cancer (TNBC). <i>Cellular Physiology and Biochemistry</i> , 2018, 50, 1945-1963.	1.1	35
1099	Predicting Tumor Growth and Ligand Dependence from mRNA by Combining Machine Learning with Mechanistic Modeling. <i>Methods in Pharmacology and Toxicology</i> , 2018, , 1.	0.1	0
1100	Down-regulation of OGT promotes cisplatin resistance by inducing autophagy in ovarian cancer. <i>Theranostics</i> , 2018, 8, 5200-5212.	4.6	83
1101	Programming of Cell Resistance to Genotoxic and Oxidative Stress. <i>Biomedicines</i> , 2018, 6, 5.	1.4	13
1102	Adapted ATPase domain communication overcomes the cytotoxicity of p97 inhibitors. <i>Journal of Biological Chemistry</i> , 2018, 293, 20169-20180.	1.6	10

#	ARTICLE	IF	CITATIONS
1103	Transporter and Lysosomal Mediated (Multi)drug Resistance to Tyrosine Kinase Inhibitors and Potential Strategies to Overcome Resistance. <i>Cancers</i> , 2018, 10, 503.	1.7	44
1104	CD44 exerts a functional role during EMT induction in cisplatin-resistant head and neck cancer cells. <i>Oncotarget</i> , 2018, 9, 10029-10041.	0.8	38
1105	P-glycoprotein-targeted photodynamic therapy boosts cancer nanomedicine by priming tumor microenvironment. <i>Theranostics</i> , 2018, 8, 6274-6290.	4.6	34
1106	Measuring Single-Cell Phenotypic Growth Heterogeneity Using a Microfluidic Cell Volume Sensor. <i>Scientific Reports</i> , 2018, 8, 17809.	1.6	9
1107	Trastuzumab induces PUMA dependent apoptosis and inhibits tumor growth in gastric cancer. <i>FEBS Open Bio</i> , 2018, 8, 1911-1919.	1.0	7
1108	Sensitization of Drug Resistant Cancer Cells: A Matter of Combination Therapy. <i>Cancers</i> , 2018, 10, 483.	1.7	120
1109	Identification and validation of NOLC1 as a potential target for enhancing sensitivity in multidrug resistant non-small cell lung cancer cells. <i>Cellular and Molecular Biology Letters</i> , 2018, 23, 54.	2.7	16
1110	Tackling tumor heterogeneity and phenotypic plasticity in cancer precision medicine: our experience and a literature review. <i>Cancer and Metastasis Reviews</i> , 2018, 37, 655-663.	2.7	18
1111	miRâ€¹144â€³p regulates the resistance of lung cancer to cisplatin by targeting Nrf2. <i>Oncology Reports</i> , 2018, 40, 3479-3488.	1.2	28
1112	PI3K pathway in prostate cancer: All resistant roads lead to PI3K. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2018, 1870, 198-206.	3.3	27
1113	The Unfolded Protein Response in Breast Cancer. <i>Cancers</i> , 2018, 10, 344.	1.7	62
1114	Emerging ways to treat breast cancer: will promises be met?. <i>Cellular Oncology (Dordrecht)</i> , 2018, 41, 605-621.	2.1	43
1115	Reviving oncogenic addiction to MET bypassed by BRAF (G469A) mutation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 10058-10063.	3.3	17
1116	Scalable Multiplexed Drugâ€³Combination Screening Platforms Using 3D Microtumor Model for Precision Medicine. <i>Small</i> , 2018, 14, e1703617.	5.2	35
1117	Polyethylene Glycol-Encapsulated Histone Deacetylase Inhibitor Drug-Composite Nanoparticles for Combination Therapy with Artesunate. <i>ACS Omega</i> , 2018, 3, 11504-11516.	1.6	12
1118	In search of constrained FTY720 and phytosphingosine analogs as dual acting anticancer agents targeting metabolic and epigenetic pathways. <i>European Journal of Medicinal Chemistry</i> , 2018, 159, 217-242.	2.6	8
1119	Is adaptive therapy natural?. <i>PLoS Biology</i> , 2018, 16, e2007066.	2.6	23
1120	Discovery of traditional Chinese medicine monomers and their synthetic intermediates, analogs or derivatives for battling P-gp-mediated multi-drug resistance. <i>European Journal of Medicinal Chemistry</i> , 2018, 159, 381-392.	2.6	38

#	ARTICLE	IF	CITATIONS
1121	Synthesis, theoretical, spectroscopic and electrochemical DNA binding investigations of 1, 3, 4-thiadiazole derivatives of ibuprofen and ciprofloxacin: Cancer cell line studies. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2018, 189, 104-118.	1.7	60
1122	APOBEC3 Mediates Resistance to Oncolytic Viral Therapy. <i>Molecular Therapy - Oncolytics</i> , 2018, 11, 1-13.	2.0	14
1123	FOXC2 promotes epithelial-mesenchymal transition and cisplatin resistance of non-small cell lung cancer cells. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 1049-1059.	1.1	26
1124	Harnessing copper-palladium alloy tetrapod nanoparticle-induced pro-survival autophagy for optimized photothermal therapy of drug-resistant cancer. <i>Nature Communications</i> , 2018, 9, 4236.	5.8	139
1125	Dual-Targeted Supramolecular Vesicles Based on the Complex of Galactose Capped Pillar[5]Arene and Triphenylphosphonium Derivative for Drug Delivery. <i>Israel Journal of Chemistry</i> , 2018, 58, 1241-1245.	1.0	11
1126	Programmable Chemotherapy and Immunotherapy against Breast Cancer Guided by Multiplexed Fluorescence Imaging in the Second Near-Infrared Window. <i>Advanced Materials</i> , 2018, 30, e1804437.	11.1	113
1127	Progression-dependent transport heterogeneity of breast cancer liver metastases as a factor in therapeutic resistance. <i>Journal of Controlled Release</i> , 2018, 291, 99-105.	4.8	13
1128	Novel dihydroartemisinin derivative DHA-37 induces autophagic cell death through upregulation of HMGB1 in A549 cells. <i>Cell Death and Disease</i> , 2018, 9, 1048.	2.7	29
1129	Targeting SPINK1 in the damaged tumour microenvironment alleviates therapeutic resistance. <i>Nature Communications</i> , 2018, 9, 4315.	5.8	82
1130	Raman micro-spectroscopy monitors acquired resistance to targeted cancer therapy at the cellular level. <i>Scientific Reports</i> , 2018, 8, 15278.	1.6	26
1131	Overcoming multiple drug resistance in cancer using polymeric micelles. <i>Expert Opinion on Drug Delivery</i> , 2018, 15, 1127-1142.	2.4	39
1132	The Role of Intercellular Communication in Cancer Progression. <i>Russian Journal of Bioorganic Chemistry</i> , 2018, 44, 473-480.	0.3	1
1133	Cyclin B1 stability is increased by interaction with BRCA1, and its overexpression suppresses the progression of BRCA1-associated mammary tumors. <i>Experimental and Molecular Medicine</i> , 2018, 50, 1-16.	3.2	16
1134	Synthesis of new coumarin tethered isoxazolines as potential anticancer agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 3606-3612.	1.0	40
1135	Effects of extracellular acidity on resistance to chemotherapy treatment: a systematic review. <i>Medical Oncology</i> , 2018, 35, 161.	1.2	16
1136	Modulation of MKNK2 alternative splicing by splice-switching oligonucleotides as a novel approach for glioblastoma treatment. <i>Nucleic Acids Research</i> , 2018, 46, 11396-11404.	6.5	60
1137	MicroRNA-495-3p inhibits multidrug resistance by modulating autophagy through GRP78/mTOR axis in gastric cancer. <i>Cell Death and Disease</i> , 2018, 9, 1070.	2.7	80
1138	CD44/CD44v6 a Reliable Companion in Cancer-Initiating Cell Maintenance and Tumor Progression. <i>Frontiers in Cell and Developmental Biology</i> , 2018, 6, 97.	1.8	95

#	ARTICLE	IF	CITATIONS
1139	Particles and Nanoparticles in Pharmaceutical Products. AAPS Advances in the Pharmaceutical Sciences Series, 2018, , .	0.2	3
1140	Immuno-MALDI (iMALDI) mass spectrometry for the analysis of proteins in signaling pathways. Expert Review of Proteomics, 2018, 15, 701-708.	1.3	8
1141	Glucosamine decreases the stemness of human ALDH+ breast cancer stem cells by inactivating STAT3. Oncology Letters, 2018, 16, 4737-4744.	0.8	14
1142	Cell-to-Cell Heterogeneity in p38-Mediated Cross-Inhibition of JNK Causes Stochastic Cell Death. Cell Reports, 2018, 24, 2658-2668.	2.9	74
1143	Pharmacological insights into antioxidants against colorectal cancer: A detailed review of the possible mechanisms. Biomedicine and Pharmacotherapy, 2018, 107, 1514-1522.	2.5	19
1144	Overcoming Drug Resistance by Targeting Cancer Bioenergetics with an Activatable Prodrug. Chem, 2018, 4, 2370-2383.	5.8	85
1145	Human non-small cell lung cancer cells can be sensitized to camptothecin by modulating autophagy. International Journal of Oncology, 2018, 53, 1967-1979.	1.4	28
1146	Involvement of telomerase activity inhibition and telomere dysfunction in silver nanoparticles anticancer effects. Nanomedicine, 2018, 13, 2067-2082.	1.7	6
1147	In Situ Synthesis of Ultrathin ZIF-8 Film-Coated MSNs for Codelivering Bcl 2 siRNA and Doxorubicin to Enhance Chemotherapeutic Efficacy in Drug-Resistant Cancer Cells. ACS Applied Materials & Interfaces, 2018, 10, 33070-33077.	4.0	82
1148	Mitochondria- and Lysosomes-Targeted Synergistic Chemo-Photodynamic Therapy Associated with Self-Monitoring by Dual Light-Up Fluorescence. Advanced Functional Materials, 2018, 28, 1804362.	7.8	101
1149	Bio-nano: Theranostic at Cellular Level. AAPS Advances in the Pharmaceutical Sciences Series, 2018, , 85-170.	0.2	1
1150	The CD44 variant induces K562 cell acquired with resistance to adriamycin via NF- κ B/Snail/Bcl-2 pathway. Medical Hypotheses, 2018, 121, 142-148.	0.8	4
1152	New 2-Oxoindolin Phosphonates as Novel Agents to Treat Cancer: A Green Synthesis and Molecular Modeling. Molecules, 2018, 23, 1981.	1.7	12
1153	Corosolic acid reduces 5-FU chemoresistance in human gastric cancer cells by activating AMPK. Molecular Medicine Reports, 2018, 18, 2880-2888.	1.1	14
1154	Apoptosis-inducing effect of 6,7-dimethoxy-4'-hydroxy-8-formylflavon from <i>Nicotiana tabacum</i> L leaf in human hepatoma HepG2 cells via activation of mitochondriamediated apoptotic pathway. Tropical Journal of Pharmaceutical Research, 2018, 17, 1271.	0.2	1
1155	Recent Advances in Targeted Tumor Chemotherapy Based on Smart Nanomedicines. Small, 2018, 14, e1802417.	5.2	98
1156	FoxG1 facilitates proliferation and inhibits differentiation by downregulating FoxO/Smad signaling in glioblastoma. Biochemical and Biophysical Research Communications, 2018, 504, 46-53.	1.0	26
1157	BMP4 Upregulation Is Associated with Acquired Drug Resistance and Fatty Acid Metabolism in EGFR-Mutant Non-Small-Cell Lung Cancer Cells. Molecular Therapy - Nucleic Acids, 2018, 12, 817-828.	2.3	39

#	ARTICLE	IF	CITATIONS
1158	Simultaneous Fluorescence Visualization of Epithelial→Mesenchymal Transition and Apoptosis Processes in Tumor Cells for Evaluating the Impact of Epithelial→Mesenchymal Transition on Drug Efficacy. <i>Analytical Chemistry</i> , 2018, 90, 10951-10957.	3.2	28
1159	Exploring major signaling cascades in melanomagenesis: a rationale route for targeted skin cancer therapy. <i>Bioscience Reports</i> , 2018, 38, .	1.1	28
1160	Immune Checkpoint Blockade and Immune Monitoring. , 0, , .		1
1161	Overview on Anticancer Drug Design and Development. <i>Current Medicinal Chemistry</i> , 2018, 25, 1704-1719.	1.2	51
1162	Nano-targeted induction of dual ferroptotic mechanisms eradicates high-risk neuroblastoma. <i>Journal of Clinical Investigation</i> , 2018, 128, 3341-3355.	3.9	406
1163	Drug metabolizing enzymes and their inhibitors' role in cancer resistance. <i>Biomedicine and Pharmacotherapy</i> , 2018, 105, 53-65.	2.5	73
1165	<sc>FLIP</sc> as a therapeutic target in cancer. <i>FEBS Journal</i> , 2018, 285, 4104-4123.	2.2	54
1166	Restraining Network Response to Targeted Cancer Therapies Improves Efficacy and Reduces Cellular Resistance. <i>Cancer Research</i> , 2018, 78, 4344-4359.	0.4	21
1167	Effects of purified Omphalia→lapedescens protein on metastasis, cell cycle, apoptosis and the JAK-STAT signaling pathway in SGC-7901 human gastric cells. <i>Oncology Letters</i> , 2018, 15, 4161-4170.	0.8	5
1168	Synchronous Chemoradiation Nanovesicles by X-Ray Triggered Cascade of Drug Release. <i>Angewandte Chemie</i> , 2018, 130, 8599-8603.	1.6	4
1169	Counting on Death → Quantitative aspects of Bcl→2 family regulation. <i>FEBS Journal</i> , 2018, 285, 4124-4138.	2.2	13
1170	Augmentation of the therapeutic efficacy of <sc>WEE</sc>1 kinase inhibitor <sc>AZD</sc>1775 by inhibiting the <sc>YAP</sc>→E2F1→<sc>DNA</sc> damage response pathway axis. <i>FEBS Open Bio</i> , 2018, 8, 1001-1012.	1.0	18
1171	Poly (amidoamine) (PAMAM) dendrimer mediated delivery of drug and pDNA/siRNA for cancer therapy. <i>International Journal of Pharmaceutics</i> , 2018, 546, 215-225.	2.6	200
1172	Multi-branched ionic liquid-chitosan as a smart and biocompatible nano-vehicle for combination chemotherapy with stealth and targeted properties. <i>Carbohydrate Polymers</i> , 2018, 196, 299-312.	5.1	58
1173	Platinum(IV) complex-based two-in-one polyprodrug for a combinatorial chemo-photodynamic therapy. <i>Biomaterials</i> , 2018, 177, 67-77.	5.7	82
1174	CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma. <i>Cell Death and Disease</i> , 2018, 9, 646.	2.7	88
1175	Escin-induced DNA damage promotes escin-induced apoptosis in human colorectal cancer cells via p62 regulation of the ATM/→H2AX pathway. <i>Acta Pharmacologica Sinica</i> , 2018, 39, 1645-1660.	2.8	21
1176	Targeting RNA polymerase I transcription machinery in cancer cells by a novel monofunctional platinum-based agent. <i>European Journal of Medicinal Chemistry</i> , 2018, 155, 434-444.	2.6	3

#	ARTICLE	IF	CITATIONS
1177	ACPred-FL: a sequence-based predictor using effective feature representation to improve the prediction of anti-cancer peptides. <i>Bioinformatics</i> , 2018, 34, 4007-4016.	1.8	326
1178	Reverting doxorubicin resistance in colon cancer by targeting a key signaling protein, steroid receptor coactivator. <i>Experimental and Therapeutic Medicine</i> , 2018, 15, 3751-3758.	0.8	13
1179	Microfluidics for Cancer Nanomedicine: From Fabrication to Evaluation. <i>Small</i> , 2018, 14, e1800360.	5.2	29
1180	Research Progress on Reversing Multidrug Resistance in Tumors by Using Chinese Medicine. <i>Chinese Journal of Integrative Medicine</i> , 2018, 24, 474-480.	0.7	17
1181	Pro-apoptotic peptides-based cancer therapies: challenges and strategies to enhance therapeutic efficacy. <i>Archives of Pharmacal Research</i> , 2018, 41, 594-616.	2.7	20
1182	Discovery of 5-Cyano-6-phenylpyrimidin Derivatives Containing an Acylurea Moiety as Orally Bioavailable Reversal Agents against P-Glycoprotein-Mediated Mutidrug Resistance. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 5988-6001.	2.9	53
1183	Epithelial-Mesenchymal Transition during Metastasis of HPV-Negative Pharyngeal Squamous Cell Carcinoma. <i>BioMed Research International</i> , 2018, 2018, 1-12.	0.9	10
1184	Sensitization of Gastric Cancer Cells to 5-FU by MicroRNA-204 Through Targeting the TGFBR2-Mediated Epithelial to Mesenchymal Transition. <i>Cellular Physiology and Biochemistry</i> , 2018, 47, 1533-1545.	1.1	49
1185	Valproic acid inhibits the protective effects of stromal cells against chemotherapy in breast cancer: Insights from proteomics and systems biology. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 9270-9283.	1.2	13
1186	Functionalization of silica nanoparticles for nucleic acid delivery. <i>Nano Research</i> , 2018, 11, 5219-5239.	5.8	41
1187	Bacterial cellulose hydrogel loaded with lipid nanoparticles for localized cancer treatment. <i>Colloids and Surfaces B: Biointerfaces</i> , 2018, 170, 596-608.	2.5	63
1188	Tumorigenic Cell Reprogramming and Cancer Plasticity: Interplay between Signaling, Microenvironment, and Epigenetics. <i>Stem Cells International</i> , 2018, 2018, 1-16.	1.2	54
1189	Natural Products for the Management and Prevention of Breast Cancer. <i>Evidence-based Complementary and Alternative Medicine</i> , 2018, 2018, 1-23.	0.5	141
1190	Predicting resistance of clinical Abl mutations to targeted kinase inhibitors using alchemical free-energy calculations. <i>Communications Biology</i> , 2018, 1, 70.	2.0	66
1191	Real-time dynamics of mutagenesis reveal the chronology of DNA repair and damage tolerance responses in single cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E6516-E6525.	3.3	47
1192	Dual role of HDAC10 in lysosomal exocytosis and DNA repair promotes neuroblastoma chemoresistance. <i>Scientific Reports</i> , 2018, 8, 10039.	1.6	36
1193	Low expression of KCNN3 may affect drug resistance in ovarian cancer. <i>Molecular Medicine Reports</i> , 2018, 18, 1377-1386.	1.1	13
1194	Salubrinal Enhances Doxorubicin Sensitivity in Human Cholangiocarcinoma Cells Through Promoting DNA Damage. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2018, 33, 258-265.	0.7	5

#	ARTICLE	IF	CITATIONS
1195	TPGS-functionalized and ortho ester-crosslinked dextran nanogels for enhanced cytotoxicity on multidrug resistant tumor cells. <i>Carbohydrate Polymers</i> , 2018, 198, 142-154.	5.1	26
1196	Design, synthesis, inÂvitro and in silico evaluation of a new series of oxadiazole-based anticancer agents as potential Akt and FAK inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2018, 155, 905-924.	2.6	55
1197	A nanomedicine approach enables co-delivery of cyclosporin A and gefitinib to potentiate the therapeutic efficacy in drug-resistant lung cancer. <i>Signal Transduction and Targeted Therapy</i> , 2018, 3, 16.	7.1	71
1198	Effect of AQP-5 silencing by siRNA interference on chemosensitivity of breast cancer cells. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 3359-3368.	1.0	17
1199	Molecular Targeted Therapies Elicit Concurrent Apoptotic and GSDME-Dependent Pyroptotic Tumor Cell Death. <i>Clinical Cancer Research</i> , 2018, 24, 6066-6077.	3.2	178
1200	Recent advances in fragment-based computational drug design: tackling simultaneous targets/biological effects. <i>Future Medicinal Chemistry</i> , 2018, 10, 2021-2024.	1.1	20
1201	The role of metabolism and tunneling nanotube-mediated intercellular mitochondria exchange in cancer drug resistance. <i>Biochemical Journal</i> , 2018, 475, 2305-2328.	1.7	73
1202	SPZ1 is critical for chemoresistance and aggressiveness in drug-resistant breast cancer cells. <i>Biochemical Pharmacology</i> , 2018, 156, 43-51.	2.0	7
1203	Design, Synthesis, and Biological Evaluation of Novel 1,3,4-Thiadiazole Derivatives as Potential Antitumor Agents against Chronic Myelogenous Leukemia: Striking Effect of Nitrothiazole Moiety. <i>Molecules</i> , 2018, 23, 59.	1.7	48
1204	Downregulation of MicroRNA-147 Inhibits Cell Proliferation and Increases the Chemosensitivity of Gastric Cancer Cells to 5-Fluorouracil by Directly Targeting PTEN. <i>Oncology Research</i> , 2018, 26, 901-911.	0.6	40
1205	Inhibiting β -Catenin by β -Carboline-Type MDM2 Inhibitor for Pancreatic Cancer Therapy. <i>Frontiers in Pharmacology</i> , 2018, 9, 5.	1.6	21
1206	Three-Dimensional in Vitro Cell Culture Models in Drug Discovery and Drug Repositioning. <i>Frontiers in Pharmacology</i> , 2018, 9, 6.	1.6	1,038
1207	Time Dependent Stochastic mRNA and Protein Synthesis in Piecewise-Deterministic Models of Gene Networks. <i>Frontiers in Physics</i> , 2018, 6, .	1.0	7
1208	Plant-Derived Anticancer Agents: Lessons from the Pharmacology of Geniposide and Its Aglycone, Genipin. <i>Biomedicines</i> , 2018, 6, 39.	1.4	60
1209	Platelet-camouflaged nanococktail: Simultaneous inhibition of drug-resistant tumor growth and metastasis via a cancer cells and tumor vasculature dual-targeting strategy. <i>Theranostics</i> , 2018, 8, 2683-2695.	4.6	96
1210	CCL20 triggered by chemotherapy hinders the therapeutic efficacy of breast cancer. <i>PLoS Biology</i> , 2018, 16, e2005869.	2.6	60
1211	Theranostic micelles combined with multiple strategies to effectively overcome multidrug resistance. <i>Nanomedicine</i> , 2018, 13, 1517-1533.	1.7	9
1212	Design, synthesis and preclinical evaluation of 5-methyl-N4-aryl-furo[2,3-d]pyrimidines as single agents with combination chemotherapy potential. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 3085-3093.	1.0	11

#	ARTICLE	IF	CITATIONS
1213	In vitro and in vivo anticancer efficacy potential of Quercetin loaded polymeric nanoparticles. <i>Biomedicine and Pharmacotherapy</i> , 2018, 106, 1513-1526.	2.5	113
1214	BCL9 promotes epithelial mesenchymal transition and invasion in cisplatin resistant NSCLC cells via β -catenin pathway. <i>Life Sciences</i> , 2018, 208, 284-294.	2.0	23
1215	Class III β -Tubulin Overexpression Induces Chemoresistance to Eribulin in a Leiomyosarcoma Cell Line. <i>Analytical Cellular Pathology</i> , 2018, 2018, 1-11.	0.7	4
1216	Drug-delivering-drug platform-mediated potent protein therapeutics via a non-endo-lysosomal route. <i>Theranostics</i> , 2018, 8, 3474-3489.	4.6	29
1217	Customizable biomaterials as tools for advanced anti-angiogenic drug discovery. <i>Biomaterials</i> , 2018, 181, 53-66.	5.7	4
1218	FGF2 Dual Warhead Conjugate with Monomethyl Auristatin E and β -Amanitin Displays a Cytotoxic Effect towards Cancer Cells Overproducing FGF Receptor 1. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2098.	1.8	22
1219	P-glycoprotein targeted and near-infrared light-guided depletion of chemoresistant tumors. <i>Journal of Controlled Release</i> , 2018, 286, 289-300.	4.8	18
1221	Overcoming tumor cell chemoresistance using nanoparticles: lysosomes are beneficial for (stearoyl) gemcitabine-incorporated solid lipid nanoparticles. <i>International Journal of Nanomedicine</i> , 2018, Volume 13, 319-336.	3.3	28
1222	Effect of β -Eudesmol on NQO1 suppression-enhanced sensitivity of cholangiocarcinoma cells to chemotherapeutic agents. <i>BMC Pharmacology & Toxicology</i> , 2018, 19, 32.	1.0	22
1223	Nitric Oxide Generated by Tumor-Associated Macrophages Is Responsible for Cancer Resistance to Cisplatin and Correlated With Syntaxin 4 and Acid Sphingomyelinase Inhibition. <i>Frontiers in Immunology</i> , 2018, 9, 1186.	2.2	76
1224	New Insights Into DNA Helicases as Druggable Targets for Cancer Therapy. <i>Frontiers in Molecular Biosciences</i> , 2018, 5, 59.	1.6	58
1225	Metabolic Reprogramming During Multidrug Resistance in Leukemias. <i>Frontiers in Oncology</i> , 2018, 8, 90.	1.3	19
1226	Non-Coding RNAs and Resistance to Anticancer Drugs in Gastrointestinal Tumors. <i>Frontiers in Oncology</i> , 2018, 8, 226.	1.3	56
1227	Structure and energy based quantitative missense variant effect analysis provides insights into drug resistance mechanisms of anaplastic lymphoma kinase mutations. <i>Scientific Reports</i> , 2018, 8, 10664.	1.6	13
1228	Anthocyanin complex exerts anti-cholangiocarcinoma activities and improves the efficacy of drug treatment in a gemcitabine-resistant cell line. <i>International Journal of Oncology</i> , 2018, 52, 1715-1726.	1.4	2
1229	Induction of the Endoplasmic Reticulum Stress Pathway by Highly Cytotoxic Organoruthenium Schiff-Base Complexes. <i>Molecular Pharmaceutics</i> , 2018, 15, 3020-3031.	2.3	30
1230	Doxorubicin@Bcl-2 siRNA Core@Shell Nanoparticles for Synergistic Anticancer Chemotherapy. <i>ACS Applied Bio Materials</i> , 2018, 1, 289-297.	2.3	14
1231	The Emerging Therapeutic Landscape of Advanced Melanoma. <i>Current Pharmaceutical Design</i> , 2018, 24, 549-558.	0.9	16

#	ARTICLE	IF	CITATIONS
1232	Melatonin Promotes Apoptosis of Colorectal Cancer Cells <i>via</i> Superoxide-mediated ER Stress by Inhibiting Cellular Prion Protein Expression. <i>Anticancer Research</i> , 2018, 38, 3951-3960.	0.5	29
1233	Platinum-induced muscle wasting in cancer chemotherapy: Mechanisms and potential targets for therapeutic intervention. <i>Life Sciences</i> , 2018, 208, 1-9.	2.0	42
1234	Heterogeneity in tumor chromatin-doxorubicin binding revealed by <i>in vivo</i> fluorescence lifetime imaging confocal endomicroscopy. <i>Nature Communications</i> , 2018, 9, 2662.	5.8	37
1235	Regulation of Cell Signaling Pathways and miRNAs by Resveratrol in Different Cancers. <i>International Journal of Molecular Sciences</i> , 2018, 19, 652.	1.8	45
1236	Therapy-induced stress response is associated with downregulation of pre-mRNA splicing in cancer cells. <i>Genome Medicine</i> , 2018, 10, 49.	3.6	40
1237	Design and Investigation of Core/Shell QDs/hMSN Nanoparticles as an Enhanced Drug Delivery Platform in Triple-Negative Breast Cancer. <i>Bioconjugate Chemistry</i> , 2018, 29, 2776-2785.	1.8	29
1238	Active Tumor-Targeted co-Delivery of Epigallocatechin Gallate and Doxorubicin in Nanoparticles for Combination Gastric Cancer Therapy. <i>ACS Biomaterials Science and Engineering</i> , 2018, 4, 2847-2859.	2.6	21
1239	Anticancer drug discovery from Chinese medicinal herbs. <i>Chinese Medicine</i> , 2018, 13, 35.	1.6	73
1240	ABT737 reverses cisplatin resistance by targeting glucose metabolism of human ovarian cancer cells. <i>International Journal of Oncology</i> , 2018, 53, 1055-1068.	1.4	36
1241	Epithelialâ€mesenchymal-transition-inducing transcription factors: new targets for tackling chemoresistance in cancer?. <i>Oncogene</i> , 2018, 37, 6195-6211.	2.6	131
1242	A novel design of a polynuclear co-delivery system for safe and efficient cancer therapy. <i>Chemical Communications</i> , 2018, 54, 8737-8740.	2.2	7
1243	Anti-EGFR antibody cetuximab is secreted by oral squamous cell carcinoma and alters EGF-driven mesenchymal transition. <i>Biochemical and Biophysical Research Communications</i> , 2018, 503, 1267-1272.	1.0	51
1244	Targeted genome editing in acute lymphoblastic leukemia: a review. <i>BMC Biotechnology</i> , 2018, 18, 45.	1.7	13
1245	Self-Assembled Glycosylated Chalconeâ€Boronic Acid Nanodrug Exhibits Anticancer Activity through Mitochondrial Impairment. <i>ACS Applied Bio Materials</i> , 2018, 1, 347-355.	2.3	0
1246	Overcoming Chemoresistance in Cancer via Combined MicroRNA Therapeutics with Anticancer Drugs Using Multifunctional Magnetic Coreâ€Shell Nanoparticles. <i>ACS Applied Materials & Interfaces</i> , 2018, 10, 26954-26963.	4.0	52
1247	Microenvironmental Signals and Biochemical Information Processing: Cooperative Determinants of Intratumoral Plasticity and Heterogeneity. <i>Frontiers in Cell and Developmental Biology</i> , 2018, 6, 44.	1.8	38
1248	Low-dose irradiated mesenchymal stromal cells break tumor defensive properties <i>in vivo</i> . <i>International Journal of Cancer</i> , 2018, 143, 2200-2212.	2.3	13
1249	Optimal Therapy Scheduling Based on a Pair of Collaterally Sensitive Drugs. <i>Bulletin of Mathematical Biology</i> , 2018, 80, 1776-1809.	0.9	36

#	ARTICLE	IF	CITATIONS
1250	Synchronous Chemoradiation Nanovesicles by X-ray Triggered Cascade of Drug Release. <i>Angewandte Chemie - International Edition</i> , 2018, 57, 8463-8467.	7.2	59
1251	Deoxyribozyme-nanosponges for improved photothermal therapy by overcoming thermoresistance. <i>NPG Asia Materials</i> , 2018, 10, 373-384.	3.8	27
1252	Transcription factor E2F3a regulates CASP8AP2 transcription and enhances sensitivity to chemotherapeutic drugs in acute lymphoblastic leukemia. <i>Cancer Cell International</i> , 2018, 18, 40.	1.8	6
1253	The p53 activator overcomes resistance to ALK inhibitors by regulating p53-target selectivity in ALK-driven neuroblastomas. <i>Cell Death Discovery</i> , 2018, 4, 56.	2.0	23
1254	A vanillin-based copper(II) metal complex with a DNA-mediated apoptotic activity. <i>RSC Advances</i> , 2018, 8, 16873-16886.	1.7	21
1255	Big Data Approaches for Modeling Response and Resistance to Cancer Drugs. <i>Annual Review of Biomedical Data Science</i> , 2018, 1, 1-27.	2.8	27
1256	Survivin Inhibitors Mitigate Chemotherapeutic Resistance in Breast Cancer Cells by Suppressing Genotoxic Nuclear Factor- κ B Activation. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 366, 184-193.	1.3	37
1257	Leptin promotes the growth of breast cancer by upregulating the Wnt/ β -catenin pathway. <i>Experimental and Therapeutic Medicine</i> , 2018, 16, 767-771.	0.8	14
1258	Current Challenges of Cancer Anti-angiogenic Therapy and the Promise of Nanotherapeutics. <i>Theranostics</i> , 2018, 8, 533-548.	4.6	188
1259	Fluorescence Probes for ALKBH2 Allow the Measurement of DNA Alkylation Repair and Drug Resistance Responses. <i>Angewandte Chemie</i> , 2018, 130, 13078-13082.	1.6	8
1260	Fluorescence Probes for ALKBH2 Allow the Measurement of DNA Alkylation Repair and Drug Resistance Responses. <i>Angewandte Chemie - International Edition</i> , 2018, 57, 12896-12900.	7.2	23
1261	Identification of NMU as a potential gene conferring alectinib resistance in non-small cell lung cancer based on bioinformatics analyses. <i>Gene</i> , 2018, 678, 137-142.	1.0	26
1262	The role of cancer stem cells and the therapeutic potential of TRX-E-002-1 in ovarian cancer. <i>Expert Opinion on Orphan Drugs</i> , 2018, 6, 465-475.	0.5	2
1263	Fatty acid oxidation: An emerging facet of metabolic transformation in cancer. <i>Cancer Letters</i> , 2018, 435, 92-100.	3.2	279
1264	Reduction-sensitive mixed micelles for selective intracellular drug delivery to tumor cells and reversal of multidrug resistance. <i>International Journal of Pharmaceutics</i> , 2018, 550, 1-13.	2.6	27
1265	miR-206 regulates 5-FU resistance by targeting Bcl-2 in colon cancer cells. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 1757-1765.	1.0	53
1266	Tertiary Lymphoid Structures. <i>Methods in Molecular Biology</i> , 2018, . .	0.4	3
1267	miRNAs and lncRNAs as Predictive Biomarkers of Response to FOLFOX Therapy in Colorectal Cancer. <i>Frontiers in Pharmacology</i> , 2018, 9, 846.	1.6	27

#	ARTICLE	IF	CITATIONS
1268	TGM2 knockdown reverses cisplatin chemoresistance in osteosarcoma. <i>International Journal of Molecular Medicine</i> , 2018, 42, 1799-1808.	1.8	20
1269	Combining Mutational Signatures, Clonal Fitness, and Drug Affinity to Define Drug-Specific Resistance Mutations in Cancer. <i>Cell Chemical Biology</i> , 2018, 25, 1359-1371.e2.	2.5	17
1270	Targeting Tertiary Lymphoid Structures for Tumor Immunotherapy. <i>Methods in Molecular Biology</i> , 2018, 1845, 275-286.	0.4	9
1271	Targeting Notch signalling pathway of cancer stem cells. <i>Stem Cell Investigation</i> , 2018, 5, 5-5.	1.3	234
1272	Building Micelle Analog Nanoparticle for Multidrug Delivery: Dual-Polymer Nanoparticles with Hydrophilic Shell and Double Hydrophobic Layers. <i>Macromolecular Materials and Engineering</i> , 2018, 303, 1800330.	1.7	4
1273	Comparison of the Kinase Profile of Midostaurin (Rydapt) with That of Its Predominant Metabolites and the Potential Relevance of Some Newly Identified Targets to Leukemia Therapy. <i>Biochemistry</i> , 2018, 57, 5576-5590.	1.2	21
1274	Appendage and Scaffold Diverse Fully Functionalized Small-Molecule Probes via a Minimalist Terminal Alkyne-Aliphatic Diazirine Isocyanide. <i>Journal of Organic Chemistry</i> , 2018, 83, 11245-11253.	1.7	10
1275	ALDH1A3 upregulation and spontaneous metastasis formation is associated with acquired chemoresistance in colorectal cancer cells. <i>BMC Cancer</i> , 2018, 18, 848.	1.1	39
1276	PTEN deficiency confers colorectal cancer cell resistance to dual inhibitors of FLT3 and aurora kinase A. <i>Cancer Letters</i> , 2018, 436, 28-37.	3.2	10
1277	Photodynamic Therapy for Metastatic Melanoma Treatment: A Review. <i>Technology in Cancer Research and Treatment</i> , 2018, 17, 153303381879179.	0.8	96
1278	Antigen presentation of the Oct4 and Sox2 peptides by CD154-activated B lymphocytes enhances the killing effect of cytotoxic T lymphocytes on tumor stem-like cells derived from cisplatin-resistant lung cancer cells. <i>Journal of Cancer</i> , 2018, 9, 367-374.	1.2	11
1280	Cell cycle-dependent force transmission in cancer cells. <i>Molecular Biology of the Cell</i> , 2018, 29, 2528-2539.	0.9	27
1281	miR-149 in Human Cancer: A Systemic Review. <i>Journal of Cancer</i> , 2018, 9, 375-388.	1.2	46
1282	Induction of apoptosis via proteasome inhibition in leukemia/lymphoma cells by two potent piperidones. <i>Cellular Oncology (Dordrecht)</i> , 2018, 41, 623-636.	2.1	22
1283	Engineering Anticancer Amphipathic Peptide-Dendronized Compounds for Highly-Efficient Plasma/Organelle Membrane Perturbation and Multidrug Resistance Reversal. <i>ACS Applied Materials & Interfaces</i> , 2018, 10, 30952-30962.	4.0	22
1284	Let There be Light: Polymeric Micelles with Upper Critical Solution Temperature as Light-Triggered Heat Nanogenerators for Combating Drug-Resistant Cancer. <i>Small</i> , 2018, 14, e1802420.	5.2	63
1285	TP53-dependence on the effect of doxorubicin and Src inhibitor combination therapy. <i>Tumor Biology</i> , 2018, 40, 101042831879421.	0.8	6
1286	Molecular analysis of gastric cancer identifies genomic markers of drug sensitivity in Asian gastric cancer. <i>Journal of Cancer</i> , 2018, 9, 2973-2980.	1.2	10

#	ARTICLE	IF	CITATIONS
1287	Nrp-1 receptor targeting peptide-functionalized TPGS micellar nanosystems to deliver 10-hydroxycamptothecin for enhanced cancer chemotherapy. <i>International Journal of Pharmaceutics</i> , 2018, 547, 582-592.	2.6	15
1288	A novel series of pyrazole-platinum(II) complexes as potential anti-cancer agents that induce cell cycle arrest and apoptosis in breast cancer cells. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2018, 33, 1006-1023.	2.5	50
1289	Discovery and Identification of Small Molecules as Methuosis Inducers with <i>in Vivo</i> Antitumor Activities. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 5424-5434.	2.9	31
1290	Cyclophilin B induces chemoresistance by degrading wild-type p53 via interaction with MDM2 in colorectal cancer. <i>Journal of Pathology</i> , 2018, 246, 115-126.	2.1	21
1291	Effects of taxol resistance gene 1 on the cisplatin response in gastric cancer. <i>Oncology Letters</i> , 2018, 15, 8287-8294.	0.8	4
1292	Overcoming Resistance to Targeted Anticancer Therapies through Small-Molecule-Mediated MEK Degradation. <i>Cell Chemical Biology</i> , 2018, 25, 996-1005.e4.	2.5	18
1293	Ultrasound Triggered Conversion of Porphyrin/Camptothecin-Fluoroxymidine Triad Microbubbles into Nanoparticles Overcomes Multidrug Resistance in Colorectal Cancer. <i>ACS Nano</i> , 2018, 12, 7312-7326.	7.3	115
1294	PAX2 expression is correlated with better survival in tamoxifen-treated breast carcinoma patients. <i>Tissue and Cell</i> , 2018, 52, 135-142.	1.0	9
1295	Ternary copper(II) complex: NCI60 screening, toxicity studies, and evaluation of efficacy in xenograft models of nasopharyngeal carcinoma. <i>PLoS ONE</i> , 2018, 13, e0191295.	1.1	15
1296	Cholesterol esterification inhibition and gemcitabine synergistically suppress pancreatic ductal adenocarcinoma proliferation. <i>PLoS ONE</i> , 2018, 13, e0193318.	1.1	43
1297	Tuning Spatial Profiles of Selection Pressure to Modulate the Evolution of Drug Resistance. <i>Physical Review Letters</i> , 2018, 120, 238102.	2.9	34
1298	<i>Achillea millefolium</i> L. hydroethanolic extract inhibits growth of human tumor cell lines by interfering with cell cycle and inducing apoptosis. <i>Food and Chemical Toxicology</i> , 2018, 118, 635-644.	1.8	25
1299	Role of Zerumbone in the Chemosensitization of Cancer Cells. , 2018, , 343-349.		0
1300	The action mechanism of lncRNA-HOTAIR on the drug resistance of non-small cell lung cancer by regulating Wnt signaling pathway. <i>Experimental and Therapeutic Medicine</i> , 2018, 15, 4885-4889.	0.8	36
1301	Harnessing Tumor Evolution to Circumvent Resistance. <i>Trends in Genetics</i> , 2018, 34, 639-651.	2.9	49
1302	The Emerging Roles and Clinical Potential of Exosomes in Cancer. , 2018, , 285-311.		2
1303	The Fabrication of rGO/(PLL/PASP) ₃ @DOX Nanorods with pH-Switch for Photothermal Therapy and Chemotherapy. <i>Chemistry - A European Journal</i> , 2018, 24, 13830-13838.	1.7	8
1304	The Onus of Sphingolipid Enzymes in Cancer Drug Resistance. <i>Advances in Cancer Research</i> , 2018, 140, 235-263.	1.9	16

#	ARTICLE	IF	CITATIONS
1305	Intratumor Heterogeneity and Circulating Tumor Cell Clusters. <i>Molecular Biology and Evolution</i> , 2018, 35, 2135-2144.	3.5	16
1306	TIGAR knockdown enhanced the anticancer effect of aescin via regulating autophagy and apoptosis in colorectal cancer cells. <i>Acta Pharmacologica Sinica</i> , 2019, 40, 111-121.	2.8	20
1307	A Structural View on Medicinal Chemistry Strategies against Drug Resistance. <i>Angewandte Chemie - International Edition</i> , 2019, 58, 3300-3345.	7.2	48
1308	Eine strukturelle Evaluierung medizinalchemischer Strategien gegen Wirkstoffresistenzen. <i>Angewandte Chemie</i> , 2019, 131, 3336-3383.	1.6	5
1309	Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn's disease. <i>Gut</i> , 2019, 68, 814-828.	6.1	146
1310	GECO: gene expression correlation analysis after genetic algorithm-driven deconvolution. <i>Bioinformatics</i> , 2019, 35, 156-159.	1.8	5
1311	Engineered collagen-binding serum albumin as a drug conjugate carrier for cancer therapy. <i>Science Advances</i> , 2019, 5, eaaw6081.	4.7	58
1312	TOPK inhibits autophagy by phosphorylating ULK1 and promotes glioma resistance to TMZ. <i>Cell Death and Disease</i> , 2019, 10, 583.	2.7	33
1313	The Effects of Eribulin on Breast Cancer Microenvironment Identified Using Eribulin-resistant Breast Cancer Cell Lines. <i>Anticancer Research</i> , 2019, 39, 4031-4041.	0.5	10
1314	Metal-based phosphorus dendrimers as novel nanotherapeutic strategies to tackle cancers: A concise overview. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2019, 11, e1577.	3.3	13
1315	Numerical investigation of drug transport from blood vessels to tumour tissue using a Tumour-Vasculature-on-a-Chip. <i>Chemical Engineering Science</i> , 2019, 208, 115155.	1.9	11
1316	Synthesis and biological evaluation of novel triazolyl 4-anilinoquinazolines as anticancer agents. <i>Medicinal Chemistry Research</i> , 2019, 28, 1766-1772.	1.1	6
1317	Doxorubicin/cisplatin co-loaded hyaluronic acid/chitosan-based nanoparticles for in vitro synergistic combination chemotherapy of breast cancer. <i>Carbohydrate Polymers</i> , 2019, 225, 115206.	5.1	57
1318	Graphene quantum dots (GQDs)-based nanomaterials for improving photodynamic therapy in cancer treatment. <i>European Journal of Medicinal Chemistry</i> , 2019, 182, 111620.	2.6	92
1319	Predicting Synergism of Cancer Drug Combinations Using NCI-ALMANAC Data. <i>Frontiers in Chemistry</i> , 2019, 7, 509.	1.8	101
1320	In silico design and optimization of selective membranolytic anticancer peptides. <i>Scientific Reports</i> , 2019, 9, 11282.	1.6	40
1321	Bioinformatics analysis identifies potential chemoresistance-associated genes across multiple types of cancer. <i>Oncology Letters</i> , 2019, 18, 2576-2583.	0.8	3
1322	The nuclear hypoxia-regulated NLUCAT1 long non-coding RNA contributes to an aggressive phenotype in lung adenocarcinoma through regulation of oxidative stress. <i>Oncogene</i> , 2019, 38, 7146-7165.	2.6	75

#	ARTICLE	IF	CITATIONS
1323	A Pharmacogenomic Landscape in Human Liver Cancers. <i>Cancer Cell</i> , 2019, 36, 179-193.e11.	7.7	127
1324	In Situ Autophagy Disruption Generator for Cancer Theranostics. <i>ACS Applied Materials & Interfaces</i> , 2019, 11, 29641-29654.	4.0	19
1325	Sulforaphane inhibits epithelial-mesenchymal transition by activating extracellular signal-regulated kinase 5 in lung cancer cells. <i>Journal of Nutritional Biochemistry</i> , 2019, 72, 108219.	1.9	19
1326	Molecular interaction studies on ellagic acid for its anticancer potential targeting pyruvate dehydrogenase kinase 3. <i>RSC Advances</i> , 2019, 9, 23302-23315.	1.7	44
1327	Ruthenium dendrimers against acute promyelocytic leukemia: <i>in vitro</i> studies on HL-60 cells. <i>Future Medicinal Chemistry</i> , 2019, 11, 1741-1756.	1.1	14
1328	Molecular Energetics of Doxorubicin Pumping by Human P-Glycoprotein. <i>Journal of Chemical Information and Modeling</i> , 2019, 59, 3889-3898.	2.5	11
1329	Stochastic modeling of phenotypic switching and chemoresistance in cancer cell populations. <i>Scientific Reports</i> , 2019, 9, 10845.	1.6	18
1330	Inhibitory effects of Semaphorin 3F as an alternative candidate to anti-VEGF monoclonal antibody on angiogenesis. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 2019, 55, 756-765.	0.7	2
1331	Proteomic Analysis of Breast Cancer Resistance to the Anticancer Drug RH1 Reveals the Importance of Cancer Stem Cells. <i>Cancers</i> , 2019, 11, 972.	1.7	4
1332	Bioactive Natural Products for the Management of Cancer: from Bench to Bedside. , 2019, , .		4
1333	MiR-223 inhibitor suppresses proliferation and induces apoptosis of thyroid cancer cells by down-regulating aquaporin-1. <i>Journal of Receptor and Signal Transduction Research</i> , 2019, 39, 146-153.	1.3	6
1334	Molecular mechanisms of natural compounds in cell death induction and sensitization to chemotherapeutic drugs in lung cancer. <i>Phytotherapy Research</i> , 2019, 33, 2531-2547.	2.8	32
1335	SET Domain-Containing Protein 4 Epigenetically Controls Breast Cancer Stem Cell Quiescence. <i>Cancer Research</i> , 2019, 79, 4729-4743.	0.4	41
1337	TET1 regulates DNA repair in human glial cells. <i>Toxicology and Applied Pharmacology</i> , 2019, 380, 114646.	1.3	7
1338	Role of protein kinase CK2 in antitumor drug resistance. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 287.	3.5	74
1339	Branched-Chain Amino Acid Metabolic Reprogramming Orchestrates Drug Resistance to EGFR Tyrosine Kinase Inhibitors. <i>Cell Reports</i> , 2019, 28, 512-525.e6.	2.9	59
1340	Anti-cancer effects of oxymatrine are mediated through multiple molecular mechanism(s) in tumor models. <i>Pharmacological Research</i> , 2019, 147, 104327.	3.1	64
1341	Quantitative proteomic analyses in blood: A window to human health and disease. <i>Journal of Leukocyte Biology</i> , 2019, 106, 759-775.	1.5	8

#	ARTICLE	IF	CITATIONS
1342	Targeting the Tumor Microenvironment to Overcome Resistance to Therapy. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 35-61.	0.1	1
1343	Drug Resistance in Cancer and Role of Nanomedicine-Based Natural Products. , 2019, , 177-218.		0
1344	Computer-assisted engineering of programmed drug releasing multilayer nanomedicine via indomethacin-mediated ternary complex for therapy against a multidrug resistant tumor. Acta Biomaterialia, 2019, 97, 461-473.	4.1	15
1345	Stem Cell Plasticity and Dormancy in the Development of Cancer Therapy Resistance. Frontiers in Oncology, 2019, 9, 626.	1.3	144
1346	CS-PEI/Beclin-siRNA Downregulate Multidrug Resistance Proteins and Increase Paclitaxel Therapeutic Efficacy against NSCLC. Molecular Therapy - Nucleic Acids, 2019, 17, 477-490.	2.3	25
1347	Precision Cancer Nanotherapy: Evolving Role of Multifunctional Nanoparticles for Cancer Active Targeting. Journal of Medicinal Chemistry, 2019, 62, 10475-10496.	2.9	110
1348	Remote and real time control of an FVI0â€“enzyme hybrid nanocatalyst using magnetic stimulation. Nanoscale, 2019, 11, 18081-18089.	2.8	25
1349	Circular RNAs in drug resistant tumors. Biomedicine and Pharmacotherapy, 2019, 118, 109233.	2.5	63
1350	Targeting cellular cholesterol for anticancer therapy. FEBS Journal, 2019, 286, 4192-4208.	2.2	39
1351	Epigenetic alterations are associated with tumor mutation burden in non-small cell lung cancer. , 2019, 7, 198.		28
1352	Non-viral nano-immunotherapeutics targeting tumor microenvironmental immune cells. Biomaterials, 2019, 219, 119401.	5.7	51
1353	AsiDNA Treatment Induces Cumulative Antitumor Efficacy with a Low Probability of Acquired Resistance. Neoplasia, 2019, 21, 863-871.	2.3	9
1354	A Simple, Yet Multifunctional, Nanoformulation for Eradicating Tumors and Preventing Recurrence with Safely Low Administration Dose. Nano Letters, 2019, 19, 5515-5523.	4.5	31
1355	In Silico Identification of Anticancer Peptides with Stacking Heterogeneous Ensemble Learning Model and Sequence Information. Lecture Notes in Computer Science, 2019, , 313-323.	1.0	1
1356	Noise-precision tradeoff in predicting combinations of mutations and drugs. PLoS Computational Biology, 2019, 15, e1006956.	1.5	13
1357	pH- and photothermal-driven multistage delivery nanoplatfrom for overcoming cancer drug resistance. Theranostics, 2019, 9, 3825-3839.	4.6	38
1358	Tackling drug resistance with efflux pump inhibitors: from bacteria to cancerous cells. Critical Reviews in Microbiology, 2019, 45, 334-353.	2.7	41
1359	Drug delivery micelles with efficient near-infrared photosensitizer for combined image-guided photodynamic therapy and chemotherapy of drug-resistant cancer. Biomaterials, 2019, 218, 119330.	5.7	118

#	ARTICLE	IF	CITATIONS
1360	Interplay of Darwinian Selection, Lamarckian Induction and Microvesicle Transfer on Drug Resistance in Cancer. <i>Scientific Reports</i> , 2019, 9, 9332.	1.6	31
1361	Prenylated Bibenzyls from the Chinese Liverwort <i>Radula constricta</i> and Their Mitochondria-Derived Paraptotic Cytotoxic Activities. <i>Journal of Natural Products</i> , 2019, 82, 1741-1751.	1.5	24
1362	The roles of DNA, RNA and histone methylation in ageing and cancer. <i>Nature Reviews Molecular Cell Biology</i> , 2019, 20, 573-589.	16.1	359
1363	Bromodomains: a new target class for drug development. <i>Nature Reviews Drug Discovery</i> , 2019, 18, 609-628.	21.5	302
1364	The Role of ATP-Binding Cassette Transporters in the Chemoresistance of Anaplastic Thyroid Cancer: A Systematic Review. <i>Endocrinology</i> , 2019, 160, 2015-2023.	1.4	23
1365	Evolution of cancer cell populations under cytotoxic therapy and treatment optimisation: insight from a phenotype-structured model. <i>ESAIM: Mathematical Modelling and Numerical Analysis</i> , 2019, 53, 1157-1190.	0.8	31
1366	Structure-guided probing of the leukotriene C ₄ binding site in human multidrug resistance protein 1 (MRP1; ABCC1). <i>FASEB Journal</i> , 2019, 33, 10692-10704.	0.2	21
1367	Napabucasin, a novel STAT3 inhibitor suppresses proliferation, invasion and stemness of glioblastoma cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 289.	3.5	71
1368	A Hierarchical Peptide-Lanthanide Framework To Accurately Redress Intracellular Carcinogenic Protein-Protein Interaction. <i>Nano Letters</i> , 2019, 19, 7918-7926.	4.5	22
1369	Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	451
1370	Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma. <i>Cancer Discovery</i> , 2019, 9, 1686-1695.	7.7	75
1371	Extracellular vesicles as a novel source of biomarkers in liquid biopsies for monitoring cancer progression and drug resistance. <i>Drug Resistance Updates</i> , 2019, 47, 100647.	6.5	104
1372	STS-NLSP: A Network-Based Label Space Partition Method for Predicting the Specificity of Membrane Transporter Substrates Using a Hybrid Feature of Structural and Semantic Similarity. <i>Frontiers in Bioengineering and Biotechnology</i> , 2019, 7, 306.	2.0	17
1373	Improved In Vivo Anti-Tumor and Anti-Metastatic Effect of GnRH-III-Daunorubicin Analogs on Colorectal and Breast Carcinoma Bearing Mice. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4763.	1.8	20
1375	Recent Advances in Nanomaterials-Based Chemo-Photothermal Combination Therapy for Improving Cancer Treatment. <i>Frontiers in Bioengineering and Biotechnology</i> , 2019, 7, 293.	2.0	99
1376	A High-Content Screening Approach to Identify MicroRNAs Against Head and Neck Cancer Cell Survival and EMT in an Inflammatory Microenvironment. <i>Frontiers in Oncology</i> , 2019, 9, 1100.	1.3	9
1377	Small Extracellular Vesicles Released from Ovarian Cancer Spheroids in Response to Cisplatin Promote the Pro-Tumorigenic Activity of Mesenchymal Stem Cells. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4972.	1.8	33
1378	Nanoparticles-Mediated Combination Therapies for Cancer Treatment. <i>Advanced Therapeutics</i> , 2019, 2, 1900076.	1.6	47

#	ARTICLE	IF	CITATIONS
1379	DIGREM: an integrated web-based platform for detecting effective multi-drug combinations. <i>Bioinformatics</i> , 2019, 35, 1792-1794.	1.8	8
1380	Targeting amphiregulin (AREG) derived from senescent stromal cells diminishes cancer resistance and averts programmed cell death 1 ligand (PD-L1)-mediated immunosuppression. <i>Aging Cell</i> , 2019, 18, e13027.	3.0	79
1381	Aldehyde dehydrogenase 1A1 confers erlotinib resistance via facilitating the reactive oxygen species-reactive carbonyl species metabolic pathway in lung adenocarcinomas. <i>Theranostics</i> , 2019, 9, 7122-7139.	4.6	38
1382	The opportunistic effect of exosomes on Non-Hodgkin Lymphoma microenvironment modulation. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 144, 102825.	2.0	9
1383	SIGNOR 2.0, the SIGnaling Network Open Resource 2.0: 2019 update. <i>Nucleic Acids Research</i> , 2020, 48, D504-D510.	6.5	160
1384	Lineage tracing of acute myeloid leukemia reveals the impact of hypomethylating agents on chemoresistance selection. <i>Nature Communications</i> , 2019, 10, 4986.	5.8	24
1385	Personalized Drug Efficacy Monitoring Chip. <i>Analytical Chemistry</i> , 2019, 91, 14927-14935.	3.2	16
1386	Evaluation and Clinical Significance of Jagged-1-activated Notch Signaling by APEX1 in Colorectal Cancer. <i>Anticancer Research</i> , 2019, 39, 6097-6105.	0.5	12
1387	Genome landscapes of rectal cancer before and after preoperative chemoradiotherapy. <i>Theranostics</i> , 2019, 9, 6856-6866.	4.6	27
1388	Tumor acidity activated triphenylphosphonium-based mitochondrial targeting nanocarriers for overcoming drug resistance of cancer therapy. <i>Theranostics</i> , 2019, 9, 7033-7050.	4.6	38
1389	The Landscape of Atypical and Eukaryotic Protein Kinases. <i>Trends in Pharmacological Sciences</i> , 2019, 40, 818-832.	4.0	87
1390	Differential regulatory network-based quantification and prioritization of key genes underlying cancer drug resistance based on time-course RNA-seq data. <i>PLoS Computational Biology</i> , 2019, 15, e1007435.	1.5	19
1391	Heterogeneity and Plasticity of Human Breast Cancer Cells in Response to Molecularly-Targeted Drugs. <i>Frontiers in Oncology</i> , 2019, 9, 1070.	1.3	9
1392	Bivalent SMAC Mimetics for Treating Cancer by Antagonizing Inhibitor of Apoptosis Proteins. <i>ChemMedChem</i> , 2019, 14, 1951-1962.	1.6	10
1393	<p>Resveratrol As A Natural Regulator Of Autophagy For Prevention And Treatment Of Cancer</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 8601-8609.	1.0	47
1394	Recent Progress of Rare-Earth Doped Upconversion Nanoparticles: Synthesis, Optimization, and Applications. <i>Advanced Science</i> , 2019, 6, 1901358.	5.6	228
1395	miR-210 β mediates metabolic adaptation and sustains DNA damage repair of resistant colon cancer cells to treatment with 5-fluorouracil. <i>Molecular Carcinogenesis</i> , 2019, 58, 2181-2192.	1.3	11
1396	High drug efflux pump capacity and low DNA damage response induce doxorubicin resistance in canine hemangiosarcoma cell lines. <i>Research in Veterinary Science</i> , 2019, 127, 1-10.	0.9	6

#	ARTICLE	IF	CITATIONS
1397	Circulating tumor cell free DNA from plasma and urine in the clinical management of colorectal cancer. <i>Cancer Biomarkers</i> , 2019, 27, 29-37.	0.8	27
1398	The effect of apatinib combined with chemotherapy or targeted therapy on non-small cell lung cancer in vitro and vivo. <i>Thoracic Cancer</i> , 2019, 10, 1868-1878.	0.8	13
1399	Analysis of total column CO ₂ and CH ₄ measurements in Berlin with WRF-GHG. <i>Atmospheric Chemistry and Physics</i> , 2019, 19, 11279-11302.	1.9	30
1400	DrugCombDB: a comprehensive database of drug combinations toward the discovery of combinatorial therapy. <i>Nucleic Acids Research</i> , 2020, 48, D871-D881.	6.5	99
1401	Enhanced generation efficiency of singlet oxygen for methylene blue released from hydroxyapatite-MB@tannic acid-Fe(III) ions. <i>Pigment and Resin Technology</i> , 2019, 48, 185-196.	0.5	4
1402	TRPC6 inactivation does not affect loss of renal function in nephrotoxic serum glomerulonephritis in rats, but reduces severity of glomerular lesions. <i>Biochemistry and Biophysics Reports</i> , 2019, 17, 139-150.	0.7	15
1403	Co-delivery of chlorin e6 and doxorubicin using PEGylated hollow nanocapsules for "all-in-one" tumor theranostics. <i>Nanomedicine</i> , 2019, 14, 2273-2292.	1.7	6
1404	A Y1 receptor ligand synergized with a P-glycoprotein inhibitor improves the therapeutic efficacy of multidrug resistant breast cancer. <i>Biomaterials Science</i> , 2019, 7, 4748-4757.	2.6	15
1405	Cooperative adaptation to therapy (CAT) confers resistance in heterogeneous non-small cell lung cancer. <i>PLoS Computational Biology</i> , 2019, 15, e1007278.	1.5	23
1406	Integrated Transcriptome Analysis Reveals KLK5 and L1CAM Predict Response to Anlotinib in NSCLC at 3rd Line. <i>Frontiers in Oncology</i> , 2019, 9, 886.	1.3	20
1407	Recent advances in the targeting of human DNA ligase I as a potential new strategy for cancer treatment. <i>European Journal of Medicinal Chemistry</i> , 2019, 182, 111657.	2.6	16
1408	Mechanisms of acquired tumor drug resistance. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1872, 188310.	3.3	111
1409	Low UBE4B expression increases sensitivity of chemoresistant neuroblastoma cells to EGFR and STAT5 inhibition. <i>Cancer Biology and Therapy</i> , 2019, 20, 1416-1429.	1.5	10
1410	Intracellular Delivery of siRNAs Targeting AKT and ERBB2 Genes Enhances Chemosensitization of Breast Cancer Cells in a Culture and Animal Model. <i>Pharmaceutics</i> , 2019, 11, 458.	2.0	5
1411	Lopinavir and Curcumin Directly Alters BAX/BCL2 and VEGF165b mRNA Levels to Suppress Human Squamous Cervical Carcinoma Cell Growth. <i>International Journal of Morphology</i> , 2019, 37, 584-591.	0.1	1
1412	Principles of Cancer Treatment and Anticancer Drug Development. , 2019, , .		10
1413	Designing combination therapies with modeling chaperoned machine learning. <i>PLoS Computational Biology</i> , 2019, 15, e1007158.	1.5	8
1414	A Novel Drug Resistance Mechanism: Genetic Loss of Xeroderma Pigmentosum Complementation Group C (XPC) Enhances Glycolysis-Mediated Drug Resistance in DLD-1 Colon Cancer Cells. <i>Frontiers in Pharmacology</i> , 2019, 10, 912.	1.6	7

#	ARTICLE	IF	CITATIONS
1415	Doxorubicin-loaded human serum albumin nanoparticles overcome transporter-mediated drug resistance in drug-adapted cancer cells. <i>Beilstein Journal of Nanotechnology</i> , 2019, 10, 1707-1715.	1.5	48
1416	Stimuli-responsive nanodrug self-assembled from amphiphilic drug-inhibitor conjugate for overcoming multidrug resistance in cancer treatment. <i>Theranostics</i> , 2019, 9, 5755-5768.	4.6	43
1417	Anti-parasitic Drug Ivermectin Exhibits Potent Anticancer Activity Against Gemcitabine-resistant Cholangiocarcinoma <i><i>In Vitro</i></i> . <i>Anticancer Research</i> , 2019, 39, 4837-4843.	0.5	24
1418	Programmed degradation of a hierarchical nanoparticle with redox and light responsivity for self-activated photo-chemical enhanced chemodynamic therapy. <i>Biomaterials</i> , 2019, 224, 119498.	5.7	99
1419	Enhancing Cytotoxicity of a Monofunctional Platinum Complex via a Dual-DNA-Damage Approach. <i>Inorganic Chemistry</i> , 2019, 58, 13150-13160.	1.9	26
1420	P-Glycoprotein and Breast Cancer Resistance Protein in Canine Inflammatory and Noninflammatory Grade III Mammary Carcinomas. <i>Veterinary Pathology</i> , 2019, 56, 840-847.	0.8	9
1421	The multi-factorial nature of clinical multidrug resistance in cancer. <i>Drug Resistance Updates</i> , 2019, 46, 100645.	6.5	324
1422	FRET biosensor-based kinase inhibitor screen for ERK and AKT activity reveals differential kinase dependencies for proliferation in TNBC cells. <i>Biochemical Pharmacology</i> , 2019, 169, 113640.	2.0	8
1423	Proteomics advances for precision therapy in ovarian cancer. <i>Expert Review of Proteomics</i> , 2019, 16, 841-850.	1.3	5
1424	Targeting MUC1-C Inhibits TWIST1 Signaling in Triple-Negative Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1744-1754.	1.9	49
1425	Role of GOLPH3 and TPX2 in Neuroblastoma DNA Damage Response and Cell Resistance to Chemotherapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4764.	1.8	16
1426	<p>Personalized treatment options for thyroid cancer: current perspectives</p>. <i>Pharmacogenomics and Personalized Medicine</i> , 2019, Volume 12, 235-245.	0.4	16
1427	Dehydrogenase/reductase SDR family member;1/22 silencing sensitizes an oxaliplatinâ€resistant cell line to oxaliplatin by inhibiting excision repair crossâ€complementing group 1 protein expression. <i>Oncology Reports</i> , 2019, 42, 1725-1734.	1.2	5
1428	Cellular Resistance Mechanisms to Targeted Protein Degradation Converge Toward Impairment of the Engaged Ubiquitin Transfer Pathway. <i>ACS Chemical Biology</i> , 2019, 14, 2215-2223.	1.6	74
1429	Current role of non-coding RNAs in the clinical setting. <i>Non-coding RNA Research</i> , 2019, 4, 82-85.	2.4	25
1430	RPL22L1 induction in colorectal cancer is associated with poor prognosis and 5-FU resistance. <i>PLoS ONE</i> , 2019, 14, e0222392.	1.1	19
1431	Gambogic acid increases the sensitivity to paclitaxel in drugâ€resistant tripleâ€negative breast cancer via the SHH signaling pathway. <i>Molecular Medicine Reports</i> , 2019, 20, 4515-4522.	1.1	13
1432	Verteporfin-induced lysosomal compartment dysregulation potentiates the effect of sorafenib in hepatocellular carcinoma. <i>Cell Death and Disease</i> , 2019, 10, 749.	2.7	64

#	ARTICLE	IF	CITATIONS
1433	Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical Overview. <i>Cancers</i> , 2019, 11, 1270.	1.7	25
1434	Deciphering the Molecular Profile of Lung Cancer: New Strategies for the Early Detection and Prognostic Stratification. <i>Journal of Clinical Medicine</i> , 2019, 8, 108.	1.0	6
1435	Therapy resistance beyond cellular dormancy. <i>Nature Cell Biology</i> , 2019, 21, 117-119.	4.6	7
1436	Multipronged design of theranostic nanovehicles with endogenous and exogenous stimuli-responsiveness for precise cancer therapy. <i>Journal of Materials Chemistry B</i> , 2019, 7, 1160-1166.	2.9	4
1437	Tumour microenvironment-responsive semiconducting polymer-based self-assembling nanotheranostics. <i>Nanoscale Horizons</i> , 2019, 4, 426-433.	4.1	75
1438	Taking a prospector local-market focus and foreign subsidiary performance: evidence from China. <i>Management Decision</i> , 2019, 57, 569-582.	2.2	6
1439	Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient-Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 642-655.	1.9	39
1440	Prediction of ultra-high-order antibiotic combinations based on pairwise interactions. <i>PLoS Computational Biology</i> , 2019, 15, e1006774.	1.5	49
1441	The palladacycle complex AJ-5 induces apoptotic cell death while reducing autophagic flux in rhabdomyosarcoma cells. <i>Cell Death Discovery</i> , 2019, 5, 60.	2.0	11
1442	Improving human $\hat{1}^2$ -cell maturation in vitro. <i>Nature Cell Biology</i> , 2019, 21, 119-121.	4.6	0
1443	The genomic imprint of cancer therapies helps timing the formation of metastases. <i>International Journal of Cancer</i> , 2019, 145, 694-704.	2.3	4
1444	LXR $\hat{1}$ Promotes the Differentiation of Human Gastric Cancer Cells through Inactivation of Wnt/ $\hat{1}^2$ -catenin Signaling. <i>Journal of Cancer</i> , 2019, 10, 156-167.	1.2	8
1445	Targeted Co-delivery of the Iron Chelator Deferoxamine and a HIF1 $\hat{1}$ Inhibitor Impairs Pancreatic Tumor Growth. <i>ACS Nano</i> , 2019, 13, 2176-2189.	7.3	46
1446	<i>L</i> -Carnitine-Mediated Tumor Cell Protection and Poor Patient Survival Associated with OCTN2 Overexpression in Glioblastoma Multiforme. <i>Clinical Cancer Research</i> , 2019, 25, 2874-2886.	3.2	35
1447	The Protective Effects of Ciji-Hua $\hat{1}$ ™-Baosheng II Formula on Chemotherapy-Treated H22 Hepatocellular Carcinoma Mouse Model by Promoting Tumor Apoptosis. <i>Frontiers in Pharmacology</i> , 2018, 9, 1539.	1.6	8
1448	Lung resistance-related protein (LRP) predicts favorable therapeutic outcome in Acute Myeloid Leukemia. <i>Scientific Reports</i> , 2019, 9, 378.	1.6	8
1449	Improved Anticancer Effect of Recombinant Protein izTRAIL Combined with Sorafenib and Peptide iRGD. <i>International Journal of Molecular Sciences</i> , 2019, 20, 525.	1.8	20
1450	Hypoxia-Modified Cancer Cell Metabolism. <i>Frontiers in Cell and Developmental Biology</i> , 2019, 7, 4.	1.8	359

#	ARTICLE	IF	CITATIONS
1451	Pharmacology of Orexin/Hypocretin Receptors. , 2019, , 31-68.		0
1452	Association Between CD133, CD44, and Nestin Expression and Prognostic Factors in High-Grade Meningioma. <i>World Neurosurgery</i> , 2019, 124, e188-e196.	0.7	10
1453	Microfluidic modelling of the tumor microenvironment for anti-cancer drug development. <i>Lab on A Chip</i> , 2019, 19, 369-386.	3.1	182
1454	Biotin-conjugated PEGylated porphyrin self-assembled nanoparticles co-targeting mitochondria and lysosomes for advanced chemo-photodynamic combination therapy. <i>Journal of Materials Chemistry B</i> , 2019, 7, 65-79.	2.9	56
1455	A multifunctional toolkit for target-directed cancer therapy. <i>Chemical Communications</i> , 2019, 55, 802-805.	2.2	1
1456	Regulostat Inferelator: a novel network biology platform to uncover molecular devices that predetermine cellular response phenotypes. <i>Nucleic Acids Research</i> , 2019, 47, e82-e82.	6.5	8
1457	Dual Inhibitors-Loaded Nanotherapeutics that Target Kinase Signaling Pathways Synergize with Immune Checkpoint Inhibitor. <i>Cellular and Molecular Bioengineering</i> , 2019, 12, 357-373.	1.0	12
1458	Chitosan-Based Nanogel Enhances Chemotherapeutic Efficacy of 10-Hydroxycamptothecin against Human Breast Cancer Cells. <i>International Journal of Polymer Science</i> , 2019, 2019, 1-6.	1.2	8
1459	Drug metabolizing enzymes-associated chemo resistance and strategies to overcome it. <i>Drug Metabolism Reviews</i> , 2019, 51, 196-223.	1.5	33
1460	Cancer Stem Cells in Lung Cancer: Roots of Drug Resistance and Targets for Novel Therapeutic Strategies. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2019, , 51-92.	0.1	1
1461	Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen. <i>Nature Communications</i> , 2019, 10, 2674.	5.8	240
1462	Adaptive Responses to Monotherapy in Head and Neck Cancer: Interventions for Rationale-Based Therapeutic Combinations. <i>Trends in Cancer</i> , 2019, 5, 365-390.	3.8	11
1463	Design, Synthesis, and Structure-Activity Relationship of 7-Propanamide Benzoxaboroles as Potent Anticancer Agents. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 6765-6784.	2.9	32
1464	Fluorescence polarization-based detection of cancer-related mutations using target-initiated rolling circle amplification. <i>Analyst</i> , The, 2019, 144, 4149-4152.	1.7	8
1465	Effective MDR reversers through phytochemical study of <i>Euphorbia boetica</i> . <i>Phytochemical Analysis</i> , 2019, 30, 498-511.	1.2	7
1466	Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia. <i>Nature Communications</i> , 2019, 10, 2723.	5.8	126
1467	EIF2A promotes cell survival during paclitaxel treatment in vitro and in vivo. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 6060-6071.	1.6	38
1468	Synthesis and in vitro evaluation of substituted tetrahydroquinoline-isoxazole hybrids as anticancer agents. <i>Medicinal Chemistry Research</i> , 2019, 28, 1182-1196.	1.1	9

#	ARTICLE	IF	CITATIONS
1469	Novel Method for Preparation of Site-Specific, Stoichiometric-Controlled Dual Warhead Conjugate of FGF2 via Dimerization Employing Sortase A-Mediated Ligation. <i>Molecular Pharmaceutics</i> , 2019, 16, 3588-3599.	2.3	21
1470	ABT737 enhances ovarian cancer cells sensitivity to cisplatin through regulation of mitochondrial fission via Sirt3 activation. <i>Life Sciences</i> , 2019, 232, 116561.	2.0	22
1471	ACP-DL: A Deep Learning Long Short-Term Memory Model to Predict Anticancer Peptides Using High-Efficiency Feature Representation. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 17, 1-9.	2.3	123
1472	A Cancer Stem Cell Perspective on Minimal Residual Disease in Solid Malignancies. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2019, , 31-49.	0.1	1
1473	Androgen receptor plasticity and its implications for prostate cancer therapy. <i>Cancer Treatment Reviews</i> , 2019, 81, 101871.	3.4	40
1474	Nanoparticle ferritin-bound erastin and rapamycin: a nanodrug combining autophagy and ferroptosis for anticancer therapy. <i>Biomaterials Science</i> , 2019, 7, 3779-3787.	2.6	65
1475	Trackable Water-Soluble Prodrug Micelles Capable of Rapid Mitochondrial-Targeting and Alkaline pH-Responsive Drug Release for Highly Improved Anticancer Efficacy. <i>ACS Macro Letters</i> , 2019, 8, 719-723.	2.3	13
1476	Tracking tumor evolution one-cell-at-a-time. <i>Molecular and Cellular Oncology</i> , 2019, 6, 1590089.	0.3	6
1477	An image-based assay to quantify changes in proliferation and viability upon drug treatment in 3D microenvironments. <i>BMC Cancer</i> , 2019, 19, 502.	1.1	18
1478	Biological Rationale for Targeting MEK/ERK Pathways in Anti-Cancer Therapy and to Potentiate Tumour Responses to Radiation. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2530.	1.8	47
1479	Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities. <i>Nature Cell Biology</i> , 2019, 21, 778-790.	4.6	24
1481	Ancistrobreveines A&D and related dehydrogenated naphthylisoquinoline alkaloids with antiproliferative activities against leukemia cells, from the West African liana <i>Ancistrocladus abbreviatus</i> . <i>RSC Advances</i> , 2019, 9, 15738-15748.	1.7	15
1482	Modulation of miRNA function by natural and synthetic RNA-binding proteins in cancer. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 3745-3752.	2.4	49
1483	Exosomal transfer of miR-501 confers doxorubicin resistance and tumorigenesis via targeting of BLID in gastric cancer. <i>Cancer Letters</i> , 2019, 459, 122-134.	3.2	80
1484	Dual acid-responsive bola-type supramolecular vesicles for efficient intracellular anticancer drug delivery. <i>Journal of Materials Chemistry B</i> , 2019, 7, 3944-3949.	2.9	34
1485	A polyherbal formulation, HC9 regulated cell growth and expression of cell cycle and chromatin modulatory proteins in breast cancer cell lines. <i>Journal of Ethnopharmacology</i> , 2019, 242, 112022.	2.0	17
1486	Phosphorylation of STAT1 serine 727 enhances platinum resistance in uterine serous carcinoma. <i>International Journal of Cancer</i> , 2019, 145, 1635-1647.	2.3	6
1487	Targeting ERK beyond the boundaries of the kinase active site in melanoma. <i>Molecular Carcinogenesis</i> , 2019, 58, 1551-1570.	1.3	26

#	ARTICLE	IF	CITATIONS
1488	Combination of PARP inhibitor and temozolomide to suppress chordoma progression. <i>Journal of Molecular Medicine</i> , 2019, 97, 1183-1193.	1.7	22
1489	PTENP1/miR-20a/PTEN axis contributes to breast cancer progression by regulating PTEN via PI3K/AKT pathway. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 256.	3.5	116
1490	Time-resolved protein activation by proximal decaging in living systems. <i>Nature</i> , 2019, 569, 509-513.	13.7	146
1491	In silico identification of genetic mutations conferring resistance to acetohydroxyacid synthase inhibitors: A case study of <i>Kochia scoparia</i> . <i>PLoS ONE</i> , 2019, 14, e0216116.	1.1	6
1492	Aminoacyl-tRNA synthetases as therapeutic targets. <i>Nature Reviews Drug Discovery</i> , 2019, 18, 629-650.	21.5	162
1493	Intelligent polymeric micelles for multidrug co-delivery and cancer therapy. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2019, 47, 1476-1487.	1.9	61
1494	Tumor-targeted drug delivery and sensitization by MMP2-responsive polymeric micelles. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2019, 19, 71-80.	1.7	50
1495	Gold-Nanoparticle-Assisted Plasmonic Photothermal Therapy Advances Toward Clinical Application. <i>Journal of Physical Chemistry C</i> , 2019, 123, 15375-15393.	1.5	245
1496	Contribution of Epithelial Plasticity to Therapy Resistance. <i>Journal of Clinical Medicine</i> , 2019, 8, 676.	1.0	42
1497	Perturbational Gene-Expression Signatures for Combinatorial Drug Discovery. <i>IScience</i> , 2019, 15, 291-306.	1.9	27
1498	Exploring Gatekeeper Mutations in <i>EGFR</i> through Computer Simulations. <i>Journal of Chemical Information and Modeling</i> , 2019, 59, 2850-2858.	2.5	8
1499	Natural Product Target Network Reveals Potential for Cancer Combination Therapies. <i>Frontiers in Pharmacology</i> , 2019, 10, 557.	1.6	40
1500	Deregulation of lncRNA <i>AC078883.3</i> and microRNA <i>19a</i> is involved in the development of chemoresistance to cisplatin via modulating signaling pathway of PTEN/AKT. <i>Journal of Cellular Physiology</i> , 2019, 234, 22657-22665.	2.0	26
1501	Breast Tumor Cells Highly Resistant to Drugs Are Controlled Only by the Immune Response Induced in an Immunocompetent Mouse Model. <i>Integrative Cancer Therapies</i> , 2019, 18, 153473541984804.	0.8	19
1502	Interaction of tumor-associated macrophages and cancer chemotherapy. <i>Oncolmmunology</i> , 2019, 8, e1596004.	2.1	205
1503	Fisetin and Quercetin: Promising Flavonoids with Chemopreventive Potential. <i>Biomolecules</i> , 2019, 9, 174.	1.8	167
1504	Therapeutic targeting of gastrointestinal cancer stem cells. <i>Regenerative Medicine</i> , 2019, 14, 331-343.	0.8	9
1505	FAM83A and FAM83B as Prognostic Biomarkers and Potential New Therapeutic Targets in NSCLC. <i>Cancers</i> , 2019, 11, 652.	1.7	45

#	ARTICLE	IF	CITATIONS
1506	Relevance of neuroendocrine tumours models assessed by kinomic profiling. <i>Annales D'Endocrinologie</i> , 2019, 80, 144-148.	0.6	1
1507	Targeting Ferroptosis to Iron Out Cancer. <i>Cancer Cell</i> , 2019, 35, 830-849.	7.7	1,385
1508	Chemosensitizing activity of Cuban propolis and nemorosone in doxorubicin resistant human colon carcinoma cells. <i>FÃ-toterapÃ-Ãç</i> , 2019, 136, 104173.	1.1	24
1509	Prognostic significance of pretreatment neutrophil-to-lymphocyte ratio in older patients with metastatic cancer. <i>Journal of Geriatric Oncology</i> , 2019, 10, 757-762.	0.5	2
1510	Dual drug-loaded PLA nanoparticles bypassing drug resistance for improved leukemia therapy. <i>Journal of Nanoparticle Research</i> , 2019, 21, 1.	0.8	14
1511	PLGA based particles as "drug reservoir" for antitumor drug delivery: characterization and cytotoxicity studies. <i>Colloids and Surfaces B: Biointerfaces</i> , 2019, 180, 495-502.	2.5	10
1512	Salinomycin reduces growth, proliferation and metastasis of cisplatin resistant breast cancer cells via NF-kB deregulation. <i>Toxicology in Vitro</i> , 2019, 60, 125-133.	1.1	31
1513	Epigenetic inhibition of the tumor suppressor ARHI by light at night-induced circadian melatonin disruption mediates STAT3-driven paclitaxel resistance in breast cancer. <i>Journal of Pineal Research</i> , 2019, 67, e12586.	3.4	59
1514	Commonly integrated epigenetic modifications of differentially expressed genes lead to adaptive resistance in cancer. <i>Epigenomics</i> , 2019, 11, 732-737.	1.0	11
1515	Interferon regulatory factor-1 reverses chemoresistance by downregulating the expression of P-glycoprotein in gastric cancer. <i>Cancer Letters</i> , 2019, 457, 28-39.	3.2	23
1516	NIR-responsive ROS generating core and ROS-triggered 5'-Deoxy-5-fluorocytidine releasing shell structured water-swelling microgel for locoregional combination cancer therapy. <i>Journal of Controlled Release</i> , 2019, 305, 120-129.	4.8	25
1517	Insights into Red Sea Brine Pool Specialized Metabolism Gene Clusters Encoding Potential Metabolites for Biotechnological Applications and Extremophile Survival. <i>Marine Drugs</i> , 2019, 17, 273.	2.2	14
1518	Development of selective small molecule MDM2 degraders based on nutlin. <i>European Journal of Medicinal Chemistry</i> , 2019, 176, 476-491.	2.6	51
1519	Impaired autophagic degradation of lncRNA ARHGAP5-AS1 promotes chemoresistance in gastric cancer. <i>Cell Death and Disease</i> , 2019, 10, 383.	2.7	128
1520	Mitochondrially targeted p53 or DBD subdomain is superior to wild type p53 in ovarian cancer cells even with strong dominant negative mutant p53. <i>Journal of Ovarian Research</i> , 2019, 12, 45.	1.3	7
1521	Discovery of 2,4-diarylaminopyrimidine derivatives bearing dithiocarbamate moiety as novel FAK inhibitors with antitumor and anti-angiogenesis activities. <i>European Journal of Medicinal Chemistry</i> , 2019, 177, 32-46.	2.6	31
1522	ATP-binding Cassette Transporters Substantially Reduce Estimates of ALDH-positive Cancer Cells based on Aldefluor and AldeRed588 Assays. <i>Scientific Reports</i> , 2019, 9, 6462.	1.6	7
1523	Resistance mechanisms and cross-resistance for a pyridine-pyrimidine amide inhibitor of microtubule polymerization. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 1647-1653.	1.0	4

#	ARTICLE	IF	CITATIONS
1524	Self-Assembled Oxaliplatin(IV) Prodrugâ€“Porphyrin Conjugate for Combinational Photodynamic Therapy and Chemotherapy. <i>ACS Applied Materials & Interfaces</i> , 2019, 11, 16391-16401.	4.0	56
1525	Proteomic analysis of flavokawain C-induced cell death in HCT 116 colon carcinoma cell line. <i>European Journal of Pharmacology</i> , 2019, 853, 388-399.	1.7	5
1526	CACNA2D3 Enhances the Chemosensitivity of Esophageal Squamous Cell Carcinoma to Cisplatin via Inducing Ca ²⁺ -Mediated Apoptosis and Suppressing PI3K/Akt Pathways. <i>Frontiers in Oncology</i> , 2019, 9, 185.	1.3	20
1527	PI3K/AKT Inhibitors as Sensitizing Agents for Cancer Chemotherapy. , 2019, , 187-205.		2
1528	Targeted protein degradation: elements of PROTAC design. <i>Current Opinion in Chemical Biology</i> , 2019, 50, 111-119.	2.8	363
1529	Probing and regulating the activity of cellular enzymes by using DNA tetrahedron nanostructures. <i>Chemical Science</i> , 2019, 10, 5959-5966.	3.7	79
1530	Prodrugs for targeted cancer therapy. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 483-502.	1.1	44
1531	A Versatile Carbon Monoxide Nanogenerator for Enhanced Tumor Therapy and Anti-Inflammation. <i>ACS Nano</i> , 2019, 13, 5523-5532.	7.3	89
1532	The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells. <i>Cancer Discovery</i> , 2019, 9, 910-925.	7.7	215
1533	Cytotoxicity of cucurbitacin E from <i>Citrullus colocynthis</i> against multidrug-resistant cancer cells. <i>Phytomedicine</i> , 2019, 62, 152945.	2.3	42
1534	Deuterium Depleted Water Inhibits the Proliferation of Human MCF7 Breast Cancer Cell Lines by Inducing Cell Cycle Arrest. <i>Nutrition and Cancer</i> , 2019, 71, 1019-1029.	0.9	19
1535	Hepatitis C Virus-Induced FUT8 Causes 5-FU Drug Resistance in Human Hepatoma Huh7.5.1 Cells. <i>Viruses</i> , 2019, 11, 378.	1.5	15
1536	Discovery of novel phenoxybenzamide analogues as Raf/HDAC dual inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 1605-1608.	1.0	15
1537	Multi-targeted anti-leukemic drug design with the incorporation of silicon into Nelarabine: How silicon increases bioactivity. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 134, 266-273.	1.9	6
1538	An energy-blocking nanoparticle decorated with anti-VEGF antibody to reverse chemotherapeutic drug resistance. <i>RSC Advances</i> , 2019, 9, 12110-12123.	1.7	7
1539	Confirmation of Selected Synergistic Cancer Drug Combinations Identified in an HTS Campaign and Exploration of Drug Efflux Transporter Contributions to the Mode of Synergy. <i>SLAS Discovery</i> , 2019, 24, 653-668.	1.4	7
1540	Identification of miR-29c and its Target FBXO31 as a Key Regulatory Mechanism in Esophageal Cancer Chemoresistance: Functional Validation and Clinical Significance. <i>Theranostics</i> , 2019, 9, 1599-1613.	4.6	46
1541	Dual blockage of STAT3 and ERK1/2 eliminates radioresistant GBM cells. <i>Redox Biology</i> , 2019, 24, 101189.	3.9	35

#	ARTICLE	IF	CITATIONS
1542	Multidrug Cancer Therapy in Metastatic Castrate-Resistant Prostate Cancer: An Evolution-Based Strategy. <i>Clinical Cancer Research</i> , 2019, 25, 4413-4421.	3.2	85
1543	Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy. <i>Cell Research</i> , 2019, 29, 446-459.	5.7	32
1544	Biomarkers of basal cell carcinoma resistance to methyl-aminolevulinate photodynamic therapy. <i>PLoS ONE</i> , 2019, 14, e0215537.	1.1	10
1545	mACPred: A Support Vector Machine-Based Meta-Predictor for Identification of Anticancer Peptides. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1964.	1.8	134
1546	Modified fractional order IMC design based drug scheduling for cancer treatment. <i>Computers in Biology and Medicine</i> , 2019, 109, 121-137.	3.9	28
1547	TIAM1 promotes chemoresistance and tumor invasiveness in colorectal cancer. <i>Cell Death and Disease</i> , 2019, 10, 267.	2.7	55
1548	Photostable and Biocompatible Fluorescent Silicon Nanoparticles for Imaging-Guided Co-Delivery of siRNA and Doxorubicin to Drug-Resistant Cancer Cells. <i>Nano-Micro Letters</i> , 2019, 11, 27.	14.4	36
1549	The Small Molecule Ephrin Receptor Inhibitor, GLPG1790, Reduces Renewal Capabilities of Cancer Stem Cells, Showing Anti-Tumour Efficacy on Preclinical Glioblastoma Models. <i>Cancers</i> , 2019, 11, 359.	1.7	42
1550	Enhanced antiproliferative effect of resveratrol in head and neck squamous cell carcinoma using GE11 peptide conjugated liposome. <i>International Journal of Molecular Medicine</i> , 2019, 43, 1635-1642.	1.8	13
1551	Polyelectrolyte Carboxymethyl Cellulose for Enhanced Delivery of Doxorubicin in MCF7 Breast Cancer Cells: Toxicological Evaluations in Mice Model. <i>Pharmaceutical Research</i> , 2019, 36, 68.	1.7	13
1552	Stiffness heterogeneity-induced double-edged sword behaviors of carcinoma-associated fibroblasts in antitumor therapy. <i>Science China Materials</i> , 2019, 62, 873-884.	3.5	3
1553	Study on preparation, characterization and multidrug resistance reversal of red blood cell membrane-camouflaged tetrandrine-loaded PLGA nanoparticles. <i>Drug Delivery</i> , 2019, 26, 199-207.	2.5	31
1554	Targeting Burkitt lymphoma with a tumor cell-specific heptamethine carbocyanine-cisplatin conjugate. <i>Cancer</i> , 2019, 125, 2222-2232.	2.0	18
1555	An injectable nanocomposite hydrogel co-constructed with gold nanorods and paclitaxel-loaded nanoparticles for local chemo-photothermal synergetic cancer therapy. <i>Journal of Materials Chemistry B</i> , 2019, 7, 2667-2677.	2.9	43
1556	Cascade therapy with doxorubicin and survivin-targeted tailored nanoparticles: An effective alternative for sensitization of cancer cells to chemotherapy. <i>International Journal of Pharmaceutics</i> , 2019, 561, 74-81.	2.6	7
1557	A chemoenzymatically synthesized cholesterol-g-poly(amine-co-ester)-mediated p53 gene delivery for achieving antitumor efficacy in prostate cancer. <i>International Journal of Nanomedicine</i> , 2019, Volume 14, 1149-1161.	3.3	4
1558	Interaction of Discoidin Domain Receptor 1 with a 14-3-3-Bcln-1-Akt1 Complex Modulates Glioblastoma Therapy Sensitivity. <i>Cell Reports</i> , 2019, 26, 3672-3683.e7.	2.9	48
1559	Polymer encapsulation of ruthenium complexes for biological and medicinal applications. <i>Nature Reviews Chemistry</i> , 2019, 3, 261-282.	13.8	119

#	ARTICLE	IF	CITATIONS
1560	A robust panel based on tumour microenvironment genes for prognostic prediction and tailoring therapies in stage III colon cancer. <i>EBioMedicine</i> , 2019, 42, 420-430.	2.7	46
1561	In Situ Monitoring Apoptosis Process by a Self-Reporting Photosensitizer. <i>Journal of the American Chemical Society</i> , 2019, 141, 5612-5616.	6.6	196
1562	On fitness: how do mutations shape the biology of cancer?. <i>Biochemical Society Transactions</i> , 2019, 47, 559-569.	1.6	2
1563	Platycodin D, a bioactive component of <i>Platycodon grandiflorum</i> , induces cancer cell death associated with extreme vacuolation. <i>Animal Cells and Systems</i> , 2019, 23, 118-127.	0.8	16
1564	On-chip anticancer drug screening – Recent progress in microfluidic platforms to address challenges in chemotherapy. <i>Biosensors and Bioelectronics</i> , 2019, 137, 236-254.	5.3	68
1565	Systematic Analysis of Different Cell Spheroids with a Microfluidic Device Using Scanning Electrochemical Microscopy and Gene Expression Profiling. <i>Analytical Chemistry</i> , 2019, 91, 4307-4311.	3.2	24
1566	Micellar Formulation of Talazoparib and Buparlisib for Enhanced DNA Damage in Breast Cancer Chemoradiotherapy. <i>ACS Applied Materials & Interfaces</i> , 2019, 11, 12342-12356.	4.0	17
1567	Elevated signature of a gene module coexpressed with CDC20 marks genomic instability in glioma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 6975-6984.	3.3	37
1569	Polytherapy and Targeted Cancer Drug Resistance. <i>Trends in Cancer</i> , 2019, 5, 170-182.	3.8	183
1570	Improved in vivo targeting of BCL-2 phenotypic conversion through hollow gold nanoshell delivery. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2019, 24, 529-537.	2.2	6
1571	Selected Aspects of Chemoresistance Mechanisms in Colorectal Carcinoma – A Focus on Epithelial-to-Mesenchymal Transition, Autophagy, and Apoptosis. <i>Cells</i> , 2019, 8, 234.	1.8	46
1572	The Ecology of Cancer. , 2019, , 153-174.		3
1573	Cytotoxic and Apoptotic Activity of Majoranolide from <i>Mezilaurus crassiramea</i> on HL-60 Leukemia Cells. <i>Evidence-based Complementary and Alternative Medicine</i> , 2019, 2019, 1-8.	0.5	5
1574	Two-in-One Chemogene Assembled from Drug-Integrated Antisense Oligonucleotides To Reverse Chemoresistance. <i>Journal of the American Chemical Society</i> , 2019, 141, 6955-6966.	6.6	84
1575	SETD2 mutations confer chemoresistance in acute myeloid leukemia partly through altered cell cycle checkpoints. <i>Leukemia</i> , 2019, 33, 2585-2598.	3.3	29
1576	Mathematical Approach to Differentiate Spontaneous and Induced Evolution to Drug Resistance During Cancer Treatment. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-20.	1.0	52
1577	PGC-1 β Controls Mitochondrial Biogenesis in Drug-Resistant Colorectal Cancer Cells by Regulating Endoplasmic Reticulum Stress. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1707.	1.8	26
1578	Fluid Shear Stress Induces Drug Resistance to Doxorubicin and Paclitaxel in the Breast Cancer Cell Line MCF7. <i>Advanced Therapeutics</i> , 2019, 2, 1800112.	1.6	10

#	ARTICLE	IF	CITATIONS
1579	Novel dodecyl-containing azido and glucuronamide-based nucleosides exhibiting anticancer potential. <i>Pure and Applied Chemistry</i> , 2019, 91, 1085-1105.	0.9	7
1580	Targeting Chemoresistant Tumors: Could TRIM Proteins-p53 Axis Be a Possible Answer?. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1776.	1.8	49
1581	Tumor microenvironment-driven non-cell-autonomous resistance to antineoplastic treatment. <i>Molecular Cancer</i> , 2019, 18, 69.	7.9	78
1582	Light-Induced ROS Generation and Ca^{2+} -Activated Endoplasmic Reticulum Stress by Antitumor Nanosystems: An Effective Combination Therapy by Regulating the Tumor Microenvironment. <i>Small</i> , 2019, 15, e1900212.	5.2	32
1583	Synergistic effect of granzyme B-azurin fusion protein on breast cancer cells. <i>Molecular Biology Reports</i> , 2019, 46, 3129-3140.	1.0	8
1584	Emerging role of PI3K/AKT in tumor-related epigenetic regulation. <i>Seminars in Cancer Biology</i> , 2019, 59, 112-124.	4.3	113
1585	Functional-genetic approaches to understanding drug response and resistance. <i>Current Opinion in Genetics and Development</i> , 2019, 54, 41-47.	1.5	3
1586	Tetrandrine isolated from <i>Cyclea peltata</i> induces cytotoxicity and apoptosis through ROS and caspase pathways in breast and pancreatic cancer cells. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 2019, 55, 331-340.	0.7	24
1587	Overcoming BET Inhibitor Resistance in Malignant Peripheral Nerve Sheath Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 3404-3416.	3.2	21
1588	Blockade of PDGFR β circumvents resistance to MEK-JAK inhibition via intratumoral CD8+ T-cells infiltration in triple-negative breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 85.	3.5	13
1589	Role of Stemness Factors in Neuroblastoma. , 2019, , 187-202.		0
1590	Microphysiological Systems as Enabling Tools for Modeling Complexity in the Tumor Microenvironment and Accelerating Cancer Drug Development. <i>Advanced Functional Materials</i> , 2019, 29, 1807553.	7.8	32
1591	Combating insulin resistance with the paleo diet. <i>Nurse Practitioner</i> , 2019, 44, 49-55.	0.2	1
1592	Pulsed Microwave-Pumped Drug-Free Thermoacoustic Therapy by Highly Biocompatible and Safe Metabolic Polyarginine Probes. <i>Nano Letters</i> , 2019, 19, 1728-1735.	4.5	28
1593	Nanotechnology in metastatic cancer treatment: Current Achievements and Future Research Trends. <i>Journal of Cancer</i> , 2019, 10, 1358-1369.	1.2	23
1594	Cytochrome <i>c</i> Deficiency Confers Apoptosome and Mitochondrial Dysfunction in African-American Men with Prostate Cancer. <i>Cancer Research</i> , 2019, 79, 1353-1368.	0.4	22
1595	Imatinib inhibits the regrowth of human colon cancer cells after treatment with 5-FU and cooperates with vitamin D analogue PRI-2191 in the downregulation of expression of stemness-related genes in 5-FU refractory cells. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2019, 189, 48-62.	1.2	18
1596	An oncoinformatics study to predict the inhibitory potential of recent FDA-approved anti-cancer drugs against human Polo-like kinase 1 enzyme: a step towards dual-target cancer medication. <i>3 Biotech</i> , 2019, 9, 70.	1.1	3

#	ARTICLE	IF	CITATIONS
1597	Fatty acid receptor GPR120 promotes breast cancer chemoresistance by upregulating ABC transporters expression and fatty acid synthesis. <i>EBioMedicine</i> , 2019, 40, 251-262.	2.7	43
1598	Sequential Delivery and Cascade Targeting of Peptide Therapeutics for Triplexed Synergistic Therapy with Real-Time Monitoring Shuttled by Magnetic Gold Nanostars. <i>Analytical Chemistry</i> , 2019, 91, 4608-4617.	3.2	12
1599	Cancer-associated fibroblasts in gastrointestinal cancer. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 282-295.	8.2	371
1600	Emerging roles of microRNAs as a regulator in the progression of lung cancer and their implications in its diagnosis and therapy. , 2019, , 293-318.		1
1601	Integrin-independent support of cancer drug resistance by tetraspanin CD151. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 1595-1604.	2.4	18
1602	Secretome profiling of heterotypic spheroids suggests a role of fibroblasts in HIF-1 pathway modulation and colorectal cancer photodynamic resistance. <i>Cellular Oncology (Dordrecht)</i> , 2019, 42, 173-196.	2.1	20
1603	PROteolysis TARgeting Chimeras (PROTACs) â€” Past, present and future. <i>Drug Discovery Today: Technologies</i> , 2019, 31, 15-27.	4.0	458
1604	The role and mechanisms of action of microRNAs in cancer drug resistance. <i>Clinical Epigenetics</i> , 2019, 11, 25.	1.8	468
1605	Multiscale Stochastic Modeling Connects Cancer Drug Resistance Mechanisms to Population Survival Rates. , 0, , .		0
1606	Understanding of ROS-Inducing Strategy in Anticancer Therapy. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-12.	1.9	237
1607	3-benzazecine-based cyclic allene derivatives as highly potent P-glycoprotein inhibitors overcoming doxorubicin multidrug resistance. <i>Future Medicinal Chemistry</i> , 2019, 11, 2095-2106.	1.1	8
1608	Triazol: a privileged scaffold for proteolysis targeting chimeras. <i>Future Medicinal Chemistry</i> , 2019, 11, 2919-2973.	1.1	32
1609	Precise ratiometric co-loading, co-delivery and intracellular co-release of paclitaxel and curcumin by aid of their conjugation to the same gold nanorods to exert synergistic effects on MCF-7/ADR cells. <i>Journal of Drug Delivery Science and Technology</i> , 2019, 54, 101383.	1.4	4
1610	Lactate in the Regulation of Tumor Microenvironment and Therapeutic Approaches. <i>Frontiers in Oncology</i> , 2019, 9, 1143.	1.3	522
1611	Cancer nanomedicine: focus on recent developments and self-assembled peptide nanocarriers. <i>Journal of Materials Chemistry B</i> , 2019, 7, 7639-7655.	2.9	60
1612	PROTACs: great opportunities for academia and industry. <i>Signal Transduction and Targeted Therapy</i> , 2019, 4, 64.	7.1	367
1613	Stepwise dual stimuli triggered dual drug release by a single naphthalene based two-photon chromophore to reverse MDR for alkylating agents with dual surveillance in uncaging steps. <i>Chemical Communications</i> , 2019, 55, 13140-13143.	2.2	15
1614	Zhankuic Acids A, B and C from Taiwanofungus camphoratus Act as Cytotoxicity Enhancers by Regulating P-Glycoprotein in Multi-Drug Resistant Cancer Cells. <i>Biomolecules</i> , 2019, 9, 759.	1.8	7

#	ARTICLE	IF	CITATIONS
1615	Delineation of Tumor Migration Paths by Using a Bayesian Biogeographic Approach. <i>Cancers</i> , 2019, 11, 1880.	1.7	7
1616	<p>Smart Targeting To Improve Cancer Therapeutics</p>. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 3753-3772.	2.0	91
1617	Cisplatin-resistant A549 non-small cell lung cancer cells can be identified by increased mitochondrial mass and are sensitive to pemetrexed treatment. <i>Cancer Cell International</i> , 2019, 19, 317.	1.8	19
1618	The Emerging Role of the SLCO1B3 Protein in Cancer Resistance. <i>Protein and Peptide Letters</i> , 2019, 27, 17-29.	0.4	16
1619	Advances of proteomics technologies for multidrug-resistant mechanisms. <i>Future Medicinal Chemistry</i> , 2019, 11, 2573-2593.	1.1	8
1621	Quantitative characterization of mechano-biological interrelationships of single cells. <i>International Journal of Advanced Manufacturing Technology</i> , 2019, 105, 4967-4972.	1.5	4
1622	The pro-tumorigenic host response to cancer therapies. <i>Nature Reviews Cancer</i> , 2019, 19, 667-685.	12.8	135
1623	Establishment of Drug-resistant Cell Lines as a Model in Experimental Oncology: A Review. <i>Anticancer Research</i> , 2019, 39, 6443-6455.	0.5	22
1624	Introductory Chapter: Tyrosine Kinases as Drug Targets in Cancer Treatment. , 2019, , .		0
1625	CD36-Mediated Metabolic Rewiring of Breast Cancer Cells Promotes Resistance to HER2-Targeted Therapies. <i>Cell Reports</i> , 2019, 29, 3405-3420.e5.	2.9	104
1626	Nanocarrier-based targeted pulmonary delivery: novel approaches for effective lung cancer treatment. , 2019, , 129-161.		4
1627	A polyprodrug-based nanoplatform for cisplatin prodrug delivery and combination cancer therapy. <i>Chemical Communications</i> , 2019, 55, 13987-13990.	2.2	14
1628	Novel anti-HER2 peptide-conjugated theranostic nanoliposomes combining NaYF ₄ :Yb,Er nanoparticles for NIR-activated bioimaging and chemo-photodynamic therapy against breast cancer. <i>Nanoscale</i> , 2019, 11, 20598-20613.	2.8	37
1629	Contribution of Autophagy in Acquired Drug Resistance of Human Breast Cancer Cells MCF7 to Doxorubicin. <i>Applied in Vitro Toxicology</i> , 2019, 5, 173-179.	0.6	2
1630	mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer. <i>Oncogene</i> , 2019, 38, 622-636.	2.6	37
1631	Magnolin targeting of ERK1/2 inhibits cell proliferation and colony growth by induction of cellular senescence in ovarian cancer cells. <i>Molecular Carcinogenesis</i> , 2019, 58, 88-101.	1.3	21
1632	Preclinical three-dimensional colorectal cancer model: The next generation of in vitro drug efficacy evaluation. <i>Journal of Cellular Physiology</i> , 2019, 234, 181-191.	2.0	22
1633	Antitumor potential of Pllansâ€“II, an acidic Asp49â€“PLA2 from <i>Porthidium lansbergii lansbergii</i> snake venom on human cervical carcinoma HeLa cells. <i>International Journal of Biological Macromolecules</i> , 2019, 122, 1053-1061.	3.6	20

#	ARTICLE	IF	CITATIONS
1634	ONS-donor ligand based Pt(II) complexes display extremely high anticancer potency through autophagic cell death pathway. <i>European Journal of Medicinal Chemistry</i> , 2019, 164, 546-561.	2.6	23
1635	STAT3- and GSK3 β -mediated Mcl-1 regulation modulates TPF resistance in oral squamous cell carcinoma. <i>Carcinogenesis</i> , 2019, 40, 173-183.	1.3	38
1636	Regulation of Ca ²⁺ Signaling for Drug-Resistant Breast Cancer Therapy with Mesoporous Silica Nanocapsule Encapsulated Doxorubicin/siRNA Cocktail. <i>ACS Nano</i> , 2019, 13, 274-283.	7.3	110
1637	Implementation of the NCI-60 Human Tumor Cell Line Panel to Screen 2260 Cancer Drug Combinations to Generate >3 Million Data Points Used to Populate a Large Matrix of Anti-Neoplastic Agent Combinations (ALMANAC) Database. <i>SLAS Discovery</i> , 2019, 24, 242-263.	1.4	19
1638	Role of mesenchymal stromal cell-derived extracellular vesicles in tumour microenvironment. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1871, 192-198.	3.3	43
1639	A potential carrier for anti-tumor targeted delivery-hyaluronic acid nanoparticles. <i>Carbohydrate Polymers</i> , 2019, 208, 356-364.	5.1	72
1640	Biodegradable Polymer-Coated Multifunctional Graphene Quantum Dots for Light-Triggered Synergetic Therapy of Pancreatic Cancer. <i>ACS Applied Materials & Interfaces</i> , 2019, 11, 2768-2781.	4.0	58
1641	Curcumin in combination with anti-cancer drugs: A nanomedicine review. <i>Pharmacological Research</i> , 2019, 139, 91-105.	3.1	111
1642	Dormant, quiescent, tolerant and persister cells: Four synonyms for the same target in cancer. <i>Biochemical Pharmacology</i> , 2019, 162, 169-176.	2.0	147
1643	MicroRNAs and signaling networks involved in epithelial-mesenchymal transition. <i>Journal of Cellular Physiology</i> , 2019, 234, 5775-5785.	2.0	29
1644	Cancer Stem Cells. , 2019, , 77-87.		8
1645	Neural regulation of drug resistance in cancer treatment. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1871, 20-28.	3.3	8
1646	Enzyme-Constructed Supramolecular Self-Assembly with Anticancer Activity. <i>Advanced Materials</i> , 2019, 31, e1804814.	11.1	75
1647	Design, synthesis and cytotoxicity of chimeric erlotinib-alkylphospholipid hybrids. <i>Bioorganic Chemistry</i> , 2019, 84, 51-62.	2.0	25
1648	The lncRNA BORG facilitates the survival and chemoresistance of triple-negative breast cancers. <i>Oncogene</i> , 2019, 38, 2020-2041.	2.6	70
1649	Proteomic Signature of Neuroblastoma Cells UKF-NB-4 Reveals Key Role of Lysosomal Sequestration and the Proteasome Complex in Acquiring Chemoresistance to Cisplatin. <i>Journal of Proteome Research</i> , 2019, 18, 1255-1263.	1.8	6
1650	Targeting Cancer Cell Dormancy. <i>Trends in Pharmacological Sciences</i> , 2019, 40, 128-141.	4.0	224
1651	Synthesis, molecular modelling and anticancer evaluation of new pyrrolo[1,2- <i>b</i>]pyridazine and pyrrolo[2,1- <i>a</i>]phthalazine derivatives. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2019, 34, 230-243.	2.5	24

#	ARTICLE	IF	CITATIONS
1652	Targeting cancer energy metabolism: a potential systemic cure for cancer. Archives of Pharmacal Research, 2019, 42, 140-149.	2.7	25
1653	Construction of Dual Stimuli-Responsive Platinum(IV) Hybrids with NQO1 Targeting Ability and Overcoming Cisplatin Resistance. Inorganic Chemistry, 2019, 58, 2191-2200.	1.9	45
1654	Blockade of integrin β 3 signals to reverse the stem-like phenotype and drug resistance in melanoma. Cancer Chemotherapy and Pharmacology, 2019, 83, 615-624.	1.1	13
1655	Gain Fat \rightarrow Lose Metastasis: Converting Invasive Breast Cancer Cells into Adipocytes Inhibits Cancer Metastasis. Cancer Cell, 2019, 35, 17-32.e6.	7.7	205
1656	ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken replication forks. Nature Communications, 2019, 10, 87.	5.8	133
1657	Microarray-based identification of genes associated with prognosis and drug resistance in ovarian cancer. Journal of Cellular Biochemistry, 2019, 120, 6057-6070.	1.2	26
1658	Chemosensitization effect of cerium oxide nanosheets by suppressing drug detoxification and efflux. Ecotoxicology and Environmental Safety, 2019, 167, 301-308.	2.9	13
1659	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells. European Journal of Medicinal Chemistry, 2019, 161, 456-467.	2.6	13
1660	Dual responsive micelles capable of modulating miRNA-34a to combat taxane resistance in prostate cancer. Biomaterials, 2019, 192, 95-108.	5.7	52
1661	Paeoniflorin Inhibits Migration- and Invasion-Promoting Capacities of Gastric Cancer Associated Fibroblasts. Chinese Journal of Integrative Medicine, 2019, 25, 837-844.	0.7	17
1662	The role of the unfolded protein response in cancer progression: From oncogenesis to chemoresistance. Biology of the Cell, 2019, 111, 1-17.	0.7	225
1663	Modeling drug-drug interactions of AZD1208 with Vincristine and Daunorubicin on ligand-extrusion binding TMD-domains of multidrug resistance P-glycoprotein (ABCB1). Toxicology, 2019, 411, 81-92.	2.0	7
1664	Intricate role of mitochondrial lipid in mitophagy and mitochondrial apoptosis: its implication in cancer therapeutics. Cellular and Molecular Life Sciences, 2019, 76, 1641-1652.	2.4	74
1665	Beyond the message: advantages of snapshot proteomics with single-cell mass cytometry in solid tumors. FEBS Journal, 2019, 286, 1523-1539.	2.2	26
1666	Proteins Regulating Microvesicle Biogenesis and Multidrug Resistance in Cancer. Proteomics, 2019, 19, e1800165.	1.3	37
1667	Development and Characterization of MDR1 (<i>Mdr1a/b</i>) CRISPR/Cas9 Knockout Rat Model. Drug Metabolism and Disposition, 2019, 47, 71-79.	1.7	22
1668	Exploiting Nanomaterial-Mediated Autophagy for Cancer Therapy. Small Methods, 2019, 3, 1800365.	4.6	25
1669	Overcoming chemotherapy resistance via simultaneous drug-efflux circumvention and mitochondrial targeting. Acta Pharmaceutica Sinica B, 2019, 9, 615-625.	5.7	61

#	ARTICLE	IF	CITATIONS
1670	Synthesis of Modified RGD-Based Peptides and Their in vitro Activity. <i>ChemMedChem</i> , 2019, 14, 282-288.	1.6	15
1671	In vitro selection of DNA aptamers recognizing drug-resistant ovarian cancer by cell-SELEX. <i>Talanta</i> , 2019, 194, 437-445.	2.9	35
1672	Astrocytes, the rising stars of the glioblastoma microenvironment. <i>Glia</i> , 2019, 67, 779-790.	2.5	115
1673	Tannic acid-inspired paclitaxel nanoparticles for enhanced anticancer effects in breast cancer cells. <i>Journal of Colloid and Interface Science</i> , 2019, 535, 133-148.	5.0	109
1674	Deciphering the metabolic role of AMPK in cancer multi-drug resistance. <i>Seminars in Cancer Biology</i> , 2019, 56, 56-71.	4.3	25
1675	Raman spectroscopy investigation of biochemical changes in tumor spheroids with aging and after treatment with staurosporine. <i>Journal of Biophotonics</i> , 2019, 12, e201800201.	1.1	6
1676	Sequentially self-assembled polysaccharide-based nanocomplexes for combined chemotherapy and photodynamic therapy of breast cancer. <i>Carbohydrate Polymers</i> , 2019, 203, 203-213.	5.1	70
1677	In vitro and in silico evaluation of P-glycoprotein inhibition through ^{99m} Tc-methoxyisobutylisonitrile uptake. <i>Chemical Biology and Drug Design</i> , 2019, 93, 283-289.	1.5	11
1678	Redox-responsive hyaluronic acid nanogels for hyperthermia- assisted chemotherapy to overcome multidrug resistance. <i>Carbohydrate Polymers</i> , 2019, 203, 378-385.	5.1	39
1679	Loss of RBMS3 Confers Platinum Resistance in Epithelial Ovarian Cancer via Activation of miR-126-5p/ β -catenin/CBP signaling. <i>Clinical Cancer Research</i> , 2019, 25, 1022-1035.	3.2	36
1680	Targeting Oncogenic Nuclear Factor Kappa B Signaling with Redox-Active Agents for Cancer Treatment. <i>Antioxidants and Redox Signaling</i> , 2019, 30, 1096-1123.	2.5	21
1681	Single-Molecule Fluorescence Detection of the Epidermal Growth Factor Receptor in Membrane Discs. <i>Biochemistry</i> , 2019, 58, 286-294.	1.2	10
1682	New insights into RAS biology reinvigorate interest in mathematical modeling of RAS signaling. <i>Seminars in Cancer Biology</i> , 2019, 54, 162-173.	4.3	16
1683	Design, identification, antifungal evaluation and molecular modeling of chlorotetaine derivatives as new anti-fungal agents. <i>Natural Product Research</i> , 2020, 34, 1712-1720.	1.0	5
1684	SOX2 in cancer stemness: tumor malignancy and therapeutic potentials. <i>Journal of Molecular Cell Biology</i> , 2020, 12, 85-98.	1.5	59
1685	Multi-pharmacophore Approach to Bio-therapeutics: Piperazine Bridged Pseudo-peptidic Urea/Thiourea Derivatives as Anti-oxidant Agents. <i>International Journal of Peptide Research and Therapeutics</i> , 2020, 26, 151-158.	0.9	3
1686	Cardamonin, a natural chalcone, reduces 5-fluorouracil resistance of gastric cancer cells through targeting Wnt/ β -catenin signal pathway. <i>Investigational New Drugs</i> , 2020, 38, 329-339.	1.2	40
1687	Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion. <i>Gut</i> , 2020, 69, 122-132.	6.1	89

#	ARTICLE	IF	CITATIONS
1688	Metformin in breast cancer: preclinical and clinical evidence. <i>Current Problems in Cancer</i> , 2020, 44, 100488.	1.0	81
1689	Intracellular Signaling. , 2020, , 24-46.e12.		0
1690	JOSD1 inhibits mitochondrial apoptotic signalling to drive acquired chemoresistance in gynaecological cancer by stabilizing MCL1. <i>Cell Death and Differentiation</i> , 2020, 27, 55-70.	5.0	53
1691	HIF-1 α forms regulatory loop with YAP to coordinate hypoxia-induced adriamycin resistance in acute myeloid leukemia cells. <i>Cell Biology International</i> , 2020, 44, 456-466.	1.4	11
1692	Silica nano supra-assembly for the targeted delivery of therapeutic cargo to overcome chemoresistance in cancer. <i>Colloids and Surfaces B: Biointerfaces</i> , 2020, 185, 110571.	2.5	21
1693	The ABC subfamily A transporters: Multifaceted players with incipient potentialities in cancer. <i>Seminars in Cancer Biology</i> , 2020, 60, 57-71.	4.3	90
1694	Role of therapeutic agents on repolarisation of tumour-associated macrophage to halt lung cancer progression. <i>Journal of Drug Targeting</i> , 2020, 28, 166-175.	2.1	10
1695	Engineered stem cells targeting multiple cell surface receptors in tumors. <i>Stem Cells</i> , 2020, 38, 34-44.	1.4	7
1696	microRNA-10b confers cisplatin resistance by activating AKT/mTOR/P70S6K signaling via targeting PPAR γ 3 in esophageal cancer. <i>Journal of Cellular Physiology</i> , 2020, 235, 1247-1258.	2.0	44
1697	Paradoxical effects of chemotherapy on tumor relapse and metastasis promotion. <i>Seminars in Cancer Biology</i> , 2020, 60, 351-361.	4.3	122
1698	A new series of acetohydroxamates shows in vitro and in vivo anticancer activity against melanoma. <i>Investigational New Drugs</i> , 2020, 38, 977-989.	1.2	11
1699	Delivery across the blood-brain barrier: nanomedicine for glioblastoma multiforme. <i>Drug Delivery and Translational Research</i> , 2020, 10, 304-318.	3.0	101
1700	ACPred-Fuse: fusing multi-view information improves the prediction of anticancer peptides. <i>Briefings in Bioinformatics</i> , 2020, 21, 1846-1855.	3.2	100
1701	A stimuli-responsive combination therapy for recovering p53-inactivation associated drug resistance. <i>Materials Science and Engineering C</i> , 2020, 108, 110403.	3.8	11
1702	15 α -LOX-1 has diverse roles in the resensitization of resistant cancer cell lines to doxorubicin. <i>Journal of Cellular Physiology</i> , 2020, 235, 4965-4978.	2.0	8
1703	JMJD2A sensitizes gastric cancer to chemotherapy by cooperating with CCDC8. <i>Gastric Cancer</i> , 2020, 23, 426-436.	2.7	15
1704	Soft and Condensed Nanoparticles and Nanoformulations for Cancer Drug Delivery and Repurpose. <i>Advanced Therapeutics</i> , 2020, 3, 1900102.	1.6	21
1705	PROTACs as Potential Therapeutic Agents for Cancer Drug Resistance. <i>Biochemistry</i> , 2020, 59, 240-249.	1.2	47

#	ARTICLE	IF	CITATIONS
1706	Patient-Derived Colorectal Cancer Organoids Upregulate Revival Stem Cell Marker Genes following Chemotherapeutic Treatment. <i>Journal of Clinical Medicine</i> , 2020, 9, 128.	1.0	38
1707	Metabolic Fitness and Plasticity in Cancer Progression. <i>Trends in Cancer</i> , 2020, 6, 49-61.	3.8	76
1708	SERS analysis of carcinoma-associated fibroblasts in a tumor microenvironment based on targeted 2D nanosheets. <i>Nanoscale</i> , 2020, 12, 2133-2141.	2.8	20
1709	Formulation of a triple combination gemcitabine plus romidepsin+ cisplatin regimen to efficaciously and safely control triple-negative breast cancer tumor development. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 141-152.	1.1	9
1710	Anticancer properties, apoptosis and catecholase mimic activities of dinuclear cobalt(II) and copper(II) Schiff base complexes. <i>Bioorganic Chemistry</i> , 2020, 95, 103561.	2.0	40
1711	Redox-responsive polyprodrug nanoparticles for targeted siRNA delivery and synergistic liver cancer therapy. <i>Biomaterials</i> , 2020, 234, 119760.	5.7	89
1712	A potentiated cooperation of carbonic anhydrase IX and histone deacetylase inhibitors against cancer. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2020, 35, 391-397.	2.5	19
1713	How the ageing microenvironment influences tumour progression. <i>Nature Reviews Cancer</i> , 2020, 20, 89-106.	12.8	408
1714	Gene/paclitaxel co-delivering nanocarriers prepared by framework-induced self-assembly for the inhibition of highly drug-resistant tumors. <i>Acta Biomaterialia</i> , 2020, 103, 247-258.	4.1	53
1715	Fluorescent Polysaccharide Nanogels for the Detection of Tumor Heterogeneity in Drug-Surviving Cancer Cells. <i>Advanced Biology</i> , 2020, 4, 1900213.	3.0	8
1716	ROS and GSH-responsive S-nitrosoglutathione functionalized polymeric nanoparticles to overcome multidrug resistance in cancer. <i>Acta Biomaterialia</i> , 2020, 103, 259-271.	4.1	85
1717	Stimuli-responsive charge-reversal nano drug delivery system: The promising targeted carriers for tumor therapy. <i>International Journal of Pharmaceutics</i> , 2020, 575, 118841.	2.6	44
1718	Charge-reversal nanocarriers: An emerging paradigm for smart cancer nanomedicine. <i>Journal of Controlled Release</i> , 2020, 319, 46-62.	4.8	84
1719	A Proteomic Connectivity Map for Characterizing the Tumor Adaptive Response to Small Molecule Chemical Perturbagens. <i>ACS Chemical Biology</i> , 2020, 15, 140-150.	1.6	8
1720	Macrophages reprogrammed by lung cancer microparticles promote tumor development via release of IL-1 β . <i>Cellular and Molecular Immunology</i> , 2020, 17, 1233-1244.	4.8	41
1721	Aptamer-Functionalized DNA Origami for Targeted Codelivery of Antisense Oligonucleotides and Doxorubicin to Enhance Therapy in Drug-Resistant Cancer Cells. <i>ACS Applied Materials & Interfaces</i> , 2020, 12, 400-409.	4.0	99
1722	Identification of chemoresistance-related mRNAs based on gemcitabine-resistant pancreatic cancer cell lines. <i>Cancer Medicine</i> , 2020, 9, 1115-1130.	1.3	19
1723	Principles and mechanisms of non-genetic resistance in cancer. <i>British Journal of Cancer</i> , 2020, 122, 465-472.	2.9	102

#	ARTICLE	IF	CITATIONS
1724	Evolved resistance to partial GAPDH inhibition results in loss of the Warburg effect and in a different state of glycolysis. <i>Journal of Biological Chemistry</i> , 2020, 295, 111-124.	1.6	11
1725	MicroRNAs, a Promising Target for Breast Cancer Stem Cells. <i>Molecular Diagnosis and Therapy</i> , 2020, 24, 69-83.	1.6	22
1726	Co-localized delivery of nanomedicine and nanovaccine augments the postoperative cancer immunotherapy by amplifying T-cell responses. <i>Biomaterials</i> , 2020, 230, 119649.	5.7	102
1727	Identification of candidate genes and miRNAs for sensitizing resistant colorectal cancer cells to oxaliplatin and irinotecan. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 153-171.	1.1	9
1728	Temozolomide induces activation of Wnt/ β -catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. <i>Cell Biology and Toxicology</i> , 2020, 36, 273-278.	2.4	52
1729	Linc01014 regulates gefitinib resistance in oesophagus cancer via EGFR-PI3K-Akt-mTOR signalling pathway. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 1670-1675.	1.6	12
1730	Role of the NF- κ B signaling pathway in the pathogenesis of colorectal cancer. <i>Gene</i> , 2020, 726, 144132.	1.0	129
1731	Ligustilide promotes apoptosis of cancer-associated fibroblasts via the TLR4 pathways. <i>Food and Chemical Toxicology</i> , 2020, 135, 110991.	1.8	13
1732	TIMP-1 Is Overexpressed and Secreted by Platinum Resistant Epithelial Ovarian Cancer Cells. <i>Cells</i> , 2020, 9, 6.	1.8	20
1733	Heat Shock Proteins: Agents of Cancer Development and Therapeutic Targets in Anti-Cancer Therapy. <i>Cells</i> , 2020, 9, 60.	1.8	180
1734	Antitumor Potential of Marine and Freshwater Lectins. <i>Marine Drugs</i> , 2020, 18, 11.	2.2	30
1735	Mathematical model predicts response to chemotherapy in advanced non-resectable non-small cell lung cancer patients treated with platinum-based doublet. <i>PLoS Computational Biology</i> , 2020, 16, e1008234.	1.5	12
1736	Specific c-Jun N-Terminal Kinase Inhibitor, JNK-IN-8 Suppresses Mesenchymal Profile of PTX-Resistant MCF-7 Cells through Modulating PI3K/Akt, MAPK and Wnt Signaling Pathways. <i>Biology</i> , 2020, 9, 320.	1.3	6
1737	The Anticancer Activity for the Bumetanide-Based Analogs via Targeting the Tumor-Associated Membrane-Bound Human Carbonic Anhydrase-IX Enzyme. <i>Pharmaceuticals</i> , 2020, 13, 252.	1.7	19
1738	<p></p>Genomics and Transcriptomics: The Powerful Technologies in Precision Medicine</p>. <i>International Journal of General Medicine</i> , 2020, Volume 13, 627-640.	0.8	19
1739	DNA Nanostructures and DNA-Functionalized Nanoparticles for Cancer Theranostics. <i>Advanced Science</i> , 2020, 7, 2001669.	5.6	47
1740	Enhanced Protein Damage Clearance Induces Broad Drug Resistance in Multitype of Cancers Revealed by an Evolution Drug-Resistant Model and Genome-Wide siRNA Screening. <i>Advanced Science</i> , 2020, 7, 2001914.	5.6	9
1741	Molecular and cellular paradigms of multidrug resistance in cancer. <i>Cancer Reports</i> , 2022, 5, e1291.	0.6	56

#	ARTICLE	IF	CITATIONS
1742	Cancer Stem Cells: New Horizons in Cancer Therapies. , 2020, , .		1
1743	MicroRNAs as mediators of drug resistance mechanisms. <i>Current Opinion in Pharmacology</i> , 2020, 54, 44-50.	1.7	19
1744	Hydroxyapatite nanocomposite as a potential agent in osteosarcoma PDT. <i>Photodiagnosis and Photodynamic Therapy</i> , 2020, 32, 102056.	1.3	10
1745	Structure and surface analysis of ibuprofen-organotin conjugate: Potential anti-cancer drug candidacy of the compound is proven by in-vitro DNA binding and cytotoxicity studies. <i>Polyhedron</i> , 2020, 192, 114845.	1.0	9
1746	A novel vitamin D gene therapy for acute myeloid leukemia. <i>Translational Oncology</i> , 2020, 13, 100869.	1.7	10
1747	Molecular biological analysis of 5-FU-resistant gastric cancer organoids; KHDRBS3 contributes to the attainment of features of cancer stem cell. <i>Oncogene</i> , 2020, 39, 7265-7278.	2.6	30
1748	Cancer Metabolism: Phenotype, Signaling and Therapeutic Targets. <i>Cells</i> , 2020, 9, 2308.	1.8	211
1749	Synthesis, In Silico and In Vitro Assessment of New Quinazolinones as Anticancer Agents via Potential AKT Inhibition. <i>Molecules</i> , 2020, 25, 4780.	1.7	23
1750	Targeting cell cycle by β^2 -carboline alkaloids in vitro: Novel therapeutic prospects for the treatment of cancer. <i>Chemico-Biological Interactions</i> , 2020, 330, 109229.	1.7	37
1751	Targeted antimicrobial peptide delivery in vivo to tumor with near infrared photoactivated mesoporous silica nanoparticles. <i>International Journal of Pharmaceutics</i> , 2020, 588, 119767.	2.6	14
1752	The Oral Microbiome and Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 591088.	2.2	134
1753	<i>SMAR1</i> repression by pluripotency factors and consequent chemoresistance in breast cancer stem-like cells is reversed by aspirin. <i>Science Signaling</i> , 2020, 13, .	1.6	16
1754	Aspirin overcomes cisplatin resistance in lung cancer by inhibiting cancer cell stemness. <i>Thoracic Cancer</i> , 2020, 11, 3117-3125.	0.8	11
1755	RCSB Protein Data Bank tools for 3D structure-guided cancer research: human papillomavirus (HPV) case study. <i>Oncogene</i> , 2020, 39, 6623-6632.	2.6	6
1756	Truncated HDAC9 identified by integrated genome-wide screen as the key modulator for paclitaxel resistance in triple-negative breast cancer. <i>Theranostics</i> , 2020, 10, 11092-11109.	4.6	22
1757	Drug resistance in cancer: mechanisms and tackling strategies. <i>Pharmacological Reports</i> , 2020, 72, 1125-1151.	1.5	118
1758	Nanotechnology in Modern Photodynamic Therapy of Cancer: A Review of Cellular Resistance Patterns Affecting the Therapeutic Response. <i>Pharmaceutics</i> , 2020, 12, 632.	2.0	41
1759	Carrier-Free Delivery of Precise Drug-Chemogene Conjugates for Synergistic Treatment of Drug-Resistant Cancer. <i>Angewandte Chemie</i> , 2020, 132, 18100-18106.	1.6	10

#	ARTICLE	IF	CITATIONS
1760	MLL3 Induced by Luteolin Causes Apoptosis in Tamoxifen-Resistant Breast Cancer Cells through H3K4 Monomethylation and Suppression of the PI3K/AKT/mTOR Pathway. <i>The American Journal of Chinese Medicine</i> , 2020, 48, 1221-1241.	1.5	33
1761	Carbon nanotubes in drug delivery: Focus on anticancer therapies. <i>Journal of Drug Delivery Science and Technology</i> , 2020, 59, 101892.	1.4	52
1762	Mechanisms of ibrutinib resistance in chronic lymphocytic leukemia and alternative treatment strategies. <i>Expert Review of Hematology</i> , 2020, 13, 871-883.	1.0	8
1763	Next Generation Kinase Inhibitors. , 2020, , .		8
1764	Pharmacotherapeutic Botanicals for Cancer Chemoprevention. , 2020, , .		4
1765	Micro RNA facilitated chemoresistance in gastric cancer: a novel biomarkers and potential therapeutics. <i>Alexandria Journal of Medicine</i> , 2020, 56, 81-92.	0.4	5
1766	Innovations in Metastatic Brain Tumor Treatment. , 2020, , .		1
1767	The promising role of noncoding RNAs in cancer-associated fibroblasts: an overview of current status and future perspectives. <i>Journal of Hematology and Oncology</i> , 2020, 13, 154.	6.9	28
1768	Challenges and Therapeutic Opportunities of Autophagy in Cancer Therapy. <i>Cancers</i> , 2020, 12, 3461.	1.7	33
1769	Iron Dysregulation in Human Cancer: Altered Metabolism, Biomarkers for Diagnosis, Prognosis, Monitoring and Rationale for Therapy. <i>Cancers</i> , 2020, 12, 3524.	1.7	24
1770	Fanconi anemia-independent DNA inter-strand crosslink repair in eukaryotes. <i>Progress in Biophysics and Molecular Biology</i> , 2020, 158, 33-46.	1.4	16
1771	Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome. <i>Nature Communications</i> , 2020, 11, 6175.	5.8	92
1772	Small molecule inhibition of Dynamin-dependent endocytosis targets multiple niche signals and impairs leukemia stem cells. <i>Nature Communications</i> , 2020, 11, 6211.	5.8	20
1773	PARPBP is a prognostic marker and confers anthracycline resistance to breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097421.	1.4	5
1774	Thrombospondin-1 Receptor CD47 Overexpression Contributes to P-Glycoprotein-Mediated Multidrug Resistance Against Doxorubicin in Thyroid Carcinoma FTC-133 Cells. <i>Frontiers in Oncology</i> , 2020, 10, 551228.	1.3	5
1775	Molecular targeted therapy: novel therapeutic approach for head and neck cancer. <i>Therapeutic Delivery</i> , 2020, 11, 637-651.	1.2	4
1776	Jianpi Yangwei decoction promotes apoptosis and suppresses proliferation of 5-fluorouracil resistant gastric cancer cells in vitro and in vivo. <i>BMC Complementary Medicine and Therapies</i> , 2020, 20, 337.	1.2	4
1777	Design of Fluorescent Coumarin-Hydroxamic Acid Derivatives as Inhibitors of HDACs: Synthesis, Anti-Proliferative Evaluation and Docking Studies. <i>Molecules</i> , 2020, 25, 5134.	1.7	14

#	ARTICLE	IF	CITATIONS
1778	Quantitative Structure–Mutation–Activity Relationship Tests (QSMART) model for protein kinase inhibitor response prediction. <i>BMC Bioinformatics</i> , 2020, 21, 520.	1.2	8
1779	Mesoporous silica nanoparticles for cancer theranostic applications. , 2020, , 577-604.		1
1780	Design, Synthesis, and Characterization of an Orally Active Dual-Specific ULK1/2 Autophagy Inhibitor that Synergizes with the PARP Inhibitor Olaparib for the Treatment of Triple-Negative Breast Cancer. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 14609-14625.	2.9	30
1781	Antimicrobial Peptide Reverses ABCB1-Mediated Chemotherapeutic Drug Resistance. <i>Frontiers in Pharmacology</i> , 2020, 11, 1208.	1.6	23
1782	In Silico Study Identified Methotrexate Analog as Potential Inhibitor of Drug Resistant Human Dihydrofolate Reductase for Cancer Therapeutics. <i>Molecules</i> , 2020, 25, 3510.	1.7	14
1783	microRNA-222-Mediated VHL Downregulation Facilitates Retinoblastoma Chemoresistance by Increasing HIF1 α Expression. , 2020, 61, 9.		11
1784	Molecular Markers Guiding Thyroid Cancer Management. <i>Cancers</i> , 2020, 12, 2164.	1.7	34
1785	Anticancer effects of the PLK4 inhibitors CFI-400945 and centrinone in Ewing's sarcoma cells. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2871-2883.	1.2	14
1786	Glioma progression is suppressed by Naringenin and APO2L combination therapy via the activation of apoptosis in vitro and in vivo. <i>Investigational New Drugs</i> , 2020, 38, 1743-1754.	1.2	11
1787	Mass spectrometry-based proteomics of single cells and organoids: The new generation of cancer research. <i>TrAC - Trends in Analytical Chemistry</i> , 2020, 130, 116005.	5.8	6
1788	A compendium of mutational cancer driver genes. <i>Nature Reviews Cancer</i> , 2020, 20, 555-572.	12.8	605
1789	Discovery through clinical sequencing in oncology. <i>Nature Cancer</i> , 2020, 1, 774-783.	5.7	29
1791	Cancer stem cell plasticity in glioblastoma multiforme: a perspective on future directions in oncolytic virotherapy. <i>Future Oncology</i> , 2020, 16, 2251-2264.	1.1	2
1792	The Role of Necroptosis in ROS-Mediated Cancer Therapies and Its Promising Applications. <i>Cancers</i> , 2020, 12, 2185.	1.7	58
1793	H ₂ O ₂ -Scavenged and Activated Iron Oxide–Hydroxide Nanospindles for MRI-Guided Photothermal Therapy and Ferroptosis in Colon Cancer. <i>Small</i> , 2020, 16, e2001356.	5.2	61
1794	Dual targeting of GSK3B and HDACs reduces tumor growth and improves survival in an ovarian cancer mouse model. <i>Gynecologic Oncology</i> , 2020, 159, 277-284.	0.6	12
1795	Antineoplastic Drug-Free Anticancer Strategy Enabled by Host-Defense Peptides-Mimicking Synthetic Polypeptides. <i>Advanced Materials</i> , 2020, 32, e2001108.	11.1	64
1796	Tetrandrine: a review of its anticancer potentials, clinical settings, pharmacokinetics and drug delivery systems. <i>Journal of Pharmacy and Pharmacology</i> , 2020, 72, 1491-1512.	1.2	62

#	ARTICLE	IF	CITATIONS
1797	A Self-Evaluating Photothermal Therapeutic Nanoparticle. <i>ACS Nano</i> , 2020, 14, 9585-9593.	7.3	61
1798	Spatiotemporally controlled O ₂ and singlet oxygen self-sufficient nanophotosensitizers enable the <i>in vivo</i> high-yield synthesis of drugs and efficient hypoxic tumor therapy. <i>Chemical Science</i> , 2020, 11, 8817-8827.	3.7	22
1799	Semisynthesis of novel magnolol-based Mannich base derivatives that suppress cancer cells via inducing autophagy. <i>European Journal of Medicinal Chemistry</i> , 2020, 205, 112663.	2.6	18
1800	Network-principled deep generative models for designing drug combinations as graph sets. <i>Bioinformatics</i> , 2020, 36, i445-i454.	1.8	24
1801	The Multidrug Resistance-Reversing Activity of a Novel Antimicrobial Peptide. <i>Cancers</i> , 2020, 12, 1963.	1.7	21
1802	Sensitization of drug resistant sarcoma tumors by membrane modulation via short chain sphingolipid-containing nanoparticles. <i>Nanoscale</i> , 2020, 12, 16967-16979.	2.8	3
1803	Combating Drug Resistance in Colorectal Cancer Using Herbal Medicines. <i>Chinese Journal of Integrative Medicine</i> , 2021, 27, 551-560.	0.7	17
1804	Patient specific circulating tumor DNA fingerprints to monitor treatment response across multiple tumors. <i>Journal of Translational Medicine</i> , 2020, 18, 293.	1.8	20
1805	Protein nanoparticles containing Cu(II) and DOX for efficient chemodynamic therapy via self-generation of H ₂ O ₂ . <i>Chinese Chemical Letters</i> , 2020, 31, 3127-3130.	4.8	49
1806	TRAIL-conjugated silver nanoparticles sensitize glioblastoma cells to TRAIL by regulating CHK1 in the DNA repair pathway. <i>Neurological Research</i> , 2020, 42, 1061-1069.	0.6	10
1807	Discovery of dihydrofuranoalcolchicinoids - Highly potent antimetabolic agents with low acute toxicity. <i>European Journal of Medicinal Chemistry</i> , 2020, 207, 112724.	2.6	12
1808	Stochastic fluctuations in apoptotic threshold of tumour cells can enhance apoptosis and combat fractional killing. <i>Royal Society Open Science</i> , 2020, 7, 190462.	1.1	10
1809	New Insights into Therapy-Induced Progression of Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7872.	1.8	14
1810	The Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: An In Silico Study. <i>Frontiers in Immunology</i> , 2020, 11, 524968.	2.2	7
1811	Tumour neoantigen heterogeneity thresholds provide a time window for combination immunotherapy. <i>Journal of the Royal Society Interface</i> , 2020, 17, 20200736.	1.5	13
1812	Patient-Derived, Drug-Resistant Colon Cancer Cells Evade Chemotherapeutic Drug Effects via the Induction of Epithelial-Mesenchymal Transition-Mediated Angiogenesis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7469.	1.8	5
1813	Partners in crime: POPX2 phosphatase and its interacting proteins in cancer. <i>Cell Death and Disease</i> , 2020, 11, 840.	2.7	6
1814	Bioactive Peptides as Therapeutic Adjuvants for Cancer. <i>Nutrition and Cancer</i> , 2021, 73, 1309-1321.	0.9	18

#	ARTICLE	IF	CITATIONS
1815	Demethoxycurcumin Inhibits In Vivo Growth of Xenograft Tumors of Human Cervical Cancer Cells. <i>In Vivo</i> , 2020, 34, 2469-2474.	0.6	4
1816	Targeting Oxidative Phosphorylation Reverses Drug Resistance in Cancer Cells by Blocking Autophagy Recycling. <i>Cells</i> , 2020, 9, 2013.	1.8	27
1817	Evolution of tumor cells during AsiDNA treatment results in energy exhaustion, decrease in responsiveness to signal, and higher sensitivity to the drug. <i>Evolutionary Applications</i> , 2020, 13, 1673-1680.	1.5	5
1818	Identification of a Novel Immune-Related Prognostic Biomarker and Small-Molecule Drugs in Clear Cell Renal Cell Carcinoma (ccRCC) by a Merged Microarray-Acquired Dataset and TCGA Database. <i>Frontiers in Genetics</i> , 2020, 11, 810.	1.1	12
1819	FUCCI Real-Time Cell-Cycle Imaging as a Guide for Designing Improved Cancer Therapy: A Review of Innovative Strategies to Target Quiescent Chemo-Resistant Cancer Cells. <i>Cancers</i> , 2020, 12, 2655.	1.7	16
1820	A Sequentially Responsive Nanosystem Breaches Cascaded Bio-barriers and Suppresses P-Glycoprotein Function for Reversing Cancer Drug Resistance. <i>ACS Applied Materials & Interfaces</i> , 2020, 12, 54343-54355.	4.0	15
1821	Cancer-specific drug-drug nanoparticles of pro-apoptotic and cathepsin B-cleavable peptide-conjugated doxorubicin for drug-resistant cancer therapy. <i>Biomaterials</i> , 2020, 261, 120347.	5.7	60
1822	FZR1 as a novel biomarker for breast cancer neoadjuvant chemotherapy prediction. <i>Cell Death and Disease</i> , 2020, 11, 804.	2.7	14
1823	The antitumor drug ABTL0812 impairs neuroblastoma growth through endoplasmic reticulum stress-mediated autophagy and apoptosis. <i>Cell Death and Disease</i> , 2020, 11, 773.	2.7	7
1824	Untangling Data in Precision Oncology – A Model for Chronic Diseases?. <i>Yearbook of Medical Informatics</i> , 2020, 29, 184-187.	0.8	0
1825	Engineering of a Core-Shell Nanoplatform to Overcome Multidrug Resistance via ATP Deprivation. <i>Advanced Healthcare Materials</i> , 2020, 9, e2000432.	3.9	20
1826	FastClone is a probabilistic tool for deconvoluting tumor heterogeneity in bulk-sequencing samples. <i>Nature Communications</i> , 2020, 11, 4469.	5.8	32
1827	Dual Inhibitors Targeting DNA and Histone Deacetylases. <i>Pharmaceutical Fronts</i> , 2020, 02, e88-e93.	0.4	0
1828	Transcription Factors in Cancer Development and Therapy. <i>Cancers</i> , 2020, 12, 2296.	1.7	72
1829	Investigating the Impact of OGT Inhibition on Doxorubicin- and Docetaxel-Induced Cytotoxicity in PC-3 and WPMY-1 Cells. <i>International Journal of Toxicology</i> , 2020, 39, 586-593.	0.6	11
1830	Novel Therapeutic Application of Self-Assembly Peptides Targeting the Mitochondria in In Vitro and In Vivo Experimental Models of Gastric Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6126.	1.8	6
1831	Tubeimoside I-induced lung cancer cell death and the underlying crosstalk between lysosomes and mitochondria. <i>Cell Death and Disease</i> , 2020, 11, 708.	2.7	20
1832	A coassembled peptide hydrogel boosts the radiosensitization of cisplatin. <i>Chemical Communications</i> , 2020, 56, 13017-13020.	2.2	11

#	ARTICLE	IF	CITATIONS
1833	Branched α -helical peptides enhanced antitumor efficacy and selectivity. <i>Biomaterials Science</i> , 2020, 8, 6387-6394.	2.6	4
1834	Molecular mechanisms and clinical implications of miRNAs in drug resistance of colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094734.	1.4	12
1835	Establishment of Facile Nanomedicine Construction Methodology to Comprehensively Overcome Hurdles across Tumor-Specific Nano-Delivery. <i>Advanced Functional Materials</i> , 2020, 30, 2002239.	7.8	13
1837	Epitranscriptomics and epiproteomics in cancer drug resistance: therapeutic implications. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 193.	7.1	66
1838	EI24 Inhibits Cell Proliferation and Drug Resistance of Esophageal Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 1570.	1.3	8
1839	Cancer Stem Cells, Quo Vadis? The Notch Signaling Pathway in Tumor Initiation and Progression. <i>Cells</i> , 2020, 9, 1879.	1.8	53
1840	Fluorescent glycan nanoparticle-based FACS assays for the identification of genuine drug-resistant cancer cells with differentiation potential. <i>Nano Research</i> , 2020, 13, 3110-3122.	5.8	7
1841	Nanocarrier anticancer drug-conjugates cause higher cellular deformations: culpable for mischief. <i>Biomaterials Science</i> , 2020, 8, 5729-5738.	2.6	5
1842	Coassembled Nanoparticles Composed of Functionalized Mesoporous Silica and Pillar[5]arene-Appended Gold Nanoparticles as Mitochondrial-Selective Dual-Drug Carriers. <i>Particle and Particle Systems Characterization</i> , 2020, 37, 2000136.	1.2	5
1843	Exploring Specific miRNA-mRNA Axes With Relationship to Taxanes-Resistance in Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1397.	1.3	12
1844	Verminoside from <i>Pseudolysimachion rotundum</i> var. <i>subintegrum</i> sensitizes cisplatin-resistant cancer cells and suppresses metastatic growth of human breast cancer. <i>Scientific Reports</i> , 2020, 10, 20337.	1.6	5
1845	Sonodynamic therapy in combination with photodynamic therapy shows enhanced long-term cure of brain tumor. <i>Scientific Reports</i> , 2020, 10, 21791.	1.6	32
1846	Carbohydrate α -sialyllactose as a novel target for theranostics in pancreatic ductal adenocarcinoma. <i>Tumor Biology</i> , 2020, 42, 101042832096527.	0.8	0
1847	Clinical Perspective of FDA Approved Drugs With P-Glycoprotein Inhibition Activities for Potential Cancer Therapeutics. <i>Frontiers in Oncology</i> , 2020, 10, 561936.	1.3	68
1848	Diosgenin Loaded Polymeric Nanoparticles with Potential Anticancer Efficacy. <i>Biomolecules</i> , 2020, 10, 1679.	1.8	14
1849	Protein array-based companion diagnostics in precision medicine. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 1183-1198.	1.5	6
1850	Large-scale comparative review and assessment of computational methods for anti-cancer peptide identification. <i>Briefings in Bioinformatics</i> , 2021, 22, .	3.2	40
1851	ncDRMarker: a computational method for identifying non-coding RNA signatures of drug resistance based on heterogeneous network. <i>Annals of Translational Medicine</i> , 2020, 8, 1395-1395.	0.7	5

#	ARTICLE	IF	CITATIONS
1852	DeepACP: A Novel Computational Approach for Accurate Identification of Anticancer Peptides by Deep Learning Algorithm. <i>Molecular Therapy - Nucleic Acids</i> , 2020, 22, 862-870.	2.3	47
1854	Efficacy of the CDK7 Inhibitor on EMT-Associated Resistance to 3rd Generation EGFR-TKIs in Non-Small Cell Lung Cancer Cell Lines. <i>Cells</i> , 2020, 9, 2596.	1.8	16
1855	Antitumor Drugs and Their Targets. <i>Molecules</i> , 2020, 25, 5776.	1.7	39
1856	Aberrant DNA Methylation of ABC Transporters in Cancer. <i>Cells</i> , 2020, 9, 2281.	1.8	23
1857	Cold Atmospheric Pressure Plasma (CAP) as a New Tool for the Management of Vulva Cancer and Vulvar Premalignant Lesions in Gynaecological Oncology. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7988.	1.8	15
1858	Therapeutic Potential of Ursolic Acid: Comparison with Ursolic Acid. <i>Biomolecules</i> , 2020, 10, 1505.	1.8	34
1859	Novel TrxR1 Inhibitors Show Potential for Glioma Treatment by Suppressing the Invasion and Sensitizing Glioma Cells to Chemotherapy. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 586146.	1.6	15
1860	Can the Docking Experiments Select the Optimum Natural Bio-macromolecule for Doxorubicin Delivery?. <i>Journal of Cluster Science</i> , 2021, 32, 1747-1751.	1.7	7
1861	ABC Efflux Transporters and the Circuitry of miRNAs: Kinetics of Expression in Cancer Drug Resistance. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2985.	1.8	12
1862	Protease-responsive mass barcoded nanotranslators for simultaneously quantifying the intracellular activity of cascaded caspases in apoptosis pathways. <i>Chemical Science</i> , 2020, 11, 5280-5288.	3.7	10
1863	YM155-Adapted Cancer Cell Lines Reveal Drug-Induced Heterogeneity and Enable the Identification of Biomarker Candidates for the Acquired Resistance Setting. <i>Cancers</i> , 2020, 12, 1080.	1.7	5
1864	Therapeutic targeting of miRNA-216b in cancer. <i>Cancer Letters</i> , 2020, 484, 16-28.	3.2	12
1865	The Utility of Liquid Biopsies in Radiation Oncology. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 873-886.	0.4	14
1866	Non-coding RNAs in drug resistance of head and neck cancers: A review. <i>Biomedicine and Pharmacotherapy</i> , 2020, 127, 110231.	2.5	18
1867	Cell Growth Measurement. , 0, , .		2
1868	TRIM11 facilitates chemoresistance in nasopharyngeal carcinoma by activating the β -catenin/ABCC9 axis via p62-selective autophagic degradation of Daple. <i>Oncogenesis</i> , 2020, 9, 45.	2.1	56
1869	The Effect of 4-hydroxy-3,4,5-trimethoxystilbene, the Metabolite of Resveratrol Analogue DMU-212, on Growth, Cell Cycle and Apoptosis in DLD-1 and LOVO Colon Cancer Cell Lines. <i>Nutrients</i> , 2020, 12, 1327.	1.7	5
1870	SRPK1 acetylation modulates alternative splicing to regulate cisplatin resistance in breast cancer cells. <i>Communications Biology</i> , 2020, 3, 268.	2.0	32

#	ARTICLE	IF	CITATIONS
1871	Achillea millefolium L. ethyl acetate fraction induces apoptosis and cell cycle arrest in human cervical cancer (HeLa) cells. <i>Annals of Agricultural Sciences</i> , 2020, 65, 42-48.	1.1	23
1872	Supramolecular combination chemotherapy: a pH-responsive co-encapsulation drug delivery system. <i>Chemical Science</i> , 2020, 11, 6275-6282.	3.7	58
1873	Senescence-Associated Pro-inflammatory Cytokines and Tumor Cell Plasticity. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 63.	1.6	38
1874	Is the Way to Fight Cancer Paved with Gold? Metal-Based Carbene Complexes with Multiple and Fascinating Biological Features. <i>Pharmaceutics</i> , 2020, 13, 91.	1.7	45
1875	Recent technological advancements in stem cell research for targeted therapeutics. <i>Drug Delivery and Translational Research</i> , 2020, 10, 1147-1169.	3.0	8
1876	Nanomedicine solutions to intricate physiological-pathological barriers and molecular mechanisms of tumor multidrug resistance. <i>Journal of Controlled Release</i> , 2020, 323, 483-501.	4.8	21
1877	The Role of a Proprotein Convertase Inhibitor in Reactivation of Tumor-Associated Macrophages and Inhibition of Glioma Growth. <i>Molecular Therapy - Oncolytics</i> , 2020, 17, 31-46.	2.0	13
1878	Acquired Resistance to Alectinib in ALK-Rearranged Lung Cancer due to ABCC11/MRP8 Overexpression in a Clinically Paired Resistance Model. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1320-1327.	1.9	5
1879	Phenotypic delay in the evolution of bacterial antibiotic resistance: Mechanistic models and their implications. <i>PLoS Computational Biology</i> , 2020, 16, e1007930.	1.5	5
1880	Emerging Therapeutic RNAs for the Targeting of Cancer Associated Fibroblasts. <i>Cancers</i> , 2020, 12, 1365.	1.7	8
1881	IOX-101 Reverses Drug Resistance Through Suppression of Akt/mTOR/NF- κ B Signaling in Cancer Stem Cell-Like, Sphere-Forming NSCLC Cell. <i>Oncology Research</i> , 2020, 28, 177-189.	0.6	9
1882	Desmoplasia and Biophysics in Pancreatic Ductal Adenocarcinoma. <i>Pancreas</i> , 2020, 49, 313-325.	0.5	18
1883	<i>Cordyceps militaris</i> Exerts Anticancer Effect on Non-Small Cell Lung Cancer by Inhibiting Hedgehog Signaling via Suppression of TCTN3. <i>Integrative Cancer Therapies</i> , 2020, 19, 153473542092375.	0.8	13
1885	Machine learning approaches to drug response prediction: challenges and recent progress. <i>Npj Precision Oncology</i> , 2020, 4, 19.	2.3	170
1886	Synthesis and biological evaluation of Schizandrin derivatives as tubulin polymerization inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127354.	1.0	8
1887	pH and singlet oxygen dual-responsive GEM prodrug micelles for efficient combination therapy of chemotherapy and photodynamic therapy. <i>Journal of Materials Chemistry B</i> , 2020, 8, 5645-5654.	2.9	16
1888	Suppression of cancer proliferation and metastasis by a versatile nanomedicine integrating photodynamic therapy, photothermal therapy, and enzyme inhibition. <i>Acta Biomaterialia</i> , 2020, 113, 541-553.	4.1	8
1889	Convergence of therapy-induced senescence (TIS) and EMT in multistep carcinogenesis: current opinions and emerging perspectives. <i>Cell Death Discovery</i> , 2020, 6, 51.	2.0	38

#	ARTICLE	IF	CITATIONS
1890	Targeting SphK2 Reverses Acquired Resistance of Regorafenib in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 694.	1.3	27
1891	The Roles of Cancer Stem Cells and Therapy Resistance in Colorectal Carcinoma. <i>Cells</i> , 2020, 9, 1392.	1.8	121
1892	Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy. <i>Journal of Hematology and Oncology</i> , 2020, 13, 64.	6.9	113
1893	Amphiphilic star copolymers-mediated co-delivery of doxorubicin and avasimibe for effective combination chemotherapy. <i>Journal of Materials Science</i> , 2020, 55, 9525-9537.	1.7	2
1894	Epithelialâ€Mesenchymal Transition Programs and Cancer Stem Cell Phenotypes: Mediators of Breast Cancer Therapy Resistance. <i>Molecular Cancer Research</i> , 2020, 18, 1257-1270.	1.5	86
1895	The functional role of long noncoding RNA in resistance to anticancer treatment. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092785.	1.4	30
1896	Necroptosis Induced by Ruthenium(II) Complexes as Dual Catalytic Inhibitors of Topoisomerase I/II. <i>Angewandte Chemie</i> , 2020, 132, 16774.	1.6	4
1897	Role of Exosomal miRNAs and the Tumor Microenvironment in Drug Resistance. <i>Cells</i> , 2020, 9, 1450.	1.8	65
1898	Long noncoding RNA ARSR is associated with a poor prognosis in patients with colorectal cancer. <i>Journal of Gene Medicine</i> , 2020, 22, e3241.	1.4	5
1899	Nuclear delivery of dual anticancer drug-based nanomedicine constructed by cisplatinum-induced peptide self-assembly. <i>Nanoscale</i> , 2020, 12, 15275-15282.	2.8	28
1900	Glycogen Synthase Kinase 3Î² in Cancer Biology and Treatment. <i>Cells</i> , 2020, 9, 1388.	1.8	46
1901	Single-Cell Transcriptomics Analysis Identifies Nuclear Protein 1 as a Regulator of Docetaxel Resistance in Prostate Cancer Cells. <i>Molecular Cancer Research</i> , 2020, 18, 1290-1301.	1.5	25
1902	Pharmacological Activity, Pharmacokinetics, and Toxicity of Timosaponin AIII, a Natural Product Isolated From <i>Anemarrhena asphodeloides</i> Bunge: A Review. <i>Frontiers in Pharmacology</i> , 2020, 11, 764.	1.6	30
1903	Chemotherapy Curability in Leukemia, Lymphoma, Germ Cell Tumors and Gestational Malignancies: A Reflection of the Unique Physiology of Their Cells of Origin. <i>Frontiers in Genetics</i> , 2020, 11, 426.	1.1	3
1904	Necroptosis Induced by Ruthenium(II) Complexes as Dual Catalytic Inhibitors of Topoisomerase I/II. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 16631-16637.	7.2	47
1905	Synthetic Biology Speeds Up Drug Target Discovery. <i>Frontiers in Pharmacology</i> , 2020, 11, 119.	1.6	13
1906	Single Cell Transcriptome in Colorectal Cancerâ€Current Updates on Its Application in Metastasis, Chemoresistance and the Roles of Circulating Tumor Cells. <i>Frontiers in Pharmacology</i> , 2020, 11, 135.	1.6	33
1907	Novel insights into astrocyte-mediated signaling of proliferation, invasion and tumor immune microenvironment in glioblastoma. <i>Biomedicine and Pharmacotherapy</i> , 2020, 126, 110086.	2.5	47

#	ARTICLE	IF	CITATIONS
1908	Using antagonistic pleiotropy to design a chemotherapy-induced evolutionary trap to target drug resistance in cancer. <i>Nature Genetics</i> , 2020, 52, 408-417.	9.4	47
1909	<p>Berberine Reverses Doxorubicin Resistance by Inhibiting Autophagy Through the PTEN/Akt/mTOR Signaling Pathway in Breast Cancer<p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 1909-1919.	1.0	42
1910	An insight on superoxide dismutase (SOD) from plants for mammalian health enhancement. <i>Journal of Functional Foods</i> , 2020, 68, 103917.	1.6	91
1911	Polyphosphazene-Based Drug Self-Framed Delivery System as a Universal Intelligent Platform for Combination Therapy against Multidrug-Resistant Tumors. <i>ACS Applied Bio Materials</i> , 2020, 3, 2284-2294.	2.3	20
1912	Silencing of circRACGAP1 sensitizes gastric cancer cells to apatinib via modulating autophagy by targeting miR-3657 and ATG7. <i>Cell Death and Disease</i> , 2020, 11, 169.	2.7	42
1913	Tumor associated macrophages and â€”NOâ€™. <i>Biochemical Pharmacology</i> , 2020, 176, 113899.	2.0	28
1914	A programmable polymer library that enables the construction of stimuli-responsive nanocarriers containing logic gates. <i>Nature Chemistry</i> , 2020, 12, 381-390.	6.6	122
1915	Postâ€”mortem tissue donation programs as platforms to accelerate cancer research. <i>Journal of Pathology: Clinical Research</i> , 2020, 6, 163-170.	1.3	4
1916	Using medical claims database to develop a population disease progression model for leuprorelin-treated subjects with hormone-sensitive prostate cancer. <i>PLoS ONE</i> , 2020, 15, e0230571.	1.1	1
1917	Tumour Cell Secretome in Chemoresistance and Tumour Recurrence. <i>Trends in Cancer</i> , 2020, 6, 489-505.	3.8	101
1918	Analysis of Dual Class I Histone Deacetylase and Lysine Demethylase Inhibitor Domatinostat (4SC-202) on Growth and Cellular and Genomic Landscape of Atypical Teratoid/Rhabdoid. <i>Cancers</i> , 2020, 12, 756.	1.7	25
1919	Advances in covalent kinase inhibitors. <i>Chemical Society Reviews</i> , 2020, 49, 2617-2687.	18.7	160
1920	Monoclonal Antibody 2C5-Modified Mixed Dendrimer Micelles for Tumor-Targeted Codelivery of Chemotherapeutics and siRNA. <i>Molecular Pharmaceutics</i> , 2020, 17, 1638-1647.	2.3	28
1921	Mitochondrial targeted strategies and their application for cancer and other diseases treatment. <i>Journal of Pharmaceutical Investigation</i> , 2020, 50, 271-293.	2.7	34
1922	Aspirin and the chemoprevention of cancers: A mathematical and evolutionary dynamics perspective. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , 2020, 12, e1487.	6.6	5
1923	Mechanism and regulation of pyroptosis-mediated in cancer cell death. <i>Chemico-Biological Interactions</i> , 2020, 323, 109052.	1.7	164
1924	Combining Allosteric and Orthosteric Drugs to Overcome Drug Resistance. <i>Trends in Pharmacological Sciences</i> , 2020, 41, 336-348.	4.0	60
1925	c-MYC Expression Is a Possible Keystone in the Colorectal Cancer Resistance to EGFR Inhibitors. <i>Cancers</i> , 2020, 12, 638.	1.7	52

#	ARTICLE	IF	CITATIONS
1926	Hippo/YAP Signaling Pathway: A Promising Therapeutic Target in Bone Paediatric Cancers?. <i>Cancers</i> , 2020, 12, 645.	1.7	21
1927	Chiral Pyridine-3,5-bis- (L-phenylalaninyl-L-leucinyl) Schiff Base Peptides as Potential Anticancer Agents: Design, Synthesis, and Molecular Docking Studies Targeting Lactate Dehydrogenase-A. <i>Molecules</i> , 2020, 25, 1096.	1.7	16
1928	N6-methyladenosine-induced ERRÎ³ triggers chemoresistance of cancer cells through upregulation of ABCB1 and metabolic reprogramming. <i>Theranostics</i> , 2020, 10, 3382-3396.	4.6	37
1929	A telomerase-responsive nanoprobe with theranostic properties in tumor cells. <i>Talanta</i> , 2020, 215, 120898.	2.9	8
1930	Case Study on Receptor Tyrosine Kinases EGFR, VEGFR, and PDGFR. <i>Topics in Medicinal Chemistry</i> , 2020, , 155-201.	0.4	0
1931	Role of colorectal cancer stem cells in resistance to apoptosis and treatment in colorectal cancer. , 2020, , 57-74.		0
1932	Cotargeting <sc>BET</sc> proteins overcomes resistance arising from <sc>PI3K</sc>/<sc>mTOR</sc> blockadeâ€induced protumorigenic senescence in colorectal cancer. <i>International Journal of Cancer</i> , 2020, 147, 2824-2837.	2.3	6
1933	Metalâ€organic frameworkâ€based cancer theranostic nanoplatfoms. <i>View</i> , 2020, 1, e20.	2.7	63
1934	Phytochemicals in cancer cell chemosensitization: Current knowledge and future perspectives. <i>Seminars in Cancer Biology</i> , 2022, 80, 306-339.	4.3	77
1935	Overcoming cancer therapeutic bottleneck by drug repurposing. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 113.	7.1	299
1936	Carrierâ€Free Delivery of Precise Drugâ€Chemogene Conjugates for Synergistic Treatment of Drugâ€Resistant Cancer. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 17944-17950.	7.2	73
1937	Pharmacological Targeting of Vacuolar H ⁺ -ATPase via Subunit V1G Combats Multidrug-Resistant Cancer. <i>Cell Chemical Biology</i> , 2020, 27, 1359-1370.e8.	2.5	13
1938	<p>Inhibition of Serine Metabolism Promotes Resistance to Cisplatin in Gastric Cancer</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 4833-4842.	1.0	11
1939	Unprecedented Theranostic LaB 6 Nanocubesâ€Mediated NIRâ€b Photodynamic Therapy to Conquer Hypoxiaâ€Induced Chemoresistance. <i>Advanced Functional Materials</i> , 2020, 30, 2002940.	7.8	16
1940	Unfolded Protein Response in Leukemia: From Basic Understanding to Therapeutic Opportunities. <i>Trends in Cancer</i> , 2020, 6, 960-973.	3.8	19
1941	HSP27 regulates viability and migration of cancer cell lines following irradiation. <i>Journal of Proteomics</i> , 2020, 226, 103886.	1.2	6
1942	<p>Adipose-Derived Stem Cells Can Replace Fibroblasts as Cell Control for Anti-Tumor Screening Assay</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 6417-6423.	1.0	2
1943	Antiproliferative effect of Moringa oleifera methanolic leaf extract by down-regulation of Notch signaling in DU145 prostate cancer cells. <i>Gene Reports</i> , 2020, 19, 100619.	0.4	12

#	ARTICLE	IF	CITATIONS
1944	A combination strategy targeting enhancer plasticity exerts synergistic lethality against BETi-resistant leukemia cells. <i>Nature Communications</i> , 2020, 11, 740.	5.8	36
1945	Screening of potential miRNA therapeutics for the prevention of multi-drug resistance in cancer cells. <i>Scientific Reports</i> , 2020, 10, 1970.	1.6	28
1946	Quantification of fluorophore distribution and therapeutic response in matched in vivo and ex vivo pancreatic cancer model systems. <i>PLoS ONE</i> , 2020, 15, e0229407.	1.1	2
1947	TiO ₂ nanoparticles enhance the chemotherapeutic effects of 5-fluorouracil in human AGS gastric cancer cells via autophagy blockade. <i>Life Sciences</i> , 2020, 248, 117466.	2.0	29
1948	Mathematical modelling of multi-mutation and drug resistance model with fractional derivative. <i>AJ - Alexandria Engineering Journal</i> , 2020, 59, 2291-2304.	3.4	13
1949	The anti-tumoral potential of the saporin-based uPAR-targeting chimera ATF-SAP. <i>Scientific Reports</i> , 2020, 10, 2521.	1.6	15
1950	Hyperthermia and smart drug delivery systems for solid tumor therapy. <i>Advanced Drug Delivery Reviews</i> , 2020, 163-164, 125-144.	6.6	133
1951	Tumor microenvironment-responsive intelligent nanoplatforms for cancer theranostics. <i>Nano Today</i> , 2020, 32, 100851.	6.2	249
1952	Human Serum Albumin-Based Dual-Agent Delivery Systems for Combination Therapy: Acting against Cancer Cells and Inhibiting Neovascularization in the Tumor Microenvironment. <i>Molecular Pharmaceutics</i> , 2020, 17, 1405-1414.	2.3	15
1953	NoncoRNA: a database of experimentally supported non-coding RNAs and drug targets in cancer. <i>Journal of Hematology and Oncology</i> , 2020, 13, 15.	6.9	56
1954	Tumor-Oriented Telomerase-Terminated Nanoplatform as Versatile Strategy for Multidrug Resistance Reversal in Cancer Treatment. <i>Advanced Healthcare Materials</i> , 2020, 9, e1901739.	3.9	12
1955	Endoplasmic Reticulum Stress Signaling in Cancer Cells. <i>American Journal of Pathology</i> , 2020, 190, 934-946.	1.9	187
1956	Nanocarriers for the Delivery of Medical, Veterinary, and Agricultural Active Ingredients. <i>ACS Nano</i> , 2020, 14, 2678-2701.	7.3	113
1957	<i>Cordyceps militaris</i> Exerts Antitumor Effect on Carboplatin-Resistant Ovarian Cancer via Activation of ATF3/TP53 Signaling In Vitro and In Vivo. <i>Natural Product Communications</i> , 2020, 15, 1934578X2090255.	0.2	0
1958	A post-transcriptional program of chemoresistance by AU-rich elements and TTP in quiescent leukemic cells. <i>Genome Biology</i> , 2020, 21, 33.	3.8	22
1959	miR-125b lowers sensitivity to apoptosis following mitotic arrest: Implications for breast cancer therapy. <i>Journal of Cellular Physiology</i> , 2020, 235, 6335-6344.	2.0	11
1960	Dynamic surveillance of tamoxifen-resistance in ER-positive breast cancer by CAIX-targeted ultrasound imaging. <i>Cancer Medicine</i> , 2020, 9, 2414-2426.	1.3	8
1961	In silico Methods for Design of Kinase Inhibitors as Anticancer Drugs. <i>Frontiers in Chemistry</i> , 2019, 7, 873.	1.8	71

#	ARTICLE	IF	CITATIONS
1962	Bioinspired Membrane-Disruptive Macromolecules as Drug-Free Therapeutics. <i>ACS Applied Bio Materials</i> , 2020, 3, 1267-1275.	2.3	13
1963	Alleviation of Multidrug Resistance by Flavonoid and Non-Flavonoid Compounds in Breast, Lung, Colorectal and Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 401.	1.8	48
1964	Thiol antioxidants sensitize malabaricone C induced cancer cell death via reprogramming redox sensitive p53 and NF- κ B proteins in vitro and in vivo. <i>Free Radical Biology and Medicine</i> , 2020, 148, 182-199.	1.3	14
1965	ZRANB2 and SYF2-mediated splicing programs converging on ECT2 are involved in breast cancer cell resistance to doxorubicin. <i>Nucleic Acids Research</i> , 2020, 48, 2676-2693.	6.5	30
1966	Design, eco-friendly synthesis, molecular modeling and anticancer evaluation of thiazol-5(4 <i>H</i>)-ones as potential tubulin polymerization inhibitors targeting the colchicine binding site. <i>RSC Advances</i> , 2020, 10, 2791-2811.	1.7	51
1967	SERCA and P-glycoprotein inhibition and ATP depletion are necessary for celastrol-induced autophagic cell death and collateral sensitivity in multidrug-resistant tumor cells. <i>Pharmacological Research</i> , 2020, 153, 104660.	3.1	29
1968	Statistical Modelling and Machine Learning Principles for Bioinformatics Techniques, Tools, and Applications. <i>Algorithms for Intelligent Systems</i> , 2020, , .	0.5	5
1969	From patent to patient: analysing access to innovative cancer drugs. <i>Drug Discovery Today</i> , 2020, 25, 1561-1568.	3.2	11
1970	Quinazoline Ligands Induce Cancer Cell Death through Selective STAT3 Inhibition and G-Quadruplex Stabilization. <i>Journal of the American Chemical Society</i> , 2020, 142, 2876-2888.	6.6	47
1971	Maximizing the Value of Cancer Drug Screening in Multicellular Tumor Spheroid Cultures: A Case Study in Five Head and Neck Squamous Cell Carcinoma Cell Lines. <i>SLAS Discovery</i> , 2020, 25, 329-349.	1.4	13
1972	Functional and transcriptomic characterization of cisplatin-resistant AGS and MKN-28 gastric cancer cell lines. <i>PLoS ONE</i> , 2020, 15, e0228331.	1.1	7
1973	Piezoelectric Materials as Sonodynamic Sensitizers to Safely Ablate Tumors: A Case Study Using Black Phosphorus. <i>Journal of Physical Chemistry Letters</i> , 2020, 11, 1228-1238.	2.1	105
1974	Longâ€Circulating Drugâ€Dyeâ€Based Micelles with Ultrahigh pHâ€Sensitivity for Deep Tumor Penetration and Superior Chemoâ€Photothermal Therapy. <i>Advanced Functional Materials</i> , 2020, 30, 1906309.	7.8	60
1975	Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives. <i>Acta Pharmaceutica Sinica B</i> , 2020, 10, 1253-1278.	5.7	57
1976	Identification of drug resistance associated ncRNAs based on comprehensive heterogeneous network. <i>Life Sciences</i> , 2020, 243, 117256.	2.0	4
1977	Deep Hypersaline Anoxic Basins as Untapped Reservoir of Polyextremophilic Prokaryotes of Biotechnological Interest. <i>Marine Drugs</i> , 2020, 18, 91.	2.2	11
1978	Therapeutic potential of targeting SHP2 in human developmental disorders and cancers. <i>European Journal of Medicinal Chemistry</i> , 2020, 190, 112117.	2.6	55
1979	Non-Apoptotic Cell Death Signaling Pathways in Melanoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2980.	1.8	39

#	ARTICLE	IF	CITATIONS
1980	A mitochondria-targeting magnetothermogenic nanozyme for magnet-induced synergistic cancer therapy. <i>Biomaterials</i> , 2020, 251, 120079.	5.7	106
1981	DDP-resistant ovarian cancer cells-derived exosomal microRNA-30a-5p reduces the resistance of ovarian cancer cells to DDP. <i>Open Biology</i> , 2020, 10, 190173.	1.5	14
1982	Mining Drug-Target Associations in Cancer: Analysis of Gene Expression and Drug Activity Correlations. <i>Biomolecules</i> , 2020, 10, 667.	1.8	9
1983	Asarone Increases Chemosensitivity by Inhibiting Tumor Glycolysis in Gastric Cancer. Evidence-based Complementary and Alternative Medicine, 2020, 2020, 1-13.	0.5	10
1984	Drug-Induced Resistance in Micrometastases: Analysis of Spatio-Temporal Cell Lineages. <i>Frontiers in Physiology</i> , 2020, 11, 319.	1.3	21
1985	Combination of tetrandrine and cisplatin synergises cytotoxicity and apoptosis in triple negative breast cancer. <i>Synergy</i> , 2020, 10, 100063.	1.1	6
1986	Multi-stimuli responsive polymeric prodrug micelles for combined chemotherapy and photodynamic therapy. <i>Journal of Materials Chemistry B</i> , 2020, 8, 5267-5279.	2.9	35
1987	Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance. <i>Cancer Cell</i> , 2020, 37, 471-484.	7.7	485
1988	Monitoring of drug resistance towards reducing the toxicity of pharmaceutical compounds: Past, present and future. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 186, 113265.	1.4	13
1989	Photoactivatable Prodrug-Backboned Polymeric Nanoparticles for Efficient Light-Controlled Gene Delivery and Synergistic Treatment of Platinum-Resistant Ovarian Cancer. <i>Nano Letters</i> , 2020, 20, 3039-3049.	4.5	92
1990	Fixed-point ablating triggered by second near-infrared window light for augmented interventional photothermal therapy. <i>Biomaterials Science</i> , 2020, 8, 2955-2965.	2.6	5
1991	Quantitative Evaluation of the Transcriptional Activity of Steroid Hormone Receptor Mutants and Variants Using a Single Vector With Two Reporters and a Receptor Expression Cassette. <i>Frontiers in Endocrinology</i> , 2020, 11, 167.	1.5	3
1992	Analysis of the Circadian Regulation of Cancer Hallmarks by a Cross-Platform Study of Colorectal Cancer Time-Series Data Reveals an Association with Genes Involved in Huntington's Disease. <i>Cancers</i> , 2020, 12, 963.	1.7	15
1993	Dual P-Glycoprotein and CA XII Inhibitors: A New Strategy to Reverse the P-gp Mediated Multidrug Resistance (MDR) in Cancer Cells. <i>Molecules</i> , 2020, 25, 1748.	1.7	30
1994	An update on chemical classes targeting ERK1/2 for the management of cancer. <i>Future Medicinal Chemistry</i> , 2020, 12, 593-611.	1.1	7
1995	GRHL2 induces liver fibrosis and intestinal mucosal barrier dysfunction in non-alcoholic fatty liver disease via microRNA-200 and the MAPK pathway. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 6107-6119.	1.6	15
1996	Severe metabolic alterations in liver cancer lead to ERK pathway activation and drug resistance. <i>EBioMedicine</i> , 2020, 54, 102699.	2.7	36
1997	Combination therapy based on nano codelivery for overcoming cancer drug resistance. <i>Medicine in Drug Discovery</i> , 2020, 6, 100024.	2.3	66

#	ARTICLE	IF	CITATIONS
1998	Necroptosis in Cholangiocarcinoma. <i>Cells</i> , 2020, 9, 982.	1.8	13
1999	The multiple function of long noncoding RNAs in osteosarcoma progression, drug resistance and prognosis. <i>Biomedicine and Pharmacotherapy</i> , 2020, 127, 110141.	2.5	27
2000	Synthesis and anticancer activity of thiourea derivatives bearing a benzodioxole moiety with EGFR inhibitory activity, apoptosis assay and molecular docking study. <i>European Journal of Medicinal Chemistry</i> , 2020, 198, 112363.	2.6	54
2001	Smart gold nanocages for mild heat-triggered drug release and breaking chemoresistance. <i>Journal of Controlled Release</i> , 2020, 323, 387-397.	4.8	37
2002	miRNA signature in small extracellular vesicles and their association with platinum resistance and cancer recurrence in ovarian cancer. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2020, 28, 102207.	1.7	36
2003	Silencing of PRDX2 Inhibits the Proliferation and Invasion of Non-Small Cell Lung Cancer Cells. <i>BioMed Research International</i> , 2020, 2020, 1-10.	0.9	7
2004	Revealing Acquired Resistance Mechanisms of Kinase-Targeted Drugs Using an on-the-Fly, Function-Site Interaction Fingerprint Approach. <i>Journal of Chemical Theory and Computation</i> , 2020, 16, 3152-3161.	2.3	8
2005	The Role of Exosomal microRNA in Cancer Drug Resistance. <i>Frontiers in Oncology</i> , 2020, 10, 472.	1.3	36
2006	Curcumin effect on cancer cells' multidrug resistance: An update. <i>Phytotherapy Research</i> , 2020, 34, 2534-2556.	2.8	35
2007	Chemotherapy, host response and molecular dynamics in periampullary cancer: the CHAMP study. <i>BMC Cancer</i> , 2020, 20, 308.	1.1	9
2008	Metabolic reprogramming in childhood acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28255.	0.8	6
2009	Natural product-based nanomedicine: polymeric nanoparticles as delivery cargoes of food bioactives and nutraceuticals for anticancer purposes. , 2020, , 37-67.		4
2010	Super-Enhancer Redistribution as a Mechanism of Broad Gene Dysregulation in Repeatedly Drug-Treated Cancer Cells. <i>Cell Reports</i> , 2020, 31, 107532.	2.9	29
2011	MSC-induced lncRNA HCP5 drove fatty acid oxidation through miR-3619-5p/AMPK/PGC1 β /CEBPB axis to promote stemness and chemo-resistance of gastric cancer. <i>Cell Death and Disease</i> , 2020, 11, 233.	2.7	138
2012	Exploiting evolutionary steering to induce collateral drug sensitivity in cancer. <i>Nature Communications</i> , 2020, 11, 1923.	5.8	79
2013	Overcoming Wnt β -catenin dependent anticancer therapy resistance in leukaemia stem cells. <i>Nature Cell Biology</i> , 2020, 22, 689-700.	4.6	89
2014	Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 847-857.	1.9	91
2015	Let-7e Suppresses DNA Damage Repair and Sensitizes Ovarian Cancer to Cisplatin through Targeting PARP1. <i>Molecular Cancer Research</i> , 2020, 18, 436-447.	1.5	17

#	ARTICLE	IF	CITATIONS
2016	An integrated prognosis model of pharmacogenomic gene signature and clinical information for diffuse large B-cell lymphoma patients following CHOP-like chemotherapy. <i>Journal of Translational Medicine</i> , 2020, 18, 144.	1.8	10
2017	Ensartinib (X-396) Effectively Modulates Pharmacokinetic Resistance Mediated by ABCB1 and ABCG2 Drug Efflux Transporters and CYP3A4 Biotransformation Enzyme. <i>Cancers</i> , 2020, 12, 813.	1.7	20
2018	CD44s Induces miR-629-3p Expression in Association with Cisplatin Resistance in Head and Neck Cancer Cells. <i>Cancers</i> , 2020, 12, 856.	1.7	9
2019	Roles of Sorcin in Drug Resistance in Cancer: One Protein, Many Mechanisms, for a Novel Potential Anticancer Drug Target. <i>Cancers</i> , 2020, 12, 887.	1.7	25
2020	MK2 is a therapeutic target for high-risk multiple myeloma. <i>Haematologica</i> , 2021, 106, 1774-1777.	1.7	6
2021	Investigations of Bioactivity of <i>Acalypha indica</i> (L.), <i>Centella asiatica</i> (L.) and <i>Croton bonplandianus</i> (Baill) against Multidrug Resistant Bacteria and Cancer Cells. <i>Journal of Herbal Medicine</i> , 2021, 28, 100359.	1.0	8
2022	Immune cell infiltration-based signature for prognosis and immunogenomic analysis in breast cancer. <i>Briefings in Bioinformatics</i> , 2021, 22, 2020-2031.	3.2	99
2023	New aryl Schiff bases of thiadiazole derivative of ibuprofen as DNA binders and potential anticancer drug candidates. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, 39, 3548-3564.	2.0	11
2024	Microbiome and host crosstalk: A new paradigm to cancer therapy. <i>Seminars in Cancer Biology</i> , 2021, 70, 71-84.	4.3	18
2025	Design, Synthesis, and Biological Evaluation of 1,2,4-Thiadiazole-1,2,4-Triazole Derivatives Bearing Amide Functionality as Anticancer Agents. <i>Arabian Journal for Science and Engineering</i> , 2021, 46, 225-232.	1.7	26
2026	Deep learning for drug response prediction in cancer. <i>Briefings in Bioinformatics</i> , 2021, 22, 360-379.	3.2	116
2027	Turning liabilities into opportunities: Off-target based drug repurposing in cancer. <i>Seminars in Cancer Biology</i> , 2021, 68, 209-229.	4.3	39
2028	Lichens exerts an anti-proliferative effect on human breast and lung cancer cells through induction of apoptosis. <i>Drug and Chemical Toxicology</i> , 2021, 44, 259-267.	1.2	18
2029	Combination of cancer-specific prodrug nanoparticle with Bcl-2 inhibitor to overcome acquired drug resistance. <i>Journal of Controlled Release</i> , 2021, 330, 920-932.	4.8	41
2030	Targeting of HER/ErbB family proteins using broad spectrum Sec61 inhibitors coibamide A and apratoxin A. <i>Biochemical Pharmacology</i> , 2021, 183, 114317.	2.0	13
2031	An azo dye for photodynamic therapy that is activated selectively by two-photon excitation. <i>Chemical Science</i> , 2021, 12, 427-434.	3.7	33
2032	Molecular genomic features associated with <i>in vitro</i> response of the NCI60 cancer cell line panel to natural products. <i>Molecular Oncology</i> , 2021, 15, 381-406.	2.1	14
2033	Nanomedicine and chemotherapeutics drug delivery: challenges and opportunities. <i>Journal of Drug Targeting</i> , 2021, 29, 185-198.	2.1	16

#	ARTICLE	IF	CITATIONS
2034	Microbiome dysbiosis in cancer: Exploring therapeutic strategies to counter the disease. <i>Seminars in Cancer Biology</i> , 2021, 70, 61-70.	4.3	25
2035	Co-administration of paclitaxel and 2-methoxyestradiol using folate-conjugated human serum albumin nanoparticles for improving drug resistance and antitumor efficacy. <i>Pharmaceutical Development and Technology</i> , 2021, 26, 1-10.	1.1	6
2036	ACPS: An accurate bioinformatics tool for precision-based anti-cancer peptide generation via omics data. <i>Chemical Biology and Drug Design</i> , 2021, 97, 372-382.	1.5	5
2037	LncRNA regulation: New frontiers in epigenetic solutions to drug chemoresistance. <i>Biochemical Pharmacology</i> , 2021, 189, 114228.	2.0	33
2038	A targeted and redox/pH-responsive chitosan oligosaccharide derivatives based nano hybrids for overcoming multidrug resistance of breast cancer cells. <i>Carbohydrate Polymers</i> , 2021, 251, 117008.	5.1	32
2039	Tumor-responsive copper-activated disulfiram for synergetic nanocatalytic tumor therapy. <i>Nano Research</i> , 2021, 14, 205-211.	5.8	39
2040	Tumor-specific carrier-free nanodrugs with GSH depletion and enhanced ROS generation for endogenous synergistic anti-tumor by a chemotherapy-photodynamic therapy. <i>Chemical Engineering Journal</i> , 2021, 407, 127212.	6.6	106
2041	Dual EGFR/VEGFR2 inhibitors and apoptosis inducers: Synthesis and antitumor activity of novel pyrazoline derivatives. <i>Archiv Der Pharmazie</i> , 2021, 354, e2000351.	2.1	9
2042	Addressing the tumour microenvironment in early drug discovery: a strategy to overcome drug resistance and identify novel targets for cancer therapy. <i>Drug Discovery Today</i> , 2021, 26, 663-676.	3.2	22
2043	The emerging roles of exosomes in anti-cancer drug resistance and tumor progression: An insight towards tumor-microenvironment interaction. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1875, 188488.	3.3	45
2044	Reemergence of neural crest stem cell-like states in melanoma during disease progression and treatment. <i>Stem Cells Translational Medicine</i> , 2021, 10, 522-533.	1.6	41
2045	Recent advances in microfluidic technology and applications for anti-cancer drug screening. <i>TrAC - Trends in Analytical Chemistry</i> , 2021, 134, 116118.	5.8	28
2046	Turnover Modulates the Need for a Cost of Resistance in Adaptive Therapy. <i>Cancer Research</i> , 2021, 81, 1135-1147.	0.4	71
2047	Circulating platelets as liquid biopsy sources for cancer detection. <i>Molecular Oncology</i> , 2021, 15, 1727-1743.	2.1	37
2048	Mitochondria-specific Agents for Photodynamic Cancer Therapy: A Key Determinant to Boost the Efficacy. <i>Advanced Healthcare Materials</i> , 2021, 10, e2001240.	3.9	42
2049	Unbiased High-Throughput Drug Combination Pilot Screening Identifies Synergistic Drug Combinations Effective against Patient-Derived and Drug-Resistant Melanoma Cell Lines. <i>SLAS Discovery</i> , 2021, 26, 712-729.	1.4	3
2050	The Bromodomain Inhibitor PFI-3 Sensitizes Cancer Cells to DNA Damage by Targeting SWI/SNF. <i>Molecular Cancer Research</i> , 2021, 19, 900-912.	1.5	16
2051	Poly(anhydride-ester) gemcitabine: Synthesis and particle engineering of a high payload hydrolysable polymeric drug for cancer therapy. <i>Journal of Controlled Release</i> , 2021, 330, 1178-1190.	4.8	11

#	ARTICLE	IF	CITATIONS
2052	E1 Enzymes as Therapeutic Targets in Cancer. <i>Pharmacological Reviews</i> , 2021, 73, 1-56.	7.1	60
2053	Discovery of a potent β -catenin destabilizer for overcoming the resistance of 5-fluorouracil in colorectal cancer. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 30, 115929.	1.4	7
2054	PCL and PCL/bioactive glass biomaterials as carriers for biologically active polyphenolic compounds: Comprehensive physicochemical and biological evaluation. <i>Bioactive Materials</i> , 2021, 6, 1811-1826.	8.6	30
2055	Cytotoxicity and DNA interaction in a series of aryl terminated iminopyridine Pt(II) complexes. <i>Journal of Inorganic Biochemistry</i> , 2021, 216, 111335.	1.5	3
2056	Harnessing adaptive novelty for automated generation of cancer treatments. <i>BioSystems</i> , 2021, 199, 104290.	0.9	8
2057	Co-delivery of cisplatin and doxorubicin by carboxylic acid functionalized poly (hydroxyethyl) Tj ETQq1 1 0.784314 rgBT /Overlock 10 ff cells. <i>Journal of Biomaterials Science, Polymer Edition</i> , 2021, 32, 657-677.	1.9	8
2058	Mutant p53 Gain-of-Function: Role in Cancer Development, Progression, and Therapeutic Approaches. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 607670.	1.8	64
2059	Neuregulin Signaling in the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1270, 1-29.	0.8	1
2060	SHOC2 Is a Critical Modulator of Sensitivity to EGFR TKIs in Non-Small Cell Lung Cancer Cells. <i>Molecular Cancer Research</i> , 2021, 19, 317-328.	1.5	12
2061	Redox dual-responsive dendrimeric nanoparticles for mutually synergistic chemo-photodynamic therapy to overcome drug resistance. <i>Journal of Controlled Release</i> , 2021, 329, 1210-1221.	4.8	27
2062	Ponatinib is a potential therapeutic approach for malignant pleural mesothelioma. <i>Experimental Lung Research</i> , 2021, 47, 9-25.	0.5	1
2063	Cytotoxic and chemotaxonomic study of isolated metabolites from <i>Centaurea aegyptiaca</i> . <i>Journal of the Chinese Chemical Society</i> , 2021, 68, 159-168.	0.8	10
2064	Cell Death Mediated by the Pyroptosis Pathway with the Aid of Nanotechnology: Prospects for Cancer Therapy. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 8018-8034.	7.2	141
2065	Cell Death Mediated by the Pyroptosis Pathway with the Aid of Nanotechnology: Prospects for Cancer Therapy. <i>Angewandte Chemie</i> , 2021, 133, 8096-8112.	1.6	87
2066	Controlling the speed and trajectory of evolution with counterdiabatic driving. <i>Nature Physics</i> , 2021, 17, 135-142.	6.5	61
2067	Mechanisms of drug resistance mediated by long non-coding RNAs in non-small-cell lung cancer. <i>Cancer Gene Therapy</i> , 2021, 28, 175-187.	2.2	14
2068	Protective role of zinc in liver damage in experimental diabetes demonstrated via different biochemical parameters. <i>Journal of Biochemical and Molecular Toxicology</i> , 2021, 35, e22617.	1.4	10
2069	The effects of anticancer medicinal herbs on vascular endothelial growth factor based on pharmacological aspects: a review study. <i>Nutrition and Cancer</i> , 2021, 73, 1-15.	0.9	24

#	ARTICLE	IF	CITATIONS
2070	Models of Cancer Drug Discovery and Response to Therapy. , 2021, , 269-276.		0
2071	A-CaMP: a tool for anti-cancer and antimicrobial peptide generation. Journal of Biomolecular Structure and Dynamics, 2021, 39, 285-293.	2.0	10
2072	COTI-2, a novel small molecule that is active against multiple human cancer cell lines <i>in vitro</i> and <i>in vivo</i> . Oncotarget, 0, 7, 41363-41379.	0.8	124
2073	Cancer drug resistance: redox resetting renders a way. Oncotarget, 0, 7, 42740-42761.	0.8	144
2074	Gut microbiota: impacts on gastrointestinal cancer immunotherapy. Gut Microbes, 2021, 13, 1-21.	4.3	33
2075	CCL299, a Benzimidazole Derivative Induces G ₁ Phase Arrest and Apoptosis in Cancer Cells. Anticancer Research, 2021, 41, 699-706.	0.5	1
2076	Nanotoxicology profiling of cancer nanomedicines. , 2021, , 291-301.		1
2077	Cross-linked (R)-(+)-lipoic acid nanoparticles with prodrug loading for synergistic cancer therapy. Journal of Materials Chemistry B, 2021, 9, 1583-1591.	2.9	7
2078	In-Tether Chiral Center Induced Helical Peptide Modulators Target p53-MDM2/MDMX and Inhibit Tumor Growth in Cancer Stem Cell. Springer Theses, 2021, , 65-99.	0.0	0
2079	The role of YY1 in drug resistant cancer: Involvement of the YY1/PTEN/PP2A/H2Ax/Rad51 axis. , 2021, , 225-242.		0
2080	Rediscovering and repurposing natural microbial macromolecules through computational approaches. , 2021, , 373-400.		2
2081	Design, Synthesis, Characterization, Evaluation for Anticancer and Cytotoxic Properties of New Pyrazole Carbothioamides. Asian Journal of Organic & Medicinal Chemistry, 2021, 6, 53-58.	0.1	3
2083	Ferroptosis in cancer therapeutics: a materials chemistry perspective. Journal of Materials Chemistry B, 2021, 9, 8906-8936.	2.9	23
2084	ZEB1: New advances in fibrosis and cancer. Molecular and Cellular Biochemistry, 2021, 476, 1643-1650.	1.4	20
2085	Net charge tuning modulates the antiplasmodial and anticancer properties of peptides derived from scorpion venom. Journal of Peptide Science, 2021, 27, e3296.	0.8	7
2086	Taxanes in cancer treatment: Activity, chemoresistance and its overcoming. Drug Resistance Updates, 2021, 54, 100742.	6.5	121
2087	Tannic acid-based metal phenolic networks for bio-applications: a review. Journal of Materials Chemistry B, 2021, 9, 4098-4110.	2.9	118
2088	Multiple screening approaches reveal HDAC6 as a novel regulator of glycolytic metabolism in triple-negative breast cancer. Science Advances, 2021, 7, .	4.7	38

#	ARTICLE	IF	CITATIONS
2089	Intranasal delivery of self-assembled nanoparticles of therapeutic peptides and antagomirs elicits anti-tumor effects in an intracranial glioblastoma model. <i>Nanoscale</i> , 2021, 13, 14745-14759.	2.8	16
2090	Recent developments in the medicinal chemistry of single boron atom-containing compounds. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 3035-3059.	5.7	70
2091	A NIR-triggered multifunctional nanoplatform mediated by Hsp70 siRNA for chemo-hypothermal photothermal synergistic therapy. <i>Biomaterials Science</i> , 2021, 9, 6501-6509.	2.6	17
2092	Unlocking the Power of Exosomes for Crossing Biological Barriers in Drug Delivery. <i>Pharmaceutics</i> , 2021, 13, 122.	2.0	112
2093	Elevated CDK5R1 predicts worse prognosis in hepatocellular carcinoma based on TCGA data. <i>Bioscience Reports</i> , 2021, 41, .	1.1	9
2094	A tumor microenvironment responsive nanosystem for chemodynamic/chemical synergistic theranostics of colorectal cancer. <i>Theranostics</i> , 2021, 11, 8909-8925.	4.6	12
2095	Akt regulates RSK2 to alter phosphorylation level of H2A.X in breast cancer. <i>Oncology Letters</i> , 2021, 21, 187.	0.8	10
2096	New Anti-Leukemic Effect of Carvacrol and Thymol Combination through Synergistic Induction of Different Cell Death Pathways. <i>Molecules</i> , 2021, 26, 410.	1.7	17
2097	Nitroreductase-responsive polymeric micelles based on 4-nitrobenzyl and AIE moieties for intracellular doxorubicin release. <i>Polymer Chemistry</i> , 2021, 12, 2618-2626.	1.9	14
2098	Recent advances in bionanomaterials for liver cancer diagnosis and treatment. <i>Biomaterials Science</i> , 2021, 9, 4821-4842.	2.6	16
2099	Alternative approaches to overcome chemoresistance to apoptosis in cancer. <i>Advances in Protein Chemistry and Structural Biology</i> , 2021, 126, 91-122.	1.0	13
2100	Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models. <i>MAbs</i> , 2021, 13, 1914883.	2.6	4
2101	Ferroptosis/pyroptosis dual-inductive combinational anti-cancer therapy achieved by transferrin decorated nanoMOF. <i>Nanoscale Horizons</i> , 2021, 6, 348-356.	4.1	65
2102	Gadolinium- μ -porphyrin based polymer nanotheranostics for fluorescence/magnetic resonance imaging guided photodynamic therapy. <i>Nanoscale</i> , 2021, 13, 16197-16206.	2.8	16
2103	MEDAG enhances breast cancer progression and reduces epirubicin sensitivity through the AKT/AMPK/mTOR pathway. <i>Cell Death and Disease</i> , 2021, 12, 97.	2.7	17
2104	Intracellular Ca ²⁺ Imbalance Critically Contributes to Paraptosis. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 607844.	1.8	30
2105	The phospholipid membrane compositions of bacterial cells, cancer cell lines and biological samples from cancer patients. <i>Chemical Science</i> , 2021, 12, 13273-13282.	3.7	13
2106	Extracellular Vesicles in Chemoresistance. <i>Sub-Cellular Biochemistry</i> , 2021, 97, 211-245.	1.0	3

#	ARTICLE	IF	CITATIONS
2107	Epigenetic Regulation and Nonepigenetic Mechanisms of Ferroptosis Drive Emerging Nanotherapeutics in Tumor. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-14.	1.9	4
2110	Drug Resistance in Diabetes. , 2021, , 423-459.		0
2111	Prodrug Nanomedicine Inhibits Chemotherapy-Induced Proliferative Burst by Altering the Deleterious Intercellular Communication. <i>ACS Nano</i> , 2021, 15, 781-796.	7.3	8
2112	MicroRNA-624-mediated ARRDC3/YAP/HIF1 α axis enhances esophageal squamous cell carcinoma cell resistance to cisplatin and paclitaxel. <i>Bioengineered</i> , 2021, 12, 5334-5347.	1.4	15
2113	Oxygenated phosphatidylethanolamine navigates phagocytosis of ferroptotic cells by interacting with TLR2. <i>Cell Death and Differentiation</i> , 2021, 28, 1971-1989.	5.0	101
2114	Ailanthus Altissima-derived Ailanthone enhances Gastric Cancer Cell Apoptosis by Inducing the Repression of Base Excision Repair by Downregulating p23 Expression. <i>International Journal of Biological Sciences</i> , 2021, 17, 2811-2825.	2.6	9
2115	Notch signaling in female cancers: a multifaceted node to overcome drug resistance. , 2021, 4, 805-836.		2
2116	Necroptosis-inducing iridium($\langle scp \rangle iii \langle /scp \rangle$) complexes as regulators of cyclin-dependent kinases. <i>Inorganic Chemistry Frontiers</i> , 2021, 8, 1788-1794.	3.0	10
2117	Genome-scale CRISPRa screening identifies MTX1 as a contributor for sorafenib resistance in hepatocellular carcinoma by augmenting autophagy. <i>International Journal of Biological Sciences</i> , 2021, 17, 3133-3144.	2.6	8
2118	Systematic screening reveals synergistic interactions that overcome MAPK inhibitor resistance in cancer cells. <i>Cancer Biology and Medicine</i> , 2021, 18, 0-0.	1.4	0
2119	Deep neural networks identify signaling mechanisms of ErbB-family drug resistance from a continuous cell morphology space. <i>Cell Reports</i> , 2021, 34, 108657.	2.9	10
2120	Multifunctional nanoplatfoms co-delivering combinatorial dual-drug for eliminating cancer multidrug resistance. <i>Theranostics</i> , 2021, 11, 6334-6354.	4.6	25
2121	In Vitro and In Vivo Tumor Models for the Evaluation of Anticancer Nanoparticles. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1295, 271-299.	0.8	5
2122	Efflux pumps, NHE1, monocarboxylate transporters, and ABC transporter subfamily inhibitors. , 2021, , 95-120.		0
2123	Drug Resistance in Cancer. , 2021, , 367-386.		1
2124	Star-Shaped Polylactide Dipyrindamole Conjugated to 5-Fluorouracil and 4-Piperidinopiperidine Nanocarriers for Bioimaging and Dual Drug Delivery in Cancer Cells. <i>ACS Applied Polymer Materials</i> , 2021, 3, 737-756.	2.0	10
2125	Cascade Drug-Release Strategy for Enhanced Anticancer Therapy. <i>Matter</i> , 2021, 4, 26-53.	5.0	38
2126	Predicting chemosensitivity using drug perturbed gene dynamics. <i>BMC Bioinformatics</i> , 2021, 22, 15.	1.2	1

#	ARTICLE	IF	CITATIONS
2127	Integrated genetic and metabolic landscapes predict vulnerabilities of temozolomide resistant glioblastoma cells. <i>Npj Systems Biology and Applications</i> , 2021, 7, 2.	1.4	3
2128	Assessing the capacity for mental manipulation in patients with statically-determined mild cognitive impairment using digital technology. <i>Exploration of Medicine</i> , 0, , .	1.5	1
2129	Aptamers and antibodies: rivals or allies in cancer targeted therapy?. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , .	0.5	5
2130	Platycodin D reverses histone deacetylase inhibitor resistance in hepatocellular carcinoma cells by repressing ERK1/2-mediated cofilin-1 phosphorylation. <i>Phytomedicine</i> , 2021, 82, 153442.	2.3	17
2131	Mycomedicine: A Unique Class of Natural Products with Potent Anti-tumour Bioactivities. <i>Molecules</i> , 2021, 26, 1113.	1.7	17
2132	Glycolysis-induced drug resistance in tumorsâ€”A response to danger signals?. <i>Neoplasia</i> , 2021, 23, 234-245.	2.3	55
2133	OTS964, a TOPK Inhibitor, Is Susceptible to ABCG2-Mediated Drug Resistance. <i>Frontiers in Pharmacology</i> , 2021, 12, 620874.	1.6	8
2134	Comparative characteristic of lung cancer stem-like cells generated in vitro under different culture conditions. <i>Ukrainian Biochemical Journal</i> , 2021, 93, 88-95.	0.1	0
2135	Tanshinones and their Derivatives: Heterocyclic Ring-Fused Diterpenes of Biological Interest. <i>Mini-Reviews in Medicinal Chemistry</i> , 2021, 21, 171-185.	1.1	7
2136	Adaptive Therapy for Metastatic Melanoma: Predictions from Patient Calibrated Mathematical Models. <i>Cancers</i> , 2021, 13, 823.	1.7	44
2137	Molecular mechanism and pharmacokinetics of flavonoids in the treatment of resistant EGF receptorâ€”mutated nonâ€”smallâ€”cell lung cancer: A narrative review. <i>British Journal of Pharmacology</i> , 2021, 178, 1388-1406.	2.7	10
2138	Macrophage polarization by phytotherapy in the tumor microenvironment. <i>Phytotherapy Research</i> , 2021, 35, 3632-3648.	2.8	8
2139	Calixareneâ€”Embedded Nanoparticles for Interferenceâ€”Free Geneâ€”Drug Combination Cancer Therapy. <i>Small</i> , 2021, 17, e2006223.	5.2	24
2140	GABARAP suppresses EMT and breast cancer progression via the AKT/mTOR signaling pathway. <i>Aging</i> , 2021, 13, 5858-5874.	1.4	12
2141	A styrylpyrone dimer isolated from <i>Aniba heringeri</i> causes apoptosis in MDA-MB-231 triple-negative breast cancer cells. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 32, 115994.	1.4	2
2142	Circulating tumor cell profiling for precision oncology. <i>Molecular Oncology</i> , 2021, 15, 1622-1646.	2.1	33
2143	Biophysical informatics approach for quantifying phenotypic heterogeneity in cancer cell migration in confined microenvironments. <i>Bioinformatics</i> , 2021, , .	1.8	9
2144	Mechanisms of stearyl CoA desaturase inhibitor sensitivity and acquired resistance in cancer. <i>Science Advances</i> , 2021, 7, .	4.7	38

#	ARTICLE	IF	CITATIONS
2145	Cancer-associated fibroblast-derived exosomal microRNA-24-3p enhances colon cancer cell resistance to MTX by down-regulating CDX2/HEPH axis. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 3699-3713.	1.6	45
2146	The Deubiquitinating Enzyme UCHL1 Induces Resistance to Doxorubicin in HER2+ Breast Cancer by Promoting Free Fatty Acid Synthesis. <i>Frontiers in Oncology</i> , 2021, 11, 629640.	1.3	5
2148	Mechanisms of Resistance to Conventional Therapies for Osteosarcoma. <i>Cancers</i> , 2021, 13, 683.	1.7	71
2149	LXR β activation and Raf inhibition trigger lethal lipotoxicity in liver cancer. <i>Nature Cancer</i> , 2021, 2, 201-217.	5.7	27
2150	Monofunctional Platinum(II) Anticancer Agents. <i>Pharmaceuticals</i> , 2021, 14, 133.	1.7	33
2151	Newly Developed Self-Assembling Antioxidants as Potential Therapeutics for the Cancers. <i>Journal of Personalized Medicine</i> , 2021, 11, 92.	1.1	14
2153	Thyroid Carcinoma: Phenotypic Features, Underlying Biology and Potential Relevance for Targeting Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1950.	1.8	40
2154	Fascinating Chemopreventive Story of Wogonin: A Chance to Hit on the Head in Cancer Treatment. <i>Current Pharmaceutical Design</i> , 2021, 27, 467-478.	0.9	10
2155	High-Performance Self-Cascade Pyrite Nanozymes for Apoptosis-Ferroptosis Synergistic Tumor Therapy. <i>ACS Nano</i> , 2021, 15, 5735-5751.	7.3	266
2156	Synergistic Combination of Bioactive Hydroxyapatite Nanoparticles and the Chemotherapeutic Doxorubicin to Overcome Tumor Multidrug Resistance. <i>Small</i> , 2021, 17, e2007672.	5.2	42
2157	A Novel Peptide Derived from Ginger Induces Apoptosis through the Modulation of p53, BAX, and BCL2 Expression in Leukemic Cell Lines. <i>Planta Medica</i> , 2021, 87, 560-569.	0.7	9
2158	Chromatin assembly factor 1 suppresses epigenetic reprogramming toward adaptive drug resistance. <i>Journal of the National Cancer Center</i> , 2021, 1, 15-22.	3.0	6
2159	Advances in Drug Resistance of Esophageal Cancer: From the Perspective of Tumor Microenvironment. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 664816.	1.8	17
2160	Pleiotropic Roles of ABC Transporters in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3199.	1.8	29
2161	Optimum multi-drug regime for compartment model of tumour: cell-cycle-specific dynamics in the presence of resistance. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2021, 48, 543-562.	0.8	19
2163	Role of Reductive versus Oxidative Stress in Tumor Progression and Anticancer Drug Resistance. <i>Cells</i> , 2021, 10, 758.	1.8	25
2164	Insights on recent approaches in drug discovery strategies and untapped drug targets against drug resistance. <i>Future Journal of Pharmaceutical Sciences</i> , 2021, 7, 56.	1.1	17
2165	The Role of Cancer Stem Cells in Colorectal Cancer: From the Basics to Novel Clinical Trials. <i>Cancers</i> , 2021, 13, 1092.	1.7	40

#	ARTICLE	IF	CITATIONS
2166	Development of a protein signature to enable clinical positioning of IAP inhibitors in colorectal cancer. <i>FEBS Journal</i> , 2021, 288, 5374-5388.	2.2	5
2167	Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 641469.	1.8	76
2168	Development of cell-based high throughput luminescence assay for drug discovery in inhibiting OCT4/DNA-PKcs and OCT4-MK2 interactions. <i>Biotechnology and Bioengineering</i> , 2021, 118, 1987-2000.	1.7	2
2170	Immunogenic Cell Death: A Step Ahead of Autophagy in Cancer Therapy. , 2021, 3, 47-59.		12
2171	Dissecting miRNA signature in colorectal cancer progression and metastasis. <i>Cancer Letters</i> , 2021, 501, 66-82.	3.2	42
2172	CMPK1 Regulated by miR-130b Attenuates Response to 5-FU Treatment in Gastric Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 637470.	1.3	8
2173	Altered glycolysis results in drug-resistant in clinical tumor therapy (Review). <i>Oncology Letters</i> , 2021, 21, 369.	0.8	29
2174	Supramolecular nanofibers increase the efficacy of 10-hydroxycamptothecin by enhancing nuclear accumulation and depleting cellular ATP. <i>Acta Biomaterialia</i> , 2021, 122, 343-353.	4.1	9
2176	Role of cancer-associated fibroblasts in the resistance to antitumor therapy, and their potential therapeutic mechanisms in non-small cell lung cancer (Review). <i>Oncology Letters</i> , 2021, 21, 413.	0.8	17
2177	GRP78 in lung cancer. <i>Journal of Translational Medicine</i> , 2021, 19, 118.	1.8	40
2178	The next frontier of oncotherapy: accomplishing clinical translation of oncolytic bacteria through genetic engineering. <i>Future Microbiology</i> , 2021, 16, 341-368.	1.0	5
2179	Ferroptosis Photoinduced by New Cyclometalated Iridium(III) Complexes and Its Synergism with Apoptosis in Tumor Cell Inhibition. <i>Angewandte Chemie</i> , 2021, 133, 8255-8262.	1.6	28
2181	Apoptosis-Inducing TNF Superfamily Ligands for Cancer Therapy. <i>Cancers</i> , 2021, 13, 1543.	1.7	25
2182	MicroRNAs as Predictive Biomarkers of Resistance to Targeted Therapies in Gastrointestinal Tumors. <i>Biomedicines</i> , 2021, 9, 318.	1.4	7
2183	Ferroptosis Photoinduced by New Cyclometalated Iridium(III) Complexes and Its Synergism with Apoptosis in Tumor Cell Inhibition. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 8174-8181.	7.2	154
2184	Physical plasma-derived oxidants sensitize pancreatic cancer cells to ferroptotic cell death. <i>Free Radical Biology and Medicine</i> , 2021, 166, 187-200.	1.3	24
2185	A Systematic Strategy of Combinational Blow for Overcoming Cascade Drug Resistance via NIR-Light-Triggered Hyperthermia. <i>Advanced Materials</i> , 2021, 33, e2100599.	11.1	78
2187	Mitochondria: Insights into Crucial Features to Overcome Cancer Chemoresistance. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4770.	1.8	30

#	ARTICLE	IF	CITATIONS
2188	The onco-immunological implications of <i>Fusobacterium nucleatum</i> in breast cancer. <i>Immunology Letters</i> , 2021, 232, 60-66.	1.1	15
2189	Crosstalk between motor neurons and myotubes via endogenously secreted neural and muscular growth factors. <i>Physiological Reports</i> , 2021, 9, e14791.	0.7	11
2190	In Vivo and Ex Vivo Pediatric Brain Tumor Models: An Overview. <i>Frontiers in Oncology</i> , 2021, 11, 620831.	1.3	15
2191	DNA repair and cholesterol-mediated drug efflux induce dose-dependent chemoresistance in nutrient-deprived neuroblastoma cells. <i>IScience</i> , 2021, 24, 102325.	1.9	3
2192	The Role of Notch, Hedgehog, and Wnt Signaling Pathways in the Resistance of Tumors to Anticancer Therapies. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 650772.	1.8	81
2193	Plant species used in Brazil and Asia regions with toxic properties. <i>Phytotherapy Research</i> , 2021, 35, 4703-4726.	2.8	24
2194	Chemotherapy-induced CDA expression renders resistant non-small cell lung cancer cells sensitive to 5- β -deoxy-5-fluorocytidine (5-DFCR). <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 138.	3.5	9
2195	Phenylboronic acid-functionalized co-delivery micelles with synergistic effect and down-regulation of HIF-1 α to overcome multidrug resistance. <i>Journal of Drug Delivery Science and Technology</i> , 2021, 62, 102346.	1.4	2
2196	New Platinum(II) Complexes Affecting Different Biomolecular Targets in Resistant Ovarian Carcinoma Cells. <i>ChemMedChem</i> , 2021, 16, 1956-1966.	1.6	14
2197	Endogenous Stimuli-Activatable Nanomedicine for Immune Theranostics for Cancer. <i>Advanced Functional Materials</i> , 2021, 31, 2100386.	7.8	36
2198	Smart transformable nanomedicines for cancer therapy. <i>Biomaterials</i> , 2021, 271, 120737.	5.7	64
2199	Vitamin C induces ferroptosis in anaplastic thyroid cancer cells by ferritinophagy activation. <i>Biochemical and Biophysical Research Communications</i> , 2021, 551, 46-53.	1.0	42
2200	The Role of Extracellular Vesicles in Mediating Resistance to Anticancer Therapies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4166.	1.8	10
2201	The Sensitivity Prediction of Neoadjuvant Chemotherapy for Gastric Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 641304.	1.3	13
2202	Targeting Ubiquitin-Specific Protease 7 (USP7) in Cancer: A New Insight to Overcome Drug Resistance. <i>Frontiers in Pharmacology</i> , 2021, 12, 648491.	1.6	24
2203	Using 3D in vitro cell culture models in anti-cancer drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 841-850.	2.5	16
2204	DUSP16 promotes cancer chemoresistance through regulation of mitochondria-mediated cell death. <i>Nature Communications</i> , 2021, 12, 2284.	5.8	28
2205	Hybrid Drugs—A Strategy for Overcoming Anticancer Drug Resistance?. <i>Molecules</i> , 2021, 26, 2601.	1.7	63

#	ARTICLE	IF	CITATIONS
2206	Anti-Angiogenic Therapy: Current Challenges and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3765.	1.8	136
2207	Analysis of the Differences in the Expression of mRNAs and miRNAs Associated with Drug Resistance in Endometrial Cancer Cells Treated with Salinomycin. <i>Current Pharmaceutical Biotechnology</i> , 2021, 22, 541-548.	0.9	8
2208	Ferroptosis Resistance in Cancer: An Emerging Crisis of New Hope. <i>BIO Integration</i> , 2021, 2, .	0.9	3
2209	Hypermoins Aâ€D: Rearranged Nor-Polyprenylated Acylphloroglucinols from the Flowers of <i>Hypericum monogynum</i> . <i>Journal of Organic Chemistry</i> , 2021, 86, 7021-7027.	1.7	7
2210	Metabolic Control by Heat Stress Determining Cell Fate to Ferroptosis for Effective Cancer Therapy. <i>ACS Nano</i> , 2021, 15, 7179-7194.	7.3	91
2211	A two-fold interpenetration pillar-layered metal-organic frameworks based on BODIPY for chemo-photodynamic therapy. <i>Dyes and Pigments</i> , 2021, 188, 109174.	2.0	13
2212	Spike-in normalization for single-cell RNA-seq reveals dynamic global transcriptional activity mediating anticancer drug response. <i>NAR Genomics and Bioinformatics</i> , 2021, 3, lqab054.	1.5	5
2213	Interactive effects of <i>Andrographis paniculata</i> extracts and cancer chemotherapeutic 5-Fluorouracil on cytochrome P450s expression in human hepatocellular carcinoma HepG2 cells. <i>Journal of Herbal Medicine</i> , 2021, 26, 100421.	1.0	8
2214	Stapled Wasp Venom-Derived Oncolytic Peptides with Side Chains Induce Rapid Membrane Lysis and Prolonged Immune Responses in Melanoma. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 5802-5815.	2.9	18
2215	Stimuliâ€Responsive Nanoparticles Combining Photodynamic Therapy and Mitochondria Disruption Suppressed Tumor Metastasis. <i>Advanced Materials Interfaces</i> , 2021, 8, 2002200.	1.9	10
2216	Tuning biological activity in dinuclear Cu (II) complexes derived from pyrazine ligands: Structure, magnetism, catecholase, antimicrobial, antibiofilm, and antibreast cancer activity. <i>Applied Organometallic Chemistry</i> , 2021, 35, e6221.	1.7	5
2217	A FOXM1-Targeted Peptide Overcomes 5-Fluorouracil Resistance via Modulating ABC Transporters in Liver Cancer HepG2 Cells. <i>International Journal of Peptide Research and Therapeutics</i> , 2021, 27, 1815-1826.	0.9	1
2218	Genetic diversity through social heterosis can increase virulence in RNA viral infections and cancer progression. <i>Royal Society Open Science</i> , 2021, 8, 202219.	1.1	1
2219	PROTACs: Promising Approaches for Epigenetic Strategies to Overcome Drug Resistance. <i>Current Cancer Drug Targets</i> , 2021, 21, 306-325.	0.8	4
2220	Therapeutics Targeting the Core Apoptotic Machinery. <i>Cancers</i> , 2021, 13, 2618.	1.7	14
2221	A Chemical Toolbox for Labeling and Degrading Engineered Cas Proteins. <i>Jacs Au</i> , 2021, 1, 777-785.	3.6	10
2222	Spontaneous Selection of <i>Cryptosporidium</i> Drug Resistance in a Calf Model of Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	12
2223	Nicotinamide N-Methyltransferase in Acquisition of Stem Cell Properties and Therapy Resistance in Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5681.	1.8	14

#	ARTICLE	IF	CITATIONS
2224	Redox Resetting of cisplatin-resistant ovarian cancer cells by cisplatin-encapsulated nanostructured lipid carriers. <i>Nanomedicine</i> , 2021, 16, 979-995.	1.7	5
2225	Nanodiamonds and their potential applications in breast cancer therapy: a narrative review. <i>Drug Delivery and Translational Research</i> , 2022, 12, 1017-1028.	3.0	7
2226	Strongly preserved modules between cancer tissue and cell line contribute to drug resistance analysis across multiple cancer types. <i>Genomics</i> , 2021, 113, 1026-1036.	1.3	3
2227	Multifunctional Liposomes Enable Active Targeting and Twinfilin 1 Silencing to Reverse Paclitaxel Resistance in Brain Metastatic Breast Cancer. <i>ACS Applied Materials & Interfaces</i> , 2021, 13, 23396-23409.	4.0	24
2228	Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer. <i>Cancers</i> , 2021, 13, 2666.	1.7	79
2229	Single cell RNA sequencing for breast cancer: present and future. <i>Cell Death Discovery</i> , 2021, 7, 104.	2.0	28
2231	The Epigenetic Factors that Drive Cancer Drug Resistance. <i>Current Cancer Drug Targets</i> , 2021, 21, 269-273.	0.8	1
2232	Cross-resistance and drug sequence in prostate cancer. <i>Drug Resistance Updates</i> , 2021, 56, 100761.	6.5	36
2233	Implications of Enhancer Transcription and eRNAs in Cancer. <i>Cancer Research</i> , 2021, 81, 4174-4182.	0.4	38
2234	Synthesis of new β -Aryl- β -tetralones and β -Fluoro- β -aryl- β -tetralones, preliminary antiproliferative evaluation on drug resistant cell lines and in silico prediction of ADMETox properties. <i>Bioorganic Chemistry</i> , 2021, 110, 104790.	2.0	6
2236	Statin as a Potential Chemotherapeutic Agent: Current Updates as a Monotherapy, Combination Therapy, and Treatment for Anti-Cancer Drug Resistance. <i>Pharmaceuticals</i> , 2021, 14, 470.	1.7	25
2237	Capsaicin on stem cell proliferation and fate determination - a novel perspective. <i>Pharmacological Research</i> , 2021, 167, 105566.	3.1	5
2238	Association of SMAD4 loss with drug resistance in clinical cancer patients: A systematic meta-analysis. <i>PLoS ONE</i> , 2021, 16, e0250634.	1.1	5
2239	Targeting Lactate Dehydrogenase A with Catechin Resensitizes SNU620/5FU Gastric Cancer Cells to 5-Fluorouracil. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5406.	1.8	24
2240	Emerging nanotaxanes for cancer therapy. <i>Biomaterials</i> , 2021, 272, 120790.	5.7	25
2241	The role of ferroptosis in breast cancer patients: a comprehensive analysis. <i>Cell Death Discovery</i> , 2021, 7, 93.	2.0	65
2242	Insulin-like growth factors: Ligands, binding proteins, and receptors. <i>Molecular Metabolism</i> , 2021, 52, 101245.	3.0	90
2243	An Updated Review on Implications of Autophagy and Apoptosis in Tumorigenesis: Possible Alterations in Autophagy through Engineered Nanomaterials and Their Importance in Cancer Therapy. <i>Molecular Pharmacology</i> , 2021, 100, 119-143.	1.0	12

#	ARTICLE	IF	CITATIONS
2244	A KLF4/PiHL/EZH2/HMGA2 regulatory axis and its function in promoting oxaliplatin-resistance of colorectal cancer. <i>Cell Death and Disease</i> , 2021, 12, 485.	2.7	39
2245	Evaluation of Biological Activity of Different Wavelengths of Low-Level Laser Therapy on the Cancer Prostate Cell Line Compared With Cisplatin. <i>Journal of Lasers in Medical Sciences</i> , 2021, 12, e17-e17.	0.4	2
2246	ACP-DA: Improving the Prediction of Anticancer Peptides Using Data Augmentation. <i>Frontiers in Genetics</i> , 2021, 12, 698477.	1.1	22
2247	Loss of <i>SNAI2</i> in Prostate Cancer Correlates With Clinical Response to Androgen Deprivation Therapy. <i>JCO Precision Oncology</i> , 2021, 5, 1048-1059.	1.5	9
2248	IL-6 regulates autophagy and chemotherapy resistance by promoting BECN1 phosphorylation. <i>Nature Communications</i> , 2021, 12, 3651.	5.8	89
2249	A Synergistic Combination of Niclosamide and Doxorubicin as an Efficacious Therapy for All Clinical Subtypes of Breast Cancer. <i>Cancers</i> , 2021, 13, 3299.	1.7	17
2250	Tumor spheroid-based microtumor models for preclinical evaluation of anticancer nanomedicines. <i>Journal of Pharmaceutical Investigation</i> , 2021, 51, 541-553.	2.7	13
2251	Design of acid-activated cell-penetrating peptides with nuclear localization capacity for anticancer drug delivery. <i>Journal of Peptide Science</i> , 2021, 27, e3354.	0.8	12
2252	Isolation and Characterization of Chemo-Resistant Stem Cells from a Mouse Model of Hereditary Non-Polyposis Colon Cancer. <i>Stem Cells and Cloning: Advances and Applications</i> , 2021, Volume 14, 19-25.	2.3	3
2253	Solid state and solubility study of a potential anticancer drug-drug molecular salt of diclofenac and metformin. <i>Journal of Molecular Structure</i> , 2021, 1234, 130166.	1.8	13
2254	Triple-layered Metal-Organic Framework Hybrid for Tandem Response-Driven Enhanced Chemotherapy. <i>Chemistry - an Asian Journal</i> , 2021, 16, 2068-2074.	1.7	4
2255	Applications of Single-Cell Omics in Tumor Immunology. <i>Frontiers in Immunology</i> , 2021, 12, 697412.	2.2	21
2256	A Comprehensive Review on Deep Synergistic Drug Prediction Techniques for Cancer. <i>Archives of Computational Methods in Engineering</i> , 2022, 29, 1443-1461.	6.0	14
2257	Therapy Induced Genome Chaos: A Novel Mechanism of Rapid Cancer Drug Resistance. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 676344.	1.8	17
2258	Mutagenic Consequences of Sublethal Cell Death Signaling. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6144.	1.8	7
2259	Atiprimod triggered apoptotic cell death via acting on PERK/eIF2 α /ATF4/CHOP and STAT3/NF- κ B axis in MDA-MB-231 and MDA-MB-468 breast cancer cells. <i>Molecular Biology Reports</i> , 2021, 48, 5233-5247.	1.0	9
2260	The Long-Term DEHP Exposure Confers Multidrug Resistance of Triple-Negative Breast Cancer Cells through ABC Transporters and Intracellular ROS. <i>Antioxidants</i> , 2021, 10, 949.	2.2	14
2261	Blocking the JAK2/STAT3 and ERK pathways suppresses the proliferation of gastrointestinal cancers by inducing apoptosis. <i>Journal of Zhejiang University: Science B</i> , 2021, 22, 492-503.	1.3	6

#	ARTICLE	IF	CITATIONS
2262	Mimicking Pathogens to Augment the Potency of Liposomal Cancer Vaccines. <i>Pharmaceutics</i> , 2021, 13, 954.	2.0	7
2263	Updates on Receptors Targeted by Heterocyclic Scaffolds: New Horizon in Anticancer Drug Development. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2021, 21, 1338-1349.	0.9	6
2264	Design, Synthesis and In-Vitro Biological Evaluation of Antofine and Tylophorine Prodrugs as Hypoxia-Targeted Anticancer Agents. <i>Molecules</i> , 2021, 26, 3327.	1.7	2
2265	MicroRNA-10b modulates cisplatin tolerance by targeting p53 directly in lung cancer cells. <i>Oncology Reports</i> , 2021, 46, .	1.2	7
2266	Tannic acid/Fe ³⁺ complex coated mesoporous silica nanoparticles for controlled drug release and combined chemo-photothermal therapy. <i>Colloids and Surfaces A: Physicochemical and Engineering Aspects</i> , 2021, 618, 126475.	2.3	22
2267	Drug resistance reversal by intervening cancer bioenergetics with spherical helical polypeptide-potented gene silencing. <i>Chemical Engineering Journal</i> , 2021, 414, 128545.	6.6	13
2268	Recombinant Expression of Cec-B Peptide in Escherichia coli with a Significant Anticancer Effect on Hepatocellular Carcinoma. <i>Current Pharmaceutical Biotechnology</i> , 2021, 22, 1235-1245.	0.9	7
2269	Histone deacetylase 10, a potential epigenetic target for therapy. <i>Bioscience Reports</i> , 2021, 41, .	1.1	14
2270	Multi-functionalized dendrimers for targeted co-delivery of sorafenib and paclitaxel in liver cancers. <i>Journal of Drug Delivery Science and Technology</i> , 2021, 63, 102493.	1.4	13
2271	Impact of Concomitant Aberrant CD200 and BCL2 Overexpression on Outcome of Acute Myeloid Leukemia: A Cohort Study from a Single Center. <i>Turkish Journal of Haematology</i> , 2021, 38, 119-125.	0.2	2
2272	Combinatorial delivery of doxorubicin and acridine orange by gold core silica shell nanospheres functionalized with poly(ethylene glycol) and 4-methoxybenzamide for cancer targeted therapy. <i>Journal of Inorganic Biochemistry</i> , 2021, 219, 111433.	1.5	4
2273	BMI1 activates P-glycoprotein via transcription repression of miR-3682-3p and enhances chemoresistance of bladder cancer cell. <i>Aging</i> , 2021, 13, 18310-18330.	1.4	13
2274	A tumor-penetrable drug nanococktail made from human histones for interventional nucleus-targeted chemophotothermal therapy of drug-resistant tumors. <i>Bioactive Materials</i> , 2022, 9, 554-565.	8.6	10
2275	Activation of the integrated stress response confers vulnerability to mitochondria-targeting antibiotics in melanoma. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	31
2276	Doxorubicin-Bound Hydroxyethyl Starch Conjugate Nanoparticles with pH/Redox Responsive Linkage for Enhancing Antitumor Therapy. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 4527-4544.	3.3	7
2277	xDeep-AcPEP: Deep Learning Method for Anticancer Peptide Activity Prediction Based on Convolutional Neural Network and Multitask Learning. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 3789-3803.	2.5	45
2278	Microenvironment-triggered multimodal precision diagnostics. <i>Nature Materials</i> , 2021, 20, 1440-1448.	13.3	42
2279	Discovery of Novel 2,4-Dianilino-pyrimidine Derivatives Containing 4-(Morpholinomethyl)phenyl and N-Substituted Benzamides as Potential FAK Inhibitors and Anticancer Agents. <i>Molecules</i> , 2021, 26, 4187.	1.7	4

#	ARTICLE	IF	CITATIONS
2280	Learning epistatic gene interactions from perturbation screens. <i>PLoS ONE</i> , 2021, 16, e0254491.	1.1	5
2281	Design, synthesis and in vitro antitumor evaluation of novel pyrazole-benzimidazole derivatives. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 43, 128097.	1.0	15
2282	mRNA expression level of CDH2, LEP, POSTN, TIMP1 and VEGFC modulates 5- ϵ -fluorouracil resistance in colon cancer cells. <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 1023.	0.8	4
2283	Establishment of oxaliplatin-resistant gastric cancer organoids: importance of myoferlin in the acquisition of oxaliplatin resistance. <i>Gastric Cancer</i> , 2021, 24, 1264-1277.	2.7	20
2284	Phytomedicines Targeting Cancer Stem Cells: Therapeutic Opportunities and Prospects for Pharmaceutical Development. <i>Pharmaceuticals</i> , 2021, 14, 676.	1.7	13
2285	A novel moniliformin derivative as pan-inhibitor of histone deacetylases triggering apoptosis of leukemia cells. <i>Biochemical Pharmacology</i> , 2021, 194, 114677.	2.0	11
2286	Glutathione-responsive PLGA nanocomplex for dual delivery of doxorubicin and curcumin to overcome tumor multidrug resistance. <i>Nanomedicine</i> , 2021, 16, 1411-1427.	1.7	5
2287	TPGS and chondroitin sulfate dual-modified lipid-albumin nanosystem for targeted delivery of chemotherapeutic agent against multidrug-resistant cancer. <i>International Journal of Biological Macromolecules</i> , 2021, 183, 1270-1282.	3.6	8
2288	The Application of Inorganic Nanoparticles in Molecular Targeted Cancer Therapy: EGFR Targeting. <i>Frontiers in Pharmacology</i> , 2021, 12, 702445.	1.6	32
2289	Prognostic and Immunological Role of Gasdermin E in Pan-Cancer Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 706266.	1.3	12
2290	Targeted Glucose or Glutamine Metabolic Therapy Combined With PD-1/PD-L1 Checkpoint Blockade Immunotherapy for the Treatment of Tumors - Mechanisms and Strategies. <i>Frontiers in Oncology</i> , 2021, 11, 697894.	1.3	19
2291	Genomic alterations and possible druggable mutations in carcinoma of unknown primary (CUP). <i>Scientific Reports</i> , 2021, 11, 15112.	1.6	2
2292	Molecular docking and dynamics simulation study of bioactive compounds from <i>Ficus carica</i> L. with important anticancer drug targets. <i>PLoS ONE</i> , 2021, 16, e0254035.	1.1	32
2293	miR-137/ERR α axis mediates chemoresistance of nasopharyngeal carcinoma cells. <i>Journal of Cell Communication and Signaling</i> , 2022, 16, 103-113.	1.8	4
2294	Extracellular Vesicles as Mediators of Cancer Disease and as Nanosystems in Theranostic Applications. <i>Cancers</i> , 2021, 13, 3324.	1.7	13
2295	The impact of mitochondria on cancer treatment resistance. <i>Cellular Oncology (Dordrecht)</i> , 2021, 44, 983-995.	2.1	15
2296	Near-Infrared Fluorescent Probe for Imaging and Evaluating the Role of Vanin-1 in Chemotherapy. <i>Analytical Chemistry</i> , 2021, 93, 10378-10387.	3.2	8
2297	1'-methylspiro[indoline-3,4'-piperidine] Derivatives: Design, Synthesis, Molecular Docking and Anti-tumor Activity Studies. <i>Letters in Drug Design and Discovery</i> , 2021, 18, 490-498.	0.4	0

#	ARTICLE	IF	CITATIONS
2298	The Impact of Diet and Exercise on Drug Responses. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7692.	1.8	21
2299	Nanotechnology-Assisted RNA Delivery: From Nucleic Acid Therapeutics to COVID-19 Vaccines. <i>Small Methods</i> , 2021, 5, 2100402.	4.6	45
2300	Design, synthesis, characterization, crystal structure, Hirshfeld surface analysis, DFT calculations, anticancer, angiogenic properties of new pyrazole carboxamide derivatives. <i>Journal of Molecular Structure</i> , 2021, 1235, 130271.	1.8	6
2301	HDAC Inhibitors: Dissecting Mechanisms of Action to Counter Tumor Heterogeneity. <i>Cancers</i> , 2021, 13, 3575.	1.7	35
2302	Transferrin-based radiolabeled probe predicts the sensitivity of human renal cancer cell lines to ferroptosis inducer erastin. <i>Biochemistry and Biophysics Reports</i> , 2021, 26, 100957.	0.7	4
2303	Systems Pharmacology-Based Precision Therapy and Drug Combination Discovery for Breast Cancer. <i>Cancers</i> , 2021, 13, 3586.	1.7	4
2304	Metabolic Reprogramming: A Friend or Foe to Cancer Therapy?. <i>Cancers</i> , 2021, 13, 3351.	1.7	10
2305	Immunostimulatory photochemotherapeutic nanocapsule for enhanced colon cancer treatment. <i>Nanophotonics</i> , 2021, 10, 3321-3337.	2.9	6
2306	Small-Molecule Prodrug Nanoassemblies: An Emerging Nanoplatfor for Anticancer Drug Delivery. <i>Small</i> , 2021, 17, e2101460.	5.2	87
2308	Core Circadian Clock Proteins as Biomarkers of Progression in Colorectal Cancer. <i>Biomedicines</i> , 2021, 9, 967.	1.4	5
2309	APPTTEST is a novel protocol for the automatic prediction of peptide tertiary structures. <i>Briefings in Bioinformatics</i> , 2021, 22, .	3.2	23
2310	CEBPB knockdown sensitizes nasopharyngeal carcinoma cells to cisplatin by promoting the expression of serine protease inhibitor Kazal-type 5. <i>Anti-Cancer Drugs</i> , 2021, Publish Ahead of Print, .	0.7	3
2311	Cancer cell membrane camouflaged iridium complexes functionalized black-titanium nanoparticles for hierarchical-targeted synergistic NIR-II photothermal and sonodynamic therapy. <i>Biomaterials</i> , 2021, 275, 120979.	5.7	82
2312	Intratumoural Treatment of 18 Cytologically Diagnosed Canine High-Grade Mast Cell Tumours With Tigilanol Tiglate. <i>Frontiers in Veterinary Science</i> , 2021, 8, 675804.	0.9	4
2313	Functional metabolomics innovates therapeutic discovery of traditional Chinese medicine derived functional compounds. , 2021, 224, 107824.		31
2314	Advanced Computational Methodologies Used in the Discovery of New Natural Anticancer Compounds. <i>Frontiers in Pharmacology</i> , 2021, 12, 702611.	1.6	33
2315	The role of memory in non-genetic inheritance and its impact on cancer treatment resistance. <i>PLoS Computational Biology</i> , 2021, 17, e1009348.	1.5	11
2316	Three novel piperidones exhibit tumor-selective cytotoxicity on leukemia cells via protein degradation and stress-mediated mechanisms. <i>Pharmacological Reports</i> , 2022, 74, 159-174.	1.5	3

#	ARTICLE	IF	CITATIONS
2317	Furin-instructed aggregated gold nanoparticles for re-educating tumor associated macrophages and overcoming breast cancer chemoresistance. <i>Biomaterials</i> , 2021, 275, 120891.	5.7	54
2318	Targeting ferroptosis synergistically sensitizes apoptotic sonodynamic anti-tumor nanotherapy. <i>Nano Today</i> , 2021, 39, 101212.	6.2	59
2319	Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects. <i>Biomedicines</i> , 2021, 9, 1075.	1.4	46
2320	Optical “Magnetic probe for evaluating cancer therapy. <i>Coordination Chemistry Reviews</i> , 2021, 441, 213978.	9.5	15
2321	Metabolomics, metabolic flux analysis and cancer pharmacology. , 2021, 224, 107827.		44
2322	Acquired resistance to PRMT5 inhibition induces concomitant collateral sensitivity to paclitaxel. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	14
2323	Incidence, Risk Factors, and Outcomes from Conversion of Low-Grade to High-Grade Appendiceal Neoplasms for Patients Undergoing Multiple Cytoreductive Surgeries with Hyperthermic Intraperitoneal Chemotherapy. <i>Annals of Surgical Oncology</i> , 2022, 29, 205-211.	0.7	5
2324	Metal-coordinated nanomedicine for combined tumor therapy by inducing paraptosis and apoptosis. <i>Journal of Controlled Release</i> , 2021, 336, 159-168.	4.8	20
2325	Nanoplatform-based natural products co-delivery system to surmount cancer multidrug-resistant. <i>Journal of Controlled Release</i> , 2021, 336, 396-409.	4.8	31
2326	Cancer Biomarkers in the era of precision oncology: Addressing the needs of patients and health systems. <i>Seminars in Cancer Biology</i> , 2022, 84, 293-301.	4.3	30
2327	Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma. <i>Cancer Cell</i> , 2021, 39, 1135-1149.e8.	7.7	83
2328	Responsive polymeric drug delivery systems for combination anticancer therapy: experimental design and computational insights. <i>International Journal of Polymeric Materials and Polymeric Biomaterials</i> , 2022, 71, 1221-1239.	1.8	3
2329	Natural Bioactive Cyclopeptides from Microbes as Promising Anticancer Drug Leads: A Mini-review. <i>Indonesian Journal of Pharmacy</i> , 0, , 291-303.	0.3	1
2330	A gentle introduction to understanding preclinical data for cancer pharmaco-omic modeling. <i>Briefings in Bioinformatics</i> , 2021, 22, .	3.2	7
2331	Synthesis, anticancer activity and mechanism of action of new phthalimido-1,3-thiazole derivatives. <i>Chemico-Biological Interactions</i> , 2021, 347, 109597.	1.7	6
2332	Rutaecarpine Increases Anticancer Drug Sensitivity in Drug-Resistant Cells through MARCH8-Dependent ABCB1 Degradation. <i>Biomedicines</i> , 2021, 9, 1143.	1.4	12
2333	Machine learning methods, databases and tools for drug combination prediction. <i>Briefings in Bioinformatics</i> , 2022, 23, .	3.2	45
2334	Basic Principles of Nanotoxicology. , 2022, , 171-195.		0

#	ARTICLE	IF	CITATIONS
2335	Chromosomal instability accelerates the evolution of resistance to anti-cancer therapies. <i>Developmental Cell</i> , 2021, 56, 2427-2439.e4.	3.1	101
2336	Gene copy-number changes and chromosomal instability induced by aneuploidy confer resistance to chemotherapy. <i>Developmental Cell</i> , 2021, 56, 2440-2454.e6.	3.1	87
2337	Construction and applications of DNA-based nanomaterials in cancer therapy. <i>Chinese Chemical Letters</i> , 2022, 33, 1131-1140.	4.8	22
2338	Breaking the Silence of Tumor Response: Future Prospects of Targeted Radionuclide Therapy. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2021, 21, .	0.9	1
2339	Bridging Tumorigenesis and Therapy Resistance With a Non-Darwinian and Non-Lamarckian Mechanism of Adaptive Evolution. <i>Frontiers in Oncology</i> , 2021, 11, 732081.	1.3	3
2340	Preparation of Near-Infrared/Photoacoustic Dual-Mode Imaging and Photothermal/Chemo Synergistic Theranostic Nanoparticles and Their Imaging and Treating of Hepatic Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 750807.	1.3	4
2341	Active Semisupervised Model for Improving the Identification of Anticancer Peptides. <i>ACS Omega</i> , 2021, 6, 23998-24008.	1.6	4
2342	Discovery of New 4-Indolyl Quinazoline Derivatives as Highly Potent and Orally Bioavailable P-Glycoprotein Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 14895-14911.	2.9	27
2343	Reflecting on 20 years of progress. <i>Nature Reviews Cancer</i> , 2021, 21, 605-605.	12.8	3
2344	Breast cancer resistance to chemotherapy: When should we suspect it and how can we prevent it?. <i>Annals of Medicine and Surgery</i> , 2021, 70, 102793.	0.5	29
2345	An Exploratory Phase II Study of Eribulin Re-challenge After Short Term Therapy of 5-Fluorouracil for HER2 Negative, Advanced or Recurrent Breast Cancer. <i>Anticancer Research</i> , 2021, 41, 5007-5014.	0.5	1
2346	Breast cancer immunotherapy: Current biomarkers and the potential of in vitro assays. <i>Current Opinion in Biomedical Engineering</i> , 2022, 21, 100348.	1.8	2
2347	Comprehensive Analysis of the Prognostic Significance of Hsa-miR-100-5p and Its Related Gene Signature in Stomach Adenocarcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 736274.	1.8	7
2348	Cascade Release Nanocarriers for the Triple-Negative Breast Cancer Near-Infrared Imaging and Photothermal-Chemo Synergistic Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 747608.	1.3	3
2349	Hydroxypropyl methylcellulose/graphene oxide composite as drug carrier system for 5-fluorouracil. <i>Biotechnology Journal</i> , 2022, 17, e2100183.	1.8	19
2350	Roles of circRNAs in cancer chemoresistance (Review). <i>Oncology Reports</i> , 2021, 46, .	1.2	12
2351	Piperidine nucleus in the field of drug discovery. <i>Future Journal of Pharmaceutical Sciences</i> , 2021, 7, .	1.1	43
2352	Regulated lytic cell death in breast cancer. <i>Cell Biology International</i> , 2022, 46, 12-33.	1.4	9

#	ARTICLE	IF	CITATIONS
2353	SMAR1 Suppresses the Cancer Stem Cell Population via hTERT Repression in Colorectal Cancer Cells. <i>International Journal of Biochemistry and Cell Biology</i> , 2021, 141, 106085.	1.2	2
2354	Mitochondrial Breast Cancer Resistant Protein Sustains the Proliferation and Survival of Drug-Resistant Breast Cancer Cells by Regulating Intracellular Reactive Oxygen Species. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 719209.	1.8	4
2355	Shutting the gate: targeting endocytosis in acute leukemia. <i>Experimental Hematology</i> , 2021, 104, 17-31.	0.2	0
2356	Microfluidic Single-Cell Proteomics Assay Chip: Lung Cancer Cell Line Case Study. <i>Micromachines</i> , 2021, 12, 1147.	1.4	1
2357	Role of exosomal miRNA in chemotherapy resistance of Colorectal cancer: A systematic review. <i>Chemical Biology and Drug Design</i> , 2023, 101, 1096-1112.	1.5	7
2358	Playing on the Dark Side: SMYD3 Acts as a Cancer Genome Keeper in Gastrointestinal Malignancies. <i>Cancers</i> , 2021, 13, 4427.	1.7	7
2359	Exosomal ERp44 derived from ER-stressed cells strengthens cisplatin resistance of nasopharyngeal carcinoma. <i>BMC Cancer</i> , 2021, 21, 1003.	1.1	15
2360	Pulmonary surfactants affinity Pluronic-hybridized liposomes enhance the treatment of drug-resistant lung cancer. <i>International Journal of Pharmaceutics</i> , 2021, 607, 120973.	2.6	9
2361	Anticancer Activity of Some Ruthenium(III) Complexes with Quinolone Antibiotics: In Vitro Cytotoxicity, Cell Cycle Modulation, and Apoptosis-Inducing Properties in LoVo Colon Cancer Cell Line. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 8594.	1.3	7
2362	Assessment of elementary derivatives of 1,5-benzodiazepine as anticancer agents with synergy potential. <i>Bioorganic Chemistry</i> , 2021, 117, 105331.	2.0	11
2363	Extracellular Matrix Characterization in Gastric Cancer Helps to Predict Prognosis and Chemotherapy Response. <i>Frontiers in Oncology</i> , 2021, 11, 753330.	1.3	11
2364	CTR-DB, an omnibus for patient-derived gene expression signatures correlated with cancer drug response. <i>Nucleic Acids Research</i> , 2022, 50, D1184-D1199.	6.5	26
2365	Chemoreversal Agents from Taiwanofungus Genus and Their More Potent Methyl Derivatives Targeting Signal Transducer and Activator of Transcription 3 (STAT3) Phosphorylation. <i>Pharmaceutics</i> , 2021, 14, 916.	1.7	0
2366	Exosomal transfer of miR-106a-5p contributes to cisplatin resistance and tumorigenesis in nasopharyngeal carcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 9183-9198.	1.6	13
2367	Therapeutic potential of <i>Scutellaria baicalensis</i> Georgi in lung cancer therapy. <i>Phytomedicine</i> , 2022, 95, 153727.	2.3	21
2368	PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 286.	3.5	18
2369	Bioactive Compounds of <i>Arthrospira</i> spp. (Spirulina) with Potential Anticancer Activities: A Systematic Review. <i>ACS Chemical Biology</i> , 2021, 16, 2057-2067.	1.6	16
2370	Combating cancer by utilizing noble metallic nanostructures in combination with laser photothermal and X-ray radiotherapy. <i>Journal of Drug Delivery Science and Technology</i> , 2021, 65, 102689.	1.4	7

#	ARTICLE	IF	CITATIONS
2371	Boosting the sub-cellular biomolecular cancer signals by self-functionalized tag-free nano sensor. <i>Biosensors and Bioelectronics</i> , 2021, 190, 113407.	5.3	6
2372	Cancer-associated fibroblasts induce monocytic myeloid-derived suppressor cell generation via IL-6/exosomal miR-21-activated STAT3 signaling to promote cisplatin resistance in esophageal squamous cell carcinoma. <i>Cancer Letters</i> , 2021, 518, 35-48.	3.2	76
2373	Purified recombinant human Chromogranin A N46 peptide with remarkable anticancer effect on human colon cancer cells. <i>Bioorganic Chemistry</i> , 2021, 115, 105266.	2.0	8
2374	MoS ₂ -based nanocomposites for cancer diagnosis and therapy. <i>Bioactive Materials</i> , 2021, 6, 4209-4242.	8.6	129
2375	Implementation of docking, molecular dynamics and free energy to investigate drug potency of novel BCR-ABL T315I inhibitors as an alternative to ponatinib. <i>Computational Toxicology</i> , 2021, 20, 100180.	1.8	7
2376	Targeting cancer cell adhesion molecule, CD146, with low-dose gold nanorods and mild hyperthermia disrupts actin cytoskeleton and cancer cell migration. <i>Journal of Colloid and Interface Science</i> , 2021, 601, 556-569.	5.0	10
2377	Long non-coding RNAs orchestrate various molecular and cellular processes by modulating epithelial-mesenchymal transition in head and neck squamous cell carcinoma. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2021, 1867, 166240.	1.8	18
2378	Platinum complexes inhibit HER-2 enriched and triple-negative breast cancer cells metabolism to suppress growth, stemness and migration by targeting PKM/LDHA and CCND1/BCL2/ATG3 signaling pathways. <i>European Journal of Medicinal Chemistry</i> , 2021, 224, 113689.	2.6	17
2379	Enhanced delivery of artesunate by stimuli-responsive polymeric micelles for lung tumor therapy. <i>Journal of Drug Delivery Science and Technology</i> , 2021, 66, 102812.	1.4	5
2380	Molecular modeling approaches to address drug-metabolizing enzymes (DMEs) mediated chemoresistance: a review. <i>Drug Metabolism Reviews</i> , 2021, 53, 45-75.	1.5	11
2381	Recent advances in covalent organic frameworks for cancer diagnosis and therapy. <i>Biomaterials Science</i> , 2021, 9, 5745-5761.	2.6	33
2382	Clickable amino acid tuned self-assembly of a nucleus-selective multi-component nanoplatfor for synergistic cancer therapy. <i>Chemical Science</i> , 2021, 12, 8394-8400.	3.7	12
2383	Drug Resistance in Kidney Diseases. , 2021, , 279-294.		0
2384	Cell cycle control and DNA-damage signaling in mammals. , 2021, , 237-255.		0
2385	Molecular subtypes based on ferroptosis-related genes and tumor microenvironment infiltration characterization in lung adenocarcinoma. <i>Oncolmmunology</i> , 2021, 10, 1959977.	2.1	30
2386	Asymmetric organocatalysis: an enabling technology for medicinal chemistry. <i>Chemical Society Reviews</i> , 2021, 50, 1522-1586.	18.7	219
2388	Retinoic acid affects basic cellular processes and SOX2 and SOX18 expression in breast carcinoma cells. <i>Biocell</i> , 2021, 45, 1355-1367.	0.4	2
2389	Metal-phenolic networks for cancer theranostics. <i>Biomaterials Science</i> , 2021, 9, 2825-2849.	2.6	45

#	ARTICLE	IF	CITATIONS
2390	Recent Advances and Implication of Bioengineered Nanomaterials in Cancer Theranostics. <i>Medicina (Lithuania)</i> , 2021, 57, 91.	0.8	15
2391	Identification of AKT1/ β -catenin mutations conferring cetuximab and chemotherapeutic drug resistance in colorectal cancer treatment. <i>Oncology Letters</i> , 2021, 21, 209.	0.8	8
2392	Designer exosomes for targeted and efficient ferroptosis induction in cancer via chemo-photodynamic therapy. <i>Theranostics</i> , 2021, 11, 8185-8196.	4.6	105
2393	Targeting epigenetic regulatory machinery to overcome cancer therapy resistance. <i>Seminars in Cancer Biology</i> , 2022, 83, 487-502.	4.3	32
2394	Self-delivery nanomedicine to overcome drug resistance for synergistic chemotherapy. <i>Biomaterials Science</i> , 2021, 9, 3445-3452.	2.6	17
2395	Dual-sensitive dual-prodrug nanoparticles with light-controlled endo/lysosomal escape for synergistic photoactivated chemotherapy. <i>Biomaterials Science</i> , 2021, 9, 7115-7123.	2.6	10
2397	Renal-clearable PEGylated Porphyrin Nanoparticles for Image-Guided Photodynamic Cancer Therapy. <i>Advanced Functional Materials</i> , 2017, 27, 1702928.	7.8	113
2398	Introduction to the Acquisition of Resistance to Targeted Therapy. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2019, , 1-33.	0.1	2
2399	Resistance to Anti-Cancer Therapeutics. , 2019, , 65-82.		1
2400	Nanocarriers as Potential Targeted Drug Delivery for Cancer Therapy. <i>Environmental Chemistry for A Sustainable World</i> , 2020, , 51-88.	0.3	15
2401	Exploiting Cancer Cells Metabolic Adaptability to Enhance Therapy Response in Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1219, 297-310.	0.8	1
2402	Single-Cell Multiomics: Dissecting Cancer. <i>Algorithms for Intelligent Systems</i> , 2020, , 289-317.	0.5	1
2403	Biphasic Effects of Phytochemicals and their Relevance to Cancer Therapeutics. , 2020, , 197-219.		2
2404	Role of MSCs in Antitumor Drug Resistance. , 2017, , 295-333.		1
2405	Prediction of synergistic anti-cancer drug combinations based on drug target network and drug induced gene expression profiles. <i>Artificial Intelligence in Medicine</i> , 2017, 83, 35-43.	3.8	71
2406	An Update: Genetic Mutations and Childhood Cancers. <i>Journal for Nurse Practitioners</i> , 2018, 14, 230-237.	0.4	1
2407	The ameliorating effects of anthocyanins on the cross-linked signaling pathways of cancer dysregulated metabolism. <i>Pharmacological Research</i> , 2020, 159, 104895.	3.1	38
2408	Overcoming Resistance to Drugs Targeting KRAS Mutation. <i>Innovation(China)</i> , 2020, 1, 100035.	5.2	44

#	ARTICLE	IF	CITATIONS
2409	Comparison of Redox Responsiveness and Antitumor Capability of Paclitaxel Dimeric Nanoparticles with Different Linkers. <i>Chemistry of Materials</i> , 2020, 32, 10719-10727.	3.2	28
2410	Boron Quantum Dots for Photoacoustic Imaging-Guided Photothermal Therapy. <i>ACS Applied Materials & Interfaces</i> , 2021, 13, 306-311.	4.0	51
2411	KANSL2 and MBNL3 are regulators of pancreatic ductal adenocarcinoma invasion. <i>Scientific Reports</i> , 2020, 10, 1485.	1.6	5
2412	Overexpression of microRNA-205-5p exerts suppressive effects on stem cell drug resistance in gallbladder cancer by down-regulating PRKCE. <i>Bioscience Reports</i> , 2020, 40, .	1.1	16
2413	Erianthridin Induces Non-small Cell Lung Cancer Cell Apoptosis through the Suppression of Extracellular Signal-regulated Kinase Activity. <i>Planta Medica</i> , 2021, 87, 283-293.	0.7	12
2414	Synthesis of some quinazolinones inspired from the natural alkaloid L-tryptophan as EGFR inhibitors and radiosensitizers. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2021, 36, 218-238.	2.5	13
2436	MiR-145 in cancer therapy resistance and sensitivity: A comprehensive review. <i>Cancer Science</i> , 2020, 111, 3122-3131.	1.7	39
2437	The Combinatorial Effect of Cisplatin and Moxibustion on Tumor Growth Inhibition with Special Reference to Modulation of the Immune Microenvironment in Lewis Lung Cancer Mice. <i>Evidence-based Complementary and Alternative Medicine</i> , 2020, 2020, 1-14.	0.5	6
2438	Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1017-1024.	3.2	22
2439	Doxorubicin-Loaded All-Trans Retinoic Acid Dimer Phospholipid Liposomes as Co-Delivery System to Reverse Drug Resistance in Breast Cancer. <i>Nanoscience and Nanotechnology Letters</i> , 2019, 11, 749-759.	0.4	5
2440	Hypoxia-induced upregulation of BMX kinase mediates therapeutic resistance in acute myeloid leukemia. <i>Journal of Clinical Investigation</i> , 2017, 128, 369-380.	3.9	39
2441	Mitochondrial reprogramming via ATP5H loss promotes multimodal cancer therapy resistance. <i>Journal of Clinical Investigation</i> , 2018, 128, 4098-4114.	3.9	31
2442	Oncogenic functions of the EMT-related transcription factor ZEB1 in breast cancer. <i>Journal of Translational Medicine</i> , 2020, 18, 51.	1.8	83
2443	rGO nanomaterial-mediated cancer targeting and photothermal therapy in a microfluidic co-culture platform. <i>Nano Convergence</i> , 2020, 7, 10.	6.3	33
2444	MicroRNA-184 Modulates Doxorubicin Resistance in Osteosarcoma Cells by Targeting BCL2L1. <i>Medical Science Monitor</i> , 2016, 22, 1761-1765.	0.5	37
2445	MicroRNA-140 Inhibits Cell Proliferation in Gastric Cancer Cell Line HGC-27 by Suppressing SOX4. <i>Medical Science Monitor</i> , 2016, 22, 2243-2252.	0.5	29
2446	Interleukin-22 (IL-22) Regulates Apoptosis of Paclitaxel-Resistant Non-Small Cell Lung Cancer Cells Through C-Jun N-Terminal Kinase Signaling Pathway. <i>Medical Science Monitor</i> , 2018, 24, 2750-2757.	0.5	8
2447	Reelin Promotes Cisplatin Resistance by Induction of Epithelial-Mesenchymal Transition via p38/GSK3 β /Snail Signaling in Non-Small Cell Lung Cancer. <i>Medical Science Monitor</i> , 2020, 26, e925298.	0.5	2

#	ARTICLE	IF	CITATIONS
2448	Visualization of drug target interactions in the contexts of pathways and networks with ReactomeFIViz. <i>F1000Research</i> , 2019, 8, 908.	0.8	20
2449	Reverse Chemical Genetics: Comprehensive Fitness Profiling Reveals the Spectrum of Drug Target Interactions. <i>PLoS Genetics</i> , 2016, 12, e1006275.	1.5	13
2450	Abl Kinases Regulate HGF/Met Signaling Required for Epithelial Cell Scattering, Tubulogenesis and Motility. <i>PLoS ONE</i> , 2015, 10, e0124960.	1.1	21
2451	Selective Targeting of CTNNB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs. <i>PLoS ONE</i> , 2015, 10, e0125021.	1.1	16
2452	Inhibition of Autophagy Potentiated the Antitumor Effect of Nedaplatin in Cisplatin-Resistant Nasopharyngeal Carcinoma Cells. <i>PLoS ONE</i> , 2015, 10, e0135236.	1.1	18
2453	Inhibition of Phosphatidylcholine-Specific Phospholipase C Interferes with Proliferation and Survival of Tumor Initiating Cells in Squamous Cell Carcinoma. <i>PLoS ONE</i> , 2015, 10, e0136120.	1.1	20
2454	Pertussis Toxin Is a Robust and Selective Inhibitor of High Grade Glioma Cell Migration and Invasion. <i>PLoS ONE</i> , 2016, 11, e0168418.	1.1	10
2455	Extreme low dose of 5-fluorouracil reverses MDR in cancer by sensitizing cancer associated fibroblasts and down-regulating P-gp. <i>PLoS ONE</i> , 2017, 12, e0180023.	1.1	12
2456	Optimal control to reach eco-evolutionary stability in metastatic castrate-resistant prostate cancer. <i>PLoS ONE</i> , 2020, 15, e0243386.	1.1	39
2457	Salubrinal-Mediated Upregulation of eIF2 \pm Phosphorylation Increases Doxorubicin Sensitivity in MCF-7/ADR Cells. <i>Molecules and Cells</i> , 2016, 39, 129-135.	1.0	26
2458	Gastric Adenocarcinoma: An Update on Genomics, Immune System Modulations, and Targeted Therapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 36, 104-111.	1.8	10
2459	Construction and recombinant expression of <i>Pseudomonas aeruginosa</i> truncated exotoxin A in <i>Escherichia coli</i> . <i>Cellular and Molecular Biology</i> , 2018, 64, 64.	0.3	5
2460	CHOLINE KINASE AS A PRECISION MEDICINE TARGET FOR THERAPY IN CANCER, AUTOIMMUNE DISEASES AND MALARIA. <i>Precision Medicine</i> , 0, , .	0.5	6
2461	Molecular machineries of pH dysregulation in tumor microenvironment: potential targets for cancer therapy. <i>Biolmpacts</i> , 2017, 7, 115-133.	0.7	93
2462	Increased expressions of cellular ATP-binding cassette transporters may be a promising diagnostic marker for colorectal cancer. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2020, 41, 834-840.	0.5	1
2463	T lymphocytes against solid malignancies: winning ways to defeat tumours. <i>Cell Stress</i> , 2018, 2, 200-212.	1.4	22
2464	Resistance to drugs and cell death in cancer stem cells (CSCs). <i>Journal of Translational Science</i> , 2020, 6, .	0.2	13
2465	RKIP-Mediated Chemo-Immunosensitization of Resistant Cancer Cells via Disruption of the NF- κ B/Snail/YY1/RKIP Resistance-Driver Loop. <i>Critical Reviews in Oncogenesis</i> , 2014, 19, 431-445.	0.2	31

#	ARTICLE	IF	CITATIONS
2466	Linking Autophagy and the Dysregulated NF κ B/ SNAIL/YY1/RKIP/PTEN Loop in Cancer: Therapeutic Implications. <i>Critical Reviews in Oncogenesis</i> , 2018, 23, 307-320.	0.2	22
2467	Tumor suppressive effects of the pleiotropically acting miR-195 in colorectal cancer cells. <i>EXCLI Journal</i> , 2019, 18, 243-252.	0.5	8
2468	The natural adaptive evolution of cancer: The metastatic ability of cancer cells. <i>Bosnian Journal of Basic Medical Sciences</i> , 2020, 20, 303-309.	0.6	3
2469	Cytological and genetic consequences for the progeny of a mitotic catastrophe provoked by Topoisomerase II deficiency. <i>Aging</i> , 2019, 11, 11686-11721.	1.4	4
2470	FS-93, an Hsp90 inhibitor, induces G2/M arrest and apoptosis via the degradation of client proteins in oncogene addicted and derived resistant cancer cells. <i>Oncoscience</i> , 2015, 2, 419-427.	0.9	6
2471	Necrosis, and then stress induced necrosis-like cell death, but not apoptosis, should be the preferred cell death mode for chemotherapy: clearance of a few misconceptions. <i>Oncoscience</i> , 2014, 1, 407-422.	0.9	44
2472	Just like the rest of evolution in Mother Nature, the evolution of cancers may be driven by natural selection, and not by haphazard mutations. <i>Oncoscience</i> , 2014, 1, 580-590.	0.9	18
2473	<i>p53</i> mutant <i>MDM2</i> -amplified cell lines selected for resistance to <i>MDM2</i> -p53 binding antagonists retain sensitivity to ionizing radiation. <i>Oncotarget</i> , 2016, 7, 46203-46218.	0.8	22
2474	Dextran-Catechin: An anticancer chemically-modified natural compound targeting copper that attenuates neuroblastoma growth. <i>Oncotarget</i> , 2016, 7, 47479-47493.	0.8	40
2475	Crosstalk between the mitochondrial fission protein, Drp1, and the cell cycle is identified across various cancer types and can impact survival of epithelial ovarian cancer patients. <i>Oncotarget</i> , 2016, 7, 60021-60037.	0.8	65
2476	Regulation of cellular quiescence by YAP/TAZ and Cyclin E1 in colon cancer cells: Implication in chemoresistance and cancer relapse. <i>Oncotarget</i> , 2016, 7, 56699-56712.	0.8	36
2477	Radiofrequency hyperthermia promotes the therapeutic effects on chemotherapeutic-resistant breast cancer when combined with heat shock protein promoter-controlled HSV-TK gene therapy: Toward imaging-guided interventional gene therapy. <i>Oncotarget</i> , 2016, 7, 65042-65051.	0.8	10
2478	Modeling of signaling crosstalk-mediated drug resistance and its implications on drug combination. <i>Oncotarget</i> , 2016, 7, 63995-64006.	0.8	43
2479	Inhibition of never in mitosis A (NIMA)-related kinase-4 reduces survivin expression and sensitizes cancer cells to TRAIL-induced cell death. <i>Oncotarget</i> , 2016, 7, 65957-65967.	0.8	14
2480	Addressing intra-tumoral heterogeneity and therapy resistance. <i>Oncotarget</i> , 2016, 7, 72322-72342.	0.8	67
2481	Smac mimetic LCL161 supports neuroblastoma chemotherapy in a drug class-dependent manner and synergistically interacts with ALK inhibitor TAE684 in cells with ALK mutation F1174L. <i>Oncotarget</i> , 2016, 7, 72634-72653.	0.8	19
2482	Smoking-associated lung cancer prevention by blockade of the beta-adrenergic receptor-mediated insulin-like growth factor receptor activation. <i>Oncotarget</i> , 2016, 7, 70936-70947.	0.8	17
2483	Upregulation of microRNA-524-5p enhances the cisplatin sensitivity of gastric cancer cells by modulating proliferation and metastasis via targeting SOX9. <i>Oncotarget</i> , 2017, 8, 574-582.	0.8	42

#	ARTICLE	IF	CITATIONS
2484	Gene expression profiling of tumor-initiating stem cells from mouse Krebs-2 carcinoma using a novel marker of poorly differentiated cells. <i>Oncotarget</i> , 2017, 8, 9425-9441.	0.8	17
2485	Metformin promotes apoptosis in hepatocellular carcinoma through the CEBPD-induced autophagy pathway. <i>Oncotarget</i> , 2017, 8, 13832-13845.	0.8	56
2486	An oral quinoline derivative, MPTOB392, causes leukemic cells mitotic arrest and overcomes drug resistant cancer cells. <i>Oncotarget</i> , 2017, 8, 27772-27785.	0.8	6
2487	YAP promotes tumorigenesis and cisplatin resistance in neuroblastoma. <i>Oncotarget</i> , 2017, 8, 37154-37163.	0.8	36
2488	Regulatory functional territory of PLK-1 and their substrates beyond mitosis. <i>Oncotarget</i> , 2017, 8, 37942-37962.	0.8	12
2489	Evidence of drug-response heterogeneity rapidly generated from a single cancer cell. <i>Oncotarget</i> , 2017, 8, 41113-41124.	0.8	10
2490	KIF7 attenuates prostate tumor growth through LKB1-mediated AKT inhibition. <i>Oncotarget</i> , 2017, 8, 54558-54571.	0.8	12
2491	Structural recognition of tubulysin B derivatives by multidrug resistance efflux transporters in human cancer cells. <i>Oncotarget</i> , 2017, 8, 49973-49987.	0.8	7
2492	Noncoding RNA in drug resistant sarcoma. <i>Oncotarget</i> , 2017, 8, 69086-69104.	0.8	16
2493	Coupling to a cancer-selective heparan-sulfate-targeted branched peptide can by-pass breast cancer cell resistance to methotrexate. <i>Oncotarget</i> , 2017, 8, 76141-76152.	0.8	23
2494	Quantitative network mapping of the human kinome interactome reveals new clues for rational kinase inhibitor discovery and individualized cancer therapy. <i>Oncotarget</i> , 2014, 5, 3697-3710.	0.8	96
2495	Epidermal growth factor receptor activity is elevated in glioma cancer stem cells and is required to maintain chemotherapy and radiation resistance. <i>Oncotarget</i> , 2017, 8, 72494-72512.	0.8	27
2496	Loss of EGFR signaling-regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance. <i>Oncotarget</i> , 2014, 5, 3770-3784.	0.8	57
2497	H-Ras regulation of TRAIL death receptor mediated apoptosis. <i>Oncotarget</i> , 2014, 5, 5125-5137.	0.8	19
2498	LncRNA H19 is a major mediator of doxorubicin chemoresistance in breast cancer cells through a cullin4A-MDR1 pathway. <i>Oncotarget</i> , 2017, 8, 91990-92003.	0.8	73
2499	Targeting oral cancer stemness and chemoresistance by isoliquiritigenin-mediated GRP78 regulation. <i>Oncotarget</i> , 2017, 8, 93912-93923.	0.8	38
2500	Combinatorial effects of an epigenetic inhibitor and ionizing radiation contribute to targeted elimination of pancreatic cancer stem cell. <i>Oncotarget</i> , 2017, 8, 89005-89020.	0.8	26
2501	Selection and characterization of a human ovarian cancer cell line resistant to auranofin. <i>Oncotarget</i> , 2017, 8, 96062-96078.	0.8	42

#	ARTICLE	IF	CITATIONS
2502	The serum activity of thioredoxin reductases 1 (TrxR1) is correlated with the poor prognosis in EGFR wild-type and ALK negative non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 115270-115279.	0.8	17
2503	Dishevelled1-3 contribute to multidrug resistance in colorectal cancer via activating Wnt/ β 2-catenin signaling. <i>Oncotarget</i> , 2017, 8, 115803-115816.	0.8	24
2504	Dose- and time-dependence of the host-mediated response to paclitaxel therapy: a mathematical modeling approach. <i>Oncotarget</i> , 2018, 9, 2574-2590.	0.8	7
2505	NEK2 mediates ALDH1A1-dependent drug resistance in multiple myeloma. <i>Oncotarget</i> , 2014, 5, 11986-11997.	0.8	54
2506	Antitumor activity of HPA3P through RIPK3-dependent regulated necrotic cell death in colon cancer. <i>Oncotarget</i> , 2018, 9, 7902-7917.	0.8	18
2507	Whole exome sequencing identifies mTOR and KEAP1 as potential targets for radiosensitization of HNSCC cells refractory to EGFR and β 1 integrin inhibition. <i>Oncotarget</i> , 2018, 9, 18099-18114.	0.8	18
2508	GSTM3 and GSTP1: novel players driving tumor progression in cervical cancer. <i>Oncotarget</i> , 2018, 9, 21696-21714.	0.8	34
2509	CDX2 expression is concordant between primary colorectal cancer lesions and corresponding liver metastases independent of chemotherapy: a single-center retrospective study in Japan. <i>Oncotarget</i> , 2018, 9, 17056-17065.	0.8	14
2510	Galectin-3 leads to attenuation of apoptosis through Bax heterodimerization in human thyroid carcinoma cells. <i>Oncotarget</i> , 2014, 5, 9992-10001.	0.8	45
2511	Stromal cells in breast cancer as a potential therapeutic target. <i>Oncotarget</i> , 2018, 9, 23761-23779.	0.8	30
2512	UniPR1331, a small molecule targeting Eph/ephrin interaction, prolongs survival in glioblastoma and potentiates the effect of antiangiogenic therapy in mice. <i>Oncotarget</i> , 2018, 9, 24347-24363.	0.8	28
2513	Overcoming drug-tolerant cancer cell subpopulations showing AXL activation and epithelial-mesenchymal transition is critical in conquering ALK-positive lung cancer. <i>Oncotarget</i> , 2018, 9, 27242-27255.	0.8	31
2514	ATF4 contributes to autophagy and survival in sunitinib treated brain tumor initiating cells (BTICs). <i>Oncotarget</i> , 2019, 10, 368-382.	0.8	16
2515	Mesenchymal stem cells confer chemoresistance in breast cancer via a CD9 dependent mechanism. <i>Oncotarget</i> , 2019, 10, 3435-3450.	0.8	44
2516	The landscape of novel and complementary targets for immunotherapy: an analysis of gene expression in the tumor microenvironment. <i>Oncotarget</i> , 2019, 10, 4532-4545.	0.8	8
2517	Photodynamic therapy of cervical cancer by eradication of cervical cancer cells and cervical cancer stem cells. <i>Oncotarget</i> , 2019, 10, 4380-4396.	0.8	27
2518	Targeting the non-canonical roles of PCNA modifies and increases the response to targeted anti-cancer therapy. <i>Oncotarget</i> , 2019, 10, 7185-7197.	0.8	14
2519	Irinotecan treatment and senescence failure promote the emergence of more transformed and invasive cells that depend on anti-apoptotic Mcl-1. <i>Oncotarget</i> , 2015, 6, 409-426.	0.8	42

#	ARTICLE	IF	CITATIONS
2520	Prostate cancer stem cells: deciphering the origins and pathways involved in prostate tumorigenesis and aggression. <i>Oncotarget</i> , 2015, 6, 1900-1919.	0.8	80
2521	MiR-125b regulates epithelial-mesenchymal transition via targeting Sema4C in paclitaxel-resistant breast cancer cells. <i>Oncotarget</i> , 2015, 6, 3268-3279.	0.8	107
2522	Human bone marrow niche chemoprotection mediated by cytochrome p450 enzymes. <i>Oncotarget</i> , 2015, 6, 14905-14912.	0.8	44
2523	Phospho-T356RB1 predicts survival in HPV-negative squamous cell carcinoma of the head and neck. <i>Oncotarget</i> , 2015, 6, 18863-18874.	0.8	18
2524	Repairing of N-mustard derivative BO-1055 induced DNA damage requires NER, HR, and MGMT-dependent DNA repair mechanisms. <i>Oncotarget</i> , 2015, 6, 25770-25783.	0.8	13
2525	Non-thermal plasma induces AKT degradation through turn-on the MUL1 E3 ligase in head and neck cancer. <i>Oncotarget</i> , 2015, 6, 33382-33396.	0.8	50
2526	MDP, a database linking drug response data to genomic information, identifies dasatinib and statins as a combinatorial strategy to inhibit YAP/TAZ in cancer cells. <i>Oncotarget</i> , 2015, 6, 38854-38865.	0.8	54
2527	Characterization of adipose-derived stem cells from subcutaneous and visceral adipose tissues and their function in breast cancer cells. <i>Oncotarget</i> , 2015, 6, 34475-34493.	0.8	65
2528	Differentiation and transdifferentiation potentials of cancer stem cells. <i>Oncotarget</i> , 2015, 6, 39550-39563.	0.8	70
2529	Identifying anti-cancer drug response related genes using an integrative analysis of transcriptomic and genomic variations with cell line-based drug perturbations. <i>Oncotarget</i> , 2016, 7, 9404-9419.	0.8	12
2530	An individualized prognostic signature for gastric cancer patients treated with 5-Fluorouracil-based chemotherapy and distinct multi-omics characteristics of prognostic groups. <i>Oncotarget</i> , 2016, 7, 8743-8755.	0.8	36
2531	Acquired resistance to combination treatment through loss of synergy with MEK and PI3K inhibitors in colorectal cancer. <i>Oncotarget</i> , 2016, 7, 29187-29198.	0.8	4
2532	Antivascular and antitumor properties of the tubulin-binding chalcone TUB091. <i>Oncotarget</i> , 2017, 8, 14325-14342.	0.8	50
2533	FAM83 proteins: Fostering new interactions to drive oncogenic signaling and therapeutic resistance. <i>Oncotarget</i> , 2016, 7, 52597-52612.	0.8	45
2534	Targeting BET bromodomain proteins in solid tumors. <i>Oncotarget</i> , 2016, 7, 53997-54009.	0.8	86
2535	Enginar YapraÄ± Sulu EkstraktÄ± KullanÄ±larak Åžinko Oksit NanopartikÄ¼llerinin YeÅŸil Sentezi, Karakterizasyonu, Anti-Bakteriyel ve Sitotoksik Etkileri. <i>Duzce Universitesi Tıp FakÄ¼ltesi Dergisi</i> , 2019, 21, 19-26.	0.3	13
2536	Lectin-like transcript 1 as a natural killer cell-mediated immunotherapeutic target for triple negative breast cancer and prostate cancer. <i>Journal of Cancer Metastasis and Treatment</i> , 2019, 2019, .	0.5	2
2537	Influence of lysosomal sequestration on multidrug resistance in cancer cells. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2019, 2, 31-42.	0.9	14

#	ARTICLE	IF	CITATIONS
2538	Emerging targets in cancer drug resistance. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2019, 2, 161-177.	0.9	25
2539	Drug-adapted cancer cell lines as preclinical models of acquired resistance. , 2019, 2, 447-456.		16
2540	Drug resistance and combating drug resistance in cancer. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2019, 2, 141-160.	0.9	388
2541	The role of histone lysine demethylases in cancer cellsâ€™ resistance to tyrosine kinase inhibitors. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2019, 2, 326-334.	0.9	2
2542	Recent advances in the search of BCRP- and dual P-gp/BCRP-based multidrug resistance modulators. , 2019, 2, 710-743.		9
2543	Long non-coding RNAs regulation of therapeutic resistance. , 2019, 2, 550-567.		1
2544	Gut microbiota: a new player in regulating immune- and chemo-therapy efficacy. , 2020, 3, 356-370.		15
2545	The crosstalk between autophagy and ferroptosis: what can we learn to target drug resistance in cancer?. <i>Cancer Biology and Medicine</i> , 2019, 16, 630-646.	1.4	90
2546	Adaptive response of resistant cancer cells to chemotherapy. <i>Cancer Biology and Medicine</i> , 2020, 17, 842-863.	1.4	30
2547	Acquired resistance mechanisms to immunotherapy. <i>Annals of Translational Medicine</i> , 2016, 4, 547-547.	0.7	2
2548	State of the art of overcoming efflux transporter mediated multidrug resistance of breast cancer. <i>Translational Cancer Research</i> , 2019, 8, 319-329.	0.4	10
2549	Metallo drugs in Targeted Cancer Therapeutics: Aiming at Chemoresistance- related Patterns and Immunosuppressive Tumor Networks. <i>Current Medicinal Chemistry</i> , 2019, 26, 607-623.	1.2	16
2550	ABC Transporters: Regulation and Association with Multidrug Resistance in Hepatocellular Carcinoma and Colorectal Carcinoma. <i>Current Medicinal Chemistry</i> , 2019, 26, 1224-1250.	1.2	61
2551	Gene Silencing Strategies in Cancer Therapy: An Update for Drug Resistance. <i>Current Medicinal Chemistry</i> , 2019, 26, 6282-6303.	1.2	14
2552	Unlocking the Potential of HK2 in Cancer Metabolism and Therapeutics. <i>Current Medicinal Chemistry</i> , 2020, 26, 7285-7322.	1.2	122
2553	Progress of Individualized Chemotherapy for Gastric Carcinoma Under the Guidance of Genetic Testing. <i>Current Medicinal Chemistry</i> , 2020, 27, 2322-2334.	1.2	6
2554	Drug Repurposing for the Treatment of Staphylococcal Infections. <i>Current Pharmaceutical Design</i> , 2015, 21, 2089-2100.	0.9	40
2555	Anticancer Triazenes: from Bioprecursors to Hybrid Molecules. <i>Current Pharmaceutical Design</i> , 2019, 25, 1623-1642.	0.9	23

#	ARTICLE	IF	CITATIONS
2556	Expression of P-gp in Glioblastoma: What we can Learn from Brain Development. <i>Current Pharmaceutical Design</i> , 2020, 26, 1428-1437.	0.9	22
2557	Cancer Stem Cell Niche in Colorectal Cancer and Targeted Therapies. <i>Current Pharmaceutical Design</i> , 2020, 26, 1979-1993.	0.9	6
2558	Genetic and Epigenetic Modulation of Drug Resistance in Cancer: Challenges and Opportunities. <i>Current Drug Metabolism</i> , 2020, 20, 1114-1131.	0.7	20
2559	Decoding Novel Mechanisms and Emerging Therapeutic Strategies in Breast Cancer Resistance. <i>Current Drug Metabolism</i> , 2020, 21, 199-210.	0.7	10
2560	Anti-Cancer Phytometabolites Targeting Cancer Stem Cells. <i>Current Genomics</i> , 2017, 18, 156-174.	0.7	25
2561	Derivatives and Analogues of Resveratrol: Recent Advances in Structural Modification. <i>Mini-Reviews in Medicinal Chemistry</i> , 2019, 19, 809-825.	1.1	20
2562	The QSAR Paradigm in Fragment-Based Drug Discovery: From the Virtual Generation of Target Inhibitors to Multi-Scale Modeling. <i>Mini-Reviews in Medicinal Chemistry</i> , 2020, 20, 1357-1374.	1.1	10
2563	How Cancer Cells Resist Chemotherapy: Design and Development of Drugs Targeting Protein-Protein Interactions. <i>Current Topics in Medicinal Chemistry</i> , 2019, 19, 394-412.	1.0	14
2564	5-Nitro-Thiophene-Thiosemicarbazone Derivatives Present Antitumor Activity Mediated by Apoptosis and DNA Intercalation. <i>Current Topics in Medicinal Chemistry</i> , 2019, 19, 1075-1091.	1.0	26
2565	The Use of Conformational Restriction in Medicinal Chemistry. <i>Current Topics in Medicinal Chemistry</i> , 2019, 19, 1712-1733.	1.0	26
2566	Novel Tri-substituted Thiazoles Bearing Piperazine Ring: Synthesis and Evaluation of their Anticancer Activity. <i>Letters in Drug Design and Discovery</i> , 2019, 16, 547-555.	0.4	11
2567	Combinatorial Use of DNA Ligase Inhibitor L189 and Temozolomide Potentiates Cell Growth Arrest in HeLa. <i>Current Cancer Therapy Reviews</i> , 2019, 15, 65-73.	0.2	1
2568	Synthesis of New Hydrazone Derivatives and Evaluation of their Efficacy as Proliferation Inhibitors in Human Cancer Cells. <i>Medicinal Chemistry</i> , 2019, 15, 903-910.	0.7	5
2569	Targeting Peptidyl-prolyl Cis-trans Isomerase NIMA-interacting 1: A Structure-based Virtual Screening Approach to Find Novel Inhibitors. <i>Current Computer-Aided Drug Design</i> , 2020, 16, 605-617.	0.8	10
2570	Novel Therapeutics Against Breast Cancer Stem Cells by Targeting Surface Markers and Signaling Pathways. <i>Current Stem Cell Research and Therapy</i> , 2019, 14, 669-682.	0.6	15
2571	Prognosis, Significance and Positive Correlation of Rab1A and p-S6K/Gli1 Expression in Gastric Cancer. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2019, 19, 1359-1367.	0.9	8
2572	Natural Compounds Targeting Cancer Stem Cells: A Promising Resource for Chemotherapy. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2019, 19, 1796-1808.	0.9	20
2573	Synthesis and Biological Evaluation of Structurally Diverse Benzimidazole Scaffolds as Potential Chemotherapeutic Agents. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2020, 20, 301-314.	0.9	3

#	ARTICLE	IF	CITATIONS
2574	A Functionally Robust Phenotypic Screen that Identifies Drug Resistance-associated Genes Using 3D Cell Culture. <i>Bio-protocol</i> , 2018, 8, .	0.2	5
2575	Vitamin D and Myofibroblasts in Fibrosis and Cancer: At Cross-purposes with TGF- β ² /SMAD Signaling. <i>Anticancer Research</i> , 2016, 36, 6225-6234.	0.5	29
2576	GRP78 Regulates Apoptosis, Cell Survival and Proliferation in 5-Fluorouracil-resistant SNUC5 Colon Cancer Cells. <i>Anticancer Research</i> , 2017, 37, 4943-4951.	0.5	14
2577	Dual Role of Mitophagy in Cancer Drug Resistance. <i>Anticancer Research</i> , 2018, 38, 617-621.	0.5	66
2578	Melatonin Promotes Apoptosis of Oxaliplatin-resistant Colorectal Cancer Cells Through Inhibition of Cellular Prion Protein. <i>Anticancer Research</i> , 2018, 38, 1993-2000.	0.5	24
2579	A Model of the Development of Cisplatin Resistance in Human Small Cell Lung Cancer Xenografts. <i>In Vivo</i> , 2016, 30, 745-750.	0.6	7
2580	Design, Synthesis and Biological Evaluation of Ciprofloxacin- Peptide Conjugates as Anticancer Agents. <i>Iranian Journal of Pharmaceutical Research</i> , 2019, 18, 1823-1830.	0.3	6
2581	Alterations of The Stem-Like Properties in The Breast Cancer Cell Line MDA-MB-231 Induced by Single Pulsed Doxorubicin Treatment. <i>Proceedings of the Latvian Academy of Sciences</i> , 2019, 73, 89-99.	0.0	4
2582	Retinoids offer new and promising cancer therapeutic avenues. <i>Journal of Molecular and Clinical Medicine</i> , 2019, 2, 23.	0.2	3
2583	Patterns of Dual-Specific Phosphatase 4 mRNA Expression Before and after Neoadjuvant Chemotherapy in Breast Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2019, 20, 1051-1055.	0.5	5
2584	Crocic Increases Gastric Cancer Cells's Sensitivity to Doxorubicin. <i>Asian Pacific Journal of Cancer Prevention</i> , 2020, 21, 1959-1967.	0.5	13
2585	In Situ-Induced Multivalent Anticancer Drug Clusters in Cancer Cells for Enhancing Drug Efficacy. <i>CCS Chemistry</i> , 0, , 97-105.	4.6	48
2586	Intratumoral Morphological Heterogeneity of Breast Cancer As an Indicator of the Metastatic Potential and Tumor Chemosensitivity. <i>Acta Naturae</i> , 2017, 9, 56-67.	1.7	21
2587	PVT1 Long Non-coding RNA in Gastrointestinal Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 38.	1.3	43
2588	HDAC6"An Emerging Target Against Chronic Myeloid Leukemia?. <i>Cancers</i> , 2020, 12, 318.	1.7	11
2589	The Effects of TiO ₂ Nanoparticles on Cisplatin Cytotoxicity in Cancer Cell Lines. <i>International Journal of Molecular Sciences</i> , 2020, 21, 605.	1.8	13
2590	Adaptation to Endoplasmic Reticulum Stress Enhances Resistance of Oral Cancer Cells to Cisplatin by Up-Regulating Polymerase β and Increasing DNA Repair Efficiency. <i>International Journal of Molecular Sciences</i> , 2021, 22, 355.	1.8	11
2591	Curcumin-Loaded Solid Lipid Nanoparticles Bypass P-Glycoprotein Mediated Doxorubicin Resistance in Triple Negative Breast Cancer Cells. <i>Pharmaceutics</i> , 2020, 12, 96.	2.0	83

#	ARTICLE	IF	CITATIONS
2592	Unmet Clinical Need: Developing Prognostic Biomarkers and Precision Medicine to Forecast Early Tumor Relapse, Detect Chemo-Resistance and Improve Overall Survival in High-Risk Breast Cancer. <i>Annals of Breast Cancer and Therapy</i> , 2020, 4, 48-57.	0.8	11
2593	Gastrointestinal cancer stem cells as targets for innovative immunotherapy. <i>World Journal of Gastroenterology</i> , 2020, 26, 1580-1593.	1.4	9
2594	Epigenetic activation of FOXF1 confers cancer stem cell properties to cisplatin-resistant non-small cell lung cancer. <i>International Journal of Oncology</i> , 2020, 56, 1083-1092.	1.4	8
2595	Cx32 mediates cisplatin resistance in human ovarian cancer cells by affecting drug efflux transporter expression and activating the EGFR-Akt pathway. <i>Molecular Medicine Reports</i> , 2019, 19, 2287-2296.	1.1	8
2596	Poly (ADP-ribosylation) of HMGB1 facilitates its acetylation and promotes HMGB1 translocation-associated chemotherapy-induced autophagy in leukaemia cells. <i>Oncology Letters</i> , 2020, 19, 368-378.	0.8	11
2597	Role of HSP27 in the multidrug sensitivity and resistance of colon cancer cells. <i>Oncology Letters</i> , 2020, 19, 2021-2027.	0.8	10
2598	Phenotypic screening using large-scale genomic libraries to identify drug targets for the treatment of cancer (Review). <i>Oncology Letters</i> , 2020, 19, 3617-3626.	0.8	7
2599	Enhancement of piperlongumine chemosensitivity by silencing heme oxygenase-1 expression in cholangiocarcinoma cell lines. <i>Oncology Letters</i> , 2020, 20, 2483-2492.	0.8	8
2600	Digitoxin inhibits proliferation of multidrug-resistant HepG2 cells through G2/M cell cycle arrest and apoptosis. <i>Oncology Letters</i> , 2020, 20, 71.	0.8	6
2601	Enhancement of cisplatin sensitivity in human breast cancer MCF-7 cell line through BiP and 14-3-3 σ co-knockdown. <i>Oncology Reports</i> , 2020, 45, 665-679.	1.2	10
2602	Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine?. <i>Annals of Translational Medicine</i> , 2014, 2, 107.	0.7	107
2603	Protein Phosphatase 1H, Cyclin-Dependent Kinase Inhibitor p27, and Cyclin-Dependent Kinase 2 in Paclitaxel Resistance for Triple Negative Breast Cancers. <i>Journal of Breast Cancer</i> , 2020, 23, 162.	0.8	5
2604	Cellular Prion Protein Enhances Drug Resistance of Colorectal Cancer Cells via Regulation of a Survival Signal Pathway. <i>Biomolecules and Therapeutics</i> , 2018, 26, 313-321.	1.1	25
2605	Crude extracts of marine-derived and soil fungi of the genus <i>Neosartorya</i> exhibit selective anticancer activity by inducing cell death in colon, breast and skin cancer cell lines. <i>Pharmacognosy Research (discontinued)</i> , 2016, 8, 8.	0.3	14
2606	The Level of TWIST1 expression determines the response of colon cancer cells to mitogen-activated protein kinases inhibitors. <i>Saudi Journal of Gastroenterology</i> , 2018, 24, 37.	0.5	2
2607	Cancer-Associated Fibroblasts Promote the Chemo-resistance in Gastric Cancer through Secreting IL-11 Targeting JAK/STAT3/Bcl2 Pathway. <i>Cancer Research and Treatment</i> , 2019, 51, 194-210.	1.3	52
2608	Non-coding RNA in drug resistance of gastric cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2019, 11, 957-970.	0.8	15
2609	Defining lung cancer stem cells exosomal payload of miRNAs in clinical perspective. <i>World Journal of Stem Cells</i> , 2020, 12, 406-421.	1.3	16

#	ARTICLE	IF	CITATIONS
2610	Therapies targeting cancer stem cells: Current trends and future challenges. <i>World Journal of Stem Cells</i> , 2015, 7, 1185.	1.3	202
2611	Monobodies as possible next-generation protein therapeutics – a perspective. <i>Swiss Medical Weekly</i> , 2017, 147, w14545.	0.8	11
2612	Naturally occurring reoviruses for human cancer therapy. <i>BMB Reports</i> , 2015, 48, 454-460.	1.1	4
2613	Drug resistance in topoisomerase-targeting therapy. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2018, 72, 1073-1083.	0.1	3
2614	Cancer stem-like cells in Epstein-Barr virus-associated nasopharyngeal carcinoma. <i>Chinese Journal of Cancer</i> , 2014, 33, 529-38.	4.9	25
2615	An Epigenetic Mechanism Underlying Doxorubicin Induced EMT in the Human BGC-823 Gastric Cancer Cell. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 4271-4274.	0.5	21
2616	Induction of P3NS1 Myeloma Cell Death and Cell Cycle Arrest by Simvastatin and/or β -Radiation. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 16, 7103-7110.	0.5	9
2617	NFATc2 enhances tumor-initiating phenotypes through the NFATc2/SOX2/ALDH axis in lung adenocarcinoma. <i>ELife</i> , 2017, 6, .	2.8	47
2618	Blockade of the LRP16-PKR-NF- κ B signaling axis sensitizes colorectal carcinoma cells to DNA-damaging cytotoxic therapy. <i>ELife</i> , 2017, 6, .	2.8	19
2619	CCL5 promotes breast cancer recurrence through macrophage recruitment in residual tumors. <i>ELife</i> , 2019, 8, .	2.8	131
2620	PCK1 and DHODH drive colorectal cancer liver metastatic colonization and hypoxic growth by promoting nucleotide synthesis. <i>ELife</i> , 2019, 8, .	2.8	59
2621	Comparison of different sample preparation methods for platinum determination in cultured cells by graphite furnace atomic absorption spectrometry. <i>PeerJ</i> , 2017, 5, e2873.	0.9	7
2622	Isolation of cancer stem cells by selection for miR-302 expressing cells. <i>PeerJ</i> , 2019, 7, e6635.	0.9	8
2623	Tumor Biology and Natural History. <i>UNIPA Springer Series</i> , 2021, , 15-31.	0.1	0
2624	Targeted Delivery of Dual Anticancer Drugs Based on Self-Assembled iRGD-Modified Soluble Drug-Polymer Pattern Conjugate Nanoparticles. <i>ACS Applied Bio Materials</i> , 2021, 4, 1499-1507.	2.3	5
2625	JAK2 regulates paclitaxel resistance in triple negative breast cancers. <i>Journal of Molecular Medicine</i> , 2021, 99, 1783-1795.	1.7	17
2626	Simvastatin induced ferroptosis for triple-negative breast cancer therapy. <i>Journal of Nanobiotechnology</i> , 2021, 19, 311.	4.2	80
2627	Theoretical modeling of collaterally sensitive drug cycles: shaping heterogeneity to allow adaptive therapy. <i>Journal of Mathematical Biology</i> , 2021, 83, 47.	0.8	9

#	ARTICLE	IF	CITATIONS
2628	Gold(I) Bis(1,2,3-triazol-5-ylidene) Complexes as Promising Selective Anticancer Compounds. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 15747-15757.	2.9	10
2629	RNF8-mediated regulation of Akt promotes lung cancer cell survival and resistance to DNA damage. <i>Cell Reports</i> , 2021, 37, 109854.	2.9	17
2630	The Current Landscape of NKT Cell Immunotherapy and the Hills Ahead. <i>Cancers</i> , 2021, 13, 5174.	1.7	47
2631	Bioactive Synthetic Polymers. <i>Advanced Materials</i> , 2022, 34, e2105063.	11.1	66
2632	Anti-cancer adjuvant drug screening via epithelial-mesenchymal transition-related aptamer probe. <i>Analytical and Bioanalytical Chemistry</i> , 2021, 413, 6951-6962.	1.9	1
2633	Tumor Microenvironment Modulating Functional Nanoparticles for Effective Cancer Treatments. <i>Tissue Engineering and Regenerative Medicine</i> , 2022, 19, 205-219.	1.6	14
2634	Innovative nanochemotherapy for overcoming cancer multidrug resistance. <i>Nanotechnology</i> , 2021, 33, .	1.3	6
2635	Shift in MSL1 alternative polyadenylation in response to DNA damage protects cancer cells from chemotherapeutic agent-induced apoptosis. <i>Cell Reports</i> , 2021, 37, 109815.	2.9	13
2636	Anti-Cancer Drug Screening with Microfluidic Technology. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 9418.	1.3	14
2637	Identification of Novel Anthracycline Resistance Genes and Their Inhibitors. <i>Pharmaceuticals</i> , 2021, 14, 1051.	1.7	2
2638	Construction of a Drug Delivery System via pH-Responsive Polymeric Nanomicelles Containing Ferrocene for DOX Release and Enhancement of Therapeutic Effects. <i>ACS Omega</i> , 2021, 6, 28242-28253.	1.6	11
2639	Contribution of p53 in sensitivity to EGFR tyrosine kinase inhibitors in non-small cell lung cancer. <i>Scientific Reports</i> , 2021, 11, 19667.	1.6	28
2640	Targeted in situ self-assembly augments peptide drug conjugate cell-entry efficiency. <i>Biomaterials</i> , 2021, 278, 121139.	5.7	39
2641	P-glycoprotein suppression by photothermal-responsive nitric oxide releasing nanoplatform for triple-combination therapy of multidrug resistant cancer. <i>Materials and Design</i> , 2021, 211, 110160.	3.3	17
2642	Musarin, a novel protein with tyrosine kinase inhibitory activity from <i>Trametes versicolor</i> , inhibits colorectal cancer stem cell growth. <i>Biomedicine and Pharmacotherapy</i> , 2021, 144, 112339.	2.5	7
2643	Systems Biology Approaches in the Design of Effective miRNA-Targeted Therapeutics. , 2014, , 327-337.		0
2644	Tumor Angiogenesis and Lymphangiogenesis: Microenvironmental Soil for Tumor Progression and Metastatic Dissemination. , 2014, , 283-306.		0
2645	Marine Sponge Sesterpenoids as Potent Apoptosis-Inducing Factors in Human Carcinoma Cell Lines. , 2015, , 439-479.		1

#	ARTICLE	IF	CITATIONS
2646	Isolation and Initial Characterization of Resistant Cells to Photodynamic Therapy. Resistance To Targeted Anti-cancer Therapeutics, 2015, , 117-145.	0.1	1
2647	Epithelial Mesenchymal Transition Influence on CTL Activity. Resistance To Targeted Anti-cancer Therapeutics, 2015, , 267-284.	0.1	0
2648	Cell Signaling and Resistance to Immunotoxins. Resistance To Targeted Anti-cancer Therapeutics, 2015, , 75-87.	0.1	0
2649	Targeting apoptosis is the major battle field for killing cancers. World Journal of Translational Medicine, 2015, 4, 69.	3.5	0
2651	The benefits of treating undetectable tumors. ELife, 2015, 4, e09713.	2.8	0
2653	Actionable intelligence provided by pancreatic cancer genomic landscape: are targets for curative therapy on the map?. Translational Cancer Research, 2016, 5, S243-S247.	0.4	1
2654	Targeting Cancer Stem Cellsâ€”A Renewed Therapeutic Paradigm. Oncology & Hematology Review, 2017, 13, 45.	0.2	1
2655	Gene Signature. , 2017, , 279-292.		1
2656	Cancer Stem Cells and Multi-drug Resistance by Flow Cytometry. Series in Bioengineering, 2017, , 253-266.	0.3	0
2657	Understanding the Biology Behind the EGFR to Improve NSCLC Patientsâ€™ Treatment. Journal of Molecular and Genetic Medicine: an International Journal of Biomedical Research, 2017, 11, .	0.1	0
2660	Cancer Tissue Classification, Associated Therapeutic Implications and PDT as an Alternative. Anticancer Research, 2017, 37, 2785-2807.	0.5	8
2669	Pathology of Tumor Angiogenesis. , 2018, , 1-22.		1
2670	Deep Neural Networks Identify Signaling Mechanisms of ErbB-Family Drug Resistance From a Continuous Cell Morphology State Space. SSRN Electronic Journal, 0, , .	0.4	0
2679	Drug-induced resistance: nipping it in the â€˜buddingâ€™. Oncotarget, 2018, 9, 35873-35874.	0.8	0
2680	Biological Events and Barriers to Effective Delivery of Cancer Therapeutics. Bioanalysis, 2019, , 13-31.	0.1	0
2681	Induction of Apoptotic Death and Cell Cycle Arrest in HeLa Cells by Extracellular Factors of Breast Cancer Cells. Asian Pacific Journal of Cancer Prevention, 2018, 19, 3307-3316.	0.5	8
2682	Cancer Genomics. , 2019, , 1-52.		0
2683	Pathology of Tumor Angiogenesis. , 2019, , 253-274.		0

#	ARTICLE	IF	CITATIONS
2685	Teichoic acid differentially modulates TLR4 expression in sensitive and resistant to cisplatin. Bulletin of Taras Shevchenko National University of Kyiv Series Biology, 2019, 79, 90-94.	0.1	0
2686	Chitosan-Based Systems for Theranostic Applications. , 2019, , 343-384.		1
2687	Cancer Drug Resistance. , 2019, , 77-85.		0
2688	Ferroptosis in Cancer Disease. , 2019, , 285-301.		0
2689	CANCER STEM CELL BIOLOGY. Trakya University Journal of Natural Sciences, 0, 20, 33-44.	0.4	0
2691	Recombinant deoxyribonucleoside kinase from Drosophila melanogaster can improve gemcitabine based combined gene/chemotherapy for targeting cancer cells. Bosnian Journal of Basic Medical Sciences, 2019, 19, 342-349.	0.6	0
2692	Induction of S-phase Cell Cycle Arrest and Apoptosis in HeLa Cells by Small RNAs Fraction of Solanum tuberosum L. MicroRNA (Sharjah, United Arab Emirates), 2019, 8, 180-188.	0.6	1
2697	AVALIAÇÃO DOS FEITOS DA LECTINA DE FOLHAS DE Schinus terebinthifolia Raddi SOBRE A FORMAÇÃO DE NOVOS VASOS SANGUÍNEOS. , 0, , .		0
2701	Natural product like ðœshikoninðœ might be a hope for Breast cancer cure. Malaysian Journal of Halal Research, 2019, 2, 14-18.	0.3	2
2702	Hepatocyte Growth Factor and Macrophage-stimulating Protein ðœHingeðœ Analogs to Treat Pancreatic Cancer. Current Cancer Drug Targets, 2019, 19, 782-795.	0.8	1
2708	Integration of Phytochemicals and Phytotherapy into Cancer Precision Medicine. Human Perspectives in Health Sciences and Technology, 2020, , 355-392.	0.2	1
2709	Nanoparticle-based formulation for drug repurposing in cancer treatment. , 2020, , 335-351.		2
2710	A dendritic, redox-responsive, supramolecular (Dr.S) system for lysis-triggered delivery for drug-resistant renal cancer. RSC Advances, 2020, 10, 37826-37833.	1.7	0
2715	Anticancer Effect of Heracleum persicum Alcoholic Extract and Leishmania Major Promastigote in Comparison with Doxorubicin in MCF7 Breast Cancer Cell Line and Natural HU02 Fibroblast. Majallah-i Dānīshgāh-i Ālī Ām, 2020, 28, 53-62.	0.1	1
2716	Harnessing the predictive power of preclinical models for oncology drug development. Nature Reviews Drug Discovery, 2022, 21, 99-114.	21.5	41
2717	Carboxylated chitosan-mediated improved efficacy of mesoporous silica nanoparticle-based targeted drug delivery system for breast cancer therapy. Carbohydrate Polymers, 2022, 277, 118822.	5.1	59
2718	Degradation of Protein Kinases: Ternary Complex, Cooperativity, and Selectivity. ACS Medicinal Chemistry Letters, 2021, 12, 1629-1632.	1.3	4
2719	Neural is Fundamental: Neural Stemness as the Ground State of Cell Tumorigenicity and Differentiation Potential. Stem Cell Reviews and Reports, 2022, 18, 37-55.	1.7	7

#	ARTICLE	IF	CITATIONS
2720	Studies of Glyoxalase 1-Linked Multidrug Resistance Reveal Glycolysis-Derived Reactive Metabolite, Methylglyoxal, Is a Common Contributor in Cancer Chemotherapy Targeting the Spliceosome. <i>Frontiers in Oncology</i> , 2021, 11, 748698.	1.3	10
2721	ScaffComb: A Phenotype-Based Framework for Drug Combination Virtual Screening in Large-Scale Chemical Datasets. <i>Advanced Science</i> , 2021, 8, e2102092.	5.6	7
2722	Circumventing Drug Resistance Pathways with a Nanoparticle-Based Photodynamic Method. <i>Nano Letters</i> , 2021, 21, 9115-9123.	4.5	6
2723	Cinnamophilin overcomes cancer multi-drug resistance via allosterically modulating human P-glycoprotein on both drug binding sites and ATPase binding sites. <i>Biomedicine and Pharmacotherapy</i> , 2021, 144, 112379.	2.5	7
2724	Development of a Prototype of a Wearable Flexible Electro-Optical Imaging System for the Breast. , 2020, , .		0
2725	(+/-)-Borneol Reverses Mitoxantrone Resistance against P-Glycoprotein. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 252-262.	2.5	7
2726	Photo-Responsive Supramolecular Micelles for Controlled Drug Release and Improved Chemotherapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 154.	1.8	12
2729	Anti-inflammatory and anti-cell proliferative effects of dieckol in the prevention and treatment of colon cancer induced by 1,2-dimethyl hydrazine in experimental animals. <i>Pharmacognosy Magazine</i> , 2020, 16, 856.	0.3	2
2730	Exploring near-infrared absorbing nanocarriers to overcome cancer drug resistance. , 2020, 3, 302-333.		4
2731	High level of RNF187 contributes to the progression and drug resistance of osteosarcoma. <i>Journal of Cancer</i> , 2020, 11, 1351-1358.	1.2	4
2732	Pharmacogenetics of Cancer- Cancer Drug Resistance special issue. , 2020, 3, 225-231.		1
2733	Developing Kinase Inhibitors Using Computer-Aided Drug Design Approaches. , 2020, , 81-108.		0
2734	History of Drug Reaction in Children Suffering from Cancer. , 2020, , 381-389.		0
2735	Drug Delivery Applications of Peptide Materials. <i>RSC Soft Matter</i> , 2020, , 291-334.	0.2	3
2737	MuTaTo&sup>©>A Novel Concept for Curing Cancer. <i>Journal of Cancer Therapy</i> , 2020, 11, 55-73.	0.1	1
2738	Development of Pharmacodynamic Biomarkers for Phase I Trials. , 2020, , 139-158.		0
2739	Technological Advancement in Cancer Stem Cell Research. , 2020, , 241-256.		2
2742	Bishonokiol A Induces Multiple Cell Death in Human Breast Cancer MCF-7 Cells. <i>Asian Pacific Journal of Cancer Prevention</i> , 2020, 21, 1073-1080.	0.5	3

#	ARTICLE	IF	CITATIONS
2743	m6A Modification in Non-Coding RNA: The Role in Cancer Drug Resistance. <i>Frontiers in Oncology</i> , 2021, 11, 746789.	1.3	10
2744	Cisplatin Chemotherapy and Cochlear Damage: Otoprotective and Chemosensitization Properties of Polyphenols. <i>Antioxidants and Redox Signaling</i> , 2022, 36, 1229-1245.	2.5	9
2746	Clinical Development of Metal Complexes as Photosensitizers for Photodynamic Therapy of Cancer. <i>Angewandte Chemie - International Edition</i> , 2022, 61, .	7.2	170
2747	Teapotinib Inhibits Several Drug Efflux Transporters and Biotransformation Enzymes: The Role in Drug-Drug Interactions and Targeting Cytostatic Resistance In Vitro and Ex Vivo. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11936.	1.8	7
2748	Anticancer properties of dried-pericarp water extracts of <i>Camellia japonica</i> L. fermented with <i>Aspergillus oryzae</i> through regulation of IGF1R/mTOR pathway. <i>Scientific Reports</i> , 2021, 11, 21527.	1.6	2
2749	Clinical Development of Metal Complexes as Photosensitizers for Photodynamic Therapy of Cancer. <i>Angewandte Chemie</i> , 0, , .	1.6	15
2750	Targeting Cancer Chemotherapy Resistance by Precision Medicine-Driven Nanoparticle-Formulated Cisplatin. <i>ACS Nano</i> , 2021, 15, 18541-18556.	7.3	17
2751	Long Non-Coding RNAs in Epithelial-Mesenchymal Transition of Pancreatic Cancer. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 717890.	1.6	16
2752	Supramolecular Drug Delivery System from Macrocyclic-Based Self-Assembled Amphiphiles for Effective Tumor Therapy. <i>ACS Applied Materials & Interfaces</i> , 2021, 13, 53564-53573.	4.0	22
2753	Shikonin Inhibits Non-Small-Cell Lung Cancer H1299 Cell Growth through Survivin Signaling Pathway. <i>Analytical Cellular Pathology</i> , 2021, 2021, 1-10.	0.7	6
2754	Celastrol Inhibits the Proliferation and Induces Apoptosis of Colorectal Cancer Cells via Downregulating NF- κ B/COX-2 Signaling Pathways. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 1921-1932.	0.9	4
2755	The apoptotic potential of ergolide to induce apoptosis in molt4 cell lines. <i>Journal of Medicinal Plants</i> , 2020, 19, 155-162.	0.3	0
2758	Knockdown of CRAD suppresses the growth and promotes the apoptosis of human lung cancer cells via Claudin 4. <i>Bioscience Reports</i> , 2020, 40, .	1.1	1
2759	Introducing, OncoTarget. <i>Oncotarget</i> , 2010, 1, 2-2.	0.8	0
2760	Introducing, OncoTarget. <i>Oncotarget</i> , 2010, 1, 2-2.	0.8	0
2761	Introducing, OncoTarget. <i>Oncotarget</i> , 2010, 1, 2-2.	0.8	0
2762	Introducing, OncoTarget. <i>Oncotarget</i> , 2010, 1, 2-2.	0.8	0
2763	Introducing, OncoTarget. <i>Oncotarget</i> , 2010, 1, 2-2.	0.8	0

#	ARTICLE	IF	CITATIONS
2764	Introducing, OncoTarget. Oncotarget, 2010, 1, 2-2.	0.8	0
2765	Introducing, OncoTarget. Oncotarget, 2010, 1, 2-2.	0.8	0
2766	Introducing, OncoTarget. Oncotarget, 2010, 1, 2-2.	0.8	0
2767	Combining kinase inhibitors for optimally co-targeting cancer and drug escape by exploitation of drug target promiscuities. Drug Development Research, 2021, 82, 133-142.	1.4	0
2768	Anticancer drug FL118 is more than a survivin inhibitor: where is the Achilles' heel of cancer?. American Journal of Cancer Research, 2014, 4, 304-11.	1.4	10
2770	Membranous expressions of Lewis y and CAM-DR-related markers are independent factors of chemotherapy resistance and poor prognosis in epithelial ovarian cancer. American Journal of Cancer Research, 2015, 5, 830-43.	1.4	22
2771	FL118, a novel camptothecin analogue, overcomes irinotecan and topotecan resistance in human tumor xenograft models. American Journal of Translational Research (discontinued), 2015, 7, 1765-81.	0.0	22
2772	Expression of KAP1 in epithelial ovarian cancer and its correlation with drug-resistance. International Journal of Clinical and Experimental Medicine, 2015, 8, 17308-20.	1.3	14
2773	Heterochromatin Protein 1 Binding Protein 3 Expression as a Candidate Marker of Intrinsic 5-Fluorouracil Resistance. Anticancer Research, 2016, 36, 845-52.	0.5	2
2775	HNSCC cells resistant to EGFR pathway inhibitors are hypermutated and sensitive to DNA damaging substances. American Journal of Cancer Research, 2016, 6, 1963-1975.	1.4	6
2777	Intratumoral Morphological Heterogeneity of Breast Cancer As an Indicator of the Metastatic Potential and Tumor Chemosensitivity. Acta Naturae, 2017, 9, 56-67.	1.7	12
2778	RAS pathway biomarkers for breast cancer prognosis. Clinical Laboratory International, 2016, 40, 18-23.	1.0	6
2779	Resistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators. American Journal of Cancer Research, 2017, 7, 1350-1371.	1.4	49
2780	Polyisoprenylated cysteinyl amide inhibitors induce caspase 3/7- and 8-mediated apoptosis and inhibit migration and invasion of metastatic prostate cancer cells. American Journal of Cancer Research, 2017, 7, 1515-1527.	1.4	5
2781	MIRNA-107 enhances chemosensitivity to paclitaxel by targeting antiapoptotic factor Bcl-w in non small cell lung cancer. American Journal of Cancer Research, 2017, 7, 1863-1873.	1.4	34
2782	Blocking LLT1 (CLEC2D, OCIL)-NKR1A (CD161) interaction enhances natural killer cell-mediated lysis of triple-negative breast cancer cells. American Journal of Cancer Research, 2018, 8, 1050-1063.	1.4	18
2783	Cabazitaxel, a novel chemotherapeutic alternative for drug-resistant hepatocellular carcinoma. American Journal of Cancer Research, 2018, 8, 1297-1306.	1.4	12
2784	CDRgator: An Integrative Navigator of Cancer Drug Resistance Gene Signatures. Molecules and Cells, 2019, 42, 237-244.	1.0	2

#	ARTICLE	IF	CITATIONS
2785	Genome-scale CRISPR activation screening identifies a role of ELAVL2-CDKN1A axis in paclitaxel resistance in esophageal squamous cell carcinoma. American Journal of Cancer Research, 2019, 9, 1183-1200.	1.4	6
2786	Babaodan inhibits cell growth by inducing autophagy through the PI3K/AKT/mTOR pathway and enhances antitumor effects of cisplatin in NSCLC cells. American Journal of Translational Research (discontinued), 2019, 11, 5272-5283.	0.0	3
2787	Ligustrazine reverts anthracycline chemotherapy resistance of human breast cancer by inhibiting JAK2/STAT3 signaling and decreasing fibrinogen gamma chain (FGG) expression. American Journal of Cancer Research, 2020, 10, 939-952.	1.4	5
2788	Interferon regulatory factor-1 suppresses DNA damage response and reverses chemotherapy resistance by downregulating the expression of RAD51 in gastric cancer. American Journal of Cancer Research, 2020, 10, 1255-1270.	1.4	7
2789	Downregulation of LINC01021 by curcumin analog Da0324 inhibits gastric cancer progression through activation of P53. American Journal of Translational Research (discontinued), 2020, 12, 3429-3444.	0.0	2
2790	LncRNAs link cancer stemness to therapy resistance. American Journal of Cancer Research, 2021, 11, 1051-1068.	1.4	3
2791	How Oncogenic Viruses Exploit p62-Mediated Selective Autophagy for Cancer Development. Annals of Immunology & Immunotherapy, 2021, 3, .	0.1	0
2792	StackACPred: Prediction of anticancer peptides by integrating optimized multiple feature descriptors with stacked ensemble approach. Chemometrics and Intelligent Laboratory Systems, 2022, 220, 104458.	1.8	26
2793	Zytostatische Therapie. , 2022, , 35-41.		0
2794	DNA binding graphene quantum dots inhibit dual topoisomerases for cancer chemotherapy. Carbon, 2022, 187, 365-374.	5.4	6
2795	Ferroptosis: The Silver Lining of Cancer Therapy. Frontiers in Cell and Developmental Biology, 2021, 9, 765859.	1.8	28
2796	Targeting Apoptosis to Overcome Chemotherapy Resistance. , 0, , 163-180.		5
2797	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment. International Journal of Molecular Sciences, 2021, 22, 12330.	1.8	16
2798	An NIR Discrete Metallacycle Constructed from Perylene Bisimide and Tetraphenylethylene Fluorophores for Imaging-Guided Cancer Radio-Chemotherapy. Advanced Materials, 2022, 34, e2106388.	11.1	79
2799	Mutational status of plasma exosomal KRAS predicts outcome in patients with metastatic colorectal cancer. Scientific Reports, 2021, 11, 22686.	1.6	19
2800	Mitochondrial Targeting and pH-Responsive Nanogels for Co-Delivery of Lonidamine and Paclitaxel to Conquer Drug Resistance. Frontiers in Bioengineering and Biotechnology, 2021, 9, 787320.	2.0	11
2801	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 4: Experimental Treatments in Pre-Clinical Studies (Cell Lines and Mouse Models). International Journal of Molecular Sciences, 2021, 22, 12297.	1.8	10
2802	Microbial Lipopeptide Supramolecular Self-Assemblies as a Methuosis-Like Cell Death Inducer with In Vivo Antitumor Activity. Small, 2022, 18, e2104034.	5.2	6

#	ARTICLE	IF	CITATIONS
2803	PremPLI: a machine learning model for predicting the effects of missense mutations on protein-ligand interactions. <i>Communications Biology</i> , 2021, 4, 1311.	2.0	21
2804	KRAS mutation: from undruggable to druggable in cancer. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 386.	7.1	255
2805	CAF promotes chemoresistance through NRP2 in gastric cancer. <i>Gastric Cancer</i> , 2022, 25, 503-514.	2.7	21
2806	Emerging Topics in Cancer Evolution. , 2021, , .		2
2807	Predictive and Prognostic Value of an MicroRNA Signature for Gastric Carcinoma Undergoing Adjuvant Chemotherapy. <i>DNA and Cell Biology</i> , 2021, 40, 1428-1444.	0.9	1
2808	Tumour Microenvironment Stress Promotes the Development of Drug Resistance. <i>Antioxidants</i> , 2021, 10, 1801.	2.2	29
2809	Cholesterol Regulates the Tumor Adaptive Resistance to MAPK Pathway Inhibition. <i>Journal of Proteome Research</i> , 2021, 20, 5379-5391.	1.8	4
2812	Acquired Resistance to Antiangiogenic Therapies in Hepatocellular Carcinoma Is Mediated by Yes-Associated Protein 1 Activation and Transient Expansion of Stem-Like Cancer Cells. <i>Hepatology Communications</i> , 2022, 6, 1140-1156.	2.0	6
2813	Artemisia santolinifolia-Mediated Chemosensitization via Activation of Distinct Cell Death Modes and Suppression of STAT3/Survivin-Signaling Pathways in NSCLC. <i>Molecules</i> , 2021, 26, 7200.	1.7	2
2814	Recent advances in enhancing reactive oxygen species based chemodynamic therapy. <i>Chinese Chemical Letters</i> , 2022, 33, 2213-2230.	4.8	35
2815	Quaternary Ammonium Salts Anchored on Cross-Linked (R)-(+)-Lipoic Acid Nanoparticles for Drug-Resistant Tumor Therapy. <i>ACS Applied Materials & Interfaces</i> , 2021, 13, 56850-56857.	4.0	7
2816	KRAS-G12C covalent inhibitors: A game changer in the scene of cancer therapies. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 168, 103524.	2.0	7
2817	MicroRNA-1246 Mediates Drug Resistance and Metastasis in Breast Cancer by Targeting NFE2L3. <i>Frontiers in Oncology</i> , 2021, 11, 677168.	1.3	14
2818	Low temperature photothermal therapy: Advances and perspectives. <i>Coordination Chemistry Reviews</i> , 2022, 454, 214330.	9.5	98
2819	Evaluation of the anticarcinogenic potential of the endophyte, <i>Streptomyces</i> sp. LRE541 isolated from <i>Lilium davidii</i> var. <i>unicolor</i> (Hoog) Cotton. <i>Microbial Cell Factories</i> , 2021, 20, 217.	1.9	4
2820	HA/PEI-coated acridine orange-loaded gold-core silica shell nanorods for cancer-targeted photothermal and chemotherapy. <i>Nanomedicine</i> , 2021, 16, 2569-2586.	1.7	11
2821	Modulating undruggable targets to overcome cancer therapy resistance. <i>Drug Resistance Updates</i> , 2022, 60, 100788.	6.5	15
2822	MicroRNA and Alternative mRNA Splicing Events in Cancer Drug Response/Resistance: Potent Therapeutic Targets. <i>Biomedicines</i> , 2021, 9, 1818.	1.4	20

#	ARTICLE	IF	CITATIONS
2824	Novel Fluorinated Spermine and Small Molecule PEI to Deliver Anti-PD-L1 and Anti-VEGF siRNA for Highly Efficient Tumor Therapy. <i>Pharmaceutics</i> , 2021, 13, 2058.	2.0	4
2825	Going with the Flow: Modeling the Tumor Microenvironment Using Microfluidic Technology. <i>Cancers</i> , 2021, 13, 6052.	1.7	15
2826	Ex vivo isolation, expansion and bioengineering of CCR7+CD95-/or CD62L+CD45RA+ tumor infiltrating lymphocytes from acute myeloid leukemia patients' bone marrow. <i>Neoplasia</i> , 2021, 23, 1252-1260.	2.3	4
2827	An enhanced cascade-based deep forest model for drug combination prediction. <i>Briefings in Bioinformatics</i> , 2022, 23, .	3.2	19
2828	Trustworthy Deep Neural Network for Inferring Anticancer Synergistic Combinations. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2023, 27, 1691-1700.	3.9	1
2829	Identification of novel non-toxic and anti-angiogenic $\hat{\pm}$ -fluorinated chalcones as potent colchicine binding site inhibitors. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2022, 37, 339-354.	2.5	7
2830	Influence of Liver Extracellular Matrix in Predicting Drug-Induced Liver Injury: An Alternate Paradigm. <i>ACS Biomaterials Science and Engineering</i> , 2022, 8, 834-846.	2.6	8
2831	Evaluation of novel cathepsin-X inhibitors in vitro and in vivo and their ability to improve cathepsin-B-directed antitumor therapy. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 34.	2.4	6
2832	Targeting regulated cell death in tumor nanomedicines. <i>Theranostics</i> , 2022, 12, 817-841.	4.6	46
2833	The Pyroptosis-Related Gene Signature Predicts the Prognosis of Hepatocellular Carcinoma. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 781427.	1.6	9
2834	Charge reversal nano-systems for tumor therapy. <i>Journal of Nanobiotechnology</i> , 2022, 20, 31.	4.2	49
2835	Emerging targetome and signalome landscape of gut microbial metabolites. <i>Cell Metabolism</i> , 2022, 34, 35-58.	7.2	30
2836	[18F]Fluoro-DCP, a first generation PET radiotracer for monitoring protein sulfenylation in vivo. <i>Redox Biology</i> , 2022, 49, 102218.	3.9	2
2837	H ₂ O ₂ -Responsive amphiphilic polymer with aggregation-induced emission (AIE) for DOX delivery and tumor therapy. <i>Bioorganic Chemistry</i> , 2022, 119, 105559.	2.0	8
2838	Leveraging disulfiram to treat cancer: Mechanisms of action, delivery strategies, and treatment regimens. <i>Biomaterials</i> , 2022, 281, 121335.	5.7	57
2839	Intracellular delivery of p53 gene and drug using cationised pullulan thiomers lowers the effective therapeutic doses of chemotherapeutic drug in cancer cells. <i>Materials Today Communications</i> , 2022, 30, 103129.	0.9	2
2840	EGFR-targeted photosensitizer for enhanced photodynamic therapy and imaging therapeutic effect by monitoring GSH decline. <i>Sensors and Actuators B: Chemical</i> , 2022, 355, 131275.	4.0	6
2841	Polymer-metal-organic framework hybrids for bioimaging and cancer therapy. <i>Coordination Chemistry Reviews</i> , 2022, 456, 214393.	9.5	25

#	ARTICLE	IF	CITATIONS
2842	Emerging Mechanisms and Disease Implications of Ferroptosis: Potential Applications of Natural Products. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 774957.	1.8	28
2843	Long intergenic non-protein coding RNA 1273 confers sorafenib resistance in hepatocellular carcinoma via regulation of methyltransferase 3. <i>Bioengineered</i> , 2022, 13, 3108-3121.	1.4	20
2844	Current challenges in metastasis research and future innovation for clinical translation. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 263-277.	1.7	11
2845	Advanced applications of cerium oxide based nanozymes in cancer. <i>RSC Advances</i> , 2022, 12, 1486-1493.	1.7	37
2846	Roadmap on plasticity and epigenetics in cancer. <i>Physical Biology</i> , 2022, 19, 031501.	0.8	8
2847	Metabolic Features of Tumor Dormancy: Possible Therapeutic Strategies. <i>Cancers</i> , 2022, 14, 547.	1.7	18
2848	Systemic Mobilization of Breast Cancer Resistance Protein in Response to Oncogenic Stress. <i>Cancers</i> , 2022, 14, 313.	1.7	3
2849	Recent Developments of Flavonoids with Various Activities. <i>Current Topics in Medicinal Chemistry</i> , 2022, 22, 305-329.	1.0	13
2850	Bibliometric Evaluation of 2012â€“2020 Publications on Ferroptosis in Cancer Treatment. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 793347.	1.8	13
2852	Role of Nanoparticles in Cancer Therapy. <i>Advances in Chemical and Materials Engineering Book Series</i> , 2022, , 363-388.	0.2	0
2853	Recent advances in nanomedicines for photodynamic therapy (PDT)-driven cancer immunotherapy. <i>Theranostics</i> , 2022, 12, 434-458.	4.6	154
2854	High Expression of G6PD Increases Doxorubicin Resistance in Triple Negative Breast Cancer Cells by Maintaining GSH Level. <i>International Journal of Biological Sciences</i> , 2022, 18, 1120-1133.	2.6	20
2855	Epigenetic Priming with Decitabine Augments the Therapeutic Effect of Cisplatin on Triple-Negative Breast Cancer Cells through Induction of Proapoptotic Factor NOXA. <i>Cancers</i> , 2022, 14, 248.	1.7	3
2856	Development and application of novel <sc>BiFC</sc> probes for cell sorting based on epigenetic modification. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2022, 101, 339-350.	1.1	1
2857	The role of polyphenols in overcoming cancer drug resistance: a comprehensive review. <i>Cellular and Molecular Biology Letters</i> , 2022, 27, 1.	2.7	104
2858	Network biology and artificial intelligence drive the understanding of the multidrug resistance phenotype in cancer. <i>Drug Resistance Updates</i> , 2022, 60, 100811.	6.5	13
2859	Automated detection of apoptotic versus nonapoptotic cell death using labelâ€free computational microscopy. <i>Journal of Biophotonics</i> , 2022, 15, .	1.1	12
2860	The Impact of the Microbiome on Resistance to Cancer Treatment with Chemotherapeutic Agents and Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 488.	1.8	31

#	ARTICLE	IF	CITATIONS
2861	Autophagy Modulation and Cancer Combination Therapy: A Smart Approach in Cancer Therapy. <i>Cancer Treatment and Research Communications</i> , 2022, 30, 100512.	0.7	15
2862	Bioinspired nonheme iron complex that triggers mitochondrial apoptotic signalling pathway specifically for colorectal cancer cells. <i>Chemical Science</i> , 2022, 13, 737-747.	3.7	5
2863	Galectin-1 confers resistance to doxorubicin in hepatocellular carcinoma cells through modulation of P-glycoprotein expression. <i>Cell Death and Disease</i> , 2022, 13, 79.	2.7	14
2864	Caveolae-Associated Molecules, Tumor Stroma, and Cancer Drug Resistance: Current Findings and Future Perspectives. <i>Cancers</i> , 2022, 14, 589.	1.7	8
2865	Acquired Resistance to EZH2 Inhibitor GSK343 Promotes the Differentiation of Human DLBCL Cell Lines toward an ABC-Like Phenotype. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 511-521.	1.9	3
2866	Enhanced Intracellular Reactive Oxygen Species by Photodynamic Therapy Effectively Promotes Chemoresistant Cell Death. <i>International Journal of Biological Sciences</i> , 2022, 18, 374-385.	2.6	10
2867	Î±-Catulin promotes cancer stemness by antagonizing WWP1-mediated KLF5 degradation in lung cancer. <i>Theranostics</i> , 2022, 12, 1173-1186.	4.6	9
2868	Subsets of cancer cells expressing CX3CR1 are endowed with metastasis-initiating properties and resistance to chemotherapy. <i>Oncogene</i> , 2022, , .	2.6	6
2869	Amplification of ferroptosis with a liposomal nanoreactor cooperates with low-toxicity doxorubicin apoptosis for enhanced tumor chemotherapy. <i>Biomaterials Science</i> , 2022, 10, 1544-1553.	2.6	8
2870	Amino Acid Metabolism in Cancer Drug Resistance. <i>Cells</i> , 2022, 11, 140.	1.8	40
2871	Spheroid Culture Differentially Affects Cancer Cell Sensitivity to Drugs in Melanoma and RCC Models. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1166.	1.8	19
2872	Extracellular vesicle-mediated co-delivery of TRAIL and dinaciclib for targeted therapy of resistant tumors. <i>Biomaterials Science</i> , 2022, 10, 1498-1514.	2.6	7
2873	Targeting the gp130/STAT3 Axis Attenuates Tumor Microenvironment Mediated Chemoresistance in Group 3 Medulloblastoma Cells. <i>Cells</i> , 2022, 11, 381.	1.8	7
2874	Targeting mitochondria as a therapeutic anti-gastric cancer approach. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2022, 27, 163-183.	2.2	8
2875	Anticancer properties of arylchromenes and arylchromans: an overview. <i>ChemistrySelect</i> , 2022, .	0.7	0
2876	Closed loop fractional order drug delivery control scheme for chemotherapy. <i>Results in Control and Optimization</i> , 2022, 6, 100097.	1.3	2
2877	Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours. <i>Cancer Treatment Reviews</i> , 2022, 104, 102340.	3.4	21
2878	Intracellular Co-delivery of native antibody and siRNA for combination therapy by using biodegradable silica nanocapsules. <i>Biomaterials</i> , 2022, 281, 121376.	5.7	16

#	ARTICLE	IF	CITATIONS
2879	Enhancing the anticancer effect of paclitaxel by using polymeric nanoparticles decorated with colorectal cancer targeting CPKSNGVC-peptide. <i>Journal of Drug Delivery Science and Technology</i> , 2022, 68, 103125.	1.4	6
2880	N6-methyladenosine modification regulates imatinib resistance of gastrointestinal stromal tumor by enhancing the expression of multidrug transporter MRP1. <i>Cancer Letters</i> , 2022, 530, 85-99.	3.2	20
2881	Electrophilic warheads in covalent drug discovery: an overview. <i>Expert Opinion on Drug Discovery</i> , 2022, 17, 413-422.	2.5	29
2882	Impact of Non-Coding RNAs on Chemotherapeutic Resistance in Oral Cancer. <i>Biomolecules</i> , 2022, 12, 284.	1.8	8
2883	Design Principles Governing the Development of Theranostic Anticancer Agents and Their Nanoformulations with Photoacoustic Properties. <i>Pharmaceutics</i> , 2022, 14, 362.	2.0	5
2884	The MicroRNA-Based Strategies to Combat Cancer Chemoresistance via Regulating Autophagy. <i>Frontiers in Oncology</i> , 2022, 12, 841625.	1.3	10
2885	One shoot, three birds: Targeting NEK2 orchestrates chemoradiotherapy, targeted therapy, and immunotherapy in cancer treatment. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2022, , 188696.	3.3	8
2886	CXCR4-targeted nanotoxins induce GSDME-dependent pyroptosis in head and neck squamous cell carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 49.	3.5	24
2887	Reactive Oxygen Species-Responsive Peptide-Drug Conjugate for Mitochondria-Specific Chemotherapy. <i>ChemNanoMat</i> , 0, , .	1.5	0
2888	Core-shell structured nanoparticles for photodynamic therapy-based cancer treatment and related imaging. <i>Coordination Chemistry Reviews</i> , 2022, 458, 214427.	9.5	30
2889	Targeting multidrug resistance-associated protein 1 (MRP1)-expressing cancers: Beyond pharmacological inhibition. <i>Drug Resistance Updates</i> , 2021, 59, 100795.	6.5	38
2890	Toward Best Practices for Controlling Mammalian Cell Culture Environments. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 788808.	1.8	8
2891	Boron-containing nucleosides as tools for boron-neutron capture therapy. <i>American Journal of Cancer Research</i> , 2021, 11, 4668-4682.	1.4	0
2892	Real-Time Monitoring the Efficacy of 7-Hydroxycoumarin to Cells Cultured on Microfluidics in Different Extracellular Ph Environments by Chip-Mass Spectrometry. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2894	Concluding remarks and future perspective of combination drug delivery systems. , 2022, , 353-396.		0
2895	Tumor Site-Specific Peg Detachment and Active Tumor Homing of Therapeutic Pegylated Chitosan/Folate-Decorated Polydopamine Nanoparticles to Augment Antitumor Efficacy of Photothermal/Chemo Combination Therapy. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2897	Lemon-Derived Extracellular Vesicles Nanodrugs Enable to Efficiently Overcome Cancer Multidrug Resistance by Endocytosis-Triggered Energy Dissipation and Energy Production Reduction. <i>Advanced Science</i> , 2022, 9, e2105274.	5.6	40
2898	CDC27-ODC1 Axis Promotes Metastasis, Accelerates Ferroptosis and Predicts Poor Prognosis in Neuroblastoma. <i>Frontiers in Oncology</i> , 2022, 12, 774458.	1.3	4

#	ARTICLE	IF	CITATIONS
2899	Reduced ERâ€“mitochondria connectivity promotes neuroblastoma multidrug resistance. <i>EMBO Journal</i> , 2022, 41, e108272.	3.5	16
2900	Preventing Metastasis Using Gold Nanorod-Assisted Plasmonic Photothermal Therapy in Xenograft Mice. <i>Bioconjugate Chemistry</i> , 2022, 33, 2320-2331.	1.8	6
2901	Upregulation of USP22 and ABCC1 during Sorafenib Treatment of Hepatocellular Carcinoma Contribute to Development of Resistance. <i>Cells</i> , 2022, 11, 634.	1.8	8
2902	Synthesis, Structure, and Antiproliferative Action of 2-Pyridyl Urea-Based Cu(II) Complexes. <i>Biomedicines</i> , 2022, 10, 461.	1.4	10
2903	Copper-Based Metalâ€“Organic Framework Overcomes Cancer Chemoresistance through Systemically Disrupting Dynamically Balanced Cellular Redox Homeostasis. <i>Journal of the American Chemical Society</i> , 2022, 144, 4799-4809.	6.6	77
2904	Homologous targeting nanoparticles for enhanced PDT against osteosarcoma HOS cells and the related molecular mechanisms. <i>Journal of Nanobiotechnology</i> , 2022, 20, 83.	4.2	36
2905	An engineered abcb4 expression model reveals the central role of <i>NFâ€“B</i> in the regulation of drug resistance in zebrafish. <i>Drug Development Research</i> , 2022, , .	1.4	1
2906	Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes. <i>Gut</i> , 2022, 71, 1412-1425.	6.1	79
2907	Research Progress on Natural Diterpenoids in Reversing Multidrug Resistance. <i>Frontiers in Pharmacology</i> , 2022, 13, 815603.	1.6	1
2908	Exploring binding stability of hydroxy-3-(4-hydroxyphenyl)-5-(4-nitrophenyl)-5,5a,7,8,9,9a-hexahydrothiazolo[2,3-b]quinazolin-6-one with T790M/L858R EGFR-TKD. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 3702-3716.	2.0	7
2909	Mechanistic Insights Into Co-Administration of Allosteric and Orthosteric Drugs to Overcome Drug-Resistance in T315I BCR-ABL1. <i>Frontiers in Pharmacology</i> , 2022, 13, 862504.	1.6	11
2910	Multifunctional Lipid Bilayer Nanocarriers for Cancer Immunotherapy in Heterogeneous Tumor Microenvironments, Combining Immunogenic Cell Death Stimuli with Immune Modulatory Drugs. <i>ACS Nano</i> , 2022, 16, 5184-5232.	7.3	32
2911	Carvacrol Enhance Apoptotic Effect of 5-FU on MCF-7 Cell Line via inhibiting P-glycoprotein: An In-silco and In-vitro Study. <i>Drug Research</i> , 2022, 72, 203-208.	0.7	4
2912	Circ_0011292 knockdown mitigates progression and drug resistance in <i>PTX</i> -resistant nonâ€“smallâ€“cell lung cancer cells by regulating <i>miR-433</i> / <i>CHEK1</i> axis. <i>Thoracic Cancer</i> , 2022, 13, 1276-1288.	0.8	5
2913	The Impact of Epithelialâ€“Mesenchymal Transition and Metformin on Pancreatic Cancer Chemoresistance: A Pathway towards Individualized Therapy. <i>Medicina (Lithuania)</i> , 2022, 58, 467.	0.8	5
2914	Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer. <i>Nature Reviews Cancer</i> , 2022, 22, 323-339.	12.8	107
2915	CCNA2 as an Immunological Biomarker Encompassing Tumor Microenvironment and Therapeutic Response in Multiple Cancer Types. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-35.	1.9	15
2916	A CGA/EGFR/GATA2 positive feedback circuit confers chemoresistance in gastric cancer. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	12

#	ARTICLE	IF	CITATIONS
2917	Bioresponsive Nanomaterials: Recent Advances in Cancer Multimodal Imaging and Imaging-Guided Therapy. <i>Frontiers in Chemistry</i> , 2022, 10, 881812.	1.8	5
2918	Blockade of integrin signaling reduces chemotherapy-induced premature senescence in collagen cultured bladder cancer cells. <i>Precision Clinical Medicine</i> , 2022, 5, .	1.3	4
2919	Ultrasound-activated nanomaterials for sonodynamic cancer theranostics. <i>Drug Discovery Today</i> , 2022, 27, 1590-1603.	3.2	18
2920	Single-Cell Image-Based Analysis Reveals Chromatin Changes during the Acquisition of Tamoxifen Drug Resistance. <i>Life</i> , 2022, 12, 438.	1.1	4
2921	CRISPR/Cas9 and next generation sequencing in the personalized treatment of Cancer. <i>Molecular Cancer</i> , 2022, 21, 83.	7.9	26
2922	Discovery and Structure-Based Optimization of Novel Atg4B Inhibitors for the Treatment of Castration-Resistant Prostate Cancer. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 4878-4892.	2.9	4
2923	Synthesis and Characterization of Size- and Charge-Tunable Silver Nanoparticles for Selective Anticancer and Antibacterial Treatment. <i>ACS Applied Materials & Interfaces</i> , 2022, 14, 14981-14996.	4.0	29
2924	The Effect of Beta Adrenoreceptor Blockers on Viability and Cell Colony Formation of Non-Small Cell Lung Cancer Cell Lines A549 and H1299. <i>Molecules</i> , 2022, 27, 1938.	1.7	7
2925	GSH-Responsive and Hypoxia-Activated Multifunctional Nanoparticles for Synergetically Enhanced Tumor Therapy. <i>ACS Biomaterials Science and Engineering</i> , 2022, 8, 1942-1955.	2.6	12
2926	MiR-125b-5p/TPD52 Axis Affects Proliferation, Migration and Invasion of Breast Cancer Cells. <i>Molecular Biotechnology</i> , 2022, 64, 1003-1012.	1.3	3
2927	Computational Modeling on Binding Interactions of Cyclodextrins with the Human Multidrug Resistance P-glycoprotein Toward Efficient Drug-Delivery System Applications.. <i>Current Topics in Medicinal Chemistry</i> , 2022, 22, .	1.0	3
2929	Extrachromosomal circular DNA in cancer: history, current knowledge, and methods. <i>Trends in Genetics</i> , 2022, 38, 766-781.	2.9	57
2930	Conquering multidrug resistant lung cancer by upconversion <sc>nanoparticles-mediated</sc> photodynamic therapy and gene silencing. <i>Journal of the Chinese Chemical Society</i> , 2022, 69, 1305-1317.	0.8	1
2931	Natural Small Molecules in Breast Cancer Treatment: Understandings from a Therapeutic Viewpoint. <i>Molecules</i> , 2022, 27, 2165.	1.7	47
2932	CirITGB6 promotes ovarian cancer cisplatin resistance by resetting tumor-associated macrophage polarization toward the M2 phenotype. , 2022, 10, e004029.		44
2933	Discovery of a Novel Stilbene Derivative as a Microtubule Targeting Agent Capable of Inducing Cell Ferroptosis. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 4687-4708.	2.9	11
2934	Organoid screening reveals epigenetic vulnerabilities in human colorectal cancer. <i>Nature Chemical Biology</i> , 2022, 18, 605-614.	3.9	24
2935	Lipid based nanoparticles as a novel treatment modality for hepatocellular carcinoma: a comprehensive review on targeting and recent advances. <i>Journal of Nanobiotechnology</i> , 2022, 20, 109.	4.2	42

#	ARTICLE	IF	CITATIONS
2936	Exosomal DEK removes chemoradiotherapy resistance by triggering quiescence exit of breast cancer stem cells. <i>Oncogene</i> , 2022, 41, 2624-2637.	2.6	8
2937	Applications of Nanotechnology-based Approaches to Overcome Multi-drug Resistance in Cancer. <i>Current Pharmaceutical Design</i> , 2022, 28, 3140-3157.	0.9	4
2938	Nanoprodrug ratiometrically integrating autophagy inhibitor and genotoxic agent for treatment of triple-negative breast cancer. <i>Biomaterials</i> , 2022, 283, 121458.	5.7	13
2939	Supramolecular Assembly of a Terpyridyl based Binuclear Cu(II) Complex and its DNA Docking Study. <i>Supramolecular Chemistry</i> , 2021, 33, 487-492.	1.5	3
2940	Cationic Amphiphilic Dendrons with Anticancer Activity. <i>ACS Biomaterials Science and Engineering</i> , 2022, 8, 2121-2130.	2.6	2
2941	Pheophorbide A and SN38 conjugated hyaluronan nanoparticles for photodynamic- and cascadic chemotherapy of cancer stem-like ovarian cancer. <i>Carbohydrate Polymers</i> , 2022, 289, 119455.	5.1	2
2942	Downregulation of Low-density lipoprotein receptor-related protein 1B (LRP1B) inhibits the progression of hepatocellular carcinoma cells by activating the endoplasmic reticulum stress signaling pathway. <i>Bioengineered</i> , 2022, 13, 9467-9481.	1.4	4
2943	Spatial Distribution Control of Antimicrobial Peptides through a Novel Polymeric Carrier for Safe and Efficient Cancer Treatment. <i>Advanced Materials</i> , 2022, 34, e2201945.	11.1	13
2944	Ferroptosis in hematological malignancies and its potential network with abnormal tumor metabolism. <i>Biomedicine and Pharmacotherapy</i> , 2022, 148, 112747.	2.5	23
2945	Synthesis and antiproliferative evaluation of some novel estradiol selenocyanates. <i>Steroids</i> , 2022, 181, 108992.	0.8	12
2946	Real-time monitoring the efficacy of 7-hydroxycoumarin to cells cultured on microfluidics in different extracellular pH environments by chip-mass spectrometry. <i>Talanta</i> , 2022, 243, 123331.	2.9	8
2947	A novel navigated doxorubicin delivery formulation to breast cancer therapy. <i>Materials Today Advances</i> , 2022, 14, 100235.	2.5	3
2948	Photovoltaic polymer Photosensitizer-Doped Nano-Therapeutic reagent for in vivo enhanced bioimaging guided photodynamic therapy. <i>Chemical Engineering Journal</i> , 2022, 441, 135983.	6.6	8
2950	Trident cold atmospheric plasma blocks three cancer survival pathways to overcome therapy resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	14
2951	The Cross Marks the Spot: The Emerging Role of JmjC Domain-Containing Proteins in Myeloid Malignancies. <i>Biomolecules</i> , 2021, 11, 1911.	1.8	4
2952	Diagnostic, prognostic, and therapeutic value of miR-148b in human cancers. <i>Current Molecular Medicine</i> , 2021, 21, .	0.6	0
2953	Early senescence and production of senescence-associated cytokines are major determinants of radioresistance in head-and-neck squamous cell carcinoma. <i>Cell Death and Disease</i> , 2021, 12, 1162.	2.7	23
2954	Targeting Mitochondrial Metabolism and RNA Polymerase POLRMT to Overcome Multidrug Resistance in Cancer. <i>Frontiers in Chemistry</i> , 2021, 9, 775226.	1.8	6

#	ARTICLE	IF	CITATIONS
2955	Near-infrared light-triggered nano-prodrug for cancer gas therapy. <i>Journal of Nanobiotechnology</i> , 2021, 19, 443.	4.2	31
2956	Identification of Subtypes and a Prognostic Gene Signature in Colon Cancer Using Cell Differentiation Trajectories. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 705537.	1.8	7
2957	Delivery of siRNA Using Functionalized Gold Nanorods Enhances Anti-Osteosarcoma Efficacy. <i>Frontiers in Pharmacology</i> , 2021, 12, 799588.	1.6	10
2958	Evidence of Antitumor and Antimetastatic Potential of Induced Pluripotent Stem Cell-Based Vaccines in Cancer Immunotherapy. <i>Frontiers in Medicine</i> , 2021, 8, 729018.	1.2	8
2959	Overcoming multidrug resistance by knockout of ABCB1 gene using CRISPR/Cas9 system in SW620/Ad300 colorectal cancer cells. <i>MedComm</i> , 2021, 2, 765-777.	3.1	15
2960	Adaptor SH3BGRL drives autophagy-mediated chemoresistance through promoting PIK3C3 translation and ATG12 stability in breast cancers. <i>Autophagy</i> , 2022, 18, 1822-1840.	4.3	10
2961	The role of Ubiquitination in Apoptosis and Necroptosis. <i>Cell Death and Differentiation</i> , 2022, 29, 272-284.	5.0	72
2962	Tetramethylpyrazine: A Review of Its Antitumor Potential and Mechanisms. <i>Frontiers in Pharmacology</i> , 2021, 12, 764331.	1.6	2
2963	Sea Cucumber Compounds Targeting NF- κ B in Cancer Treatment. <i>Bioinformatics and Biology Insights</i> , 2022, 16, 117793222210917.	1.0	2
2965	Phase I Targeted Combination Trial of Sorafenib and GW5074 in Patients with Advanced Refractory Solid Tumors. <i>Journal of Clinical Medicine</i> , 2022, 11, 2183.	1.0	4
2966	Overcoming Multidrug Resistance (MDR): Design, Biological Evaluation and Molecular Modelling Studies of 2,4-Substituted Quinazoline Derivatives. <i>ChemMedChem</i> , 2022, 17, .	1.6	6
2967	Application of CRISPR-Cas9 System to Study Biological Barriers to Drug Delivery. <i>Pharmaceutics</i> , 2022, 14, 894.	2.0	2
2968	Reactive oxygen species-inducing titanium peroxide nanoparticles as promising radiosensitizers for eliminating pancreatic cancer stem cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 146.	3.5	7
2969	Emerging Nanotherapeutic Approaches to Overcome Drug Resistance in Cancers with Update on Clinical Trials. <i>Pharmaceutics</i> , 2022, 14, 866.	2.0	17
2970	Heterochiral β -Peptide Polymers Combating Multidrug-Resistant Cancers Effectively without Inducing Drug Resistance. <i>Journal of the American Chemical Society</i> , 2022, 144, 7283-7294.	6.6	26
2971	Recent advances in organic and polymeric carriers for local tumor chemo-immunotherapy. <i>Science China Technological Sciences</i> , 2022, 65, 1011-1028.	2.0	7
2972	Physiological levels of poly(ADP-ribose) during the cell cycle regulate HeLa cell proliferation. <i>Experimental Cell Research</i> , 2022, 417, 113163.	1.2	4
2974	FAM98A promotes resistance to 5-fluorouracil in colorectal cancer by suppressing ferroptosis. <i>Archives of Biochemistry and Biophysics</i> , 2022, 722, 109216.	1.4	13

#	ARTICLE	IF	CITATIONS
2975	Modulating tumor physical microenvironment for fueling CAR-T cell therapy. <i>Advanced Drug Delivery Reviews</i> , 2022, 185, 114301.	6.6	28
3033	Tailored protein-conjugated DNA nanoplatform for synergistic cancer therapy. <i>Journal of Controlled Release</i> , 2022, 346, 250-259.	4.8	8
3034	Mechanism of the Notch signaling pathway in enhancing the efficacy of chemotherapy drugs in osteosarcoma. <i>Journal of Central South University (Medical Sciences)</i> , 2020, 45, 1234-1240.	0.1	1
3036	Exosomes and MicroRNAs in Biomedical Science. <i>Synthesis Lectures on Biomedical Engineering</i> , 2022, 17, 1-175.	0.1	0
3037	Spatial structure impacts adaptive therapy by shaping intra-tumoral competition. <i>Communications Medicine</i> , 2022, 2, .	1.9	26
3038	DNA Copy Number Aberrations and Expression of ABC Transporter Genes in Breast Tumour: Correlation with the Effect of Neoadjuvant Chemotherapy and Prognosis of the Disease. <i>Pharmaceutics</i> , 2022, 14, 948.	2.0	3
3039	Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2022, 15, 45.	6.9	43
3040	Dual-Targeted Therapy Circumvents Non-Genetic Drug Resistance to Targeted Therapy. <i>Frontiers in Oncology</i> , 2022, 12, 859455.	1.3	2
3041	Application of computational screening tools and nanotechnology for enhanced drug synergism in cancer therapy. <i>Current Drug Delivery</i> , 2022, 19, .	0.8	0
3042	The Role of Extracellular Vesicles in Metabolic Reprogramming of the Tumor Microenvironment. <i>Cells</i> , 2022, 11, 1433.	1.8	17
3043	Exosomal miRNAs as a Promising Source of Biomarkers in Colorectal Cancer Progression. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4855.	1.8	6
3044	Novel Insights of Herbal Remedy into NSCLC Suppression through Inducing Diverse Cell Death Pathways via Affecting Multiple Mediators. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 4868.	1.3	2
3045	Role of the Pro-Inflammatory Tumor Microenvironment in Extracellular Vesicle-Mediated Transfer of Therapy Resistance. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	7
3046	Flake Graphene-Based Nanomaterial Approach for Triggering a Ferroptosis as an Attractive Theranostic Outlook for Tackling Non-Small Lung Cancer: A Mini Review. <i>Materials</i> , 2022, 15, 3456.	1.3	2
3047	Therapeutic Options in Neuro-Oncology. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5351.	1.8	8
3048	MALAT1 as master regulator of biomarkers predictive of pan-cancer multi-drug resistance in the context of recalcitrant NRAS signaling pathway identified using systems-oriented approach. <i>Scientific Reports</i> , 2022, 12, 7540.	1.6	2
3049	Rational Design and Systemic Appraisal of an EGFR-Targeting Antibody-Drug Conjugate LR-DM1 for Pancreatic Cancer. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 7141-7153.	2.9	3
3050	The Role of miRNAs in the Resistance of Anthracyclines in Breast Cancer: A Systematic Review. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	4

#	ARTICLE	IF	CITATIONS
3051	Advancements on Small Molecule PROTACs Containing an Indole/Spiro-fused Oxindole Scaffolds: An Emerging Degradator Targeting Cancers. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, .	0.9	0
3052	Novel application of rhein and its prodrug diacerein for reversing cancer-related multidrug resistance through the dual inhibition of P-glycoprotein efflux and STAT3-mediated P-glycoprotein expression. <i>Biomedicine and Pharmacotherapy</i> , 2022, 150, 112995.	2.5	12
3053	Acacetin inhibits the tumor growth of human osteosarcoma cells through regulating Wnt/ β -catenin and JNK signaling pathways. <i>Journal of Functional Foods</i> , 2022, 93, 105103.	1.6	1
3054	Conformational adjustment overcomes multiple drug-resistance mutants of tropomyosin receptor kinase. <i>European Journal of Medicinal Chemistry</i> , 2022, 237, 114406.	2.6	3
3055	Synergistic treatment of doxorubicin-resistant breast cancer by the combination of chemotherapy and photodynamic therapy. <i>Colloids and Surfaces A: Physicochemical and Engineering Aspects</i> , 2022, 648, 129167.	2.3	5
3056	Editorial: Non-Coding RNAs in Gastrointestinal and Gynecological Cancers: New Insights Into the Mechanisms of Cancer Therapeutic Resistance. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, .	1.8	0
3057	Metabolomics studies of cell-cell interactions using single cell mass spectrometry combined with fluorescence microscopy. <i>Chemical Science</i> , 2022, 13, 6687-6695.	3.7	14
3058	SERTAD1 Sensitizes Breast Cancer Cells to Doxorubicin and Promotes Lysosomal Protein Biosynthesis. <i>Biomedicines</i> , 2022, 10, 1148.	1.4	2
3059	CAF-derived midkine promotes EMT and cisplatin resistance by upregulating lncRNA ST7-AS1 in gastric cancer. <i>Molecular and Cellular Biochemistry</i> , 2022, 477, 2493-2505.	1.4	6
3060	Advances in Nanomedicine Design: Multidisciplinary Strategies for Unmet Medical Needs. <i>Molecular Pharmaceutics</i> , 2022, 19, 1722-1765.	2.3	5
3061	β -elemene suppresses tumor metabolism and stem cell-like properties of non-small cell lung cancer cells by regulating PI3K/AKT/mTOR signaling.. <i>American Journal of Cancer Research</i> , 2022, 12, 1535-1555.	1.4	0
3062	Molecular-engineered highly photosensitive triarylphosphine oxide compounds for apoptosis imaging and selectively inducing apoptosis of tumor cells by photodynamic therapy. <i>Biomaterials Science</i> , 2022, 10, 3441-3446.	2.6	3
3064	The Curcumin Analog Da0324 Inhibits the Proliferation of Gastric Cancer Cells via HOTAIRM1/miR-29b-1-5p/PHLPP1 Axis. <i>Journal of Cancer</i> , 2022, 13, 2644-2655.	1.2	4
3065	The Role of Nonapoptotic Programmed Cell Death in Ferroptosis, Necroptosis, and Pyroptosis in Pancreatic Ductal Adenocarcinoma Treatment. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	5
3066	Combination of Elacridar with Imatinib Modulates Resistance Associated with Drug Efflux Transporters in Chronic Myeloid Leukemia. <i>Biomedicines</i> , 2022, 10, 1158.	1.4	10
3067	Characterization of the Estrogen Response Helps to Predict Prognosis and Identify Potential Therapeutic Targets in Cholangiocarcinoma. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	0
3068	Comparative Study of Autophagy in Oxaliplatin-Sensitive and Resistant SNU-C5 Colon Cancer Cells. <i>Biomolecules and Therapeutics</i> , 2022, 30, 447-454.	1.1	1
3069	GDF15 Is an Eribulin Response Biomarker also Required for Survival of DTP Breast Cancer Cells. <i>Cancers</i> , 2022, 14, 2562.	1.7	6

#	ARTICLE	IF	CITATIONS
3071	A plant immune protein enables broad antitumor response by rescuing microRNA deficiency. <i>Cell</i> , 2022, 185, 1888-1904.e24.	13.5	24
3072	GSTs, MRP and Apoptotic Markers in DLD-1 Human Colon Cancer Cell Line Before and After 5-FU Treatment. <i>International Journal of Nature and Life Sciences</i> ., 2022, 6, 25-40.	0.2	1
3073	Response to the letter by Dr. Renba Liang. <i>Cancer Letters</i> , 2022, 540, 215650.	3.2	0
3074	The HIF-1 α as a Potent Inducer of the Hallmarks in Gastric Cancer. <i>Cancers</i> , 2022, 14, 2711.	1.7	9
3075	Ferroptosis and Tumor Drug Resistance: Current Status and Major Challenges. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	17
3076	A Review of Twenty Years of Research on the Regulation of Signaling Pathways by Natural Products in Breast Cancer. <i>Molecules</i> , 2022, 27, 3412.	1.7	7
3077	Ferroptosis-Driven Nanotherapeutics to Reverse Drug Resistance in Tumor Microenvironment. <i>ACS Applied Bio Materials</i> , 2022, 5, 2481-2506.	2.3	11
3078	A wavelength-induced frequency filtering method for fluorescent nanosensors in vivo. <i>Nature Nanotechnology</i> , 2022, 17, 643-652.	15.6	27
3079	Screening of organoids derived from patients with breast cancer implicates the repressor NCOR2 in cytotoxic stress response and antitumor immunity. <i>Nature Cancer</i> , 2022, 3, 734-752.	5.7	12
3080	Deep-Sea Discovery and Detective Work: Towards Solving the Hemicalide Structural Enigma through Computational NMR Analysis and Stereocontrolled Synthesis. <i>European Journal of Organic Chemistry</i> , 2022, 2022, .	1.2	1
3081	Crosstalk of Exosomal Non-Coding RNAs in The Tumor Microenvironment: Novel Frontiers. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	19
3082	Functional Properties of Cancer Epithelium and Stroma-Derived Exosomes in Head and Neck Squamous Cell Carcinoma. <i>Life</i> , 2022, 12, 757.	1.1	6
3083	Interactions between EGFR and EphA2 promote tumorigenesis through the action of Ephexin1. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	11
3084	Combination of a STAT3 inhibitor with anti-PD-1 immunotherapy is an effective treatment regimen for a vemurafenib-resistant melanoma. <i>Molecular Therapy - Oncolytics</i> , 2022, 26, 1-14.	2.0	11
3085	Red-Light-Responsive Metallopolymer Nanocarriers with Conjugated and Encapsulated Drugs for Phototherapy Against Multidrug-Resistant Tumors. <i>Small</i> , 2022, 18, .	5.2	9
3087	Itraconazole Reverts ABCB1-Mediated Docetaxel Resistance in Prostate Cancer. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	8
3088	Epigenetic regulation of cancer stem cells: Shedding light on the refractory/relapsed cancers. <i>Biochemical Pharmacology</i> , 2022, 202, 115110.	2.0	4
3089	Tumor site-specific PEG detachment and active tumor homing of therapeutic PEGylated chitosan/folate-decorated polydopamine nanoparticles to augment antitumor efficacy of photothermal/chemo combination therapy. <i>Chemical Engineering Journal</i> , 2022, 446, 137243.	6.6	23

#	ARTICLE	IF	CITATIONS
3090	DNAzyme-assisted bioconstruction of logically activatable nanoplatfoms for enhanced cancer therapy. Journal of Colloid and Interface Science, 2022, 623, 1132-1141.	5.0	0
3091	MicroRNAs in Cancer. Synthesis Lectures on Biomedical Engineering, 2022, , 11-40.	0.1	2
3092	Glucose Metabolism Intervention-Facilitated Nanomedicine Therapy. International Journal of Nanomedicine, 0, Volume 17, 2707-2731.	3.3	9
3093	High drug loading polymer micelle@ZIF-8 hybrid core-shell nanoparticles through donor-receptor coordination interaction for pH/H ₂ O ₂ -responsive drug release. Frontiers of Materials Science, 2022, 16, .	1.1	4
3094	Albumin Paclitaxel Compared with 5-Penfluorouracil, Lobaplatin, and Albumin Paclitaxel Combined with 5-Penfluorouracil in the Treatment of Human Gastric Cancer Cell AGS Line Autophagy and Apoptosis. Canadian Journal of Gastroenterology and Hepatology, 2022, 2022, 1-14.	0.8	2
3095	Necroptosis-Related Genes Associated With Immune Activity and Prognosis of Colorectal Cancer. Frontiers in Genetics, 0, 13, .	1.1	5
3096	Sorafenib Chemosensitization by Caryophyllane Sesquiterpenes in Liver, Biliary, and Pancreatic Cancer Cells: The Role of STAT3/ABC Transporter Axis. Pharmaceutics, 2022, 14, 1264.	2.0	7
3097	Emerging Prospects of Nanozymes for Antibacterial and Anticancer Applications. Biomedicines, 2022, 10, 1378.	1.4	25
3098	Inhibitors of ABCB1 and ABCG2 overcame resistance to topoisomerase inhibitors in small cell lung cancer. Thoracic Cancer, 2022, 13, 2142-2151.	0.8	10
3099	Preclinical Evaluation of Ixabepilone in Combination with VEGF Receptor and PARP Inhibitors in Taxane-Sensitive and Taxane-Resistant MDA-MB-231 Breast Cancer Cells. Journal of Pharmaceutical Sciences, 2022, , .	1.6	0
3100	Emerging role of exosomes in cancer progression and tumor microenvironment remodeling. Journal of Hematology and Oncology, 2022, 15, .	6.9	182
3102	The Therapeutic Potential of the Restoration of the p53 Protein Family Members in the EGFR-Mutated Lung Cancer. International Journal of Molecular Sciences, 2022, 23, 7213.	1.8	4
3103	miRNAs are now starring in "No Time to Die": Overcoming the chemoresistance in cancer. IUBMB Life, 2023, 75, 238-256.	1.5	0
3104	Thymoquinone Potentiates Methotrexate Mediated-Apoptosis in Saos-2 Osteosarcoma Cell Line. Drug Research, 2022, 72, 390-395.	0.7	4
3105	AN ADAPTIVE PHARMACOKINETIC OPTIMAL CONTROL APPROACH IN CHEMOTHERAPY FOR HETEROGENEOUS TUMOR. Journal of Biological Systems, 2022, 30, 529-551.	0.5	2
3106	Cancer-associated fibroblasts strengthen cell proliferation and EGFR TKIs resistance through aryl hydrocarbon receptor dependent signals in non-small cell lung cancer. BMC Cancer, 2022, 22, .	1.1	3
3107	Interference of layered double hydroxide nanoparticles with pathways for biomedical applications. Advanced Drug Delivery Reviews, 2022, 188, 114451.	6.6	18
3108	Identifying mutant-specific multi-drug combinations using comparative network reconstruction. IScience, 2022, 25, 104760.	1.9	0

#	ARTICLE	IF	CITATIONS
3109	AACR Project GENIE: 100,000 Cases and Beyond. <i>Cancer Discovery</i> , 2022, 12, 2044-2057.	7.7	27
3110	Spatio-Temporal Controlled Gene-Chemo Drug Delivery in a DNA Nanocomplex to Overcome Multidrug Resistance of Cancer Cells. <i>ACS Applied Bio Materials</i> , 2022, 5, 3795-3805.	2.3	12
3112	Functionalized Periodic Mesoporous Organosilica Nanoparticles for Combinational Chemo-Photothermal Antitumor Therapy. <i>ACS Applied Nano Materials</i> , 2022, 5, 9646-9656.	2.4	3
3113	Detection of methylated <i>BCAT1</i> and <i>IKZF1</i> after curative-intent treatment as a prognostic indicator for colorectal cancer recurrence. <i>Cancer Medicine</i> , 2023, 12, 1319-1329.	1.3	5
3114	Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	53
3115	Doxorubicin and Imatinib co-drug delivery using non-covalently functionalized carbon nanotube: Molecular dynamics study. <i>Journal of Molecular Liquids</i> , 2022, 362, 119789.	2.3	9
3116	ACP-check: An anticancer peptide prediction model based on bidirectional long short-term memory and multi-features fusion strategy. <i>Computers in Biology and Medicine</i> , 2022, 148, 105868.	3.9	4
3117	Control cell death by endosomal trafficking of proton transistor nanophotosensitizers. , 0, , .		0
3118	High-Throughput CRISPR Screening in Hematological Neoplasms. <i>Cancers</i> , 2022, 14, 3612.	1.7	3
3119	Vitamin B6 based Pt(II) complexes: biomolecule derived potential cytotoxic agents for thyroid cancer. <i>Metallomics</i> , 2022, 14, .	1.0	1
3120	Herpes simplex virus 1 as an oncolytic viral therapy for refractory cancers. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	10
3121	Emerging mechanisms of pyroptosis and its therapeutic strategy in cancer. <i>Cell Death Discovery</i> , 2022, 8, .	2.0	24
3122	Generation and Culture of Organotypic Breast Carcinoma Spheroids for the Study of Drug Response in a 3D Microfluidic Device. <i>Methods in Molecular Biology</i> , 2022, , 49-57.	0.4	3
3123	The ixabepilone and vandetanib combination shows synergistic activity in docetaxel-resistant MDA-MB-231 breast cancer cells. <i>Pharmacological Reports</i> , 2022, 74, 998-1010.	1.5	1
3124	In Situ Synthesis of an Anticancer Peptide Amphiphile Using Tyrosine Kinase Overexpressed in Cancer Cells. <i>Jacs Au</i> , 2022, 2, 2023-2028.	3.6	8
3125	Design of ROS-Responsive Hyaluronic Acid-Methotrexate Conjugates for Synergistic Chemo-Photothermal Therapy for Cancer. <i>Molecular Pharmaceutics</i> , 2022, 19, 3323-3335.	2.3	6
3126	Cancer Stem Cells and the Tumor Microenvironment: Targeting the Critical Crosstalk through Nanocarrier Systems. <i>Stem Cell Reviews and Reports</i> , 2022, 18, 2209-2233.	1.7	12
3127	Ferroptosis As Ultimate Target of Cancer Therapy. <i>Antioxidants and Redox Signaling</i> , 2023, 39, 206-223.	2.5	9

#	ARTICLE	IF	CITATIONS
3128	Therapeutic Targeting of Cancer Stem Cells Prevents Resistance of Colorectal Cancer Cells to MEK Inhibition. <i>ACS Pharmacology and Translational Science</i> , 2022, 5, 724-734.	2.5	6
3129	Dihydroxyqingdainone Induces Apoptosis in Leukaemia and Lymphoma Cells via the Mitochondrial Pathway in a Bcl-2- and Caspase-3-Dependent Manner and Overcomes Resistance to Cytostatic Drugs In Vitro. <i>Molecules</i> , 2022, 27, 5038.	1.7	3
3130	Synthesis of Four Steroidal Carbamates with Antitumor Activity against Mouse Colon Carcinoma CT26WT Cells: In Vitro and In Silico Evidence. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8775.	1.8	0
3131	The Role and Therapeutic Potential of Macropinocytosis in Cancer. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	7
3132	A multi-responsive targeting drug delivery system for combination photothermal/chemotherapy of tumor. <i>Journal of Biomaterials Science, Polymer Edition</i> , 0, , 1-18.	1.9	2
3133	Nanomedicines for Overcoming Cancer Drug Resistance. <i>Pharmaceutics</i> , 2022, 14, 1606.	2.0	9
3134	Deciphering colorectal cancer immune microenvironment transcriptional landscape on single cell resolution – A role for immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
3135	QSAR, molecular docking, ADMET properties in silico studies for a series of 7-propanamide benzoxaboroles as potent anti-cancer agents. <i>Chinese Journal of Analytical Chemistry</i> , 2022, 50, 100163.	0.9	13
3136	Autophagy-targeted nanoparticles for effective cancer treatment: advances and outlook. <i>NPG Asia Materials</i> , 2022, 14, .	3.8	18
3137	Structural-Guided Identification of Small Molecule Inhibitor of UHRF1 Methyltransferase Activity. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	6
3138	Herbal Ingredients in the Prevention of Breast Cancer: Comprehensive Review of Potential Molecular Targets and Role of Natural Products. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-23.	1.9	3
3139	Engaging plasticity: Differentiation therapy in solid tumors. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	13
3140	Self-Assembled Aza-Boron-Dipyrromethene for Ferroptosis-Boosted Sonodynamic Therapy. <i>Angewandte Chemie - International Edition</i> , 2022, 61, .	7.2	28
3141	Cathepsin L promotes chemresistance to neuroblastoma by modulating serglycin. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1
3142	Porphyrin-Based Nanoparticles: A Promising Phototherapy Platform. <i>ChemPlusChem</i> , 2022, 87, .	1.3	9
3143	Self-Assembled Aza-Boron-Dipyrromethene for Ferroptosis-Boosted Sonodynamic Therapy. <i>Angewandte Chemie</i> , 2022, 134, .	1.6	3
3144	A Multi-Drug Pharmacokinetic Optimal Control Approach in Cancer Chemotherapy. <i>Journal of Optimization Theory and Applications</i> , 0, , .	0.8	0
3145	Metabolic reprogramming from glycolysis to fatty acid uptake and beta-oxidation in platinum-resistant cancer cells. <i>Nature Communications</i> , 2022, 13, .	5.8	56

#	ARTICLE	IF	CITATIONS
3146	Drug resistance in NSCLC is associated with tumor micro-environment. <i>Reproductive Biology</i> , 2022, 22, 100680.	0.9	7
3147	HER-2-mediated nano-delivery of molecular targeted drug potently suppresses orthotopic epithelial ovarian cancer and metastasis. <i>International Journal of Pharmaceutics</i> , 2022, 625, 122126.	2.6	4
3148	Ferroptosis in colorectal cancer: Potential mechanisms and effective therapeutic targets. <i>Biomedicine and Pharmacotherapy</i> , 2022, 153, 113524.	2.5	30
3149	BET inhibition induces vulnerability to MCL1 targeting through upregulation of fatty acid synthesis pathway in breast cancer. <i>Cell Reports</i> , 2022, 40, 111304.	2.9	1
3150	A comprehensive pancancer analysis reveals the potential value of RAR-related orphan receptor C (RORC) for cancer immunotherapy. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	3
3151	Cellular reprogramming, chemoresistance, and dietary interventions in breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 179, 103796.	2.0	6
3152	Exosomal microRNA-506 inhibits biological activity of lung adenocarcinoma cells and increases sensitivity to cisplatin-based hyperthermia. <i>Cellular Signalling</i> , 2022, 100, 110469.	1.7	2
3153	Enhanced anti-glioma efficacy of doxorubicin with BRD4 PROTAC degrader using targeted nanoparticles. <i>Materials Today Bio</i> , 2022, 16, 100423.	2.6	8
3154	Covalent organic framework nanomedicines: Biocompatibility for advanced nanocarriers and cancer theranostics applications. <i>Bioactive Materials</i> , 2023, 21, 358-380.	8.6	37
3155	Complexities of Drug Resistance in Cancer: An Overview of Strategies and Mathematical Models. <i>Emergence, Complexity and Computation</i> , 2022, , 309-332.	0.2	1
3156	Recent advances of non-coding RNAs in ovarian cancer prognosis and therapeutics. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211180.	1.4	7
3157	<i>In situ</i> monitoring of functional activity of extracellular matrix stiffness-dependent multidrug resistance protein 1 using scanning electrochemical microscopy. <i>Chemical Science</i> , 2022, 13, 10349-10360.	3.7	4
3158	The Mechanism by Which SIRT1 Regulates Autophagy and EMT in Drug-Resistant Oesophageal Cancer Cells. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
3159	Automated and Miniaturized Pico-Liter Metabolite Extraction System for Single-Cell Mass Spectrometry. <i>IEEE Transactions on Biomedical Engineering</i> , 2023, 70, 470-478.	2.5	3
3160	Microneedle patch with spongy coating to co-load multiple drugs to treat multidrug-resistant melanoma. <i>Biomaterials Science</i> , 2022, 10, 6282-6290.	2.6	1
3161	ROS Overexpression Boosting Necroptosis Mediated by Mitochondrial Targeting Liposome for Cancer Apoptotic Resistance. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
3162	Drug and apoptosis resistance in cancer stem cells (CSCs): A puzzle with many pieces. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2022, 5, 850-72.	0.9	14
3163	Research progress on classification, characteristics and mechanism of antitumor drugs. <i>AIP Conference Proceedings</i> , 2022, , .	0.3	1

#	ARTICLE	IF	CITATIONS
3164	MG53 inhibits cellular proliferation and tumor progression in colorectal carcinoma. <i>International Journal of Biological Sciences</i> , 2022, 18, 5221-5229.	2.6	5
3165	MLACP 2.0: An updated machine learning tool for anticancer peptide prediction. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 4473-4480.	1.9	25
3166	Polymeric micelles for drug codelivery. , 2022, , 451-477.		0
3168	Synthetic Retinoid Kills Drug-Resistant Cancer Stem Cells via Inducing RAR-Translocation-Mediated Tension Reduction and Chromatin Decondensation. <i>Advanced Science</i> , 2022, 9, .	5.6	6
3169	Nano-carrier Polyamidoamine Dendrimer G4 Induces Mitochondrial-dependent Apoptosis in Human Multidrug-resistant Breast Cancer Cells through G0/G1 Phase Arrest. <i>Current Pharmaceutical Biotechnology</i> , 2022, 23, .	0.9	0
3170	Emerging roles of purinergic signaling in anti-cancer therapy resistance. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	7
3171	OSW-1 induces apoptosis and cyto-protective autophagy, and synergizes with chemotherapy on triple negative breast cancer metastasis. <i>Cellular Oncology (Dordrecht)</i> , 2022, 45, 1255-1275.	2.1	3
3172	Curcumin-based-fluorescent probes targeting ALDH1A3 as a promising tool for glioblastoma precision surgery and early diagnosis. <i>Communications Biology</i> , 2022, 5, .	2.0	2
3173	Current Landscape of Therapeutic Resistance in Lung Cancer and Promising Strategies to Overcome Resistance. <i>Cancers</i> , 2022, 14, 4562.	1.7	15
3174	Mechanisms Underlying Circuit Dysfunction in Neurodevelopmental Disorders. <i>Annual Review of Genetics</i> , 2022, 56, 391-422.	3.2	12
3175	Combinatorial Anticancer Drug Screen Identifies Off-Target Effects of Epigenetic Chemical Probes. <i>ACS Chemical Biology</i> , 2022, 17, 2801-2816.	1.6	4
3176	Tracing the Anti-cancer Mechanism of <i>Pleurotus osteratus</i> by the Integrative Approach of Network Pharmacology and Experimental Studies. <i>Applied Biochemistry and Biotechnology</i> , 2023, 195, 152-171.	1.4	6
3177	Mathematical characterization of population dynamics in breast cancer cells treated with doxorubicin. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	5
3178	Responsive Role of Nanomedicine in the Tumor Microenvironment and Cancer Drug Resistance. <i>Current Medicinal Chemistry</i> , 2023, 30, 3335-3355.	1.2	4
3179	Evaluation of antioxidant and anticancer activities of fermented pericarp extract of <i>Camellia japonica</i> L. using <i>Aspergillus oryzae</i> in oral cancer. <i>Oral Biology Research</i> , 2022, 46, 111-118.	0.0	0
3180	Tumor-derived interleukin-34 creates an immunosuppressive and chemoresistant tumor microenvironment by modulating myeloid-derived suppressor cells in triple-negative breast cancer. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 851-864.	2.0	6
3181	Enzymatic Nanosphere-to-Nanofiber Transition and Autophagy Inducer Release Promote Tumor Chemotherapy. <i>Advanced Healthcare Materials</i> , 2022, 11, .	3.9	4
3182	Cell-Derived Vesicles for Nanoparticles' Coating: Biomimetic Approaches for Enhanced Blood Circulation and Cancer Therapy. <i>Advanced Healthcare Materials</i> , 2022, 11, .	3.9	4

#	ARTICLE	IF	CITATIONS
3183	The role of lncRNA H19 in tumorigenesis and drug resistance of human Cancers. <i>Frontiers in Genetics</i> , 2022, 13, .	1.1	9
3185	C�ncer de mama: resist�ncia no tratamento aos quimioter�picos. <i>Conjeturas</i> , 2022, 22, 333-351.	0.0	0
3186	In-situ vaccination using dual responsive organelle targeted nanoreactors. <i>Biomaterials</i> , 2022, 290, 121843.	5.7	7
3187	Adaptive resistance is not responsible for long-term drug resistance in a cellular model of triple negative breast cancer. <i>Gene</i> , 2023, 850, 146930.	1.0	1
3188	Design, synthesis and biological evaluation of 3-aryl-7-hydroxy scopoletin derivatives as autophagy activators against tumorigenesis. <i>European Journal of Medicinal Chemistry</i> , 2022, 244, 114805.	2.6	1
3189	Lost in translation: Revisiting the use of tyrosine kinase inhibitors in colorectal cancer. <i>Cancer Treatment Reviews</i> , 2022, 110, 102466.	3.4	4
3190	The effect and mechanistic study of encequidar on reversing the resistance of SW620/AD300 cells to doxorubicin. <i>Biochemical Pharmacology</i> , 2022, 205, 115258.	2.0	2
3191	Activation of CD44/PAK1/AKT signaling promotes resistance to FGFR1 inhibition in squamous-cell lung cancer. <i>Npj Precision Oncology</i> , 2022, 6, .	2.3	5
3192	Perspectives of metal-organic framework nanosystem to overcome tumor drug resistance. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2022, 5, 954-70.	0.9	1
3193	Small molecule induces mitochondrial impairment in colon cancer cells. <i>New Journal of Chemistry</i> , 2022, 46, 22117-22121.	1.4	2
3194	Cancer-Associated Membrane Protein as Targeted Therapy for Bladder Cancer. <i>Pharmaceutics</i> , 2022, 14, 2218.	2.0	1
3195	Rewiring glucose metabolism improves 5-FU efficacy in p53-deficient/KRASG12D glycolytic colorectal tumors. <i>Communications Biology</i> , 2022, 5, .	2.0	5
3196	Targeting drugs to tumours using cell membrane-coated nanoparticles. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 33-48.	12.5	176
3197	DRESIS: the first comprehensive landscape of drug resistance information. <i>Nucleic Acids Research</i> , 2023, 51, D1263-D1275.	6.5	28
3198	Natural killer cell-mimicking nanomaterial for overcoming the multidrug resistance of tumor via cascade catalysis. <i>Science China Materials</i> , 2023, 66, 1215-1226.	3.5	3
3199	The Self-Administered Use of Complementary and Alternative Medicine (CAM) Supplements and Antioxidants in Cancer Therapy and the Critical Role of Nrf-2: A Systematic Review. <i>Antioxidants</i> , 2022, 11, 2149.	2.2	6
3200	Cisplatin Induces Senescent Lung Cancer Cell-Mediated Stemness Induction via GRP78/Akt-Dependent Mechanism. <i>Biomedicines</i> , 2022, 10, 2703.	1.4	4
3201	Nanomedicine-Enabled/Augmented Cell Pyroptosis for Efficient Tumor Nanotherapy. <i>Advanced Science</i> , 2022, 9, .	5.6	28

#	ARTICLE	IF	CITATIONS
3202	Trends in metabolic signaling pathways of tumor drug resistance: A scientometric analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
3203	Heparin and Heparin-Based Drug Delivery Systems: Pleiotropic Molecular Effects at Multiple Drug Resistance of Osteosarcoma and Immune Cells. <i>Pharmaceutics</i> , 2022, 14, 2181.	2.0	3
3204	CREAMMIST: an integrative probabilistic database for cancer drug response prediction. <i>Nucleic Acids Research</i> , 2023, 51, D1242-D1248.	6.5	5
3205	Rerouting the drug response: Overcoming metabolic adaptation in KRAS-mutant cancers. <i>Science Signaling</i> , 2022, 15, .	1.6	2
3206	Identifying Hub Genes Associated with Neoadjuvant Chemotherapy Resistance in Breast Cancer and Potential Drug Repurposing for the Development of Precision Medicine. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12628.	1.8	4
3207	Nanosystems for chemodynamic based combination therapy: Strategies and recent advances. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	7
3208	Design and Click Synthesis of Novel 1-Substituted-4-(3,4-Dimethoxyphenyl)-1 <i>H</i> -1,2,3-Triazole Hybrids for Anticancer Evaluation and Molecular Docking. <i>Polycyclic Aromatic Compounds</i> , 2023, 43, 7547-7564.	1.4	2
3209	New Dual P-Glycoprotein (P-gp) and Human Carbonic Anhydrase XII (hCA XII) Inhibitors as Multidrug Resistance (MDR) Reversers in Cancer Cells. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 14655-14672.	2.9	9
3210	The potential effects and mechanisms of Gegen Qinlian Decoction in oxaliplatin-resistant colorectal cancer based on network pharmacology. <i>Heliyon</i> , 2022, 8, e11305.	1.4	2
3211	Multifunctional bovine serum albumin-based nanocarriers with endosomal escaping and NIR light-controlled release to overcome multidrug resistance of breast cancer cells. <i>Journal of Drug Delivery Science and Technology</i> , 2022, 77, 103869.	1.4	3
3212	Combination of niclosamide and current therapies to overcome resistance for cancer: New frontiers for an old drug. <i>Biomedicine and Pharmacotherapy</i> , 2022, 155, 113789.	2.5	5
3213	Warburg effect in colorectal cancer: the emerging roles in tumor microenvironment and therapeutic implications. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	60
3214	The therapeutic potential of natural products for treating pancreatic cancer. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	12
3215	Novel shikonin derivatives suppress cell proliferation, migration and induce apoptosis in human triple-negative breast cancer cells via regulating PDK1/PDHC axis. <i>Life Sciences</i> , 2022, 310, 121077.	2.0	8
3216	Down-regulating Nrf2 by tangeretin reverses multiple drug resistance to both chemotherapy and EGFR tyrosine kinase inhibitors in lung cancer. <i>Pharmacological Research</i> , 2022, 186, 106514.	3.1	5
3217	Promising anticancer activity with high selectivity of DNA/plasma protein targeting new phthalazin-1(2H)-one heterocyclic scaffolds. <i>Journal of Molecular Structure</i> , 2023, 1274, 134423.	1.8	1
3218	Drug Resistance in Lung Cancer. , 2022, , .		0
3219	Epigenetic compounds targeting pharmacological target lysine specific demethylase 1 and its impact on immunotherapy, chemotherapy and radiotherapy for treatment of tumor recurrence and resistance. <i>Biomedicine and Pharmacotherapy</i> , 2023, 157, 113934.	2.5	0

#	ARTICLE	IF	CITATIONS
3220	Natural quinazolinones: From a treasure house to promising anticancer leads. <i>European Journal of Medicinal Chemistry</i> , 2023, 245, 114915.	2.6	13
3221	Upregulation of YKL-40 Promotes Metastatic Phenotype and Correlates with Poor Prognosis and Therapy Response in Patients with Colorectal Cancer. <i>Cells</i> , 2022, 11, 3568.	1.8	8
3222	Synthesis of estrone selenocyanate Compounds, anti-tumor activity evaluation and Structure-activity relationship analysis. <i>Bioorganic and Medicinal Chemistry</i> , 2022, 76, 117086.	1.4	8
3223	Multidimensional Quantitative Measurement of Cancer Chemoresistance through Differential ZIF-8 Nanoparticle Cellular Retention. <i>ACS Applied Materials & Interfaces</i> , 2022, 14, 51798-51807.	4.0	1
3224	Reactivity of Covalent Fragments and Their Role in Fragment Based Drug Discovery. <i>Pharmaceuticals</i> , 2022, 15, 1366.	1.7	14
3225	Pan-cancer Analysis of UBE2T with a focus on prognostic and immunological roles in lung adenocarcinoma. <i>Respiratory Research</i> , 2022, 23, .	1.4	3
3226	Multifunctional nanomedicine strategies to manage brain diseases. <i>Drug Delivery and Translational Research</i> , 0, , .	3.0	4
3228	Hydroxyethyl starch-folic acid conjugates stabilized theranostic nanoparticles for cancer therapy. <i>Journal of Controlled Release</i> , 2023, 353, 391-410.	4.8	20
3229	A helical oncolytic polypeptide with potent membranolytic activity for cancer therapy. <i>Biomaterials Science</i> , 2023, 11, 1451-1458.	2.6	2
3230	The therapeutic value of alstonine: An updated review. <i>South African Journal of Botany</i> , 2023, 152, 288-295.	1.2	1
3231	Targeting cancer drug resistance utilizing organoid technology. <i>Biomedicine and Pharmacotherapy</i> , 2023, 158, 114098.	2.5	6
3232	Tumor acidic environment directs nanoparticle impacts on cancer cells. <i>Journal of Colloid and Interface Science</i> , 2023, 634, 684-692.	5.0	3
3233	Fluorescence microscopic approach for detection of two different modes of breast cancer cell death induced by nanosecond pulsed electric field. <i>Sensors and Actuators B: Chemical</i> , 2023, 378, 133199.	4.0	5
3234	The magic bullet: Niclosamide. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	14
3235	Extracellular vesicles derived from cancer-associated fibroblasts carry tumor-promotive microRNA-1228-3p to enhance the resistance of hepatocellular carcinoma cells to sorafenib. <i>Human Cell</i> , 2023, 36, 296-311.	1.2	9
3236	Current Status of Natural Products/siRNA Co-Delivery for Cancer Therapy. <i>ChemistrySelect</i> , 2022, 7, .	0.7	0
3237	Substrate Type and Concentration Differently Affect Colon Cancer Cells Ultrastructural Morphology, EMT Markers, and Matrix Degrading Enzymes. <i>Biomolecules</i> , 2022, 12, 1786.	1.8	2
3238	DeepPROTACs is a deep learning-based targeted degradation predictor for PROTACs. <i>Nature Communications</i> , 2022, 13, .	5.8	23

#	ARTICLE	IF	CITATIONS
3239	Deep tumor-penetrating nano-delivery strategy to improve diagnosis and therapy in patient-derived xenograft (PDX) oral cancer model and patient tissue. <i>Nano Research</i> , 2023, 16, 2927-2937.	5.8	2
3240	The unfolded protein response (UPR) pathway: the unsung hero in breast cancer management. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2023, 28, 263-276.	2.2	3
3241	Gut microbiota: a potential target for improved cancer therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 541-552.	1.2	4
3242	Combination Chemotherapy of Multidrug-resistant Early-stage Colon Cancer: Determining Optimal Dose Schedules by High-performance Computer Simulation. <i>Cancer Research Communications</i> , 2023, 3, 21-30.	0.7	1
3243	CCSynergy: an integrative deep-learning framework enabling context-aware prediction of anti-cancer drug synergy. <i>Briefings in Bioinformatics</i> , 2023, 24, .	3.2	9
3244	Breast cancer: emerging principles of metastasis, adjuvant and neoadjuvant treatment from cancer registry data. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 721-735.	1.2	5
3245	Advances in Stigmasterol on its anti-tumor effect and mechanism of action. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	11
3246	Synergistic Effects of the Combinational Use of Escitalopram Oxalate and 5-Fluorouracil on the Inhibition of Gastric Cancer SNU-1 Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 16179.	1.8	2
3248	Hypoxia-Inducible Factor-1: A Novel Therapeutic Target for the Management of Cancer, Drug Resistance, and Cancer-Related Pain. <i>Cancers</i> , 2022, 14, 6054.	1.7	20
3249	Therapeutic Importance of Kaempferol in the Treatment of Cancer through the Modulation of Cell Signalling Pathways. <i>Molecules</i> , 2022, 27, 8864.	1.7	18
3250	DAB2IP attenuates chemoresistance of triple-negative breast cancer through sequestration of RAC1 to prevent β -catenin nuclear accumulation. <i>Clinical and Translational Medicine</i> , 2022, 12, .	1.7	7
3251	Cellular and Molecular Effects of Eribulin in Preclinical Models of Hematologic Neoplasms. <i>Cancers</i> , 2022, 14, 6080.	1.7	0
3252	Deep learning-based multi-drug synergy prediction model for individually tailored anti-cancer therapies. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
3253	The Integration of Nanomedicine with Traditional Chinese Medicine: Drug Delivery of Natural Products and Other Opportunities. <i>Molecular Pharmaceutics</i> , 2023, 20, 886-904.	2.3	3
3254	An overview of PROTACs: a promising drug discovery paradigm. <i>Molecular Biomedicine</i> , 2022, 3, .	1.7	35
3255	Ribitol alters multiple metabolic pathways of central carbon metabolism with enhanced glycolysis: A metabolomics and transcriptomics profiling of breast cancer. <i>PLoS ONE</i> , 2022, 17, e0278711.	1.1	4
3256	Preparation of targeted theranostic red blood cell membranes-based nanobubbles for treatment of colon adenocarcinoma. <i>Expert Opinion on Drug Delivery</i> , 2023, 20, 131-143.	2.4	3
3257	Chemical and Biological Insights on <i>Phaulopsis falcisepala</i> : A Source of Bioactive Compounds with Multifunctional Anticancer Potentials. <i>Chemistry Africa</i> , 0, , .	1.2	0

#	ARTICLE	IF	CITATIONS
3258	Shikonin enhances chemosensitivity of oral cancer through β -catenin pathway. <i>Oral Diseases</i> , 0, , .	1.5	1
3259	Molecular Recognition and <i>In Vivo</i> Detection of Temozolomide and 5-Aminoimidazole-4-carboxamide for Glioblastoma Using Near-Infrared Fluorescent Carbon Nanotube Sensors. <i>ACS Nano</i> , 2023, 17, 240-250.	7.3	7
3260	Mechanisms of Drug Resistance in Ovarian Cancer and Associated Gene Targets. <i>Cancers</i> , 2022, 14, 6246.	1.7	17
3261	GCNCPR-ACPs: a novel graph convolution network method for ACPs prediction. <i>BMC Bioinformatics</i> , 2022, 23, .	1.2	0
3262	LncRNA EBLN3P attributes methotrexate resistance in osteosarcoma cells through miR-200a-3p/O-GlcNAc transferase pathway. <i>Journal of Orthopaedic Surgery and Research</i> , 2022, 17, .	0.9	7
3263	The Glycosylated N-Terminal Domain of MUC1 Is Involved in Chemoresistance by Modulating Drug Permeation Across the Plasma Membrane. <i>Molecular Pharmacology</i> , 2023, 103, 166-175.	1.0	3
3264	PI3K Pathway Alterations in Peritoneal Metastases are Associated with Earlier Recurrence in Patients with Colorectal Cancer Undergoing Optimal Cytoreductive Surgery. <i>Annals of Surgical Oncology</i> , 0, , .	0.7	2
3265	Drug repurposing: Recent advancements, challenges, and future therapeutics for cancer treatment. <i>Journal of Bacteriology & Mycology Open Access</i> , 2022, 10, 26-30.	0.2	0
3266	Biological Role and Mechanism of Lipid Metabolism Reprogramming Related Gene ECHS1 in Cancer. <i>Technology in Cancer Research and Treatment</i> , 2022, 21, 153303382211406.	0.8	4
3267	Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592211383.	1.4	3
3268	Immune evasion in esophageal squamous cell cancer: From the perspective of tumor microenvironment. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
3269	Zn ^{0.4} Mg ^{0.6} Fe ₂ O ₄ nanoenzyme: a novel chemo-sensitizer for the chemotherapy treatment of oral squamous cell carcinoma. <i>Nanoscale Advances</i> , 0, , .	2.2	2
3270	Engineering lactate-modulating nanomedicines for cancer therapy. <i>Chemical Society Reviews</i> , 2023, 52, 973-1000.	18.7	17
3271	When cancer drug resistance meets metabolomics (bulk, single-cell and/or spatial): Progress, potential, and perspective. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
3272	Pyroptosis Provides New Strategies for the Treatment of Cancer. <i>Journal of Cancer</i> , 2023, 14, 140-151.	1.2	12
3273	Cancer cell cycle heterogeneity as a critical determinant of therapeutic resistance. <i>Genes and Diseases</i> , 2024, 11, 189-204.	1.5	10
3274	Reaching new lights: a review on photo-controlled nanomedicines and their <i>in vivo</i> evaluation. <i>Biomaterials Science</i> , 2023, 11, 1607-1624.	2.6	3
3275	RNA methylation and cellular response to oxidative stress-promoting anticancer agents. <i>Cell Cycle</i> , 2023, 22, 870-905.	1.3	7

#	ARTICLE	IF	CITATIONS
3276	Recent Advances in Boosting EGFR Tyrosine Kinase Inhibitors-Based Cancer Therapy. <i>Molecular Pharmaceutics</i> , 2023, 20, 829-852.	2.3	13
3277	A Self-Reinforcing Nanoplatfor for Highly Effective Synergistic Targeted Combinatory Calcium-Overload and Photodynamic Therapy of Cancer. <i>Advanced Healthcare Materials</i> , 2023, 12, .	3.9	12
3278	Chemotherapy-induced tumor immunogenicity is mediated in part by megakaryocyte-erythroid progenitors. <i>Oncogene</i> , 2023, 42, 771-781.	2.6	2
3279	Polypodium leucotomos targets multiple aspects of oral carcinogenesis and it is a potential antitumor phytotherapy against tongue cancer growth. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1
3280	M2 tumor-associated macrophage mediates the maintenance of stemness to promote cisplatin resistance by secreting TGF- β 1 in esophageal squamous cell carcinoma. <i>Journal of Translational Medicine</i> , 2023, 21, .	1.8	6
3281	A Systems Biology Approach for Addressing Cisplatin Resistance in Non-Small Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2023, 12, 599.	1.0	10
3283	Ruthenium Complex HB324 Induces Apoptosis via Mitochondrial Pathway with an Upregulation of Harakiri and Overcomes Cisplatin Resistance in Neuroblastoma Cells In Vitro. <i>International Journal of Molecular Sciences</i> , 2023, 24, 952.	1.8	5
3284	PDT-sensitized ROS-responsive dextran nanosystem for maximizing antitumor potency of multi-target drugs. <i>International Journal of Pharmaceutics</i> , 2023, 633, 122567.	2.6	2
3285	CRISPR/Cas9-based genome editing for multimodal synergistic cancer nanotherapy. <i>Nano Today</i> , 2023, 48, 101734.	6.2	5
3286	An Overview on Gold Nanorods as Versatile Nanoparticles in Cancer Therapy. <i>Journal of Controlled Release</i> , 2023, 354, 221-242.	4.8	24
3287	Bitter taste signaling in cancer. <i>Life Sciences</i> , 2023, 315, 121363.	2.0	8
3288	Phytochemical screening and GC-MS chemical profiling of an innovative anti-cancer herbal formula (PHF6). <i>Journal of King Saud University - Science</i> , 2023, 35, 102525.	1.6	1
3289	Brd4 proteolysis-targeting chimera nanoparticles sensitized colorectal cancer chemotherapy. <i>Journal of Controlled Release</i> , 2023, 354, 155-166.	4.8	11
3290	Identifying somatic changes in drug transporters using whole genome and transcriptome sequencing data of advanced tumors. <i>Biomedicine and Pharmacotherapy</i> , 2023, 159, 114210.	2.5	0
3291	Synthesis, crystal structure and evaluation of anticancer activities of some novel heterocyclic compounds based on thymol. <i>Journal of Molecular Structure</i> , 2023, 1278, 134906.	1.8	7
3293	Long Non-Coding RNA GAS5 Promotes BAX Expression by Competing with microRNA-128-3p in Response to 5-Fluorouracil. <i>Biomedicines</i> , 2023, 11, 58.	1.4	1
3294	Effective Delivery of Paclitaxel-Loaded Ferritin via Inverso CendR Peptide for Enhanced Cancer Therapy. <i>Molecular Pharmaceutics</i> , 2023, 20, 942-952.	2.3	4
3295	In Silico Identification and In Vitro Evaluation of New ABCG2 Transporter Inhibitors as Potential Anticancer Agents. <i>International Journal of Molecular Sciences</i> , 2023, 24, 725.	1.8	3

#	ARTICLE	IF	CITATIONS
3296	Mechanisms of multidrug resistance in cancer. , 2023, , 51-83.		0
3297	Self-assembled nanomaterials for ferroptosis-based cancer theranostics. <i>Biomaterials Science</i> , 2023, 11, 1962-1980.	2.6	6
3298	Role of epithelial to mesenchymal transition in the resistant mechanism of EGFR-TKIs. , 2023, , 55-70.		0
3299	Drug repurposing: A novel strategy to target cancer stem cells and therapeutic resistance. <i>Genes and Diseases</i> , 2024, 11, 148-175.	1.5	3
3300	Tumor-associated macrophages in prostate cancer: role in progression and therapy. , 2023, , 153-180.		0
3301	Cancer: A Complex Problem Requiring Interdisciplinary Research. , 2023, , 1-45.		0
3302	Silver Is Not Equal to Silver: Synthesis and Evaluation of Silver Nanoparticles with Low Biological Activity, and Their Incorporation into C12Alanine-Based Hydrogel. <i>Molecules</i> , 2023, 28, 1194.	1.7	5
3303	Improvement of ACK1-targeted therapy efficacy in lung adenocarcinoma using chloroquine or bafilomycin A1. <i>Molecular Medicine</i> , 2023, 29, .	1.9	2
3304	An mTOR feedback loop mediates the "flare" (rebound) response to MET tyrosine kinase inhibition. <i>Scientific Reports</i> , 2023, 13, .	1.6	1
3305	Epigenetic "Metabolic Interplay in the DNA Damage Response and Therapeutic Resistance of Breast Cancer. <i>Cancer Research</i> , 2023, 83, 657-666.	0.4	4
3306	The Role of Solute Carrier Transporters in Efficient Anticancer Drug Delivery and Therapy. <i>Pharmaceutics</i> , 2023, 15, 364.	2.0	5
3307	Near-Infrared Phototheranostic Iron Pyrite Nanocrystals Simultaneously Induce Dual Cell Death Pathways via Enhanced Fenton Reactions in Triple-Negative Breast Cancer. <i>ACS Nano</i> , 2023, 17, 4261-4278.	7.3	6
3308	Carbon nanotubes for anticancer therapy: new trends and innovations. , 2023, , 175-204.		0
3309	Lenalidomide in Multiple Myeloma: Review of Resistance Mechanisms, Current Treatment Strategies and Future Perspectives. <i>Cancers</i> , 2023, 15, 963.	1.7	5
3310	Non-Linear Control of Cancer Model, Considering the Drug Resistance Using Feedback Based Chemotherapy Approach. , 2022, , .		0
3311	Mechanisms involved in cancer stem cell resistance in head and neck squamous cell carcinoma. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2023, 6, 116-137.	0.9	5
3312	New frontiers in immune checkpoint B7-H3 (CD276) research and drug development. <i>Molecular Cancer</i> , 2023, 22, .	7.9	24
3313	The WNK1 "ERK5 route plays a pathophysiological role in ovarian cancer and limits therapeutic efficacy of trametinib. <i>Clinical and Translational Medicine</i> , 2023, 13, .	1.7	0

#	ARTICLE	IF	CITATIONS
3315	The role and prospect of lysine-specific demethylases in cancer chemoresistance. <i>Medicinal Research Reviews</i> , 2023, 43, 1438-1469.	5.0	5
3316	Therapeutic strategies of dual-target small molecules to overcome drug resistance in cancer therapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2023, 1878, 188866.	3.3	10
3317	Novel gold(I) complexes induce apoptosis in leukemia cells via the ROS-induced mitochondrial pathway with an upregulation of Harakiri and overcome multi drug resistances in leukemia and lymphoma cells and sensitize drug resistant tumor cells to apoptosis in vitro. <i>Biomedicine and Pharmacotherapy</i> , 2023, 161, 114507.	2.5	4
3318	A self-amplified ferroptosis nanoagent that inhibits the tumor upstream glutathione synthesis to reverse cancer chemoresistance. <i>Journal of Controlled Release</i> , 2023, 357, 20-30.	4.8	4
3319	Dual-drug codelivery nanosystems: An emerging approach for overcoming cancer multidrug resistance. <i>Biomedicine and Pharmacotherapy</i> , 2023, 161, 114505.	2.5	5
3320	The spectrum of cell death in sarcoma. <i>Biomedicine and Pharmacotherapy</i> , 2023, 162, 114683.	2.5	0
3321	CRISPR technology: A versatile tool to model, screen, and reverse drug resistance in cancer. <i>European Journal of Cell Biology</i> , 2023, 102, 151299.	1.6	4
3322	Molecular and supramolecular engineering on lipopeptide-based hole-punching nanotoxins to trigger multimodal death of drug-resistant tumors: Apoptosis, necrosis and autophagy. <i>Chemical Engineering Journal</i> , 2023, 465, 142698.	6.6	2
3323	Mechano-modulation of T cells for cancer immunotherapy. <i>Biomaterials</i> , 2023, 297, 122101.	5.7	5
3324	Synthesis and antitumor activity of some cholesterol-based selenocyanate compounds. <i>Steroids</i> , 2023, 194, 109217.	0.8	5
3325	2-Aminobenzothiazoles in anticancer drug design and discovery. <i>Bioorganic Chemistry</i> , 2023, 135, 106477.	2.0	9
3327	Cancer Stem Cells Contribute to Drug Resistance in Multiple Different Ways. <i>Advances in Experimental Medicine and Biology</i> , 2022, , 125-139.	0.8	5
3328	Effect of paclitaxel priming on doxorubicin penetration in a multicellular layer model of human colorectal cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2023, 647, 30-36.	1.0	1
3329	Cancer stem cells in colorectal cancer: Signaling pathways involved in stemness and therapy resistance. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 182, 103920.	2.0	18
3330	Radiolabeled Biodistribution of Expansile Nanoparticles: Intraperitoneal Administration Results in Tumor Specific Accumulation. <i>ACS Nano</i> , 2023, 17, 2212-2221.	7.3	3
3331	Incorporation of paclitaxel in mesenchymal stem cells using nanoengineering upregulates antioxidant response, CXCR4 expression and enhances tumor homing. <i>Materials Today Bio</i> , 2023, 19, 100567.	2.6	3
3332	BSA-templated synthesis of Ir/Gd bimetallic oxide nanotheranostics for MR/CT imaging-guided photothermal and photodynamic synergistic therapy. <i>Nanoscale</i> , 2023, 15, 4457-4468.	2.8	6
3333	Hybrid lipid-polymer nanoplatfrom: A systematic review for targeted colorectal cancer therapy. <i>European Polymer Journal</i> , 2023, 186, 111877.	2.6	4

#	ARTICLE	IF	CITATIONS
3335	A doxorubicin and siRNA coloaded nanolamellar hydroxyapatite/PLGA electrospun scaffold as a safe antitumor drug delivery system. <i>Applied Materials Today</i> , 2023, 31, 101759.	2.3	2
3336	The hypoxia-inducible factor-1 \pm in stemness and resistance to chemotherapy in gastric cancer: Future directions for therapeutic targeting. <i>Frontiers in Cell and Developmental Biology</i> , 0, 11, .	1.8	4
3337	Meta-analysis of the prognostic impact of TP53 co-mutations in EGFR-mutant advanced non-small-cell lung cancer treated with tyrosine kinase inhibitors. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 184, 103929.	2.0	3
3339	Drug resistance mechanism of kinase inhibitors in the treatment of hepatocellular carcinoma. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	7
3340	1 α -O-methyl-averantin isolated from the endolichenic fungus <i>Jackrogersella</i> sp. EL001672 suppresses colorectal cancer stemness via sonic Hedgehog and Notch signaling. <i>Scientific Reports</i> , 2023, 13, .	1.6	1
3341	Targeted Therapy and Mechanisms of Drug Resistance in Breast Cancer. <i>Cancers</i> , 2023, 15, 1320.	1.7	13
3342	Cell membrane biomimetic nanomedicines for cancer phototherapy. , 2023, 1, .		19
3343	Few-Shot Drug Synergy Prediction With a Prior-Guided Hypernetwork Architecture. <i>IEEE Transactions on Pattern Analysis and Machine Intelligence</i> , 2023, 45, 9709-9725.	9.7	1
3344	What Is the Significance of Lysosomal-Mediated Resistance to Imatinib?. <i>Cells</i> , 2023, 12, 709.	1.8	2
3345	Induction of Drug-Resistance and Production of a Culture Medium Able to Induce Drug-Resistance in Vinblastine Untreated Murine Myeloma Cells. <i>Molecules</i> , 2023, 28, 2051.	1.7	0
3346	Insight into the Crosstalk between Photodynamic Therapy and Immunotherapy in Breast Cancer. <i>Cancers</i> , 2023, 15, 1532.	1.7	6
3347	Macrophage infiltration promotes regrowth in MYCN-amplified neuroblastoma after chemotherapy. <i>OncImmunity</i> , 2023, 12, .	2.1	3
3348	DRdriver: identifying drug resistance driver genes using individual-specific gene regulatory network. <i>Briefings in Bioinformatics</i> , 2023, 24, .	3.2	0
3349	Self-assembled nanoformulations of paclitaxel for enhanced cancer theranostics. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 3252-3276.	5.7	7
3350	Total steroidal saponins from black nightshade (<i>Solanum nigrum</i> L.) overcome tumor multidrug resistance by inducing autophagy-mediated cell death in vivo and in vitro. <i>Phytotherapy Research</i> , 2023, 37, 3009-3024.	2.8	5
3351	Zinc Finger Protein 90 Knockdown Promotes Cisplatin Sensitivity via Nrf2/HO-1 Pathway in Ovarian Cancer Cell. <i>Cancers</i> , 2023, 15, 1586.	1.7	2
3352	Shc3 facilitates breast cancer drug resistance by interacting with ErbB2 to initiate ErbB2/COX2/MDR1 axis. <i>Cancer Medicine</i> , 2023, 12, 10768-10780.	1.3	3
3353	Molecular mechanisms targeting drug-resistance and metastasis in colorectal cancer: Updates and beyond. <i>World Journal of Gastroenterology</i> , 0, 29, 1395-1426.	1.4	8

#	ARTICLE	IF	CITATIONS
3354	Oxidative versus Reductive Stress in Breast Cancer Development and Cellular Mechanism of Alleviation: A Current Perspective with Anti-breast Cancer Drug Resistance. <i>Current Molecular Medicine</i> , 2024, 24, 205-216.	0.6	1
3355	Simplified Derivatives of Tetrandrine as Potent and Specific P-gp Inhibitors to Reverse Multidrug Resistance in Cancer Chemotherapy. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 4086-4105.	2.9	6
3356	Novel Implication of the Basement Membrane for Breast Cancer Outcome and Immune Infiltration. <i>International Journal of Biological Sciences</i> , 2023, 19, 1645-1663.	2.6	4
3357	Rational Design of Biomaterials to Potentiate Cancer Thermal Therapy. <i>Chemical Reviews</i> , 2023, 123, 7326-7378.	23.0	28
3358	Gelatin-Coated ZnO Array Nanoplatfor for Capture, Drug Resistance Identification, and Recovery of Circulating Tumor Cells. <i>Advanced Materials Technologies</i> , 2023, 8, .	3.0	0
3359	Genomic Landscape and Potential Regulation of RNA Editing in Drug Resistance. <i>Advanced Science</i> , 2023, 10, .	5.6	4
3360	HMGA2 regulation by miRNAs in cancer: Affecting cancer hallmarks and therapy response. <i>Pharmacological Research</i> , 2023, 190, 106732.	3.1	9
3361	Hollow Nanoporous Prussian Blue Nanocubes Enriched with Cu ²⁺ and Loaded with Quercetin for Synergistic Tumor Therapy. <i>ACS Applied Nano Materials</i> , 2023, 6, 4969-4977.	2.4	1
3362	Inhibition of IDH3± Enhanced the Efficacy of Chemoimmunotherapy by Regulating Acidic Tumor Microenvironments. <i>Cancers</i> , 2023, 15, 1802.	1.7	0
3363	Aging microenvironment and antitumor immunity for geriatric oncology: the landscape and future implications. <i>Journal of Hematology and Oncology</i> , 2023, 16, .	6.9	5
3364	Modulation of redox homeostasis: A strategy to overcome cancer drug resistance. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	4
3365	A systematic evaluation of deep learning methods for the prediction of drug synergy in cancer. <i>PLoS Computational Biology</i> , 2023, 19, e1010200.	1.5	5
3366	HDAC Inhibition Restores Response to HER2-Targeted Therapy in Breast Cancer via PHLDA1 Induction. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6228.	1.8	0
3367	Ethanolc Extract of <i>Artemisia vulgaris</i> Leaf Promotes Apoptotic Cell Death in Non-Small-Cell Lung Carcinoma A549 Cells through Inhibition of the Wnt Signaling Pathway. <i>Metabolites</i> , 2023, 13, 480.	1.3	3
3368	Long Non-Coding RNAs (lncRNAs) as Regulators of the PI3K/AKT/mTOR Pathway in Gastric Carcinoma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6294.	1.8	11
3369	Tubeimoside-2 Triggers Methuosis in Hepatocarcinoma Cells through the MKK4±p38± Axis. <i>Pharmaceutics</i> , 2023, 15, 1093.	2.0	0
3370	Liposomes in Cancer Therapy: How Did We Start and Where Are We Now. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6615.	1.8	29
3371	Temozolomide Resistance in Glioblastoma by NRF2: Protecting the Evil. <i>Biomedicines</i> , 2023, 11, 1081.	1.4	4

#	ARTICLE	IF	CITATIONS
3372	Lysine-Specific Demethylase 1 Promises to Be a Novel Target in Cancer Drug Resistance: Therapeutic Implications. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 4275-4293.	2.9	7
3373	Evolution-Informed Strategies for Combating Drug Resistance in Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6738.	1.8	5
3374	ATM depletion induces proteasomal degradation of FANCD2 and sensitizes neuroblastoma cells to PARP inhibitors. <i>BMC Cancer</i> , 2023, 23, .	1.1	2
3375	HSF1 Pathway Inhibitor Clinical Candidate (CCT361814/NXP800) Developed from a Phenotypic Screen as a Potential Treatment for Refractory Ovarian Cancer and Other Malignancies. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 5907-5936.	2.9	2
3376	Mechanism of Resistance to the WDR5 Inhibitor in MLL-Rearranged Leukemia. <i>ACS Chemical Biology</i> , 2023, 18, 949-958.	1.6	1
3377	Lnc-ing epigenetic mechanisms with autophagy and cancer drug resistance. <i>Advances in Cancer Research</i> , 2023, , .	1.9	0
3379	Nanoparticle-Based Combination Therapy for Ovarian Cancer. <i>International Journal of Nanomedicine</i> , 0, Volume 18, 1965-1987.	3.3	4
3380	Brazilian red propolis extract free and encapsulated into polymeric nanoparticles against ovarian cancer: formulation, characterisation and biological assays in 2D and 3D models. <i>Journal of Pharmacy and Pharmacology</i> , 2023, 75, 806-818.	1.2	2
3381	Apoptotic Janus-faced mycotoxins against thoracal and breast metastases. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 0, , .	2.2	0
3382	Recent Development of Supramolecular Cancer Theranostics Based on Cyclodextrins: A Review. <i>Molecules</i> , 2023, 28, 3441.	1.7	3
3383	Revisiting the Flora of Saudi Arabia: Phytochemical and Biological Investigation of the Endangered Plant Species <i>Euphorbia saudiarabica</i> . <i>Metabolites</i> , 2023, 13, 556.	1.3	1
3384	Transcriptomic identification of differentially expressed genes in Levonorgestrel resistant endometrial cancer cell lines. <i>Molecular Carcinogenesis</i> , 0, , .	1.3	0
3385	Knockdown of BAP31 Overcomes Hepatocellular Carcinoma Doxorubicin Resistance through Downregulation of Survivin. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7622.	1.8	0
3386	Targeted protein degradation might present a novel therapeutic approach in the fight against African trypanosomiasis. <i>European Journal of Pharmaceutical Sciences</i> , 2023, 186, 106451.	1.9	3
3410	Chemically induced degradation of epigenetic targets. <i>Chemical Society Reviews</i> , 2023, 52, 4313-4342.	18.7	2
3414	Apoptosis, necrosis, and other forms of cell death. , 2024, , 749-759.		0
3417	CD44: Does CD44v6 Adversely Impact the Prognosis of Cancer Patients?. <i>Biology of Extracellular Matrix</i> , 2023, , 119-159.	0.3	0
3420	Functional anti-bone tumor biomaterial scaffold: construction and application. <i>Journal of Materials Chemistry B</i> , 2023, 11, 8565-8585.	2.9	3

#	ARTICLE	IF	CITATIONS
3438	Cancer Chemoresistance; Recent Challenges and Future Considerations. <i>Cancer Treatment and Research</i> , 2023, , 237-253.	0.2	3
3456	Rare-Earth-Doped Ternary Oxide Materials for Down-Conversion and Upconversion. <i>Progress in Optical Science and Photonics</i> , 2023, , 117-148.	0.3	0
3457	Roles of Cancer Stem Cells in Therapy Resistance and Disease Recurrence. , 2023, , 149-165.		1
3461	Current advances in nanoformulations of therapeutic agents targeting tumor microenvironment to overcome drug resistance. <i>Cancer and Metastasis Reviews</i> , 2023, 42, 959-1020.	2.7	1
3485	Evolutionary determinants of curability in cancer. <i>Nature Ecology and Evolution</i> , 0, , .	3.4	1
3496	Non-coding RNAs in leukemia drug resistance: new perspectives on molecular mechanisms and signaling pathways. <i>Annals of Hematology</i> , 0, , .	0.8	1
3497	How gallic acid regulates molecular signaling: role in cancer drug resistance. , 2023, 40, .		3
3498	Advances in the structure, mechanism and targeting of chemoresistance-linked ABC transporters. <i>Nature Reviews Cancer</i> , 2023, 23, 762-779.	12.8	12
3509	Tumor Ecosystem-Directed Therapeutic Strategies. , 2023, , 675-701.		0
3530	High-order framework nucleic acid for targeted-delivery of antisense peptide nucleic acids to overcome drug resistance. <i>Chemical Communications</i> , 0, , .	2.2	0
3532	Enhancing the Prodrug ADME Profile: An Emerging Area to Overcome the Issues of Cancer Drug Resistance. , 2023, , 1-12.		0
3547	Editorial: Molecular and cellular mechanisms for cancer therapy resistance. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
3552	Colorectal cancer stem cells: overview and potential targeted therapy. , 2024, , 185-205.		1
3575	ROS, Redox Regulation, and Anticancer Therapy. , 2023, , 311-409.		0
3589	Cellular zinc metabolism and zinc signaling: from biological functions to diseases and therapeutic targets. <i>Signal Transduction and Targeted Therapy</i> , 2024, 9, .	7.1	0
3595	A nIR fluorescent single walled carbon nanotube sensor for broad-spectrum diagnostics. <i>Sensors & Diagnostics</i> , 2024, 3, 203-217.	1.9	2
3604	Modelling adaptive therapy for tumor using reaction-diffusion equation. <i>AIP Conference Proceedings</i> , 2024, , .	0.3	0
3615	Precision medicine: Dose for anticancer therapy. , 2024, , 357-367.		0

#	ARTICLE	IF	CITATIONS
3618	Ferroptosis: Emerging mechanisms, biological function, and therapeutic potential in cancer and inflammation. Cell Death Discovery, 2024, 10, .	2.0	0
3630	Nanomaterials in drug delivery. , 2024, , 297-319.		0
3648	Tumor-Microenvironment-on-Chip Platform for Assessing Drug Response in 3D Dynamic Culture. Methods in Molecular Biology, 2024, , 265-278.	0.4	0
3658	Signaling Pathways in Drug Development. , 0, , .		0